Kinase inhibitors

ABSTRACT

Compounds of formula (I) and pharmaceutically acceptable salts thereof: 
                         
wherein R 2 , W, A, Y and R 1  are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

CROSS REFERENCES TO RELATED APPLICATIONS

This application is a Divisional Application of U.S. patent applicationSer. No. 13/708,324, filed on Dec. 7, 2012, and claims priority toEuropean Patent Application No. 11192871.9, filed on Dec. 9, 2011, andEuropean Patent Application No. 12187931.6, filed on Oct. 10, 2012.

CROSS REFERENCES TO RELATED APPLICATIONS

This application claims priority to European Patent Application No.11192871.9, filed on Dec. 9, 2011 and European Patent Application No.12187931.6, filed on Oct. 10, 2012, both of which are incorporatedherein by reference in their entireties.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to compounds and compositions that are p38MAPK inhibitors, and which are useful as anti-inflammatory agents in thetreatment of, inter alia, diseases of the respiratory tract. The presentinvention further relates to methods for the treatment and/or preventionof certain diseases and conditions by administering such a compound.

2. Discussion of the Background

Mitogen activated protein kinases (MAPK) constitute a family ofproline-directed serine/threonine kinases that activate their substratesby dual phosphorylation. There are four known human isoforms of p38 MAPkinase, p38α, p38β, p38γ, and p38δ. The p38 kinases, which are alsoknown as cytokine suppressive anti-inflammatory drug binding proteins(CSBP), stress activated protein kinases (SAPK) and RK, are responsiblefor phosphorylating (Stein et al., Ann. Rep. Med Chem., 1996, 31,289-298, which is incorporated herein by reference in its entirety) andactivating transcription factors (such as ATF-2, MAX, CHOP and C/ERPb)as well as other kinases (such as MAPKAP-K2/3 or MK2/3), and arethemselves activated by physical and chemical stress (e.g. UV, osmoticstress), pro-inflammatory cytokines and bacterial lipopolysaccharide(LPS) (see Herlaar E. & Brown Z., Molecular Medicine Today, 1999, 5,439-447, which is incorporated herein by reference in its entirety). Theproducts of p38 phosphorylation have been shown to mediate theproduction of inflammatory cytokines, including tumor necrosis factoralpha (TNF α) and interleukin-(IL)-1, and cyclooxygenase-2 (COX-2). IL-1and TNFα are also known to stimulate the production of otherproinflammatory cytokines such as IL-6 and IL-8.

IL-1 and TNFα are biological substances produced by a variety of cells,such as monocytes or macrophages. IL-1 has been demonstrated to mediatea variety of biological activities thought to be important inimmunoregulation and other physiological conditions such as inflammation(see, e.g. Dinarello et al., Rev. Infect. Disease, 1984, 6, 51, which isincorporated herein by reference in its entirety). Excessive orunregulated TNF production (particularly TNFα) has been implicated inmediating or exacerbating a number of diseases, and it is believed thatTNF can cause or contribute to the effects of inflammation in general.IL-8 is a chemotactic factor produced by several cell types includingmononuclear cells, fibroblasts, endothelial cells, and keratinocytes.Its production from endothelial cells is induced by IL-1, TNF, orlipopolysaccharide (LPS). IL-8 stimulates a number of functions invitro. It has been shown to have chemoattractant properties forneutrophils, T-lymphocytes and basophils. Increase in IL-8 production isalso responsible for chemotaxis of neutrophils into the inflammatorysite in vivo.

Inhibition of signal transduction via p38, which in addition to IL-1,TNF and IL-8 described above is also required for the synthesis and/oraction of several additional pro-inflammatory proteins (e.g., IL-6,GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highlyeffective mechanism for regulating the excessive and destructiveactivation of the immune system. This expectation is supported by thepotent and diverse anti-inflammatory activities described for p38 kinaseinhibitors (see Badger et al., J. Pharm. Exp. Thera., 1996, 279,1453-1461; Griswold et al, Pharmacol. Comm., 1996, 7, 323-229, which areincorporated herein by reference in their entireties). In particular,p38 kinase inhibitors have been described as potential agents fortreating rheumatoid arthritis. In addition to the links between p38activation and chronic inflammation and arthritis, there is also dataimplicating a role for p38 in the pathogenesis of airway diseases inparticular COPD and asthma. Stress stimuli (including tobacco smoke,infections or oxidative products) can cause inflammation within the lungenvironment. Inhibitors of p38 have been shown to inhibit LPS andovalbumin induced airway TNF-α; IL-1β, IL-6, IL-4, IL-5, and IL-13 (seeHaddad et al, Br. J. Pharmacol., 2001, 132 (8), 1715-1724; Underwood etal, Am. J. Physiol. Lung Cell. Mol. 2000, 279, 895-902; Duan et al.,2005 Am. J. Respir. Crit. Care Med., 171, 571-578; Escott et al Br. J.Pharmacol., 2000, 131, 173-176; Underwood et al., J. Pharmacol. Exp.Ther. 2000, 293, 281-288, which are incorporated herein by reference intheir entireties). Furthermore, they significantly inhibit neutrophiliaand the release of MMP-9 in LPS, ozone or cigarette smoke animal models.There is also a significant body of preclinical data highlighting thepotential benefits of inhibition of the p38 kinase that could berelevant in the lung (see Lee et al., Immunopharmacology, 2000, 47,185-200, which is incorporated herein by reference in its entirety).Thus, therapeutic inhibition of p38 activation may be important in theregulation of airway inflammation.

The implication of the p38MAPK pathway in various diseases has beenreviewed by P. Chopra et al. (Expert Opinion on Investigational Drugs,2008, 17(10), 1411-1425, which is incorporated herein by reference inits entirety).

Known P38 kinase inhibitors have been reviewed by G. J. Hanson (ExpertOpinions on Therapeutic Patents, 1997, 7, 729-733) J Hynes et al.(Current Topics in Medicinal Chemistry, 2005, 5, 967-985), C. Dominguezet al (Expert Opinions on Therapeutics Patents, 2005, 15, 801-816) andL. H. Pettus & R. P. Wurtz (Current Topics in Medicinal Chemistry, 2008,8, 1452-1467), which are incorporated herein by reference in theirentireties. P38 kinase inhibitors containing a triazolopyridine motifare known in the art, see for example WO 2007/091152, WO 2004/072072,and WO 2006/018727, which are incorporated herein by reference in theirentireties.

International Patent Application WO 2010/094956, which is incorporatedherein by reference in its entirety, discloses triazolopyridinederivatives of formula (I) as being p38 MAP Kinase inhibitors:

In such compounds, A represents an optionally substituted divalentarylene radical, an heteroarylene radical, a (C₃-C₆) divalentcycloalkylene radical having 5 or 6 ring atoms or a pyperidinyleneradical. The compounds are said to be useful in as anti-inflammatoryagents in the treatment of diseases of the respiratory tract.

There remains, however, a need for improved p38 MAP Kinase inhibitors.

SUMMARY OF THE INVENTION

Accordingly, it is one object of the present invention to provide novelp38 MAP Kinase inhibitors.

It is another object of the present invention to provide novel andpotent p38 mitogen activated protein kinase inhibitors which are usefulin the treatment of inflammatory and obstructive diseases of therespiratory tract.

It is another object of the present invention, to provide novel potentp38 mitogen activated protein kinase inhibitors which show anappropriate developability profile on inhalatory administration toeffectively treat respiratory obstructive or inflammatory diseases. Itis to be understood that such profile may be achieved in a number ofdifferent ways by modulation of specific properties; by way of example,it could be achieved by administration of a low effective dose of thedrug thus limiting side effects or via a long duration of action in thelungs which may reduce the frequency of administration.

These and other objects, which will become apparent during the followingdetailed description, have been achieved by the inventors' discoverythat compounds formula (I) described below are useful as p38 mitogenactivated protein kinase inhibitors.

Thus, the present invention provides compound of formula (I), andpharmaceutically acceptable salt thereof:

wherein;

W is a heteroatom selected from N or O, wherein N is substituted withhydrogen, C₁-C₆ alkyl, or C₃-C₅ cycloalkyl;

Y is selected from the group consisting of: a group —S(O)_(p)— wherein pis 0, 1 or 2; a group —O(CR³R⁴)_(n)—; a group —(CR⁵R⁶)_(n)—; a group—NR⁷—; a group —OC(O)—; a group —OC(O)NH—; and a group —OC(O)O—;

R³, R⁴, R⁵ and R⁶ are each independently hydrogen, fluorine orC₁-C₆alkyl, or, respectively, R³ and R⁴, or R⁵ and R⁶ may form, togetherwith the carbon atom to which they are attached, a saturated 3-6membered carbocyclic monocyclic ring optionally substituted by a groupC₁-C₆ alkyl, hydroxyl or halo;

n is 0, 1, 2 or 3;

R⁷ is hydrogen, C₁-C₆ alkyl, or C₃-C₇ cycloalkyl wherein such C₁-C₆alkyl or C₃-C₇ cycloalkyl are optionally substituted by a group C₁-C₃alkyl, C₃-C₆ cycloalkyl, hydroxyl, cyano, or halo;

R¹ is a group selected from (IIa)-(IIc):

R⁸ and R⁹ are each independently hydrogen or C₁-C₆ alkyl, or R⁸ and R⁹may form, together with the nitrogen atom to which they are attached, a5-11-membered saturated monocyclic or a fused or spiro bicyclic ringsystem optionally containing a further heteroatom which is oxygen ornitrogen, said nitrogen atom being optionally substituted by C₁-C₆alkyl; wherein such C₁-C₆ alkyl groups may be optionally substituted bya group C₁-C₆ alkyl, C₃-C₆ cycloalkyl, hydroxyl, or halo;

X¹, X², X³, X⁴ and X⁵ are each independently a carbon atom, a nitrogenatom, a group —(CH)— or a group —NH—; such that each combination thereofforms an aromatic ring system;

R¹⁰ is selected from a group consisting of: Hydrogen, —CN, —NR^(A)R^(B),—N(R^(C))(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))(C₃-C₇cycloalkylene)-NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —O—(C₂-C₆alkylene)-NR^(A)R^(B),—O—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —S—(C₂-C₆alkylene)-NR^(A)R^(B),—S—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D), —N(R^(C))C(O)NR^(A)R^(B),—C(O)NR^(A)R^(B), —N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—(C₂-C₆alkylene)-OR^(D), —(C₃-C₇cycloalkylene)-OR^(D),—O—(C₂-C₆alkylene)-OR^(D), —O—(C₃-C₇cycloalkylene)-OR^(D),—S—(C₂-C₆alkylene)-OR^(D), —S—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₂-C₆alkylene)-OR^(D),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-OR^(D), —S(O)₂N(R^(A)R^(B)),—N(R^(C))S(O)₂R^(D), —N(R^(C))C(O)R^(C), —OR^(C), —SR^(C),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl),(C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl)-, and C₃-C₇heterocycloalkylcarbonyl; wherein any of such C₁-C₆alkyl,C₃-C₆cycloalkyl, —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-,—(C₃-C₇cycloalkylene)-, —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), (C₅-C₇ heterocycloalkyl)-(C₃-C₆cycloalkyl) and (C₃-C₇heterocycloalkyl)carbonyl portion in the abovelisted groups may be optionally substituted by a group C₁-C₆ alkyl,C₃-C₇ cycloalkyl, hydroxyl or halo;

R¹¹ is linked to X⁴ and is selected from a group consisting of

hydrogen; —CN; C₁-C₆ alkyl which is substituted by a group selected from—CN, —OR^(C), —SR^(C), halo; C₃-C₆cycloalkyl which is substituted by agroup selected from C₁-C₄ alkyl, —CN, —OR^(D), —SR^(D), halo;—NR^(A)R^(B), —N(R^(C))(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))(C₃-C₇cycloalkylene)-NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —O—(C₂-C₆alkylene)-NR^(A)R^(B),—O—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —S—(C₂-C₆alkylene)-NR^(A)R^(B),—S—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B), —N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D), —N(R^(C))C(O)N(R^(A)R^(B)),—C(O)N(R^(A)R^(B)), —N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—O—(C₂-C₆alkylene)-OR^(D), —O—(C₃-C₇cycloalkylene)-OR^(D),—S—(C₂-C₆alkylene)-OR^(D), —S—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₂-C₆alkylene)-OR^(D),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-OR^(D), —S(O)₂N(R^(A)R^(B)),—N(R^(C))S(O)₂R^(D), —N(R^(C))C(O)R^(C), OR^(C), SR^(C),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl),(C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl) and (C₃-C₇heterocycloalkyl)carbonyl, wherein any of such C₁-C₆alkyl,C₃-C₆cycloalkyl, —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-,—(C₃-C₇cycloalkylene)-, —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), (C₅-C₇ heterocycloalkyl)-(C₃-C₆cycloalkyl) and (C₃-C₇heterocycloalkyl)carbonyl portion in the abovelisted groups may be optionally substituted by one, two or three groupsR²⁵ which are independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl and halo; or

R¹¹ is linked to X⁴ and is phenyl or 5- or 6-membered monocyclicheteroaryl, wherein such phenyl or 5- or 6-membered monocyclicheteroaryl is substituted by a group selected from the group consistingof: C₁-C₆ alkyl which is substituted by a group —CN; C₃-C₆ cycloalkylwhich is substituted by a group selected from: —CN, —OR^(C), —SR^(C) orhalo; —N(R^(C))(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))(C₃-C₇cycloalkylene)-NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —O—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S—(C₂-C₆alkylene)-NR^(A)R^(B), —S—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—O—(C₃-C₇cycloalkylene)-OR^(D), —S—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₂-C₆alkylene)-OR^(D),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-OR^(D), —N(R^(C))S(O)₂R^(D),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl),(C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl) and(C₃-C₇heterocycloalkyl)carbonyl, wherein any of such C₁-C₆alkyl,C₃-C₆cycloalkyl, —(C₁-C₆alkylene)- —(C₂-C₆alkylene)-,—(C₃-C₇cycloalkylene)-, —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), (C₅-C₇ heterocycloalkyl)-(C₃-C₆cycloalkyl) and (C₃-C₇heterocycloalkyl)carbonyl portion in the abovelisted groups may be optionally substituted by one, two or three groupsR²⁵ which are independently selected from the group consisting of:C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇cycloalkyl,hydroxyl, and halo;

R^(A) and R^(B) are at each occurrence independently hydrogen, C₁-C₆alkyl, or C₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇ cycloalkyl beingoptionally substituted by a group C₁-C₃ alkyl, C₃-C₇cycloalkyl, —OR^(D),—CN, or halo; alternatively, R^(A) and R^(B), may form, together withthe nitrogen atom to which they are attached, a 5-11-membered saturatedheterocyclic monocyclic or bicyclic ring system which is optionallysubstituted by one or more group —OR^(D), —CN, halo, C₁-C₆ alkyl, orC₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, C₃-C₇cycloalkyl, —OR^(D), —CN, orhalo; and which 5-11-membered saturated heterocyclic monocyclic orbicyclic ring optionally contains a further heteroatom which is oxygenor nitrogen, said nitrogen atom optionally substituted by C₁-C₆ alkyl orC₃-C₆ cycloalkyl, wherein any of such C₁-C₆ alkyl or C₃-C₆ cycloalkylmay be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,—OR^(D), —CN, or halo; and/or R^(A) and R^(B) may be linked to onecarbon atom of the —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)- or—(C₃-C₇cycloalkylene)- portion of the group linked to the nitrogen towhich they are connected to form a saturated cycle of up to 6 ringatoms;

R^(C) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, such C₁-C₆ alkyl and C₃-C₆ cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, —OR^(D), —CN, or halo;

R^(D) is at each occurrence independently hydrogen, —CH₃, or —C₂H₅;

R¹² and R¹³ are independently hydrogen, C₁-C₆ alkyl, or halogen;

A is a divalent cycloalkylene radical having 5, 6 or 7 ring atoms; saidcycloalkylene ring being attached to W and Y, and fused to a phenyl ringor to a monocyclic heteroaryl ring having 5 or 6 ring atoms, such phenylor heteroaryl ring being optionally substituted by one or two groupsR²⁴;

R²⁴ is at each occurrence independently selected from the groupconsisting of C₁-C₆ alkyl, halogen, and cyano;

R² is a radical of formula (IIIa), (IIIb), (IIIc), or (IIId):

wherein

R¹⁴ is selected from the group consisting of —F, —CH₃, —C₂H₅, —CH₂OH,—CH₂OMe, —CF₂CF₃, —CH₂SCH₃, —SCH₃, and —SC₂H₅;

R¹⁵ and R¹⁶ are independently —CH₃ or —C₂H₅;

R¹⁷ is selected from the group consisting of lone electron pair,hydrogen, —CF₃, —NR^(E)R^(F), —(C₃-C₇cycloalkyl),—(C₃-C₇heterocycloalkyl), aryl, and heteroaryl wherein any of such(C₃-C₇cycloalkyl), —(C₃-C₇heterocycloalkyl), aryl or heteroaryl may beoptionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, orhalo; or

R¹⁷ is a group of general formula (IV):

wherein

R²⁰ is selected from the group consisting of —F, —CH₃, —C₂H₅, —CH₂OH,—CH₂OMe, —CF₂CF₃, —CH₂SCH₃, —SCH₃, and —SC₂H₅;

R²¹ is —CH₃ or —C₂H₅;

or

R²⁰ and R²¹ as defined above may form, together with the carbon atom towhich they are attached, a saturated 3-7-membered monocyclic ring;

R^(E) and R^(F) are each independently C₁-C₆ alkyl, optionallysubstituted by a group C₁-C₃ alkyl, —OR^(G), —CN or halo; alternatively,R^(E) and R^(F) may form, together with the nitrogen atom to which theyare attached, a 5-11-membered saturated monocyclic or bicyclicheterocyclic ring system which is optionally substituted by one or moregroups —OR^(G), —CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, such C₁-C₆alkyl and C₃-C₇ cycloalkyl being optionally substituted by a group C₁-C₃alkyl, C₃-C₇cycloalkyl, —OR^(G), —CN or halo; and which 5-11-memberedsaturated monocyclic or bicyclic heterocyclic ring optionally contains afurther heteroatom which is oxygen or nitrogen, said nitrogen atomoptionally substituted by C₁-C₆ alkyl or C₃-C₆ cycloalkyl, wherein anyof such C₁-C₆ alkyl or C₃-C₆ cycloalkyl may be optionally substituted bya group C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

R^(G) is hydrogen, —CH₃, or —C₂H₅;

R¹⁸ is selected from the group consisting of lone electron pair,hydrogen, aryl, heteroaryl, —(C₁-C₆alkyl), —(C₃-C₇cycloalkyl),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and(C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such aryl,heteroaryl, —(C₁-C₆alkyl), —(C₃-C₇cycloalkyl), —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆cycloalkyl) may be optionally substituted by a group —CN, —OH, halo,—COOR^(M), C₁-C₆alkyl, C₃-C₆cycloalkyl, —O—(C₁-C₆alkyl),—O—(C₃-C₆cycloalkyl), —S—(C₁-C₆alkyl), —S—(C₃-C₆cycloalkyl),—NR^(H)R^(J), —N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—N(R^(L))(C₃-C₇cycloalkylene)-NR^(H)R^(J), —(C₁-C₆alkylene)-NR^(H)R^(J),—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —S—(C₂-C₆alkylene)-NR^(H)R^(J),—S—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—N(R^(L))C(O)—(C₁-C₆alkylene)-NR^(H)R^(J),—N(R^(L))C(O)—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₂-C₆alkylene)-OR^(M),—C(O)N(R^(L))—(C₃-C₇cycloalkylene)-OR^(M), —N(R^(L))C(O)N(R^(H)R^(J)),—C(O)N(R^(H)R^(J)), —N(R^(L))C(O)N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—N(R^(L))C(O)N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—O—(C₂-C₆alkylene)-OR^(M), —O—(C₃-C₇cycloalkylene)-OR^(M),—S—(C₂-C₆alkylene)-OR^(M), —S—(C₃-C₇cycloalkylene)-OR^(M),—N(R^(L))S(O)₂—(C₁-C₆alkylene)-NR^(H)R^(J),—N(R^(L))S(O)₂—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₂-C₆alkylene)-OR^(M),—S(O)₂N(R^(L))—(C₃-C₇cycloalkylene)-OR^(M),—N(R^(L))S(O)₂—(C₂-C₆alkylene)-OR^(M),—N(R^(L))S(O)₂—(C₃-C₇cycloalkylene)-OR^(M), —S(O)₂N(R^(H)R^(J)),—N(R^(L))S(O)₂R^(L), —N(R^(L))C(O)R^(L), OR^(L), SR^(L),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and(C₅-C₇ heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of suchC₁-C₆alkyl, C₃-C₆cycloalkyl, —(C₁-C₆alkylene)- —(C₂-C₆alkylene)-,—(C₃-C₇cycloalkylene)-, —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl) portion in the above listed groupsmay be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,—OR^(L), or halo;

R^(H) and R^(J), are at each occurrence independently hydrogen, C₁-C₆alkyl or C₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl beingoptionally substituted by a group C₁-C₃ alkyl, —OR^(M), CN or halo;

alternatively, R^(H) and R^(J) may also form, together with the nitrogenatom to which they are attached, a 5-11-membered saturated monocyclic orbicyclic heterocyclic ring system which is optionally substituted by oneor more groups —OR^(M), —CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, suchC₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by a groupC₁-C₃ alkyl, C₃-C₇cycloalkyl, —OR^(M), CN, or halo; and which5-11-membered saturated monocyclic or bicyclic heterocyclic ringoptionally contains a further heteroatom which is oxygen or nitrogen,said nitrogen atom optionally substituted by C₁-C₆ alkyl or C₃-C₆cycloalkyl, wherein any of such C₁-C₆ alkyl or C₃-C₆ cycloalkyl may beoptionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,—OR^(M), CN, or halo;

and/or R^(H) and R^(J) may be linked to one carbon atom of the—(C₁-C₆alkylene)-, —(C₂-C₆alkylene)- or —(C₃-C₇cycloalkylene)- portionof the group linked to the nitrogen to which they are connected to forma saturated cycle of up to 6 ring atoms;

R^(L) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, —OR^(M), —CN, or halo;

R^(M) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionallysubstituted by a group hydroxyl, —CN or halo;

z¹, z², z³, and z⁴ are independently selected from the group consistingof C, N, S, O, a group —CH—, and a group —NH—, in such a combinationthat the resulting ring formed is an aromatic system;

R¹⁹ is selected from the group consisting of hydrogen, —CF₃,—NR^(E)R^(F), —(C₃-C₇cycloalkyl), —(C₃-C₇heterocycloalkyl), aryl, andheteroaryl wherein any of such —(C₃-C₇cycloalkyl),—(C₃-C₇heterocycloalkyl), aryl or heteroaryl may be optionallysubstituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or halo; or

R¹⁹ is a group of general formula (V):

wherein R²⁰, R²¹, R^(E) and R^(F) are as above defined;

T is —N═ or —CR²³═;

R²³ is H, halo, —CH₃, or —CN;

R²² is H, halo, —CH₃, or —CN;

q is 0, 1, 2, or 3;

with the proviso that when Y is a group —O(CR³R⁴)_(n)—, n is 1, and R¹⁰is —NR^(A)R^(B), —N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(A)R^(B)),—N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B), or—N(R^(C))C(O)R^(C), then X₁ is nitrogen.

In another embodiment, the present invention provides compounds offormula (IP), and pharmaceutically acceptable salts thereof:

wherein:

W is a heteroatom selected from N and O, wherein N is substituted withhydrogen or C₁-C₆ alkyl, or C₃-C₅ cycloalkyl;

Y is selected from the group consisting of: a group —S(O)_(p)— wherein pis 0, 1 or 2; a group —O(CR³R⁴)_(n)—; a group —(CR⁵R⁶)_(n)—; a group—NR⁷—; a group —OC(O)—; a group —OC(O)NH—; and a group —OC(O)O—;

R³, R⁴, R⁵ and R⁶ are each independently hydrogen, fluorine or C₁-C₆alkyl, or, respectively, R³ and R⁴, or R⁵ and R⁶ may form, together withthe carbon atom to which they are attached, a saturated 3-6 memberedcarbocyclic monocyclic ring optionally substituted by a group C₁-C₆alkyl, hydroxyl or halo.

n is 0, 1, 2 or 3

R⁷ is hydrogen, C₁-C₆ alkyl, or C₃-C₇ cycloalkyl wherein such C₁-C₆alkyl or C₃-C₇ cycloalkyl are optionally substituted by a group C₁-C₃alkyl, C₃-C₆ cycloalkyl, hydroxyl, cyano, or halo;

R¹ is a group selected from (IIa)-(IIc):

R⁸ and R⁹ are each independently hydrogen or C₁-C₆ alkyl, or R⁸ and R⁹may form, together with the nitrogen atom to which they are attached, a5-11-membered saturated monocyclic or a fused or spiro bicyclic ringsystem optionally containing a further heteroatom which is oxygen ornitrogen, said nitrogen atom being optionally substituted by C₁-C₆alkyl; wherein such C₁-C₆ alkyl groups may be optionally substituted bya group C₁-C₆ alkyl, C₃-C₆ cycloalkyl, hydroxyl or halo;

X¹, X², X³, X⁴ and X⁵ are each independently a carbon atom, a nitrogenatom, a group —(CH)— or a group —NH—; such that each combination thereofforms an aromatic ring system;

R¹⁰ is selected from the group consisting of hydrogen, —CN,—NR^(A)R^(B), —N(R^(C))(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))(C₃-C₇cycloalkylene)-NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —O—(C₂-C₆alkylene)-NR^(A)R^(B),—O—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —S—(C₂-C₆alkylene)-NR^(A)R^(B),—S—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B), —N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D), —N(R^(C))C(O)NR^(A)R^(B),—C(O)NR^(A)R^(B), —N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—(C₂-C₆alkylene)-OR^(D), —(C₃-C₇cycloalkylene)-OR^(D),—O—(C₂-C₆alkylene)-OR^(D), —O—(C₃-C₇cycloalkylene)-OR^(D),—S—(C₂-C₆alkylene)-OR^(D), —S—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₂-C₆alkylene)-OR^(D),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-OR^(D), —S(O)₂N(R^(A)R^(B)),—N(R^(C))S(O)₂R^(D), —N(R^(C))C(O)R^(C), OR^(C), SR^(C),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl),(C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl)-, and C₃-C₇heterocycloalkylcarbonyl, wherein any of such alkylene, cycloalkylene,heterocycloalkyl, heterocycloalkyl-(C₁-C₆ alkyl),heterocycloalkyl-(C₃-C₆cycloalkyl) and heterocycloalkylcarbonyl may beoptionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,hydroxyl or halo.

R¹¹ is linked to X⁴ and is selected from a group consisting of

hydrogen; —CN; C₁-C₆ alkyl which is substituted by a group selected from—CN, —OR^(C), —SR^(C), halo; C₃-C₆cycloalkyl which is substituted by agroup selected from C₁-C₄ alkyl, —CN, —OR^(C), —SR^(D), halo;—NR^(A)R^(B), —N(R^(C))(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))(C₃-C₇cycloalkylene)-NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —O—(C₂-C₆alkylene)-NR^(A)R^(B),—O—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —S—(C₂-C₆alkylene)-NR^(A)R^(B),—S—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D), —N(R^(C))C(O)N(R^(A)R^(B)),—C(O)N(R^(A)R^(B)), —N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—O—(C₂-C₆alkylene)-OR^(D), —O—(C₃-C₇cycloalkylene)-OR^(D),—S—(C₂-C₆alkylene)-OR^(D), —S—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₂-C₆alkylene)-OR^(D),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-OR^(D), —S(O)₂N(R^(A)R^(B)),—N(R^(C))S(O)₂R^(D), —N(R^(C))C(O)R^(C), OR^(C), SR^(C),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl(C₁-C₆alkyl),(C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl), C₃-C₇heterocycloalkylcarbonyl, wherein any of such alkylene, cycloalkylene,heterocycloalkyl, heterocycloalkyl-(C₁-C₆alkyl),heterocycloalkyl-(C₃-C₆cycloalkyl) and heterocycloalkylcarbonyl may beoptionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,hydroxyl or halo; or

R¹¹ is linked to X⁴ and is phenyl or 5- or 6-membered monocyclicheteroaryl, wherein such phenyl or 5- or 6-membered monocyclicheteroaryl is substituted by a group selected from the group consistingof C₁-C₆ alkyl which is substituted by a group —CN; C₃-C₆ cycloalkylwhich is substituted by a group selected from: —CN, —OR^(C), —SR^(C) orhalo; —N(R^(C))(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))(C₃-C₇cycloalkylene)-NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),—(C₃-C₇cycloalkylene)-NR^(A)R^(B), —O—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S—(C₂-C₆alkylene)-NR^(A)R^(B), —S—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—O—(C₃-C₇cycloalkylene)-OR^(D), —S—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D),—N(R^(C))S(O)₂—(C₂-C₆alkylene)-OR^(D),—N(R^(C))S(O)₂—(C₃-C₇cycloalkylene)-OR^(D), —N(R^(C))S(O)₂R^(D),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl),(C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl), C₃-C₇heterocycloalkylcarbonyl,wherein any of such alkylene, cycloalkylene, heterocycloalkyl,heterocycloalkyl-(C₁-C₆alkyl), heterocycloalkyl-(C₃-C₆cycloalkyl) andheterocycloalkylcarbonyl may be optionally substituted by a groupC₁-C₆alkyl, C₃-C₇cycloalkyl, hydroxyl or halo;

R^(A) and R^(B) are at each occurrence independently hydrogen,C₁-C₆alkyl or C₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇cycloalkylbeing optionally substituted by a group C₁-C₃ alkyl, C₃-C₇cycloalkyl,—OR^(D), —CN or halo; alternatively, R^(A) and R^(B), may form, togetherwith the nitrogen atom to which they are attached, a 5-11-memberedsaturated monocyclic or bicyclic ring system which is optionallysubstituted by one or more group OR^(D), CN, halo, C₁-C₆ alkyl orC₃-C₇cycloalkyl, such C₁-C₆ alkyl and C₃-C₇cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, C₃-C₇cycloalkyl, OR^(D), CN or halo;and which 5-11-membered saturated monocyclic or bicyclic ring optionallycontains a further heteroatom which is oxygen or nitrogen, said nitrogenatom optionally substituted by C₁-C₆ alkyl or C₃-C₆cycloalkyl whereinany of such alkyl or cycloalkyl may be optionally substituted by a groupC₁-C₆ alkyl, C₃-C₇ cycloalkyl, —OR^(D), —CN, or halo; and/or R^(A) andR^(B) may be linked to one carbon atom of the alkylene or cycloalkyleneportion of the group linked to the nitrogen to which they are connectedto form a saturated cycle of up to 6 ring atoms;

R^(C) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, such C₁-C₆ alkyl and C₃-C₆ cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, —OR^(D), —CN, or halo;

R^(D) is at each occurrence independently hydrogen, —CH₃, or —C₂H₅;

R¹² and R¹³ are independently hydrogen, C₁-C₆ alkyl, or halogen;

A is a divalent cycloalkylene radical having 5, 6 or 7 ring atoms; saidcycloalkylene ring being attached to W and Y, and fused to a phenyl ringor to a monocyclic heteroaryl ring having 5 or 6 ring atoms, such phenylor heteroaryl ring being optionally substituted by one or two groupsR²⁴;

R²⁴ is at each occurrence independently selected from the groupconsisting of: C₁-C₆ alkyl, halogen and cyano;

R² is a radical of formula (IIIa), (IIIb), (IIIc), or (IIId):

wherein

R¹⁴ is selected from the group consisting of —F, —CH₃, —C₂H₅, —CH₂OH,—CH₂OMe, —CF₂CF₃, —CH₂SCH₃, —SCH₃, and —SC₂H₅;

R¹⁵ and R¹⁶ are independently —CH₃ or —C₂H₅;

R¹⁷ is selected from the group consisting of lone electron pair,hydrogen, —CF₃, —NR^(E)R^(F), —(C₃-C₇cycloalkyl),—(C₃-C₇heterocycloalkyl), aryl, and heteroaryl wherein any of suchcycloalkyl, heterocycloalkyl, aryl or heteroaryl may be optionallysubstituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or halo; or

R¹⁷ is a group of general formula (IV):

wherein

R²⁰ is selected in the group consisting of: —F, —CH₃, —C₂H₅, —CH₂OH,—CH₂OMe, —CF₂CF₃, —CH₂SCH₃, —SCH₃, and —SC₂H₅;

R²¹ is —CH₃ or —C₂H₅;

or;

R²⁰ and R²¹ as defined above may form, together with the carbon atom towhich they are attached, a saturated 3-7-membered monocyclic ring;

R^(E) and R^(F) are each independently C₁-C₆ alkyl, optionallysubstituted by a group C₁-C₃ alkyl, —OR^(G), —CN or halo; alternatively,R^(E) and R^(F) may form, together with the nitrogen atom to which theyare attached, a 5-11-membered saturated monocyclic or bicyclic ringsystem which is optionally substituted by one or more groups —OR^(G),—CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇cycloalkyl being optionally substituted by a group C₁-C₃ alkyl,C₃-C₇cycloalkyl, —OR^(G), —CN or halo; and which 5-11-membered saturatedmonocyclic or bicyclic ring optionally contains a further heteroatomwhich is oxygen or nitrogen, said nitrogen atom optionally substitutedby C₁-C₆ alkyl or C₃-C₆ cycloalkyl wherein any of such alkyl orcycloalkyl may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇cycloalkyl;

R^(G) is hydrogen, —CH₃, or —C₂H₅;

R¹⁸ is selected from the group consisting of lone electron pair,hydrogen, aryl, heteroaryl, —(C₁-C₆alkyl), —(C₃-C₇cycloalkyl),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) or(C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such aryl,heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkyl-(C₁-C₆alkyl), or heterocycloalkyl-(C₃-C₆ cycloalkyl) may be optionallysubstituted by a group —CN, —OH, halo, —COOR^(M), C₁-C₆alkyl,C₃-C₆cycloalkyl, —O—(C₁-C₆alkyl), —O—(C₃-C₆cycloalkyl), —S—(C₁-C₆alkyl),—S—(C₃-C₆cycloalkyl), —NR^(H)R^(J),—N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—N(R^(L))(C₃-C₇cycloalkylene)-NR^(H)R^(J), —(C₁-C₆alkylene)-NR^(H)R^(J),—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —S—(C₂-C₆alkylene)-NR^(H)R^(J),—S—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—N(R^(L))C(O)—(C₁-C₆alkylene)-NR^(H)R^(J),—N(R^(L))C(O)—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₂-C₆alkylene)-OR^(M),—C(O)N(R^(L))—(C₃-C₇cycloalkylene)-OR^(M), —N(R^(L))C(O)N(R^(H)R^(J)),—C(O)N(R^(H)R^(J)), —N(R^(L))C(O)N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—N(R^(L))C(O)N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—O—(C₂-C₆alkylene)-OR^(M), —O—(C₃-C₇cycloalkylene)-OR^(M),—S—(C₂-C₆alkylene)-OR^(M), —S—(C₃-C₇cycloalkylene)-OR^(M),—N(R^(L))S(O)₂—(C₁-C₆alkylene)-NR^(H)R^(J),—N(R^(L))S(O)₂—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₂-C₆alkylene)-OR^(M),—S(O)₂N(R^(L))—(C₃-C₇cycloalkylene)-OR^(M),—N(R^(L))S(O)₂—(C₂-C₆alkylene)-OR^(M),—N(R^(L))S(O)₂—(C₃-C₇cycloalkylene)-OR^(M), —S(O)₂N(R^(H)R^(J)),—N(R^(L))S(O)₂R^(L), —N(R^(L))C(O)R^(L), OR^(L), SR^(L),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and(C₅-C₇ heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such alkyl,cycloalkyl, alkylene, cycloalkylene, heterocycloalkyl,heterocycloalkyl-(C₁-C₆alkyl), and (heterocycloalkyl)-(C₃-C₆ cycloalkyl)may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,OR^(L) or halo;

R^(H) and R^(J), are at each occurrence independently hydrogen, C₁-C₆alkyl, or C₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl beingoptionally substituted by a group C₁-C₃ alkyl, OR^(M), CN or halo;alternatively, R^(H) and R^(J) may also form, together with the nitrogenatom to which they are attached, a 5-11-membered saturated monocyclic orbicyclic ring system which is optionally substituted by one or moregroup OR^(M), CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, such C₁-C₆alkyl and C₃-C₇ cycloalkyl being optionally substituted by a group C₁-C₃alkyl, C₃-C₇cycloalkyl, OR^(M), CN, or halo; and which 5-11-memberedsaturated monocyclic or bicyclic ring optionally contains a furtherheteroatom which is oxygen or nitrogen, said nitrogen atom optionallysubstituted by C₁-C₆ alkyl or C₃-C₆ cycloalkyl wherein any of such alkylor cycloalkyl may be optionally substituted by a group C₁-C₆ alkyl,C₃-C₇ cycloalkyl, —OR^(M), —CN, or halo; and/or R^(H) and R^(J) may belinked to one carbon atom of the alkylene or cycloalkylene portion ofthe group linked to the nitrogen to which they are connected to form asaturated cycle of up to 6 ring atoms;

R^(L) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, OR^(M), CN, or halo;

R^(M) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionallysubstituted by a group hydroxyl, CN, or halo;

z¹, z², z³, and z⁴ are independently selected from the group consistingof C, N, S, O, a group —CH—, and a group —NH—, in such a combinationthat the resulting ring formed is an aromatic system;

R¹⁹ is selected from the group consisting of hydrogen, —CF₃,—NR^(E)R^(F), —(C₃-C₇cycloalkyl), —(C₃-C₇heterocycloalkyl), aryl, andheteroaryl wherein any of such cycloalkyl, heterocycloalkyl, aryl orheteroaryl may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇cycloalkyl, or halo or;

R¹⁹ is a group of general formula (V):

wherein R²⁰, R²¹, R^(E) and R^(F) are as above defined;

T is —N═ or —CR²³═;

R²³ is H, halo, —CH₃, or —CN;

R²² is H, halo, —CH₃, or —CN;

q is 0, 1, 2 or 3;

with the proviso that when Y is a group —O(CR³R⁴)_(n)—, n is 1 and R¹⁰is —NR^(A)R^(B), —N(R^(C))C(O)—(C₁-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(A)R^(B)),—N(R^(C))C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—N(R^(C))C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B), or—N(R^(C))C(O)R^(C), then X₁ is nitrogen.

In another aspect, the invention includes pharmaceutical compositionscomprising a compound or salt thereof of the present invention, togetherwith one or more pharmaceutically acceptable carriers and/or excipients.Particularly preferred are compositions adapted for inhalation forpulmonary administration.

The compounds of the present invention are inhibitors of p38 mitogenactivated protein kinase (“p38 MAPK,” “p38 kinase,” or “p38”), includingp38α kinase, and are inhibitors of cytokine and chemokine productionincluding TNFα and IL-8 production. They have a number of therapeuticapplications, in the treatment of inflammatory diseases, particularlyallergic and non-allergic airways diseases, more particularlyobstructive or inflammatory airways diseases such as chronic obstructivepulmonary disease (“COPD”) and asthma. They are therefore particularlysuited for pulmonary delivery, by inhalation by nose or mouth.

It is believed that the compounds of the present invention can be usedto treat p38 mediated diseases such as: chronic obstructive pulmonarydisease (COPD), asthma, chronic or acute bronchoconstriction,bronchitis, acute lung injury and bronchiectasis, pulmonary arteryhypertension, tuberculosis, lung cancer, inflammation generally (e.g.inflammatory bowel disease), arthritis, neuroinflammation, pain, fever,fibrotic diseases, pulmonary disorders and diseases (e.g., hyperoxicalveolar injury), cardiovascular diseases, post-ischemic reperfusioninjury and congestive heart failure, cardiomyopathy, stroke, ischemia,reperfusion injury, renal reperfusion injury, brain edema, neurotraumaand brain trauma, neurodegenerative disorders, central nervous systemdisorders, liver disease and nephritis, gastrointestinal conditions,ulcerative diseases, Crohn's disease, ophthalmic diseases,ophthalmological conditions, glaucoma, acute injury to the eye tissueand ocular traumas, diabetes, diabetic nephropathy, skin-relatedconditions, myalgias due to infection, influenza, endotoxic shock, toxicshock syndrome, autoimmune disease, graft rejection, bone resorptiondiseases, multiple sclerosis, psoriasis, eczema, disorders of the femalereproductive system, pathological (but non-malignant) conditions, suchas hemangiomas, angiofibroma of the nasopharynx, and avascular necrosisof bone, benign and malignant tumors/neoplasia including cancer,leukaemia, lymphoma, systemic lupus erythematosus (SLE), angiogenesisincluding neoplasia, haemorrhage, coagulation, radiation damage, and/ormetastasis. Chronic release of active TNF can cause cachexia andanorexia, and TNF can be lethal. TNF has also been implicated ininfectious diseases. These include, for example, malaria, mycobacterialinfection and meningitis. These also include viral infections, such asHIV, influenza virus, and herpes virus, including herpes simplex virustype-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus(CMV), varicella-zoster virus (VZV), Epstein-Barr virus, human herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV7), human herpesvirus-8(HHV-8), pseudorabies and rhinotracheitis, among others.

Thus, in another aspect, the present invention provides the use of acompound or salt thereof of the present invention for the treatment ofdiseases or conditions which benefit from inhibition of p38 MAP kinaseactivity. The treatment of obstructive or inflammatory airways diseasesis a preferred use. All forms of obstructive or inflammatory airwaysdiseases are potentially treatable with the compounds of the presentinvention, in particular an obstructive or inflammatory airways diseasethat is a member selected from the group consisting of chroniceosinophilic pneumonia, asthma, COPD, COPD that includes chronicbronchitis, pulmonary emphysema or dyspnea associated or not associatedwith COPD, COPD that is characterized by irreversible, progressiveairways obstruction, adult respiratory distress syndrome (ARDS),exacerbation of airways hyper-reactivity consequent to other drugtherapy and airways disease that is associated with pulmonaryhypertension, chronic inflammatory diseases including cystic fibrosis,broncietasis and pulmonary fibrosis (Idiopathic). Efficacy isanticipated when p38 kinase inhibitors are administered either locallyto the lung (for example by inhalation and intranasal delivery) or viasystemic routes (for example, oral, intravenous and subcutaneousdelivery).

BRIEF DESCRIPTION OF THE DRAWINGS

A more complete appreciation of the invention and many of the attendantadvantages thereof will be readily obtained as the same become betterunderstood by reference to the following detailed description whenconsidered in connection with the accompanying drawings, wherein:

FIG. 1 is s a graph that illustrates the effect of intranasaladministration to laboratory mice with vehicle (0.2% tween 80 insaline), Example 5 (3 μg/kg), Example 5 (30 μg/kg) or Example 5 (100μg/kg) on the number of BAL cells induced by tobacco smoke 24 hours postthe final exposure.

FIG. 2 is a graph that illustrates the effect of intranasaladministration to laboratory mice with vehicle (0.2% tween 80 insaline), Example 5 (3 μg/kg), Example 5 (30 μg/kg) or Example 5 (100μg/kg) on the number of BAL neutrophils induced by tobacco smoke 24hours post the final exposure.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein, the terms “halogen” or “halo” include fluorine,chlorine, bromine, and iodine atoms.

As used herein, the term “C_(x)-C_(y)alkyl” wherein x and y areintegers, refers to a straight or branched chain alkyl radical havingfrom x to y carbon atoms. Thus when x is 1 and y is 6, for example, theterm includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein, the term “C_(x)-C_(y)haloalkyl” refers to the above“C_(x)-C_(y)alkyl” group wherein one or more hydrogen atoms are replacedby one or more halogen atoms.

As used herein, the term “C_(x)-C_(y)hydroxyalkyl” refers to the above“C_(x)-C_(y)alkyl” group wherein one hydrogen atom is replaced by onehydroxyl group.

As used herein, the term “C_(x)-C_(y)alkylene” wherein x and y areintegers, refers to a C_(x)-C_(y)alkyl radical having in total twounsatisfied valencies, such as a divalent methylene radical.

As used herein, the term “carbocyclic” refers to a mono-, bi-, ortricyclic radical having up to 16 ring atoms, all of which are carbon,and includes aryl and cycloalkyl.

As used herein, the term “C_(z)-C_(k)cycloalkyl” wherein z and k areintegers refers to a monocyclic saturated carbocyclic radical havingfrom z to k carbon atoms and includes, for example, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cyclohepty, and cyclooctyl.Comprised within the scope of the term “C_(z)-C_(k)cycloalkyl” are thoseradicals having two unsatisfied valencies on the same carbon atom whichwill link to any C_(x)-C_(y)alkyl, C_(x)-C_(y)alkyleneC_(z)-C_(k)cycloalkyl C_(z)-C_(k)cycloalkylene,C_(z)-C_(k)heterocycloalkyl,C_(z)-C_(k)heterocycloalkylC_(x)-C_(y)alkyl,C_(z)-C_(k)heterocycloalkylC_(z)-C_(k)cycloalkyl or(C_(z)-C_(k))heterocycloalkylcarbonyl group by replacement of twohydrogen atoms placed on the same carbon. In such circumstances, thisradical forms a gem-disubstituted or spiro system together with theC_(x)-C_(y)alkyl, C_(x)-C_(y)alkylene C_(z)-C_(k)cycloalkylC_(z)-C_(k)cycloalkylene, C_(z)-C_(k)heterocycloalkyl,C_(z)-C_(k)heterocycloalkylC_(x)-C_(y)alkyl,C_(z)-C_(k)heterocycloalkylC_(z)-C_(k)cycloalkyl or(C_(z)-C_(k))heterocycloalkylcarbonyl group it is linked to.

The term “C_(z)-C_(k)cycloalkylene radical” refers to aC_(z)-C_(k)cycloalkyl radical having two unsatisfied valencies ondifferent cycle carbon atoms as follows:

As used herein, the unqualified term “aryl” refers to a mono- orbi-cyclic carbocyclic aromatic radical, and includes radicals having twomonocyclic carbocyclic aromatic rings which are directly linked by acovalent bond. Illustrative of such radicals are phenyl, biphenyl andnapthyl.

As used herein, the unqualified term “heteroaryl” refers to a mono- orbi-cyclic aromatic radical containing one or more heteroatoms selectedfrom S, N, and O, and includes radicals having two such monocyclicrings, or one such monocyclic ring and one monocyclic aryl ring, whichare fused through a common bond. Illustrative examples of 5,6-memberedheteroaryl are: are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl,isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl,thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl,pyrazinyl, and triazinyl. Illustrative examples of 8,10-memberedheteroaryl are: benzothienyl, benzofuryl, benzimidazolyl,benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl,benzotriazolyl, indolyl and indazolyl.

As used herein, the unqualified term “heterocyclyl” or “heterocyclic”relates to a saturated mono-, bi-, or tri-cyclic non-aromatic radicalcontaining one or more heteroatoms selected from S, N, and O. In thecase of bicyclic heterocylic systems, included within the scope of theterm are fused, spiro and bridged bicyclic systems. In particular, theterm “C_(z)-C_(k)heterocycloalkyl” refers to monocyclic(C_(z)-C_(k))cycloalkyl groups, in which at least one ring carbon atomis replaced by a heteroatom (e.g. N, NH, S, or O). Examples of(C_(z)-C_(k))heterocycloalkyl include pyrrolidinyl, thiazolidinyl,piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl.

By analogy, the term “C_(z)-C_(k)heterocycloalkylene”, refers to adivalent C_(z)-C_(k)heterocycloalkyl radical, whereinC_(z)-C_(k)heterocycloalkyl is as above defined.

The term “C_(z)-C_(k)heterocycloalkylC_(x)-C_(y)alkyl” refers to theabove “C_(x)-C_(y)alkyl” group wherein one or more hydrogen atoms arereplaced by one or more “C_(z)-C_(k)heterocycloalkyl” groups. Comprisedwithin the scope of the term“C_(z)-C_(k)heterocycloalkylC_(x)-C_(y)alkyl” are systems where twohydrogen atoms linked to the same carbon atom in “C_(x)-C_(y)alkyl”group are replaced by one “C_(z)-C_(k)heterocycloalkyl” group. Suchradical thus form a gem-disubstituted“C_(z)-C_(k)heterocycloalkylC_(x)-C_(y)alkyl” system, such as a1,2-dimethyl-pyrrolidin-2-yl radical.

The term “C_(z)-C_(k)heterocycloalkylC_(z)-C_(k)cycloalkyl” refers tothe above “C_(z)-C_(k)cycloalkyl” group wherein one or more hydrogenatoms are replaced by one or more “C_(z)-C_(k)heterocycloalkyl” groups.

The expression “(C_(z)-C_(k))cycloalkylcarbonyl” refers to(C_(z)-C_(k))cycloalkyl-CO— groups wherein the group“(C_(z)-C_(k))cycloalkyl” has the meaning above defined.

The expression “(C_(z)-C_(k))heterocycloalkylcarbonyl” refers to(C_(z)-C_(k))heterocycloalkyl-CO— groups wherein the group“(C_(z)-C_(k))heterocycloalkyl” has the meaning above defined.

Compounds of the invention may exist in one or more geometrical,optical, enantiomeric, diastereomeric, and tautomeric forms, includingbut not limited to cis- and trans-forms, E- and Z-forms, R-, S- andmeso-forms, keto-, and enol-forms. Unless otherwise stated a referenceto a particular compound includes all such isomeric forms, includingracemic and other mixtures thereof. Where appropriate such isomers canbe separated from their mixtures by the application or adaptation ofknown methods (e.g. chromatographic techniques and recrystallisationtechniques). Where appropriate such isomers may be prepared by theapplication of adaptation of known methods (e.g. asymmetric synthesis).

Throughout the specification the use of an asterisk “*” in thedefinition of a structural formula, indicates the point of attachmentfor the radical group to the rest of the molecule.

As used herein the term “salt” includes base addition, acid addition andammonium salts. As briefly mentioned above compounds of the inventionwhich are acidic can form salts, including pharmaceutically acceptablesalts, with bases such as alkaline metal hydroxides, e.g. sodium andpotassium hydroxides; alkaline earth metal hydroxides e.g. calcium,barium and magnesium hydroxides; with organic bases e.g.N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane,L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.Those compounds of the invention which are basic can form salts,including pharmaceutically acceptable salts with inorganic acids, e.g.with hydrohalic acids such as hydrochloric or hydrobromic acids,sulphuric acid, nitric acid or phosphoric acid and the like, and withorganic acids e.g. with acetic, formic, trifluoroacetic, tartaric,succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic,p-toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, andmandelic acids and the like. Those compounds (I) which have a basicnitrogen can also form quaternary ammonium salts with a pharmaceuticallyacceptable counter-ion such as ammonium, chloride, bromide, acetate,formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene-bissulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.For a review on salts, see Handbook of Pharmaceutical Salts: Properties,Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany,2002), which is incorporated herein by reference in its entirety.

It is expected that compounds of the present invention may be preparedin the form of hydrates, and solvates. Any reference herein, includingthe claims herein, to “compounds with which the invention is concerned”or “compounds of the invention” or “the present compounds”, and thelike, includes reference to salts hydrates, and solvates of suchcompounds. The term ‘solvate’ is used herein to describe a molecularcomplex comprising the compound of the invention and a stoichiometricamount of one or more pharmaceutically acceptable solvent molecules, forexample, ethanol. The term ‘hydrate’ is employed when said solvent iswater.

Individual compounds of the present invention may exist in severalpolymorphic forms and may be obtained in different crystal or co-crystalhabits, and they are intended to be included within the meaning of theterm “compounds of the invention”.

The compounds may also be administered in the form of prodrugs thereof.Thus, certain derivatives of the present compounds which may be activein their own right or may have little or no pharmacological activitythemselves can, when administered into or onto the body, be convertedinto compounds of the invention having the desired activity, forexample, by hydrolytic cleavage. Such derivatives are referred to as‘prodrugs’. Further information on the use of prodrugs may be found inPro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T.Higuchi and V. J. Stella) and Bioreversible Carriers in Drug Design,Pergamon Press, 1987 (ed. E. B. Roche, American PharmaceuticalAssociation; C. S. Larsen and J. Østergaard, Design and application ofprodrugs, In Textbook of Drug Design and Discovery, 3^(rd) Edition,2002, Taylor and Francis, which are incorporated herein by reference intheir entireties).

Prodrugs in accordance with the present invention can, for example, beproduced by replacing appropriate functionalities present in thecompounds of formula (I) with certain moieties known to those skilled inthe art as ‘pro-moieties’ as described, for example, in Design ofProdrugs by H. Bundgaard (Elsevier, 1985), which is incorporated hereinby reference in its entirety. Such examples could be a prodrug of acarboxyl group (such as CO—O—CH₂—O—CO-tBu as used in the pivampicillinprodrug of ampicillin), an amide (—CO—NH—CH₂—NAlk₂) or an amidine(C(═N—O—CH₃)—NH₂).

It is to be understood that all preferred groups or embodimentsdescribed herebelow for compounds of formula (I) may be combined amongeach other and apply as well to compounds of formula (Ia), (Ib), (Ic),(IA), (IB), (IC), (ID), (IE) or (IF) as below defined mutatis mutandis.

In one embodiment, compounds of formula (Ia) are provided, which arecompounds of formula (I) as above defined wherein the carbon stereogeniccenter on the cycloalkylene portion of ring A which is linked to group Wand identified with number (1) herebelow, possess the absoluteconfiguration herebelow represented:

In another embodiment, compounds of formula (Ib) are provided, which arecompounds of formula (I) as above defined wherein the carbon stereogeniccenters on the cycloalkylene portion of ring A which are linked to groupW and Y and identified, respectively, with numbers (1) and (2)herebelow, possess the absolute configuration herebelow represented:

In a further embodiment, compounds of formula (Ic) are provided, whichare compounds of formula (I) as above defined wherein the carbonstereogenic centers on the cycloalkylene portion of ring A which arelinked to group W and Y and identified, respectively, with numbers (1)and (2) herebelow, possess the absolute configuration herebelowrepresented:

In one embodiment, W is NH or O. In a further embodiment, W is NH.

In one embodiment, Y is a group —S(O)_(p)—, a group —O(CR³R⁴)_(n)—, agroup —(CR⁵R⁶)_(n)—, or a group —NR⁷—; p is zero and n is 0, 1 or 2. Inanother embodiment, Y is a group —S(O)_(p)— or a group —O(CR³R⁴)_(n) or;p is zero and n is 0 or 1.

In a further embodiment, Y is a group —O(CR³R⁴)_(n)— and n is 0.

In one embodiment, R³, R⁴, R⁵ and R⁶ are each independently hydrogen,fluorine, or C₁-C₆ alkyl. In another embodiment, R³, R⁴, R⁵ and R⁶ arehydrogen.

In one embodiment, R⁷ is hydrogen, C₁-C₆ alkyl, or C₃-C₇ cycloalkyl.

In one embodiment, R⁷ is hydrogen.

In one embodiment, A is a divalent cycloalkylene radical having 5 or 6ring atoms; said cycloalkylene ring being attached to W and Y, and fusedto a phenyl ring or to a monocyclic heteroaryl ring having 5 or 6 ringatoms, such phenyl or heteroaryl ring being optionally substituted byone or two groups R²⁴.

In a further embodiment, A is group selected in the group consisting of:

In a still further embodiment, A is group:

In an additional embodiment, A is group:

In one embodiment, R²⁴ is not present or, if present, is at eachoccurrence independently selected from the group consisting of: C₁-C₂alkyl, —F, —Cl and cyano; in a further embodiment, R²⁴ is not presentor, if present, is at each occurrence independently Methyl or —F. In afurther embodiment, R²⁴ is not present.

In one embodiment, R¹ is a group of formula (IIa):

In a further embodiment, R¹ is a group of formula (IIa):

and R⁸ and R⁹ form, together with the nitrogen atom to which they areattached, a 5-11-membered saturated monocyclic or a fused or spirobicyclic ring system optionally containing a further heteroatom which isoxygen or nitrogen, said nitrogen atom being optionally substituted byC₁-C₆ alkyl; wherein such C₁-C₆ alkyl groups may be optionallysubstituted by a group C₁-C₆ alkyl, C₃-C₆ cycloalkyl, hydroxyl or halo.

In an additional embodiment, R¹ is a group of formula (IIa):

and R⁸ and R⁹ form, together with the nitrogen atom to which they areattached, a 5 to 7-membered saturated monocyclic ring system optionallycontaining a further heteroatom which is oxygen or nitrogen, saidnitrogen atom being optionally substituted by C₁-C₆ alkyl. In a stillfurther embodiment, such saturated monocyclic ring system is amorpholine ring.

In another embodiment, R¹ is a group of formula (IIb):

In one embodiment, X¹ is a group —(CH)— or a nitrogen atom. In anotherembodiment, X¹ is a group —(CH)—.

In one embodiment, R¹⁰ is selected from a group consisting of: —CN,—C(O)N(R^(A)R^(B)), and —N(R^(C))C(O)R^(C).

In one embodiment, R¹² is hydrogen, C₁-C₆ alkyl, or halogen.

In a further embodiment, R¹ is a group of formula (IIb):

wherein X¹ is a group —(CH)—, R¹⁰ is selected from a group consistingof: —CN, —C(O)N(R^(A)R^(B)), and —N(R^(C))C(O)R^(C); and R¹² ishydrogen.In a further embodiment, R¹ is a group of formula (IIc):

In one embodiment, the group (IIc) is a group of formula (IIca) or(IIcb) which is connected to the group Y through one of the carbons asbelow indicated:

In another embodiment, the group (IIc) is a group of formula (IIca) asabove defined which is connected to the group Y through the carbonadjacent to X₂

In one embodiment, X⁴ is a carbon atom.

In one embodiment, X⁵ is a nitrogen atom.

In another embodiment, X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ isa nitrogen atom, and X² is nitrogen.

In another embodiment, X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ isa nitrogen atom, and X² is group —CH—.

In another embodiment, X⁴ is a nitrogen atom, X⁵ is a group —CH— atom,X³ is a carbon atom, and X² is group —CH—.

In one embodiment, R¹³ is hydrogen, C₁-C₆ alkyl, or halogen.

In a further embodiment, the group (IIc) is a group of formula (IIca) asabove defined which is connected to the group Y through the carbonadjacent to X₂

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom, and X² is a group —CH—, and R¹³ is hydrogen.

In one embodiment, R¹¹ is selected from a group consisting of:—NR^(A)R^(B), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl),—(C₃-C₇heterocycloalkyl), wherein any of such(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) or —(C₃-C₇heterocycloalkyl) may beoptionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,hydroxyl or halo.

In another embodiment, R¹¹ is selected from a group consisting of:—NR^(A)R^(B), —(C₁-C₆alkylene)-NR^(A)R^(B),(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), —(C₃-C₇heterocycloalkyl), whereinany of such (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) or—(C₃-C₇heterocycloalkyl) may be optionally substituted by one, two orthree groups R²⁵ which are independently selected in the list consistingof: C₁-C₆ alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇cycloalkyl, hydroxyl and halo.

In another embodiment, R¹¹ is Phenyl or 5- or 6-membered monocyclicheteroaryl which is substituted by a group selected from:(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), —(C₃-C₇heterocycloalkyl), whereinany of such (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) or—(C₃-C₇heterocycloalkyl) may be optionally substituted by a group C₁-C₆alkyl, C₃-C₇ cycloalkyl, hydroxyl or halo.

In another embodiment, R¹¹ is Phenyl or 5- or 6-membered monocyclicheteroaryl which is substituted by (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl)or —(C₃-C₇heterocycloalkyl), wherein any(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), —(C₃-C₇heterocycloalkyl), may beoptionally substituted by one, two or three groups R²⁵ which areindependently selected in the list consisting of: C₁-C₆ alkyl, (C₁-C₃)haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl, hydroxyl and halo.

In one embodiment, R²⁵ is one, two or three groups independentlyselected from the group consisting of C₁-C₆ alkyl, (C₁-C₃) haloalkyl,(C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl, hydroxyl, and halo.

In one embodiment, R^(A) and R^(B) are at each occurrence independentlyhydrogen, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇cycloalkyl being optionally substituted by a group C₁-C₃ alkyl,C₃-C₇cycloalkyl, OR^(D), CN or halo.

In another embodiment, R^(A) and R^(B) form together with the nitrogenatom to which they are attached a 5-11-membered saturated monocyclic orbicyclic heterocyclic ring system which is optionally substituted by oneor more group —OR^(D), CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, suchC₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by a groupC₁-C₃ alkyl, C₃-C₇cycloalkyl, —OR^(D), —CN, or halo.

In a still further embodiment, R^(A) and R^(B) form together with thenitrogen atom to which they are attached a 5-11-membered saturatedmonocyclic or bicyclic heterocyclic ring system which is optionallysubstituted by one or more group —OR^(D), —CN, halo, C₁-C₆ alkyl orC₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionallysubstituted by a group C₁-C₃ alkyl, C₃-C₇cycloalkyl, —OR^(D), —CN, orhalo; and which 5-11-membered saturated monocyclic or bicyclicheterocyclic ring contains a further heteroatom which is oxygen ornitrogen, said nitrogen atom optionally substituted by C₁-C₆ alkyl orC₃-C₆ cycloalkyl, wherein any of such C₁-C₆ alkyl or C₃-C₆ cycloalkylmay be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl,OR^(D), CN, or halo.

In one embodiment, R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴.

In further embodiment, R¹¹ is a group:

wherein R²⁵ represents one or two C₁-C₆ alkyl substituents; and whereinthe asterisk represents the point of attachment for group R¹¹ to therest of the molecule via X⁴.

In one embodiment, R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl, and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴.

In a further embodiment, R¹¹ is a group:

wherein R²⁵ represents one, two, or three substituents independentlyselected from the group consisting of: C₁-C₆ alkyl, (C₁-C₃) haloalkyl,(C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl, hydroxyl, and halo; and whereinthe asterisk represents the point of attachment for group R¹¹ to therest of the molecule via X⁴.

In a further embodiment, R¹¹ is a group:

wherein R²⁵ represents one or two C₁-C₆ alkyl substituents; and whereinthe asterisk represents the point of attachment for group R¹¹ to therest of the molecule via X⁴.

In a further embodiment, R¹¹ is a group:

wherein the asterisk represents the point of attachment for group R¹¹ tothe rest of the molecule via X⁴.

In a further embodiment, R¹¹ is a group:

wherein the asterisk represents the point of attachment for group R¹¹ tothe rest of the molecule via X⁴.

In a still further embodiment, R¹¹ is a group:

wherein the asterisk represents the point of attachment for group R¹¹ tothe rest of the molecule via X⁴.

In one embodiment, R² is a radical of formula (IIIa):

In one embodiment, R¹⁴ is selected from the group consisting of —CH₃,—CH₂OH, or —CH₂SCH₃; in another embodiment, R¹⁴ is —CH₃.

In one embodiment, R¹⁵ and R¹⁶ are independently —CH₃ or —C₂H₅; inanother embodiment, R¹⁵ and R¹⁶ are —CH₃.

In another embodiment, R² is a radical of formula (IIIa):

R¹⁴ is —CH₃, and R¹⁵ and R¹⁶ are —CH₃.

In another embodiment, R² is a radical of formula (IIIb):

In one embodiment, R¹⁷ is selected from the group consisting of loneelectron pair, hydrogen, —CF₃, —NR^(E)R^(F), —(C₃-C₆cycloalkyl),—(C₄-C₆heterocycloalkyl), aryl, and heteroaryl wherein any of such—(C₃-C₆cycloalkyl), —(C₄-C₆heterocycloalkyl), aryl or heteroaryl may beoptionally substituted by a group methyl, isopropyl or halo. In anotherembodiment, R¹⁷ is selected from the group consisting of lone electronpair, hydrogen, —CF₃, morpholine, cyclohexyl, phenyl or pyridyl.

In another embodiment, R¹⁷ is a group of general formula (IV)

In one embodiment, R²⁰ is selected from the group consisting of F, —CH₃;—CH₂OH, —CH₂OMe, —CH₂SCH₃; in another embodiment, R²⁰ is selected fromthe group consisting of —CH₃; —CH₂OH, —CH₂OMe. In another embodiment,R²⁰ is —CH₃.

In one embodiment, R²¹ is —CH₃.

In another embodiment, R²⁰ and R²¹ as defined above may form, togetherwith the carbon atom to which they are attached, a cyclohexane orcyclopropyl ring; in a further embodiment, R²⁰ and R²¹ as defined abovemay form, together with the carbon atom to which they are attached, acyclopropyl ring.

In one embodiment, R¹⁸ is phenyl or heteroaryl which is optionallysubstituted by a group —CN, —OH, halo, —COOR^(M), C₁-C₆alkyl,C₃-C₆cycloalkyl, —O—(C₁-C₆alkyl), —O—(C₃-C₆cycloalkyl), —S—(C₁-C₆alkyl),—S—(C₃-C₆cycloalkyl), —NR^(H)R^(J),—N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—N(R^(L))(C₃-C₇cycloalkylene)-NR^(H)R^(J), —(C₁-C₆alkylene)-NR^(H)R^(J),—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —S—(C₂-C₆alkylene)-NR^(H)R^(J),—S—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—N(R^(L))C(O)—(C₁-C₆alkylene)-NR^(H)R^(J),—N(R^(L))C(O)—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—C(O)N(R^(L))—(C₂-C₆alkylene)-OR^(M),—C(O)N(R^(L))—(C₃-C₇cycloalkylene)-OR^(M), —N(R^(L))C(O)N(R^(H)R^(J)),—C(O)N(R^(H)R^(J)), —N(R^(L))C(O)N(R^(L))—(C₂-C₆alkylene)-R^(H)R^(J),—N(R^(L))C(O)N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—O—(C₂-C₆alkylene)-OR^(M), —O—(C₃-C₇cycloalkylene)-OR^(M),—S—(C₂-C₆alkylene)-OR^(M), —S—(C₃-C₇cycloalkylene)-OR^(M),—N(R^(L))S(O)₂—(C₁-C₆alkylene)-NR^(H)R^(J),—N(R^(L))S(O)₂—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₂-C₆alkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₃-C₇cycloalkylene)-NR^(H)R^(J),—S(O)₂N(R^(L))—(C₂-C₆alkylene)-OR^(M),—S(O)₂N(R^(L))—(C₃-C₇cycloalkylene)-OR^(M),—N(R^(L))S(O)₂—(C₂-C₆alkylene)-OR^(M),—N(R^(L))S(O)₂—(C₃-C₇cycloalkylene)-OR^(M), —S(O)₂N(R^(H)R^(J)),—N(R^(L))S(O)₂R^(L), —N(R^(L))C(O)R^(L), OR^(L), SR^(L),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and(C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such alkyl,cycloalkyl, alkylene, cycloalkylene, heterocycloalkyl,heterocycloalkyl-(C₁-C₆ alkyl), heterocycloalkyl)-(C₃-C₆ cycloalkyl) andheterocycloalkylcarbonyl may be optionally substituted by a group C₁-C₆alkyl, C₃-C₇ cycloalkyl, —OR^(L) or halo. In a further embodiment, R¹⁸is phenyl substituted by —(C₁-C₆alkyl).

In one embodiment, R¹⁸ is —(C₁-C₆alkyl) or —(C₃-C₇cycloalkyl).

In one embodiment, z¹=—CH—, z²=C, z³ and z⁴ are N; in anotherembodiment, z¹=O, z²=C, z³ and z⁴ are N; in a further embodiment,z¹=—CH—, z² and z³ are N, and z⁴ is —CH—; in an additional embodiment,z¹=N, z² is C, z³ is N and z⁴ is O; in a still further embodiment, z¹=N,z² is C, z³ is O and z⁴ is N.

In an additional embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ is oxygen, z⁴ is N, R¹⁸ is a lone pair, andR¹⁷ is a group of general formula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃.

In a further embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃.

In another embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and wherein R¹⁸ isphenyl, which may be optionally substituted by a group —CN, —OH,—COOR^(M), C₁-C₆alkyl, —N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—(C₁-C₆alkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₂-C₆alkylene)-OR^(M), —S—(C₂-C₆alkylene)-OR^(M),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such C₁-C₆alkyl,—(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-, (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and (C₅-C₇ heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionallysubstituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(L) or halo.

In a further embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is phenyl, whichis substituted in the para position by a group C₁-C₆alkyl.

In an additional embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is phenyl, whichis substituted in the meta position by a group—O—(C₂-C₆alkylene)-NR^(H)R^(J) or —(C₁-C₆alkylene)-NR^(H)R^(J).

In another embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is a 5 or6-membered heteroaryl which is optionally substituted by C₁-C₆alkyl,—N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J), or —(C₁-C₆alkylene)-NR^(H)R^(J),wherein any of such C₁-C₆alkyl, —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-,(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionally substituted by agroup C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(L) or halo. In one embodiment,for such compounds, R¹⁸ is an imidazole ring which is optionallysubstituted by C₁-C₆alkyl, —N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J), or—(C₁-C₆alkylene)-NR^(H)R^(J).

In another embodiment, R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is a group—(C₁-C₆alkyl), optionally substituted by a group OH or —NR^(H)R^(J), ora group (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) which may be optionallysubstituted by a group C₁-C₆ alkyl.

In a further embodiment, R² is a radical of formula (IIIc):

In one embodiment, R¹⁹ is selected from the group consisting ofhydrogen, —CF₃, —NR^(E)R^(F), —(C₃-C₆cycloalkyl),—(C₃-C₆heterocycloalkyl), aryl, and heteroaryl wherein any of suchcycloalkyl, heterocycloalkyl, aryl or heteroaryl may be optionallysubstituted by a group C₁-C₂ alkyl, C₃-C₅ cycloalkyl, or halo. Inanother embodiment, R¹⁹ is selected from the group consisting ofhydrogen, —CF₃, morpholine, cyclohexyl, phenyl or pyridyl wherein any ofsuch morpholine, cyclohexyl, phenyl or pyridyl may be optionallysubstituted by a group methyl, —F or —Cl.

In another embodiment, R¹⁹ is a group of general formula (V)

In one embodiment, T is —N═. In another embodiment, T is —CR²³═.

In one embodiment, R²² is H, F, —Cl, —CH₃, or —CN; in anotherembodiment, R²² is H or F.

In one embodiment, R²³ is H, F, —Cl, —CH₃, or —CN; in anotherembodiment, R²³ is —Cl.

In another embodiment, R² is a radical of formula (IIIc):

wherein R¹⁹ is —(C₃-C₆heterocycloalkyl), which is optionally substitutedby a group C₁-C₂ alkyl, C₃-C₅ cycloalkyl, or halo; wherein T is —CR²³═,R²² is H or F.

In a still further embodiment, R² is a radical of formula (IIId):

In one embodiment, q is 0, 1 or 2; in another embodiment, q is 0 or 1.In a further embodiment, q is zero.

In one embodiment, compounds of formula (IA) are provided wherein W isNH, Y is a group —O(CR³R⁴)_(n)— and n is 0, A is group:

wherein R¹ is a group of formula (IIca) as above defined which isconnected to the group Y through the carbon adjacent to X²

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom and X² is a group —CH—, and R¹³ is hydrogen;

wherein R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl, and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴;

wherein R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and wherein R¹⁸ isphenyl, which may be optionally substituted by a group —CN, —OH,—COOR^(M), C₁-C₆alkyl, —N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—(C₁-C₆alkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₂-C₆alkylene)-OR^(M), —S—(C₂-C₆alkylene)-OR^(M),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such C₁-C₆alkyl,—(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-, (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and (C₅-C₇ heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionallysubstituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(L) or halo.

In one embodiment, compounds of formula (IB) are provided wherein W isNH, Y is a group —O(CR³R⁴)_(n)— and n is 0, A is group:

wherein R¹ is a group of formula (IIca) as above defined which isconnected to the group Y through the carbon adjacent to X²

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom and X² is a group —CH—, and R¹³ is hydrogen;

wherein R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two or threesubstituents independently selected in the list consisting of: C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴; wherein R²is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and wherein R¹⁸ isphenyl, which may be optionally substituted by a group —CN, —OH,—COOR^(M), C₁-C₆alkyl, —N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—(C₁-C₆alkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₂-C₆alkylene)-OR^(M), —S—(C₂-C₆alkylene)-OR^(M),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl), and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such wherein any ofsuch C₁-C₆alkyl, —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-,(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionally substituted by agroup C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(L) or halo.

In one embodiment, compounds of formula (IC) are provided wherein W isNH, Y is a group —O(CR³R⁴)_(n)— and n is 0, A is group:

wherein R¹ is a group of formula (IIca) as above defined which isconnected to the group Y through the carbon adjacent to X²

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom and X² is a group —CH—, and R¹³ is hydrogen;R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl, and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴;

R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is a 5 or6-membered heteroaryl, which is optionally substituted by C₁-C₆alkyl,—N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J), or —(C₁-C₆alkylene)-NR^(H)R^(J),wherein any of such C₁-C₆alkyl, —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-,(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionally substituted by agroup C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(L) or halo.

In one embodiment, compounds of formula (ID) are provided wherein W isNH, Y is a group —O(CR³R⁴)_(n)— and n is 0, A is group:

R1 is a group of formula (IIca) as above defined which is connected tothe group Y through the carbon adjacent to X₂

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom and X² is a group —CH—, and R¹³ is hydrogen;wherein R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected in the list consisting of: C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴;

wherein R² is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is a 5 or6-membered heteroaryl, which is optionally substituted by C₁-C₆alkyl,—N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J), or —(C₁-C₆alkylene)-NR^(H)R^(J),wherein any of such C₁-C₆alkyl, —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)-,(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionally substituted by agroup C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(L) or halo.

In one embodiment, compounds of formula (IE) are provided wherein W isNH, Y is a group —O(CR³R⁴)_(n)— and n is 0, A is group:

wherein R1 is a group of formula (IIca) as above defined which isconnected to the group Y through the carbon adjacent to X₂

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom and X² is a group —CH—, and R¹³ is hydrogen;wherein R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected in the list consisting of: C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴; wherein R²is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is a group—(C₁-C₆alkyl), optionally substituted by a group OH or —NR^(H)R^(J), ora group (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) which may be optionallysubstituted by a group C₁-C₆ alkyl.

In one embodiment, compounds of formula (IF) are provided wherein W isNH, Y is a group —O(CR³R⁴)_(n)— and n is 0, A is group:

wherein R¹ is a group of formula (IIca) as above defined which isconnected to the group Y through the carbon adjacent to X₂

and wherein X⁴ is a carbon atom, X⁵ is a nitrogen atom, X³ is a nitrogenatom and X² is a group —CH—, and R¹³ is hydrogen;wherein R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected in the list consisting of: C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴; wherein R²is a radical of formula (IIIb):

wherein z¹=—CH—, z²=C, z³ and z⁴ are N and R¹⁷ is a group of generalformula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃ and R¹⁸ is a group—(C₁-C₆alkyl), optionally substituted by a group OH or —NR^(H)R^(J), ora group (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) which may be optionallysubstituted by a group C₁-C₆ alkyl.

In one embodiment, a compound of formula (I) is selected from the groupconsisting of:

-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((S)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperazin-1-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-isopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(6-cyano-pyridin-3-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   N-(4-{(1S,4S)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-pyridin-2-yl)-2-methoxy-acetamide;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[1-(2-hydroxy-ethyl)-1H-indazol-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((R)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   N-(4-{(1R,4S)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-pyridin-2-yl)-2-methoxy-acetamide;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-morpholin-4-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[6-(morpholine-4-carbonyl)-pyridin-3-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(6-morpholin-4-ylmethyl-pyridin-3-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-piperidin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[1-(2,2-difluoro-ethyl)-piperidin-4-ylmethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-(4-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-{3-[(2-hydroxy-ethyl)-methyl-amino]-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   3-[3-tert-Butyl-5-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzoic    acid ethyl ester;-   1-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(2-morpholin-4-yl-ethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea;-   1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(2-hydroxy-ethylsulfanyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-(2-Hydroxy-1,1-dimethyl-ethyl)-2-p-tolyl-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,3S)-3-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-indan-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(2-dimethylamino-ethyl)-methyl-amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-[5-tert-Butyl-2-(3-piperidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[methyl-(2-morpholin-4-yl-ethyl)-amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,2-dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxymethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-[1,4]oxazepan-4-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-{3-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-phenyl}-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]urea;-   1-(2-tert-Butyl-5-p-tolyl-3H-imidazol-4-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(4-hydroxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(2-hydroxy-ethylsulfanyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4S)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-hydroxymethyl-4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(4-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-dimethylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-ethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxyethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[(1S,4R)-4-(3-Azepan-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazine-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-[1,4]diazepan-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea;-   1-[5-tert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[5-tert-Butyl-2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4S)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(1-hydroxy-1-methyl-ethyl)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-1-methyl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxy-4-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-1-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-4-methyl-morpholin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(S)-1-(3-hydroxy-propyl)-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1,4-dimethyl-piperazin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,4,4-trimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-pyrrolidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,4R)-4-fluoro-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-(cis-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-cyclopentyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[(1S,4R)-4-(3-Amino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea;-   1-[5-tert-Butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   N-(5-tert-Butyl-2-methoxy-3-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;-   1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[8-methyl-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-(3-tert-Butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   N-[5-tert-Butyl-2-methoxy-3-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;-   1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-isoxazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[3-tert-Butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[3-tert-Butyl-1′-(3-dimethylamino-propyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[3-tert-Butyl-1′-(3-morpholin-4-yl-propyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-{(1S,4R)-4-[3-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-(3-fluoro-5-morpholin-4-yl-phenyl)-urea;-   1-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-Cyclopropyl-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[1′-(2-dimethylamino-ethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;-   1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{(1S,4R)-4-[3-(8-Aza-bicyclo[3.2.1]oct-8-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((R)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[3-tert-Butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;-   1-[5-tert-Butyl-2-(2-dimethylamino-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(2-piperidin-1-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[2-(4-methyl-piperazin-1-yl)-ethyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-morpholin-4-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(ethyl-methyl-amino)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-piperidin-1-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-[1,4]oxazepan-4-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(4-methyl-[1,4]diazepan-1-yl)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-pyrrolidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(ethyl-methyl-amino)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-urea;-   1-[5-tert-Butyl-2-(3-morpholin-4-yl-methyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[(2-dimethylamino-ethyl)-methyl-amino]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-((R)-2-dimethylamino-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-((S)-2-dimethylamino-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[2-[3-(2-Dimethylamino-ethoxy)-phenyl]-5-(2-hydroxy-1,1-dimethyl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-diethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-piperidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-{3-[2-(4-fluoropiperidin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(4-methyl-[1,4]-diazepan-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-[1,4]oxazepan-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(2-{3-[2-(8-Aza-bicyclo[3.2.1]oct-8-yl)-ethoxy]-phenyl}-5-tert-butyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(ethyl-methyl-amino)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-(3-{2-[(2-methoxy-ethyl)-methyl-amino]-ethoxy}-phenyl}-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(4-methoxy-piperidin-1-yl-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{3-[2-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(4-methoxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(4-fluoro-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-dimethylaminomethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(3-pyrrolidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-urea;-   1-[5-tert-Butyl-2-(3-piperidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-((1S,4S)-5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-aphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-dimethylaminomethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[4-(4-methoxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-pyrrolidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-piperidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[4-(4-fluoro-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-(5-tert-Butyl-2-{4-[(ethyl-methyl-amino)-methyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-[5-tert-Butyl-2-(4-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;-   1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4S)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]urea;    and pharmaceutically acceptable salts thereof.

According to another aspect of the present invention there is provided acompound of formula (J), or a pharmaceutically acceptable salt thereof:

wherein R², W, A and Y have the same meaning as provided above forcompounds of formula (I); and wherein

R¹ is a group (IIc) wherein R¹³, X², X³, X⁴ and X⁵ have the same meaningas provided above for compounds of formula (I);

and wherein R¹¹ is phenyl or 5- or 6-membered monocyclic heteroaryl,wherein such phenyl or 5- or 6-membered monocyclic heteroaryl issubstituted by a group —O—(C₂-C₆alkylene)-NR^(R)R^(S), wherein suchC₂-C₆alkylene may be optionally substituted by a group C₁-C₆alkyl,C₃-C₇cycloalkyl, hydroxyl or halo;

R^(R) and R^(S) are at each occurrence independently C₁-C₆ alkyl orC₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇ cycloalkyl beingsubstituted by one or more group OR^(T), CN, or halo; alternatively,R^(R) and R^(S), may form, together with the nitrogen atom to which theyare attached, a 5-11-membered saturated monocyclic or bicyclic ringsystem which is substituted by one or more group OR^(T), CN, halo, C₁-C₆alkyl, or C₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇ cycloalkyl beingoptionally substituted by a group C₁-C₃ alkyl, C₃-C₇cycloalkyl, OR^(D),CN, or halo; and which 5-11-membered saturated monocyclic or bicyclicring optionally contains a further heteroatom which is oxygen ornitrogen, said nitrogen atom optionally substituted by C₁-C₆ alkyl orC₃-C₆ cycloalkyl wherein any of such alkyl or cycloalkyl may beoptionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, OR^(D),CN, or halo; and

R^(T) is at each occurrence independently hydrogen, —CH₃, or —C₂H₅.

Where applicable, all preferred groups or embodiments describedherebelow for compounds of formula (I), (Ia), (Ib), and (Ic) may becombined among each other and apply as well to compounds of formula (J)as above defined mutatis mutandis.

Utility.

As mentioned above the compounds of the invention are p38MAPKinhibitors, and thus may have utility for the treatment of diseases orconditions which benefit from inhibition of the p38 enzyme. Suchdiseases and conditions are known from the literature and several havebeen mentioned above. However, the compounds are generally of use asanti-inflammatory agents, particularly for use in the treatment ofrespiratory disease. In particular, the compounds may be used in thetreatment of chronic obstructive pulmonary disease (COPD), chronicbronchitis, lung fibrosis, pneumonia, acute respiratory distresssyndrome (ARDS), pulmonary emphysema, or smoking-induced emphysema,intrinsic (non-allergic asthma and extrinsic (allergic) asthma, mildasthma, moderate asthma, severe asthma, steroid resistant asthma,neutrophilic asthma, bronchitic asthma, exercise induced asthma,occupational asthma and asthma induced following bacterial infection,cystic fibrosis, pulmonary fibrosis and bronchiectasis.

The present invention provides the use of the compounds of the inventionfor the prevention and/or treatment of any disease or condition whichbenefit from inhibition of the p38 enzyme.

In a further aspect the present invention provides the use of compoundsof the invention for the preparation of a medicament for the preventionand/or treatment of any disease or condition which benefit frominhibition of the p38 enzyme.

Moreover the present invention provides a method for prevention and/ortreatment of any disease which benefit from inhibition of the p38enzyme, said method comprises administering to a patient in need of suchtreatment a therapeutically effective amount of a compound of theinvention.

Compositions.

As mentioned above, the compounds with which the present invention isconcerned are p38 kinase inhibitors, and are useful in the treatment ofseveral diseases for example inflammatory diseases of the respiratorytract. Examples of such diseases are referred to above, and includeasthma, rhinitis, allergic airway syndrome, bronchitis and chronicobstructive pulmonary disease.

It will be understood that the specific dose level for any particularpatient will depend upon a variety of factors including the activity ofthe specific compound employed, the age, body weight, general health,sex, diet, time of administration, route of administration, rate ofexcretion, drug combination and the severity of the particular diseaseundergoing treatment. Optimum dose levels and frequency of dosing willbe determined by clinical trial, as is required in the pharmaceuticalart. In general, the daily dose range for oral administration will liewithin the range of from about 0.001 mg to about 100 mg per kg bodyweight of a human, often 0.01 mg to about 50 mg per kg, for example 0.1to 10 mg per kg, in single or divided doses. In general, the daily doserange for inhaled administration will lie within the range of from about0.1 μg to about 1 mg per kg body weight of a human, preferably 0.1 μg to50 μg per kg, in single or divided doses. On the other hand, it may benecessary to use dosages outside these limits in some cases. For thepurpose of the invention, inhaled administration is preferred.

The compounds with which the present invention is concerned may beprepared for administration by any route consistent with theirpharmacokinetic properties. Orally administrable compositions may be inthe form of tablets, capsules, powders, granules, lozenges, liquid orgel preparations, such as oral, topical, or sterile parenteral solutionsor suspensions. Tablets and capsules for oral administration may be inunit dose presentation form, and may contain conventional excipientssuch as binding agents, for example syrup, acacia, gelatin, sorbitol,tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose,sugar, maize-starch, calcium phosphate, sorbitol or glycine; tablettinglubricant, for example magnesium stearate, talc, polyethylene glycol orsilica; disintegrants for example potato starch, or acceptable wettingagents such as sodium lauryl sulfate. The tablets may be coatedaccording to methods well known in normal pharmaceutical practice. Oralliquid preparations may be in the form of, for example, aqueous or oilysuspensions, solutions, emulsions, syrups or elixirs, or may bepresented as a dry product for reconstitution with water or othersuitable vehicle before use. Such liquid preparations may containconventional additives such as suspending agents, for example sorbitol,syrup, methyl cellulose, glucose syrup, gelatin hydrogenated ediblefats; emulsifying agents, for example lecithin, sorbitan monooleate, oracacia; non-aqueous vehicles (which may include edible oils), forexample almond oil, fractionated coconut oil, oily esters such asglycerine, propylene glycol, or ethyl alcohol; preservatives, forexample methyl or propyl p-hydroxybenzoate or sorbic acid, and ifdesired conventional flavouring or colouring agents.

For topical application to the skin, the drug may be made up into acream, lotion or ointment. Cream or ointment formulations which may beused for the drug are conventional formulations well known in the art,for example as described in standard textbooks of pharmaceutics such asthe British Pharmacopoeia.

The active ingredient may also be administered parenterally in a sterilemedium. Depending on the vehicle and concentration used, the drug caneither be suspended or dissolved in the vehicle. Advantageously,adjuvants such as a local anaesthetic, preservative and buffering agentscan be dissolved in the vehicle.

However, for treatment of an inflammatory disease of the respiratorytract, compounds of the invention may also be formulated for inhalation,for example as a nasal spray, or dry powder or aerosol inhalers. Fordelivery by inhalation, the active compound is preferably in the form ofmicroparticles. They may be prepared by a variety of techniques,including spray-drying, freeze-drying and micronisation. Aerosolgeneration can be carried out using, for example, pressure-driven jetatomizers or ultrasonic atomizers, preferably using propellant-drivenmetered aerosols or propellant-free administration of micronized activecompounds from, for example, inhalation capsules or other “dry powder”delivery systems.

By way of example, a composition of the invention may be prepared as asuspension for delivery from a nebuliser or as an aerosol in a liquidpropellant, for example for use in a pressurised metered dose inhaler(PMDI). Propellants suitable for use in a PMDI are known to the skilledperson, and include CFC-12, HFA-134a, HFA-227, HCFC-22 (CCl₂F₂) andHFA-152 (CH₄F₂ and isobutane)

In a preferred embodiment of the invention, a composition of theinvention is in dry powder form, for delivery using a dry powder inhaler(DPI). Many types of DPI are known.

Microparticles for delivery by administration may be formulated withexcipients that aid delivery and release. For example, in a dry powderformulation, microparticles may be formulated with large carrierparticles that aid flow from the DPI into the lung. Suitable carrierparticles are known, and include lactose particles; they may have a massmedian aerodynamic diameter of greater than 90 μm.

In the case of an aerosol-based formulation, an example is:

Compound of the invention 24 mg/canister Lecithin, NF Liq. Conc. 1.2mg/canister Trichlorofluoromethane, NF 4.025 g/canisterDichlorodifluoromethane, NF 12.15 g/canister.

The active compounds may be dosed as described depending on the inhalersystem used. In addition to the active compounds, the administrationforms may additionally contain excipients, such as, for example,propellants (e.g. Frigen in the case of metered aerosols),surface-active substances, emulsifiers, stabilizers, preservatives,flavorings, fillers (e.g. lactose in the case of powder inhalers) or, ifappropriate, further active compounds.

For the purposes of inhalation, a large number of systems are availablewith which aerosols of optimum particle size can be generated andadministered, using an inhalation technique which is appropriate for thepatient. In addition to the use of adaptors (spacers, expanders) andpear-shaped containers (e.g. Nebulator®, Volumatic®), and automaticdevices emitting a puffer spray (Autohaler®), for metered aerosols, inparticular in the case of powder inhalers, a number of technicalsolutions are available (e.g. Diskhaler®, Rotadisk®, Turbohaler® or theinhalers for example as described EP-A-0505321). Additionally, compoundsof the invention may be delivered in multi-chamber devices thus allowingfor delivery of combination agents.

Combinations.

Other compounds may be combined with compounds with which the inventionis concerned for the prevention and treatment of inflammatory diseases,in particular respiratory diseases. Thus the present invention is alsoconcerned with pharmaceutical compositions comprising a therapeuticallyeffective amount of a compound of the invention and one or more othertherapeutic agents. Suitable therapeutic agents for a combinationtherapy with compounds of the invention include, but are not limited to:(1) corticosteroids, such as fluticasone propionate, fluticasonefuroate, mometasone furoate, beclometasone dipropionate, ciclesonide,budesonide, GSK 685698, GSK 870086, QAE 397, QMF 149, and TPI-1020; (2)β2-adrenoreceptor agonists such as salbutamol, albuterol, terbutaline,fenoterol, and long acting β2-adrenoreceptor agonists such assalmeterol, indacaterol, formoterol (including formoterol fumarate),arformoterol, carmoterol, GSK 642444, GSK 159797, GSK 159802, GSK597501, GSK 678007, and AZD3199; (3) corticosteroid/long acting β2agonist combination products such as salmeterol/fluticasone propionate(Advair/Seretide), formoterol/budesonide (Symbicort),formoterol/fluticasone propionate (Flutiform), formoterol/ciclesonide,formoterol/mometasone furoate, formoterol/beclometasone dipropionate,indacaterol/mometasone furoate, Indacaterol/QAE 397, GSK 159797/GSK685698, GSK 159802/GSK 685698, GSK 642444/GSK 685698, GSK 159797/GSK870086, GSK 159802/GSK 870086, GSK 642444/GSK 870086, andarformoterol/ciclesonide; (4) anticholinergic agents, for examplemuscarinic-3 (M3) receptor antagonists such as ipratropium bromide,tiotropium bromide, Aclidinium (LAS-34273), NVA-237, GSK 233705,Darotropium, GSK 573719, GSK 961081, QAT 370, QAX 028, and EP-101; (5)dual pharmacology M3-anticholinergic/β2-adrenoreceptor agonists such asGSK961081, AZD2115, and LAS190792; (6) leukotriene modulators, forexample leukotriene antagonists such as montelukast, zafirulast orpranlukast or leukotriene biosynthesis inhibitors such as Zileuton orBAY-1005, or LTB4 antagonists such as Amelubant, or FLAP inhibitors suchas GSK 2190914 or AM-103; (7) phosphodiesterase-IV (PDE-IV) inhibitors(oral or inhaled), such as roflumilast, cilomilast, Oglemilast,ONO-6126, Tetomilast, Tofimilast, UK 500,001, and GSK 256066; (8)antihistamines, for example selective histamine-1 (H1) receptorantagonists, such as fexofenadine, citirizine, loratidine or astemizoleor dual H1/H3 receptor antagonists such as GSK 835726, GSK 1004723, orselective histamine-4 (H4) receptor antagonists, such as ZPL3893787; (9)antitussive agents, such as codeine or dextramorphan; (10) a mucolytic,for example N acetyl cysteine or fudostein; (11) aexpectorant/mucokinetic modulator, for example ambroxol, hypertonicsolutions (e.g. saline or mannitol) or surfactant; (12) a peptidemucolytic, for example recombinant human deoxyribonoclease I(dornase-alfa and rhDNase) or helicidin; (13) antibiotics, for exampleazithromycin, tobramycin, and aztreonam; (14) non-selective COX-1/COX-2inhibitors, such as ibuprofen or ketoprofen; (15) COX-2 inhibitors, suchas celecoxib and rofecoxib; (16) VLA-4 antagonists, such as thosedescribed in WO 1997/03094 and WO 1997/02289, which are incorporatedherein by reference in their entireties; (17) TACE inhibitors and TNF-αinhibitors, for example anti-TNF monoclonal antibodies, such as Remicadeand CDP-870 and TNF receptor immunoglobulin molecules, such as Enbrel;(18) inhibitors of matrix metalloprotease, for example MMP-12; (19)human neutrophil elastase inhibitors, such as ONO-6818 or thosedescribed in WO 2005/026124, WO 2003/053930 and WO 2006/082412, whichare incorporated herein by reference in their entireties; (20) A2bantagonists such as those described in WO 2002/42298, which isincorporated herein by reference in its entirety; (21) modulators ofchemokine receptor function, for example antagonists of CCR3 and CCR8;(22) compounds which modulate the action of other prostanoid receptors,for example a thromboxane A₂ antagonist; DP1 antagonists such asMK-0524, CRTH2 antagonists such as ODC9101 and OC000459 and AZD1981 andmixed DP1/CRTH2 antagonists such as AMG 009 and AMG853; (23) PPARagonists including PPAR alpha agonists (such as fenofibrate), PPAR deltaagonists, PPAR gamma agonists such as Pioglitazone, Rosiglitazone andBalaglitazone; (24) methylxanthines such as theophylline oraminophylline and methylxanthine/corticosteroid combinations such astheophylline/budesonide, theophylline/fluticasone propionate,theophylline/ciclesonide, theophylline/mometasone furoate andtheophylline/beclometasone dipropionate; (25) A2a agonists such as thosedescribed in EP 1 052 264 and EP 1 241 176, which are incorporatedherein by reference in their entireties; (26) CXCR2 or IL-8 antagonistssuch as SCH 527123 or GSK 656933; (27) IL-R signalling modulators suchas kineret and ACZ 885; (28) MCP-1 antagonists such as ABN-912.

The present invention is also directed to a kit comprising thepharmaceutical compositions of compounds of the present invention aloneor in combination with or in admixture with one or more pharmaceuticallyacceptable carriers and/or excipients and a device which may be asingle- or multi-dose dry powder inhaler, a metered dose inhaler or anebulizer.

Methods of Synthesis.

In one aspect of the present invention, a process for the preparation ofcompounds of the invention is provided, according to general syntheticroutes described in this section. In the following reaction schemes,unless otherwise indicated, the groups mentioned assume the same meaningas those reported for compounds of formula (I).

The skilled person may introduce, where appropriate, suitable variationsto the conditions specifically described in the examples in order toadapt the synthetic routes to the provision of further compounds of theinvention. Such variations may include, but are not limited to, use ofappropriate starting materials to generate different compounds, changesin the solvent and temperature of reactions, replacements of reactiveswith analogous chemical role, introduction or removal ofprotection/deprotection stages of functional groups sensitive toreaction conditions and reagents, as well as introduction or removal ofspecific synthetic steps oriented to further functionalisation of thechemical scaffold.

Processes which can be used and are described and reported in Examplesand Schemes, should not be viewed as limiting the scope of the syntheticmethods available for the preparation of the compounds of the invention.

The process described is particularly advantageous as it is susceptibleof being properly modulated, through any proper variant known to theskilled person, so as to obtained any of the desired compounds of theinvention. Such variants are comprised within the scope of the presentinvention.

From all of the above, it should be clear to the skilled person that anyof the described groups may be present as such or in any properlyprotected form.

In particular, functional groups present in the intermediate andcompounds and which could generate unwanted side reaction andby-products, need to be properly protected before the alkylation,acylation, coupling or sulfonylation takes place. Likewise, subsequentdeprotection of those same protected groups may follow upon completionof the said reactions.

In the present invention, unless otherwise indicated, the term“protecting group” designates a protective group adapted to preserve thefunction of the group it is bound to. Typically, protective groups areused to preserve amino, hydroxyl, or carboxyl functions. Appropriateprotecting groups may thus include, for example, benzyl,benzyloxycarbonyl, t-butoxycarbonyl, alkyl or benzyl esters or the like,which are well known to those skilled in the art (see, for a generalreference, T. W. Green; Protective Groups in Organic Synthesis (Wiley,N.Y. 1981), which is incorporated herein by reference in its entirety).

Likewise, selective protection and deprotection of any of the saidgroups, for instance including carbonyl, hydroxyl or amino groups, maybe accomplished according to very well known methods commonly employedin organic synthetic chemistry.

Optional salification of the compounds of formula (I) or N-oxides on thepyridine ring thereof may be carried out by properly converting any ofthe free acidic or amino groups into the corresponding pharmaceuticallyacceptable salts. In this case too, the operative conditions beingemployed for the optional salification of the compounds of the inventionare all within the ordinary knowledge of the skilled person.

From all of the above, it should be clear that the above process,comprehensive of any variant thereof for the preparation of suitablecompounds of the invention, may be conveniently modified so that toadapt the reaction conditions to the specific needs, for instance bychoosing appropriate condensing agents, solvents and protective groups,as the case may be.

For example compounds of the invention of formula (I) may be preparedaccording to the route illustrated in Scheme 1.

Compounds of general formula (I) may be prepared from compounds ofgeneral formula (1a) by reaction with a compound of general formula(1b1) or (1b2) wherein R² is as defined in general formula (I), in asuitable solvent such as dimethyl sulfoxide, 1,4-dioxane,N,N-dimethylformamide or acetonitrile, in the presence of a base such asdiisopropylethylamine at a range of temperatures, preferably betweenroom temperature and 100° C.

Compounds of general formula (1b1) and (1b2) are either known in theliterature or may be prepared from amines of general formula (1c)according to known literature procedures (e.g. see for reference WO2006/009741 and EP 1 609 789, which are incorporated herein by referencein their entireties).

Compounds of general formula (1c) are either known in the literature ormay be synthesised by one skilled in the art by adapting appropriateliterature methods (e.g. WO 2010/077836, WO 2006/009741, WO 2008/125014,J. Med Chem., 2007, 50, 4016, Bulletin des Societes Chimiques Beiges,1987, 96, 675-709, and Organic & Biomolecular Chemistry, 2006, 4,4158-4164, which are incorporated herein by reference in theirentireties).

Compounds of general formula (1ca), i.e. compounds of formula (1c)wherein R² is a group of formula (IIIb) and R¹⁷, R¹⁸, z¹, z², z³ and z⁴are as defined above can be prepared from compounds of formula (1e):

using a suitable reducing agent such as tin (II) chloride, iron, orhydrogen gas with a suitable catalyst such as palladium on carbon, in asuitable solvent such as methanol, ethanol or acetic acid, at a range oftemperatures, preferably between room temperature and 100° C.

Compounds of general formula (1e) are known in the literature or may beprepared by those skilled in the art using literature methods (e.g. WO2008/034008, WO 2011/0189167, WO 2010/068258, which are incorporatedherein by reference in their entireties).

Alternatively, compounds of general formula (1ca) as above defined canbe prepared from compounds of formula (If), wherein R¹⁷, R¹⁸, z¹, z², z³and z⁴ are as defined above and wherein PG is a suitable compatibleprotecting group known to those skilled in the art, such as benzyl,benzyl carbamate or tert-butyl carbamate,

using suitable deprotection conditions such as hydrochloric acid,trifluoroacetic acid, or hydrogen catalysed by for example palladium oncarbon, in a suitable solvent such as dichloromethane, methanol, ethanolor acetic acid, at a range of temperatures, preferably between 0° C. and100° C.

Compounds of general formula (1f) can be prepared by reaction ofcompounds of formula (1g), wherein R¹⁷, R¹⁸, z¹, z², z³ and z⁴ are asdefined above

with compounds of formula (1h) as above reported wherein PG is asuitable protecting group known to those skilled in the art, such asbenzyl, benzyl carbamate or tert-butyl carbamate, using suitableconditions such as in the presence of a base such as potassium carbonateor diisopropylethyl amine or under Buchwald conditions (with a catalystsuch as Pd(OAc)₂, a ligand such as2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and base such as sodiumtert-butoxide), in a suitable solvent such as toluene ortetrahydrofuran, at a range of temperatures, preferably between roomtemperature and 150° C.

Compounds of general formula (1g) and (1h) are known in the literatureor may be prepared by those skilled in the art by adapting appropriateliterature methods (e.g. WO 2011/042389, and Chemistry—A EuropeanJournal, 2011, 17, 6606-6609, S6606/1-S6606/38, which are incorporatedherein by reference in their entireties).

Compounds of general formula (1a) may be prepared according to the routeillustrated in Scheme 2.

Compounds of general formula (1a) may be prepared from compounds ofgeneral formula (2a) by reaction with a compound of general formula(2b), (2c) or (2d), wherein G is a suitable chemical group known tothose skilled in the art selected such that it can facilitate a suitablecoupling reaction such as nucleophilic displacement or metal catalysedcross coupling. For example in cases such that when Y is —O—, —S— or—NR⁷—, examples of G may include halogen or a suitable leaving groupsuch as mesylate or triflate either directly linked or attached via agroup —(CR³R⁴)_(n)—. Examples of the coupling conditions used mayinclude using a base such as sodium hydride or potassium tert-butoxideand 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone in a suitablesolvent such as N,N-dimethylformamide, toluene, 1,4-dioxane oracetonitrile at a range of temperatures, preferably between roomtemperature and 150° C. For example in cases such that when Y is —O— andG is —OH or —SH a method to perform this coupling may involve Mitsunobuconditions (diethylazodicarboxylate/triphenylphosphine) in a suitablesolvent such as tetrahydrofuran or 1,4-dioxane at a range oftemperatures preferably between −10° C. and 100° C. For example in casessuch as when Y is —O—, —S— or —NR⁷— and G is a group such as halogen,triflate or boronic acid/ester a method to perform this coupling may beunder metal (for example palladium or copper) catalysed couplingconditions in the presence of a suitable ligand such as Xantphos or1,10-phenanthroline in the presence of a base such as caesium carbonatein a suitable solvent such as tetrahydrofuran, 1,4-dioxane orN,N-dimethylformamide at a range of temperatures preferably between −10°C. and 150° C. For example in cases such as when Y is —O— and G is agroup such as —COOMe, —COOH, isocyanate, —OCOCl or —NHCOOCH₂CCl₃examples of conditions to perform this coupling may involve the use of abase such as sodium hydride or triethylamine or a coupling reagent suchas HATU in a suitable solvent such as dichloromethane, tetrahydrofuran,1,4-dioxane or N,N-dimethylformamide at a range of temperaturespreferably between −10° C. and 150° C.

Compounds of formula (2b) are commercial available, are known in theliterature or may be synthesised from compounds of formula (2e), whereinR⁸ and R⁹ are as defined for compounds of formula (I), by adaptingappropriate literature methods (e.g. WO 2006/133006, which isincorporated herein by reference in its entirety) or using methods knownto those skilled in the art such as by reacting (2e) with a suitablealkylating agent such as dibromoethane or bromoethanol in the presenceof a suitable base such as sodium hydride or potassium carbonate in asuitable solvent such as tetrahydrofuran, 1,4-dioxane orN,N-dimethylformamide at a range of temperatures preferably between −10°C. and 150° C., or by reacting (2e) with a suitable aldehyde in thepresence of a reducing agent such as sodium triacetoxyborohydride in asuitable solvent such as dichloroethane or tetrahydrofuran at a range oftemperatures preferably between −10° C. and 100° C.

Compounds of formula (2e) are commercially available, are known in theliterature or may be synthesised by those skilled in the art usingliterature methods. Compounds of formula (2c) may be synthesised fromcompounds of formula (2f).

wherein X₁ and R¹² are defined as for compounds of formula (I), G is agroup such as halogen, —O-PG or —S-PG wherein PG represents a protectinggroup such as triisopropylsilyl or tert-butyldimethylsilyl (methods forwhose introduction and removal are well known by those skilled in theart) and J may represent groups such as halogen, —NH₂, —OH, —SH, —COOH,—SO₂Cl which can be modified using literature methods to introduce anappropriate group R¹⁰ by those skilled in the art. For example in casessuch as when J is halogen, a method such as nucleophilic substitutionwith a suitable alcohol, amine or thiol may be used in the presence of asuitable base such as sodium hydride, triethylamine or potassiumcarbonate in a suitable solvent such as tetrahydrofuran, 1,4-dioxane orN,N-dimethylformamide at a range of temperatures preferably between −10°C. and 150° C. For example in cases such as when J is —NH₂, —OH or SH, amethod such as alkylation may be used with a suitable alkylating agentsuch as an alkylhalide in the presence of a suitable base such as sodiumhydride or potassium carbonate in a suitable solvent such astetrahydrofuran, 1,4-dioxane or N,N-dimethylformamide at a range oftemperatures preferably between −10° C. and 150° C. For example in casessuch as where J is —COOH or —SO₂Cl a method such as reaction with asuitable amine in the presence of a suitable base such as triethylamineor a coupling reagent such as HATU in a suitable solvent such astetrahydrofuran, 1,4-dioxane or N,N-dimethylformamide at a range oftemperatures preferably between −10° C. and 150° C.

Compounds of formula (2da), i.e. compounds of formula (2a) wherein X⁴═Cmay be prepared according to the routes described in Scheme 3 herebelow:

Compounds of general formula (2da) as above defined may be prepared fromcompounds of general formula (3e) using a suitable oxidant such aschloramine T, lead tetracetate or phenyliodine(III) diacetate, in asuitable solvent such as dichloromethane or ethanol at a range oftemperatures, preferably between room temperature and 100° C.

Compounds of general formula (3e) may be prepared from compounds ofgeneral formula (3a) by reaction with an aldehyde of general formula(3c) above reported. in a suitable solvent such as ethanol ortetrahydrofuran at a range of temperatures, preferably between roomtemperature and 80° C.

Compounds of formula (3c) are commercially available, known in theliterature or may be prepared using literature methods by those skilledin the art.

Alternatively, compounds of formula (2da) may be prepared from compoundsof formula (3d) using a suitable dehydrating agent such as Burgess'reagent, triphenyl phosphine and hexachloroethane, phosphorusoxychloride, acetic acid or Mitsunobu conditions(diethylazodicarboxylate/triphenylphosphine/trimethylsilylazide), in theabsence or presence of a suitable solvent such as tetrahydrofuran,toluene, or NMP, at a range of temperatures, preferably between roomtemperature and 150° C.

Compounds of formula (3d) may be prepared from compounds of formula (3a)by reaction with a compound of general formula (3b1) using a suitableacylating/dehydrating agent such astriphenylphosphine/trichloroacetonitrile in the presence of a base suchas diisopropylethylamine, in a suitable solvent such as dichloromethaneor acetonitrile, at a range of temperatures, preferably between roomtemperature and 150° C. or by reaction with a compound of generalformula (3b2) in the presence of a base such as diisopropylethylamine,in a suitable solvent such as dichloromethane or THF at a range oftemperatures preferably between −10° C. and the boiling point of thesolvent.

Compounds of formulae (3b1) and (3b2) are commercially available, knownin the literature or may be prepared by literature methods by thoseskilled in the art.

Alternatively, compounds of formula (2da) as above defined may beprepared according to the route in Scheme 4:

Compounds of general formula (2da) may be prepared from compounds ofgeneral formula (4c), wherein G² may represent groups such as halogen,—CHO, —COOH, —COOEt and SO₂Cl. For example, compounds of general formula(2da) may be prepared from compounds of general formula (4c), wherein G²represents halogen, using methods such as a metal (for examplepalladium) catalysed coupling with a suitable R¹¹G⁵ derivative whereinG⁵ is a group such as boronate acid/ester or stannane in a suitablesolvent such as tetrahydrofuran or 1,4-dioxane at a range oftemperatures preferably between ambient temperature and 150° C. Analternative method may involve displacement of said halogen with asuitable group R¹¹H (such as that containing an —NH, —OH or —SH group)in the presence of a base such as sodium hydride, potassiumtert-butoxide or N,N-diethylisopropylamine in a suitable solvent such asN,N-dimethylformamide, toluene, 1,4-dioxane, or acetonitrile at a rangeof temperatures, preferably between room temperature and 150° C.

The group G² may be also transformed from groups such as halogen togroups such as CHO, —COOH, —COOEt and SO₂Cl by means of metal insertionmethods known to those skilled in the art such as palladium catalysis,Grignard formation or lithium halogen exchange.

Compounds of general formula (2da) wherein R¹¹ is a group such as—CH₂—NR^(A)R^(B), —C(O)N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—C(O)N(R^(C))—(C₂-C₆alkylene)-OR^(D),—C(O)N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D), —C(O)N(R^(A)R^(B)),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-NR^(A)R^(B),—S(O)₂N(R^(C))—(C₂-C₆alkylene)-OR^(D) or—S(O)₂N(R^(C))—(C₃-C₇cycloalkylene)-OR^(D) may be prepared fromcompounds of general formula (4c), wherein G² represents —CHO, —COOH,—COOEt and —SO₂Cl, by reaction with a suitable amine such asHNR^(A)R^(B) etc using methods such as reductive amination (using areagent such as sodium triacetoxyborohydride) or amide/sulphonamideformation in the presence of suitable reagents such as HATU with a basesuch as N,N-diethylisopropylamine or trimethylaluminium in a suitablesolvent such as dichloromethane, N,N-dimethylformamide, toluene,1,4-dioxane, or acetonitrile at a range of temperatures, preferablybetween room temperature and 150° C.

Compounds of general formula (4c) wherein G² is a group such as —COOEt,may be synthesised from compounds of general formula (4a) by reactionwith a compound such as diethyloxalate in the presence of an acid suchas acetic acid at a range of temperatures, preferably between roomtemperature and 120° C.

Compounds of general formula (4c) wherein G² is a group such as bromineor chlorine, may be synthesised from compounds of general formula (4b)by reaction with a compound such as N-chlorosuccinimide orN-bromosuccinimide in a solvent such as chloroform at a range oftemperatures, preferably between −10° C. and room temperature.

Compounds of general formula (4b) may be synthesised from compounds ofgeneral formula (4a) by reaction with a compound such asdiethoxymethylacetate at a range of temperatures, preferably betweenroom temperature and 100° C.

Compounds of general formula (2db), i.e. compounds of formula (2d)wherein X₄ is nitrogen, may be prepared from compounds of generalformula (4b) wherein X⁴═NH, by reaction with a suitable alkylating agentR¹¹ in the presence of a base such as caesium carbonate in a suitablesolvent such as N,N-dimethylformamide at a range of temperatures,preferably between room temperature and 150° C.

Alternatively, compounds of general formula (1aa), i.e compounds offormula (1a) wherein X⁴ is CH may be prepared according to the routeillustrated in Scheme 5.

Compounds of general formula (1aa) may be prepared from compounds ofgeneral formula (5e) wherein PG is a suitable protecting group known inthe art such as Boc by using the appropriate deprotection conditionssuch as trifluoroacetic acid in a solvent such as dichloromethane at arange of temperatures, preferably between −10° C. and room temperature.

Compounds of general formula (5e) may be prepared from compounds ofgeneral formula (5d) using a suitable dehydrating agent such as Burgess'reagent, triphenyl phosphine and hexachloroethane, phosphorusoxychloride, acetic acid or Mitsunobu conditions(diethylazodicarboxylate/triphenylphosphine/trimethylsilylazide), in theabsence or presence of a suitable solvent such as tetrahydrofuran,toluene, or NMP, at a range of temperatures, preferably between roomtemperature and 120° C.

Compounds of general formula (5d) may be prepared from compounds ofgeneral formula (5c) by reaction with a compound of general formula(3b1) as above defined using a suitable acylating/dehydrating agent suchas triphenylphosphine/trichloroacetonitrile in the presence of a basesuch as diisopropylethylamine, in a suitable solvent such asdichloromethane or acetonitrile, at a range of temperatures, preferablybetween room temperature and 150° C., or by reaction with a compound ofgeneral formula (3b2) as above defined in the presence of a base such asdiisopropylethylamine, in a suitable solvent such as dichloromethane orTHF at a range of temperatures preferably between −10° C. and theboiling point of the solvent.

Compounds of general formula (5c) may be prepared from compounds ofgeneral formula (5b) wherein G³ is a suitable leaving group such ashalogen, by reaction with a reagent such as hydrazine monohydrate in asuitable solvent such as ethanol at a range of temperatures preferablybetween room temperature and 100° C.

Compounds of general formula (5b) may be prepared from compounds ofgeneral formula (5a) by reaction with a suitable protecting groupreagent known in the art such as Boc anhydride in the presence of a basesuch as triethylamine in a suitable solvent such as dichloromethane ortetrahydrofuran at a range of temperatures preferably between roomtemperature and 100° C.

Compounds of general formula (5a) can be synthesised by the methodsdescribed above for the synthesis of (1a).

Compounds of general formula (2aa), i.e. compounds of formula (2a)wherein Y═O, W═NH and PG is a suitable protective group such astrifluoroacetate may be prepared according to the route illustrated inscheme 6:

Compounds of general formula (2aa) may be prepared from compounds ofgeneral formula (6b) and (6c) by removal of the protecting group PGusing methods known in the art such as aqueous sodium hydroxide in asolvent such as methanol at a range of temperatures preferably betweenroom temperature and 100° C.

Compounds of general formula (6b), wherein PG is a protecting group,preferably trifluoroacetamide, and the group —OH is placed on thecycloalkylene portion of ring A may be prepared from compounds ofgeneral formula (6a) by using a chiral reductive method such as usingformic acid and RuCl[S,S-Tsdpen(p-cymene)] in the presence of a basesuch as triethylamine in a solvent such as N,N-dimethylformamide at arange of temperatures preferably between room temperature and 150° C. Itwill be recognised that compounds of formula (6a) may be homochiral asillustrated or be the opposite enantiomer or racemic.

It will be realised by those skilled in the art that any combination ofstereocentres in (2aa) can be prepared using both enantiomers of (6a)and using RuCl[R,R-Tsdpen(p-cymene)] or RuCl[S,S-Tsdpen(p-cymene)].Compound (2a) is drawn with no defined stereocentres but any combinationcan be obtained as illustrated in Scheme 2.

Compounds of formula (6a) can be prepared from compounds of formula (6d)

using a suitable oxidant such as potassium permanganate and magnesiumsulfate in a suitable solvent methanol/water at a range of temperaturespreferably between room temperature and the boiling point of thesolvent. It will be recognised that compounds of formula (6d) may behomochiral as illustrated or be the opposite enantiomer or racemic.

Compounds of formula (6d) can be prepared from compounds of formula (6e)where PG is a suitable protecting group such as trifluoroacetate ortert-butyl carbonate:

using ethyl trifluoroacetate or di-tert-butyl dicarbonate in thepresence of base such as triethylamine or diisopropylethylamine in asolvent such as methanol or dichloromethane at a range of temperaturespreferably between 0° C. and the boiling point of the solvent. It willbe recognised that compounds of formula (6e) may be homochiral asillustrated or be the opposite enantiomer or racemic.

Compounds of formula (6e) are known in the literature and may beprepared by those skilled in the art by adapting literature methods(e.g. for S-(+)-1-amino-1,2,3,4-tetrahydronaphthalene, see Journal ofthe Chemical Society, Perkin Transactions 1: 1985, 2039-44; for(S)-(+)-8-amino-5,6,7,8-tetrahydroquinoline, see Journal of OrganicChemistry, 2007, 72, 669-671; and for 1-aminoindan, see TetrahedronLetters, 2011, 52, 1310-1312, which are incorporated herein by referencein their entireties).

Compounds of general formula (2ab), i.e. compounds of formula (2a)wherein Y═NR⁷ and W═NH, may be prepared according to the routeillustrated in scheme 7:

Compounds of general formula (2ab) may be prepared from compounds ofgeneral formula (7a) by removal of the protecting group PG using methodsknown in the art such as aqueous sodium hydroxide in a solvent such asmethanol or trifluoroacetic acid in dichloromethane at a range oftemperatures preferably between room temperature and 100° C.

Compounds of formula (7a) may be prepared from compounds of generalformula (6a) and amines (7b) by reaction under reductive aminationconditions, using a reducing agent such as sodium triacetoxyborohydrideand a solvent such as 1,2-dichloroethane at a range of temperaturespreferably between room temperature and 100° C.

Compounds for formula (7b) are known in the literature and may beprepared by those skilled in the art using literature procedures.Compounds of formula (6a) can be prepared as described above.

Alternatively, compounds of formula (7a) may be prepared from compoundsof general formula (7c) wherein G⁴ is a suitable chemical group known tothose skilled in the art selected such that it can facilitate a reactionsuch as a nucleophilic substitution. For example G is a suitable leavinggroup such as halogen or mesylate which can react with a suitable amine(7b) in the presence of a suitable base such as sodium hydride orpotassium tert-butoxide and1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone in a suitable solventsuch as N,N-dimethylformamide, toluene, 1,4-dioxane or acetonitrile at arange of temperatures, preferably between room temperature and 150° C.

Compounds of formula (7c) can be prepared from compounds of formulae(6b) or (6c) using halogenating conditions such as carbon tetrabromideand triphenylphosphine in dichloromethane or activation conditions suchas methane sulfonyl chloride in dichloromethane in the presence of basesuch as diisopropylamine.

Alternatively, compounds of general formula (Id), i.e. compounds offormula (I) wherein Y═S and W═NH may be prepared according to the routeillustrated in scheme 8:

Compounds of general formula (Id) may be prepared from compounds ofgeneral formula (1ab), i.e. compounds of formula (1a) wherein Y═S andW═NH: using compounds of formula (1b1) or (1b2) in a suitable solventsuch as dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide, oracetonitrile, in the presence of a base such as diisopropylethylamine ata range of temperatures, preferably between room temperature and 100° C.

Compounds of formula (1ab) as above defined may be prepared fromcompounds of formula (8g) using deprotection conditions such ashydrazine in methanol at a range of temperatures preferably between roomtemperature and the boiling point of the solvent.

Compounds of formula (8g) wherein Y═S, can be prepared from compounds offormula (8f) by reaction with compounds of formulae (2b), (2c) or (2d).Examples of the coupling conditions used may include using a base suchas sodium hydride or potassium tert-butoxide and1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone in a suitable solventsuch as N,N-dimethylformamide, toluene, 1,4-dioxane, or acetonitrile ata range of temperatures, preferably between room temperature and 150° C.Alternative methods to perform this coupling may involve Mitsunobuconditions (diethylazodicarboxylate/triphenylphosphine) or metal (forexample palladium) catalysed coupling conditions in a suitable solventsuch as tetrahydrofuran or 1,4-dioxane at a range of temperaturespreferably between −10° C. and 150° C. and starting from the appropriatederivative of formula (2b), (2c), or (2d).

Compounds of formula (8f) can be prepared from compounds of formula (8e)using dithiothreitol, monopotassium phosphate, potassium carbonate in asolvent such as methanol in the presence of acetic acid at a range oftemperatures preferably between room temperature and the boiling pointof the solvent.

Compounds of formula (8e) can be prepared from compounds of formula (8d)using 2-nitrobenzenesulfenyl chloride in acetic acid at a range oftemperatures preferably between room temperature and 100° C.

Compounds of formula (8d) can be prepared from compounds of formula (8c)using phthalimide, triphenylphosphine and diisopropyl azodicarboxylatein a solvent such as tetrahydrofuran at a range of temperaturepreferably between 0° C. and the boiling point of the solvent.

Compounds of formula (8c) can be prepared from compounds of formula (8b)using a reducing agent such as sodium borohydride in a solvent such asmethanol at a range of temperatures preferably between 0° C. and theboiling point of the solvent.

Compounds of formula (8b) can be prepared from compounds of formula (8a)using tert-butanethiol in the presence of a base such asdiisopropylethylamine in a solvent such as tetrahydrofuran at a range oftemperatures preferably between 0° C. and the boiling point of thesolvent.

Compounds of formula (8a) are known in the literature and can beprepared by those skilled in the art using literature methods (e.g.3-bromo-indan-1-one see WO 2010/108058, which is incorporated herein byreference in its entirety).

Alternatively, compounds of general formula (1ab), i.e. compounds offormula (1a) wherein Y═CH₂, W═NH and PG is a suitable protective groupsuch as trifluoroacetate may be prepared according to the routeillustrated in scheme 9:

Compounds of general formula (1ab) may be prepared from compounds ofgeneral formula (9b) by removal of the protecting group PG using methodsknown in the art such as aqueous sodium hydroxide in a solvent such asmethanol at a range of temperatures preferably between room temperatureand 100° C.

Compounds of formula (9b) may be prepared from compounds of generalformula (9a) by reaction with a suitable reduction agent for examplehydrogen gas in the presence of a suitable catalyst such as palladium onactivated charcoal in a suitable solvent such as ethanol at a range oftemperatures between room temperature and 70° C. and pressures betweenatmospheric and 4 Barr.

Compounds of formula (9a) may be prepared from compounds of generalformula (6a) by means of a reaction such as a Wittig (or one of theclosely related variants such as the Horner-Wadsworth-Emmons) with asuitable substrate such as R¹—CH₂—P(O)(OMe)₂ in the presence of asuitable base such as sodium hydride in a suitable solvent such astetrahydrofuran at a range of temperatures preferably between −10° C.and 100° C.

Compounds such as R¹—CH₂—P(O)(OMe)₂ may be synthesised from compounds ofthe general formula R¹—CH₂-Hal wherein Hal represents a halogen such as—Br or —Cl by reaction with a compound such as trimethylphosphite at arange of temperatures preferably between 0° C. and 100° C.

Compounds such as R¹—CH₂-Hal may be synthesised from compounds offormula R¹—CH₃ by means of a reaction such as a radial halogenationusing a reagent such as N-bromosuccinimide in the presence of a catalystsuch as AIBN in a suitable solvent such as carbon tetrachloride at arange of temperatures preferably between 0° C. and 80° C. Compounds suchas R¹—CH₂-Hal may also be synthesised from compounds formula R¹—CH₂—OHby means of using halogenating conditions such as carbon tetrabromideand triphenylphosphine in dichloromethane or activation conditions suchas methane sulfonyl chloride in dichloromethane in the presence of basesuch as diisopropylamine.

Compounds such as R¹—CH₃ and R¹—CH₂—OH may be prepared by methodsoutlined above for compounds (2b), (2c) and (2d).

Compounds of the invention of formula (1ac), i.e. compounds of formula(1a) where Y═(CR⁵R⁶) and W═NH, may be prepared according to the routeillustrated in Scheme 10.

Compounds of formula (1ac) may be prepared from compounds of formula(10c) wherein PG is a suitable protecting group known to those skilledin the art, such as trifluoroacetamide, tert-butyl carbamate and benzylcarbamate by using suitable deprotection conditions such as, sodiumhydroxide in methanol, trifluoroacetic acid in dichloromethane orhydrogen gas catalysed by for example palladium on carbon in ethanol, ata range of temperatures, preferably between 0° C. and 100° C.

Compounds of formula (10c) may be prepared from compounds of formula(10b) wherein PG is a suitable protecting group known to those skilledin the art, such as trifluoroacetamide, tert-butyl carbamate, and benzylcarbamate by using hydrogen gas in the presence of a catalyst such aspalladium on carbon, in a suitable solvent such as methanol or ethanol,in the presence or absence of an acid such as HCl, at a range oftemperatures, preferably between 0° C. and 100° C.

Compounds of formula (10b) may be prepared from compounds of formula(10a) and (10f) by a reaction such as a cross-coupling using a suitablecatalyst such as tetrakis(triphenylphosphine)palladium (0) or palladiumacetate, and a base such as diisopropylethylamine, sodium tert-butoxide,or caesium carbonate in a suitable solvent such as NMP, toluene, or DMF,at a range of temperatures, preferably between 0° C. and 100° C.Alternatively (10b) may be prepared by adapting literature procedures(e.g. those reported in WO 2009/022633, which is incorporated herein byreference in its entirety).

Compounds of formula (10f) are known in the literature or may beprepared by those skilled in the art by adapting literature procedures(e.g. WO 2008/063287, which is incorporated herein by reference in itsentirety).

Compounds of formula (10a) may be prepared from compounds of formula(6a) using a triflating agent such as triflic anhydride, in the presenceof a suitable base such as pyridine or2,6-bis(tert-butyl)-4-methylpyridine, in a solvent such asdichloromethane or chloroform at a range of temperatures, preferablybetween 0° C. and boiling point of the solvent. Alternatively (10a) maybe prepared by adapting literature procedures (e.g. those described inWO 2009/022633, which is incorporated herein by reference in itsentirety).

Other features of the invention will become apparent in the course ofthe following descriptions of exemplary embodiments which are given forillustration of the invention and are not intended to be limitingthereof.

EXAMPLES General Experimental Details

Abbreviations used in the experimental section:

AcOH=acetic acid;

aq.=aqueous;

DCM=dichloromethane;

DIAD=Diisopropyl azodicarboxylate;

DIPEA=diisopropylethylamine;

DMAP=N,N-dimethylaminopyridine;

DMF=N,N-dimethylformamide;

DMSO=dimethyl sulfoxide;

EDC=1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide Hydrochloride;

EtOAc=ethyl acetate;

EtOH=ethanol;

Et₂O=diethyl ether;

Et₃N=triethylamine;

EtNiPr₂=diisopropylethylamine;

FCC=flash column chromatography;

h=hour;

HATU=2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate;

HOBt=1-hydroxy-benzotriazole;

HPLC=high performance liquid chromatography;

IMS=Industrial Methylated Spirits;

LCMS=liquid chromatography mass spectrometry;

NaOH=sodium hydroxide;

MeCN=acetonitrile;

MeOH=MeOH;

min minutes;

NH₃=ammonia;

NMR=nuclear magnetic resonance;

RT=room temperature;

Rt=retention time;

sat.=saturated;

SCX-2=strong cation exchange chromatography;

TFA=trifluoroacetic acid;

THF=Tetrahydrofuran;

H₂O=water;

IMS=industrial methylated spirit;

Xantphos=4,5-Bis(diphenylphosphino)-9,9-dimethyl xanthene;

X-Select=Waters X-select HPLC column;

IPA=propan-2-ol;

LDA=lithium diisopropylamide;

MDAP=mass-directed auto-purification;

MeOH=methanol;

Ph₃P=triphenylphosphine;

TBAF=tetrabutylammonium fluoride.

In the procedures that follow, after each starting material, referenceto a Intermediate/Example number is usually provided. This is providedmerely for assistance to the skilled chemist. The starting material maynot necessarily have been prepared from the batch referred to.

When reference is made to the use of a “similar” or “analogous”procedure, as will be appreciated by those skilled in the art, such aprocedure may involve minor variations, for example reactiontemperature, reagent/solvent amount, reaction time, work-up conditionsor chromatographic purification conditions.

The nomenclature of structures was assigned using Autonom 2000 Namesoftware from MDL Inc. When the nomenclature of structures could not beassigned using Autonom, ACD/Name software utility part of the ACD/LabsRelease 12.00 Product Version 12.5 (Build 45133, 16 Dec. 2010) was used.Stereochemical assignments of compounds are based on comparisons withdata reported in WO 2008/043019, which is incorporated herein byreference in its entirety, for key intermediates. All reactions werecarried out under anhydrous conditions and an atmosphere of nitrogen orargon unless specified otherwise. Unless otherwise stated alltransformations were carried at ambient temperature (room temperature).

NMR spectra were obtained on a Varian Unity Inova 400 spectrometer witha 5 mm inverse detection triple resonance probe operating at 400 MHz oron a Bruker Avance DRX 400 spectrometer with a 5 mm inverse detectiontriple resonance TXI probe operating at 400 MHz or on a Bruker AvanceDPX 300 spectrometer with a standard 5 mm dual frequency probe operatingat 300 MHz. Shifts are given in ppm relative to tetramethylsilane (δ=0ppm). J values are given in Hz through-out. NMR spectra were assignedusing DataChord Spectrum Analyst Version 4.0.b21 or SpinWorks version 3.

Where products were purified by flash column chromatography, ‘flashsilica’ refers to silica gel for chromatography, 0.035 to 0.070 mm (220to 440 mesh) (e.g. Fluka silica gel 60), and an applied pressure ofnitrogen up to 10 p.s.i accelerated column elution or use of theCombiFlash® Companion purification system or use of the Biotage SP1purification system. All solvents and commercial reagents were used asreceived.

Compounds purified by preparative HPLC were purified using aC18-reverse-phase column (100×22.5 mm i.d Genesis column with 7 μmparticle size), or a Phenyl-Hexyl column (250×21.2 mm i.d. Gemini columnwith 5 μm particle size), UV detection between 220-254 nm, flow 5-20mL/min), eluting with gradients from 100-0 to 0-100% water/acetonitrile(containing 0.1% TFA or 0.1% formic acid) or water/MeOH (containing 0.1%TFA or 0.1% formic acid), or a C18-reverse-phase column (19×250 mm,XBridge OBD, with 5 μm particle size), eluting with gradients from 100-0to 0-100% water/acetonitrile (containing 0.1% NH₄OH); or a ChiralPak ICcolumn (10×250 mm i.d., with 5 μm particle size), unless otherwiseindicated. Fractions containing the required product (identified by LCMSanalysis) were pooled, the organic solvent removed by evaporation, andthe remaining aqueous residue lyophilised, to give the final product.Products purified by preparative HPLC were isolated as free base,formate or TFA salts, unless otherwise stated.

The Liquid Chromatography Mass Spectroscopy (LCMS) and HPLC systems usedare:

Method 1.

Waters Platform LC Quadrupole mass spectrometer with a C18-reverse-phasecolumn (30×4.6 mm Phenomenex Luna 3 μm particle size), elution with A:water+0.1% formic acid; B: acetonitrile+0.1% formic acid. Gradient:

Gradient-Time flow mL/min % A % B 0.00 2.0 95 5 0.50 2.0 95 5 4.50 2.0 595 5.50 2.0 5 95 6.00 2.0 95 5Detection—MS, ELS, UV (200 μL split to MS with in-line HP1100 DADdetector). MS ionization method—Electrospray (positive and negativeion).Method 2.

Waters ZMD quadrupole mass spectrometer with a C18-reverse-phase column(30×4.6 mm Phenomenex Luna 3 μm particle size), elution with A:water+0.1% formic acid; B: acetonitrile+0.1% formic acid. Gradient:

Gradient-Time flow mL/min % A % B 0.00 2.0 95 5 0.50 2.0 95 5 4.50 2.0 595 5.50 2.0 5 95 6.00 2.0 95 5Detection—MS, ELS, UV (200 μL split to MS with in-line Waters 996 DADdetector). MS ionization method—Electrospray (positive and negativeion).Method 3.

Waters ZMD quadrupole mass spectrometer with a C18-reverse-phase column(30×4.6 mm Phenomenex Luna 3 μm particle size), elution with A:water+0.1% formic acid; B: acetonitrile+0.1% formic acid. Gradient:

Gradient-Time flow mL/min % A % B 0.00 2.0 95 5 0.50 2.0 95 5 4.50 2.0 595 5.50 2.0 5 95 6.00 2.0 95 5Detection—MS, ELS, UV (2004 split to MS with in-line HP1100 DADdetector). MS ionization method—Electrospray (positive and negativeion).Method 4.

VG Platform II quadrupole spectrometer with a C18-reverse-phase column(30×4.6 mm Phenomenex Luna 3 μm particle size, elution with A:water+0.1% formic acid; B: acetonitrile+0.1% formic acid. Gradient:

Gradient-Time flow mL/min % A % B 0.00 2.0 95 5 0.30 2.0 95 5 4.30 2.0 595 5.30 2.0 5 95 5.80 2.0 95 5 6.00 2.0 95 5Detection—MS, ELS, UV (200 μl/min split to the ESI source with inlineHP1050 DAD detector). MS ionization method—Electrospray (positive andnegative ion).Method 5.

Waters micromass ZQ2000 quadrupole mass spectrometer with an Acquity BEHC18 1.7 um 100×2.1 mm, Acquity BEH Shield RP18 1.7 um 100×2.1 mm orAcquity HSST3 1.8 um 100×2.1 mm, maintained at 40° C. Elution with A:water+0.1% formic acid; B: acetonitrile+0.1% formic acid. Gradient:

Gradient-Time flow mL/min % A % B 0.00 0.4 95 5 0.40 0.4 95 5 6.00 0.4 595 6.80 0.4 5 95 7.00 0.4 95 5 8.00 0.4 95 5Detection—MS, UV PDA. MS ionization method—Electrospray (positive andnegative ion).Method 6.

Phenomenex Gemini C18-reverse-phase column (250×21.20 mm 5 μm particlesize), elution with A: water+0.1% formic acid; B: CH₃CN+0.1% formicacid. Gradient—90% A/10% B to 2% A/98% B over 20 min—flow rate 18mL/min. Detection—In-line UV detector set at 254 nM wavelength.

Method 7.

Agilent 1260 infinity purification system. Column: XSELECT CSH Prep C18OBD, particle size 5 μm, 30×150 mm, RT. Elution with A: water+0.1%formic acid; B: CH₃CN+0.1% formic acid. Gradient—90% A/10% B to 2% A/95%B over 22 min—flow rate 60 mL/min. Detection—In-line Agilent 6100 seriessingle Quadrupole LC/MS.

Method 8.

Agilent 1260 infinity purification system. Column: XBridge Prep C18 OBD,particle size 5 μm, 30×150 mm, RT. Elution with A: water+0.1% ammonia;B: CH₃CN+0.1% ammonia. Gradient—90% A/10% B to 2% A/95% B over 22min—flow rate 60 mL/min. Detection—In-line Agilent 6100 series singleQuadrupole LC/MS.

Differential Scanning Calorimetry (DSC).

It should be recognized that the endotherm peak as measured is dependenton a number of factors including the machine used, the rate of heating,the calibration standard, humidity and the purity of the sample used.Melting points reported in the experimentals are estimated on the basisof the onset of endotherm peaks registered during DSC analysis.

It is to be understood by the skilled person that, where the expression“partial formate salt” is used, it is to be intended as identifyingderivatives where only part of the basic compound has been convertedinto formate salt and thus containing less than one equivalent offormate counterion. Exact salt/free base ratio is provided by associatedNMS analysis.

Intermediate A. (1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-ol

a. 2,2,2-Trifluoro-N—(S)-1,2,3,4-tetrahydro-naphthalen-1-yl-acetamide(Intermediate Aa)

Ethyl trifluoroacetate (24.2 mL, 204 mmol) was added dropwise to asolution of (S)-(1,2,3,4-tetrahydro-naphthalen-1-yl)amine (Alfa Aesar;25.0 g, 170 mmol) and triethylamine (35.5 mL, 255 mmol) in MeOH (250 mL)at RT and stirred for 18 h. The mixture was concentrated toapproximately ⅓ of its volume and then partitioned between DCM (200 mL)and water (200 mL). The aqueous layer was extracted into DCM (3×) andthe combined organic layers were washed with brine, dried (MgSO₄) andconcentrated in vacuo to yield the title compound (41.1 g, 169 mmol,99%). ¹H NMR (400 MHz, CDCl₃): 1.80-1.95 (3H, m), 2.05-2.15 (1H, m),2.75-2.90 (2H, m), 5.18-5.25 (1H, q, J 5.0 Hz), 6.38-6.48 (1H, br s),7.12-7.16 (1H, m), 7.20-7.26 (3H, m).

b.2,2,2-Trifluoro-N—((S)-4-oxo-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide(Intermediate Ab)

Magnesium sulfate monohydrate (46.6 g, 338 mmol) in water (500 mL) wasadded to an ice cold solution of Intermediate Aa (41.1 g, 169 mmol) inacetone (1.0 L). Potassium permanganate (80.1 g, 507 mmol) was addedportionwise (10.0 g portions) over a period of 45 min. The mixture wasthen stirred for 18 h. Sodium thiosulfate pentahydrate (126 g, 510 mmol)in water (400 mL) was added and the reaction stirred for 30 min. Themixture was concentrated to ˜300 mL, then water (1.0 L), Celite (60 g)and EtOAc (1.0 L) were sequentially added. The mixture was thoroughlystirred, and then filtered through a pad of Celite. The aqueous layerwas extracted into EtOAc (3×) and the combined organic layers washedwith brine, dried (MgSO₄) and concentrated in vacuo to yield the titlecompound (36.6 g, 142 mmol, 84%). ¹H NMR (400 MHz, CDCl₃): 2.20-2.30(1H, dddd, J 13.3, 10.0, 8.8, 4.5 Hz), 2.43-2.52 (1H, dddd, J 13.3, 7.2,4.6, 4.6 Hz), 2.67-2.77 (1H, ddd, J 17.4, 10.1, 4.6 Hz), 2.78-2.88 (1H,ddd, J 17.4, 7.1, 4.6 Hz), 5.39-5.47 (1H, td, 8.5, 4.5 Hz), 7.32-7.37(1H, d, J 7.7 Hz), 7.44-7.49 (1H, t, J 7.6 Hz), 7.59-7.64 (1H, td, J7.6, 1.4 Hz), 8.03-8.07 (1H, dd, J 7.7, 1.4 Hz).

c.2,2,2-Trifluoro-N-((1S,4R)-4-hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide(Intermediate Ac)

Degassed DMF (argon sparged, 100 mL) was added to Intermediate Ab (8.00g, 31.3 mmol) and[N-[(1R,2R)-2-(amino-κN)-1,2-diphenylethyl]-4-methylbenzenesulfonamidato-κN]chloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene]-ruthenium(Strem Chemicals Inc.; 594 mg, 0.93 mmol). Triethylamine (8.66 mL, 62.6mmol) was added slowly to ice cold formic acid (2.34 mL, 62.6 mmol) andstirred for 20 min, this was then added to the DMF solution. Thereaction was heated to 60° C. for 18 h. After cooling, the mixture waspartitioned between DCM (200 mL) and water (600 mL). The aqueous layerwas extracted DCM (3×) and the combined organic layers washed withbrine, dried (MgSO₄) and concentrated in vacuo. Purification by FCC,using 0-100% EtOAc in cyclohexane, afforded the title compound (7.10 g,27.4 mmol, 88%). ¹H NMR (400 MHz, CDCl₃): 1.88-1.92 (1H, d, J 4.8 Hz),1.98-2.18 (4H, m), 4.80-4.88 (1H, m), 5.165-5.24 (1H, m), 6.70-6.80 (1H,br s), 7.25-7.30 (1H, m), 7.30-7.40 (2H, m), 7.45-7.50 (1H, m).

d. (1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-ol (Intermediate A)

Sodium hydroxide (2.10 g, 53.0 mmol) was added to an ice cold solutionof Intermediate Ac (3.43 g, 13.2 mmol) in MeOH/water (2:1, 50 mL) andstirred for 3.5 h. The mixture was loaded on to a SCX-2 cartridge,eluting with MeOH then 2M NH₃ in MeOH, to yield the title compound (2.30g, 13.2 mmol, 99%). ¹H NMR (400 MHz, d₆-DMSO): 1.66-1.90 (4H, m),3.71-3.77 (1H, t, J 5.4 Hz), 4.46-4.54 (1H, t, J 5.4 Hz), 7.14-7.22 (2H,m), 7.32-7.38 (1H, m), 7.40-7.46 (1H, m).

Intermediate B. (1S,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-ol

a.2,2,2-Trifluoro-N-((1S,4S)-4-hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide(Intermediate Ba)

Argon was bubbled through a solution of Intermediate Ab (8.00 g, 31.1mmol) and[N-[(1S,2S)-2-(amino-κN)-1,2-diphenylethyl]-4-methylbenzenesulfonamidato-κN]chloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene]-ruthenium(Strem Chemicals Inc.; 0.06 g, 0.93 mmol) in dry DMF (100 mL) for 10min. A premixed combination of formic acid (2.4 mL, 62.2 mmol) and Et₃N(8.60 mL, 62.2 mmol) was added and the mixture stirred at 50° C. for 24h. After cooling, the mixture was concentrated to ˜25 mL. Water (70 mL)was added and the resulting precipitate filtered, and washed with DCM(3×30 mL) and diethyl ether (30 mL) to leave a solid (4.75 g). Thefiltrate was decanted to leave a dark solid. Subsequent purification byFCC, using 0-30% EtOAc in cyclohexane, gave a solid. This was combinedwith the first obtained solid to give the title compound as a beigesolid (5.93 g, 74%). ¹H NMR (400 MHz, d₆-DMSO): 1.60-1.83 (2H, m),2.06-2.17 (2H, m), 4.60 (1H, m), 5.08 (1H, m), 5.28 (1H, d), 7.07 (1H,m), 7.25 (1H, ddd), 7.28 (1H, ddd), 7.50 (1H, dd), 9.78 (1H, d).

b. (1S,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-ol (Intermediate B)

To a grey solution of Intermediate Ba (5.55 g, 21.4 mmol) in MeOH (50mL), NaOH (1.28 g, 32.1 mmol) in water (15 mL) was added and the mixturestirred at RT for 3 days. NaOH (1.28 g, 32.1 mmol) was added and thebrown solution was stirred for 5 h. The solution was loaded on to aSCX-2 cartridge, eluting with MeOH then 2M NH₃ in MeOH, to leave a greysolid. The solid was suspended in DCM (50 mL), sonicated, filtered anddried under vacuum to leave the title compound as a pale grey solid(2.93 g, 84%). ¹H NMR (400 MHz, d₆-DMSO): 1.41-1.64 (2H, m), 2.02-2.13(2H, m), 3.82 (1H, dd), 4.55 (1H, dd), 5.08 br s), 7.13-7.22 (2H, m),7.35-7.49 (2H, m).

Example 11-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 3-Pyrrolidin-1-yl-propionic acid N′-(5-fluoro-pyridin-2-yl)-hydrazide(Intermediate 1a)

5-fluoro-2-hydrazinopyridine (285 mg, 2.24 mmol) and3-(pyrrolidin-1-yl)propanoic acid hydrochloride (400 mg, 2.24 mmol) weredissolved in DMF (15 mL). EDC (516 mg, 2.69 mmol), HOBt (30.0 mg, 0.22mmol) and triethylamine (374 μL, 2.69 mmol) were added and the reactionstirred for 18 h. The mixture was loaded onto an SCX-2 cartridge, whichwas washed with MeOH then with 2M NH₃ in MeOH. The basic fractions wereevaporated in vacuo then purified by FCC using 0-10% [2M NH₃ in MeOH] inDCM to give the title compound contaminated with several impurities (400mg). The product was used in the next step without further purification.

b. 6-Fluoro-3-(2-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 1b)

Intermediate 1a (400 mg) was dissolved in THF (20 mL) and cooled in anice/water bath. Triphenylphosphine (643 mg, 2.45 mmol) was addedfollowed by triethylamine (682 μL, 4.90 mmol) and hexachloroethane (581mg, 2.45 mmol). The reaction mixture was stirred for 18 h and thenloaded onto an SCX-2 cartridge, which was washed with MeOH then elutedwith 2M NH₃ in MeOH. The resulting residue was purified by FCC using0-10% [2M NH₃ in MeOH] in DCM to give the title compound (292 mg, 1.16mmol, 52%). ¹H NMR (400 MHz, CDCl₃): 1.80-1.87 (4H, m), 2.60-2.68 (4H,m), 3.00-3.10 (2H, t, J 7.3), 3.24-3.34 (2H, t, J 7.3), 7.13-7.21 (1H,ddd, J 9.9, 7.6, 2.3), 7.70-7.77 (1H, dd, J 9.8, 4.5), 8.00-8.04 (1H,m).

c.(1S,4R)-4-[3-(2-Pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 1c)

Intermediate A (189 mg, 1.16 mmol) was added to a suspension of sodiumhydride (60% in mineral oil, 139 mg, 3.48 mmol) in DMF (5 mL). Thereaction was stirred for 20 mins, then Intermediate 1b (292 mg, 1.16mmol) was added in DMF (5 mL) and the reaction heated to 60° C. for 2 h.The mixture was cooled and quenched by dropwise addition of MeOH. Thesolution was loaded onto an SCX-2 cartridge, which was washed with MeOHand product eluted with 2M NH₃ in MeOH. The residue was purified by FCCusing 0-10% [2M NH₃ in MeOH] in DCM to give the title compound (270 mg,0.74 mmol, 64%). ¹H NMR (400 MHz, d₄-MeOD): 1.80-1.86 (4H, m), 1.92-2.02(1H, m), 2.05-2.18 (2H, m), 2.30-2.40 (1H, m), 2.62-2.70 (4H, m),2.99-3.05 (2H, t, J 7.8), 3.28-3.36 (2H, t, J 7.8), 3.98-4.04 (1H, dd, J8.6, 5.2), 5.46-5.50 (1H, t, J 4.3), 7.22-7.40 (4H, m), 7.54-7.58 (1H,d, J 7.8), 7.63-7.68 (1H, dd, J 9.8, 0.7), 7.97 (1H, s), 8.09-8.11 (1H,d, J 1.6).

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 1).

Intermediate 1c (270 mg, 0.74 mmol) was dissolved in 1,4-dioxane (6 mL)and (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;329 mg, 0.81 mmol) and DIPEA (257 μL, 1.48 mmol) were added. Thereaction was heated to 60° C. for 18 h. After cooling, the mixture waspartitioned between EtOAc (50 mL) and water (50 mL), and then extractedinto EtOAc (3×). The combined organic extracts were washed with brine,dried (MgSO₄) and evaporated in vacuo. The residue was purified by FCC,using 0-10% [2M NH₃ in MeOH] in DCM, then further purified by HPLC (C18X-select column, 10-98% MeCN in H₂O, 0.1% formic acid) to give the titlecompound (78.0 mg, 0.12 mmol, 17%). LCMS (Method 5): Rt 3.67 mins, m/z633 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.30 (9H, s), 1.90-2.06 (6H, m),2.07-2.18 (1H, m), 2.22-2.30 (1H, m), 2.39 (3H, s), 3.08-3.16 (4H, m),3.42-3.50 (4H, m), 4.87-4.92 (1H, dd, J 9.0, 5.6), 5.43-5.47 (1H, t, J4.2), 6.33 (1H, s), 7.20-7.36 (10H, m), 7.62-7.66 (1H, d, J 9.7),8.07-8.09 (1H, d, J 1.6), 8.45 (0.6H, s).

Example 21-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{(3-[2-(4-methyl-piperazin-1-yl)-ethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-ureaformate salt

a. 3-(4-Methyl-piperazin-1-yl)-propionic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 2a)

5-fluoro-2-hydrazinopyridine (295 mg, 2.32 mmol) and3-(4-methyl-1-piperazinyl)propionic acid (400 mg, 2.32 mmol) weredissolved in DCM (15 mL). EDC (536 mg, 2.79 mmol) and HOBt (31.0 mg,0.23 mmol) were added and the reaction stirred for 18 h. The mixture wasloaded onto an SCX-2 cartridge, which was washed with MeOH producteluted with 2M NH₃ in MeOH. Further purification by FCC, using 0-10% [2MNH₃ in MeOH] in DCM, afforded the title compound (458 mg, 1.63 mmol,73%). ¹H NMR (400 MHz, CDCl₃): 2.32 (3H, s), 2.48-2.54 (2H, t, J 6.0),2.54-2.70 (8H, br s), 2.69-2.75 (2H, t, J 6.0), 6.60-6.65 (1H, dd, J8.9, 3.3), 6.75-6.78 (1H, d, J 4.4), 7.25-7.34 (1H, m), 8.02-8.05 (1H,d, J 3.0), 10.50 (1H, s).

b.6-Fluoro-3-[2-(4-methyl-piperazin-1-yl)-ethyl]-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 2b)

Intermediate 2a (458 mg, 1.63 mmol) was dissolved in THF (15 mL) andcooled in an ice/water bath. Triphenylphosphine (854 mg, 3.26 mmol) wasadded followed by triethylamine (907 μL, 6.52 mmol) and hexachloroethane(773 mg, 3.26 mmol). The reaction was stirred for 18 h and then loadedonto an SCX-2 cartridge, which was washed with MeOH and product elutedwith 2M NH₃ in MeOH. Further purification by FCC, using 0-10% [2M NH₃ inMeOH] in DCM, afforded the title compound (310 mg, 1.18 mmol, 72%). LCMS(Method 4): Rt 0.28 min, m/z 264 [MH⁺].

c.(1S,4R)-4-{3-[2-(4-Methyl-piperazin-1-yl)-ethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 2c)

Intermediate A (180 mg, 1.11 mmol) was added to a suspension of sodiumhydride (60% in mineral oil, 133 mg, 3.33 mmol) in DMF (5 mL). Thereaction was stirred for 20 min, then Intermediate 2b (310 mg, 1.11mmol) was added in DMF (5 mL) and the resulting mixture heated to 60° C.for 3 h. After cooling, the reaction was quenched by dropwise additionof MeOH. The solution was loaded onto an SCX-2 cartridge, which waswashed with MeOH and product eluted with 2M NH₃ in MeOH. The residue waspurified by FCC, using 2-20% [2M NH₃ in MeOH] in DCM, to give the titlecompound (200 mg, 0.47 mmol, 43%). LCMS (Method 4): Rt 0.28 min, m/z 407[MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-ureaformate salt (Example 2).

Intermediate 2c (85.0 mg, 0.21 mmol) was dissolved in 1,4-dioxane (2 mL)and (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;96.0 mg, 0.24 mmol) and DIPEA (75.0 μL, 0.43 mmol) were added. Thereaction was heated to 60° C. for 18 h. After cooling, the mixture waspartitioned between EtOAc (50 mL) and water (50 mL), and extracted intoEtOAc (3×). The combined organic layers were washed with brine, dried(MgSO₄) and evaporated in vacuo. The residue was purified by FCC, using0-10% [2M NH₃ in MeOH] in DCM, then further purified by HPLC (C18X-select column, 10-40% MeCN in H₂O, 0.1% formic acid) to give the titlecompound mainly as formic acid salt (43.0 mg, 0.065 mmol, 31%). LCMS(Method 5) Rt 3.54 mins, ink 662 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.30(9H, s), 1.90-2.05 (2H, m), 2.06-2.15 (1H, m), 2.20-2.30 (1H, m), 2.38(3H, s), 2.40 (3H, s), 2.55-2.75 (8H, br s), 2.90-2.95 (2H, t, J 7.4),3.29-3.32 (2H, t, J 7.4), 4.86-4.92 (1H, dd, J 8.8, 5.6), 5.43-5.47 (1H,t, J 4.2), 6.33 (1H, s), 7.21-7.35 (11H, m), 7.60-7.64 (1H, d, J 9.9),8.07-8.09 (1H, d, J 1.9), 8.40-8.50 (0.4H, br s, formate).

Example 31-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. Piperidine-1-carboxylic acid N′-(5-fluoro-pyridin-2-yl)-hydrazide(Intermediate 3a)

1-Piperidine carbonyl chloride (348 mg, 0.30 mL, 2.36 mmol) was addeddropwise to a solution of 5-fluoro-2-hydrazinyl-pyridine (see forreference WO 2010/022076, which is incorporated herein by reference inits entirety; 0.30 g, 2.36 mmol) and DIPEA (1.2 mL, 7.08 mmol) in DCM(10 mL) at RT under nitrogen and the mixture stirred for 2 h. Thesolution was washed with water (2×15 mL) and dried (Na₂SO₄). The solventwas evaporated and the residue triturated (diethyl ether) and filteredto afford the title compound as an off-white solid (475 mg, 84%). LCMS(Method 1): Rt 1.82 min, m/z 239 [MH⁺].

b. 6-Fluoro-3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 3b)

Hexachloroethane (826 mg, 3.92 mmol) was added portionwise to a solutionof Intermediate 3a (466 mg, 1.95 mmol), triphenylphosphine (1.03 g, 3.92mmol) and triethylamine (1.1 mL, 7.83 mmol) in dry THF (30 mL) at RT,and the mixture stirred for 2 h. The resulting precipitate was filteredoff and the filtrate evaporated. The residue was purified by SCX-2,eluting with MeOH followed by 2M NH₃ in MeOH, to give the title compoundas pale orange coloured gum (206 mg, 48%). LCMS (Method 1): Rt 2.44 min,m/z 221 [MH⁺].

c.(1S,4R)-4-(3-Piperidin1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cis-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 3c)

Intermediate A (100 mg, 0.61 mmol) was added portionwise to a suspensionof sodium hydride (60% in mineral oil, 73 mg, 1.84 mmol) in dry DMF (2mL) at RT, and the mixture stirred for 15 min. Intermediate 3b (135 mg,0.61 mmol) was then added in one portion and the mixture heated at 60°C. for 3 h. After cooling, saturated NH₄Cl (ca. 0.2 mL) added. Themixture was then partitioned between water (15 mL) and ethyl acetate(3×15 mL) and the combined organic extracts washed with brine (2×15 mL)and dried (Na₂SO₄). The solvent was evaporated and the residue purifiedby SCX-2, eluting with MeOH followed by NH₃ in MeOH, to give the titlecompound as brown coloured gum (133 mg, 60%). LCMS (Method 1): Rt 1.95min, m/z 364 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 3).

The title compound was prepared starting from Intermediate 3c and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety) byusing an analogous procedure to that described in Example 1 step d. LCMS(Method 5): Rt 4.79 min, m/z 916 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.32(9H, s), 1.60-1.77 (6H, m), 1.86-1.95 (1H, m), 2.01-2.11 (2H, m),2.20-2.27 (1H, m), 2.36 (3H, t), 3.15 (4H, m), 5.08 (1H, m), 5.18 (1H,m), 5.41 (1H, d, J 9.20), 6.28 (1H, s), 6.48 (1H br s), 6.96 (1H, dd, J2.12, 9.75), 7.21 (2H, d, J 8.13), 7.24-7.33 (6H, m), 7.38-7.41 (2H, m),7.45-7.48 (1H, d, J 9.65).

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureaCrystallization of Example 3

1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(3.974 g, Example 3) was dissolved in hot tert-butyl alcohol (˜130 ml)and then dried by lyophilisation overnight. The solid material was thenslurried in iso-propyl acetate (120 ml) in a maturation chamber whichcycled between ambient and 50° C. with four hours spent under eachcondition. After 3 days the reaction was cooled to RT and then stirredat RT for four days. The resulting off-white solid was isolated byfiltration and dried at 40° C./0.5 mbar. Yield=3.67 g (92%). Mpt=253° C.

Example 41-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.4-[N′-(5-fluoro-pyridin-2-yl)-hydrazinocarbonyl]-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 4a)

EDC (543 mg, 2.83 mmol) was added portionwise to a stirred solution of5-fluoro-2-hydrazinyl-pyridine (for reference procedure see WO2010/022076, which is incorporated herein by reference in its entirety;0.30 g, 2.36 mmol), piperidine-1,4-dicarboxylic acid mono-tert-butylester (Aldrich, 649 mg, 2.83 mmol) and HOBt (32 mg, 0.24 mmol) in dryDCM (20 mL). The mixture was stirred at RT for 18 h. The solution waswashed with water (2×20 mL), dried (Na₂SO₄) and evaporated. The residuewas triturated (diethyl ether) to give the title compound as anoff-white solid (713 mg, 82%). LCMS (Method 1): Rt 2.76 min, m/z 339[MH⁺].

b.4-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 4b)

Hexachloroethane (990 mg, 4.18 mmol) was added portionwise to a solutionof Intermediate 4a (707 mg, 2.09 mmol), triphenylphosphine (1.103 g,4.18 mmol) and triethylamine (1.2 mL, 8.36 mmol) in dry THF (30 mL) atRT. The mixture was stirred for 2 h. The resulting precipitate wasfiltered off and the filtrate evaporated. The residue was purified bySCX-2, eluting with MeOH followed by 2M NH₃ in MeOH, to give a paleorange coloured solid. This was triturated (diethyl ether) to give thetitle compound as a buff-coloured solid (540 mg, 80%). LCMS (Method 1):Rt 2.79 min, m/z 321 and 221(-Boc) [MH⁺].

c.4-[6-((1S,4R)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-piperidine-1-carboxylicacid tert-butyl ester. (Intermediate 4c)

Intermediate A (100 mg, 0.61 mmol) was added portionwise to a suspensionof sodium hydride (60% in mineral oil, 73 mg, 1.84 mmol) in dry DMF (2mL) at RT. The mixture was then stirred for 15 min. Intermediate 4b (193mg, 0.61 mmol) was added in one portion and the mixture heated at 60° C.for 3 h. After cooling, saturated NH₄Cl (ca. 0.2 mL) added. The mixturewas partitioned between water (15 mL) and ethyl acetate (3×15 mL) andthe combined organic extracts washed with brine (2×15 mL), dried(Na₂SO₄) and evaporated. The residue was purified by SCX-2, eluting withMeOH followed by 2M NH₃ in MeOH, to give the title compound as browncoloured foam (261 mg, 92%). LCMS (Method 1): Rt 2.19 min, m/z 464[MH⁺].

d.4-(6-[{(1S,4R)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidine-1-carboxylic acidtert-butyl ester. (Intermediate 4d)

The title compound was prepared starting from Intermediate 4c and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety) byusing an analogous procedure to that described in Example 1 step d. LCMS(Method 1): Rt 3.89 min, m/z 719 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 4).

HCl (4M in dioxane, 1 mL) was added dropwise to a solution ofIntermediate 4d (272 mg, 0.37 mmol) in MeOH (1 mL) and the mixturestirred at RT for 5 h. The reaction mixture was passed down a SCX-2cartridge, eluting with MeOH followed by 2M NH₃ in MeOH, to afford abrown foam. Further purification by HPLC (50-95% MeCN in H₂O) gave thetitle compound as a off-white powder (37 mg). LCMS (Method 5): Rt 3.65min, m/z 519 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.33 (9H, s), 1.87-1.97(5H, m), 2.05-2.13 (2H, m), 2.22-2.29 (1H, m), 2.37 (3H, s), 2.71-2.81(1H, m), 3.10 (1H, m), 3.19 (2H, m), 5.08 (1H, m), 5.22 (1H, m), 5.44(1H, m), 6.29 (1H, s), 7.06 (1H, dd, J 2.13, 9.80), 7.23-7.32 (7H, m),7.39-7.45 (3H, m), 7.63 (1H, d, J 9.75).

Example 51-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. (S)-1-Methyl-pyrrolidine-2-carboxylic acid[N′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 5a)

EDC (271 mg, 1.41 mmol) was added portionwise to a solution of5-fluoro-2-hydrazinyl-pyridine (for reference procedure see WO2010/022076, which is incorporated herein by reference in its entirety;0.15 g, 1.18 mmol), N-methyl-L-proline monohydrate (0.20 g, 1.36 mmol)and HOBt (16 mg, 0.12 mmol) in dry DCM (5 mL) at RT and stirred for 16h. The solution was diluted with DCM (15 mL), washed with water (150mL), dried (Na₂SO₄) and evaporated to give the title compound as a paleyellow gum (189 mg, 67%). LCMS (Method 1): Rt 0.31 min, m/z 239 [MH⁺].

b.6-Fluoro-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 5b)

Hexachloroethane (375 mg, 1.59 mmol) was added portionwise to a solutionof Intermediate 5a (189 mg, 0.79 mmol), triphenylphosphine (416 mg, 1.59mmol) and triethylamine (0.44 mL, 3.17 mmol) in dry THF (10 mL) at RTand stirred for 4 h. The resulting precipitate was filtered off and thefiltrate evaporated. The residue was purified by SCX-2, eluting withMeOH followed by 2M NH₃ in MeOH gave the title compound as a brown foam(136 mg, 78%). LCMS (Method 1): Rt 0.45 min, m/z 221 [MH⁺].

c.(1S,4R)-4-[3-((S)-1-Methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine.(Intermediate 5c)

Intermediate A (128 mg, 0.77 mmol) was added portionwise to a suspensionof sodium hydride (60% in mineral oil, 92 mg, 2.30 mmol) in dry DMF (3mL) at RT and stirred for 15 mins. Intermediate 5b (169 mg, 0.77 mmol)was then added in one portion and the mixture heated at 60° C. for 4 h.After cooling, saturated NH₄Cl (ca. 0.2 mL) was added. The mixture waspartitioned between water (10 mL) and ethyl acetate (3×10 mL). Theaqueous phase was concentrated in vacuo and the residue purified bySCX-2, eluting with MeOH followed by 2M NH₃ in MeOH, to give the titlecompound as brown coloured foam (103 mg, 36%). LCMS (Method 1): Rt 1.34min, m/z 364 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 5).

The title compound was prepared with Intermediate 5c and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety)using an analogous procedure to that described in Example 1 step d. LCMS(Method 5): Rt 3.76 min, m/z 319 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.33(9H, s), 1.88-2.12 (6H, m), 2.21 (3H, s), 2.21-2.30 (2H, m), 2.33-2.39(1H, m), 2.37 (3H, s), 3.19-3.24 (1H, m), 3.98-4.02 (1H, m), 5.05-5.12(1H, m), 5.17 (1H, t, J 4.0), 5.25 (1H, d, J 8.7), 6.25-6.27 (2H, m),7.03 (1H, dd, J 2.0, 9.8), 7.22-7.34 (6H, m), 7.40 (2H, d, J 8.5), 7.61(1H, d, J 9.8), 8.27 (1H, m).

Example 61-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((S)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.(S)-2-[N′-(5-fluoro-pyridin-2-yl)-hydrazinocarbonyl]-pyrrolidine-1-carboxylicacid tert-butyl ester (Intermediate 6a)

EDC (543 mg, 2.83 mmol) was added portionwise to a stirred solution of5-fluoro-2-hydrazinyl-pyridine (for reference procedure see WO2010/022076, which is incorporated herein by reference in its entirety;0.30 g, 2.36 mmol), N-tert-butylcarbonyl-L-proline (609 mg, 2.83 mmol)and HOBt (32 mg, 0.24 mmol) in dry DCM (15 mL) at RT and stirred for 18h. The solution was washed with water (2×20 mL) and dried (Na₂SO₄) andevaporated to give the title compound as a pale yellow foam (767 mg,100%). LCMS (Method 1): Rt 2.69 min, m/z 325 [MH⁺].

b.(S)-2-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester (Intermediate 6b)

Hexachloroethane (1.34 g, 5.65 mmol) was added portionwise to a solutionof Intermediate 6a (917 mg, 2.83 mmol), triphenylphosphine (1.48 g, 5.65mmol) and triethylamine (1.6 mL, 11.3 mmol) in dry THF (15 mL) at RT andstirred for 4 h. The resulting precipitate was filtered off and thefiltrate evaporated. The residue was purified by SCX-2, eluting withMeOH followed by 2M NH₃ in MeOH, to give the title compound as abuff-coloured foam (669 mg, 77%). LCMS (Method 4): Rt 2.48 min, m/z 307[MH⁺].

c.(S)-2-[6-((1S,4R)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-pyrrolidine-1-carboxylicacid tert-butyl ester. (Intermediate 6c)

Intermediate A (150 mg, 0.92 mmol) was added portionwise to a suspensionof sodium hydride (60% in mineral oil, 110 mg, 2.76 mmol) in dry DMF (2mL) at RT and stirred for 15 mins. Intermediate 6b (281 mg, 0.92 mmol)was then added in one portion and the mixture heated at 60° C. for 3 h.After cooling, saturated NH₄Cl (ca. 0.2 mL) was added. The mixture waspartitioned between water (15 mL) and ethyl acetate (3×15 mL). Thecombined organic extracts were washed with brine (20 mL), dried (Na₂SO₄)and evaporated to give the title compound as brown coloured gum (74 mg,18%). LCMS (Method 1): Rt 2.08 min, m/z 450 [MH⁺].

d.(S)-2-(6-[{(1S,4R)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester. (Intermediate 6d)

The title compound was prepared starting from Intermediate 6c and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety) byusing an analogous procedure to that described in Example 1 step d. LCMS(Method 1): Rt 3.88 min, m/z 705 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((S)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 6).

HCl (4M in dioxane; 1 mL) was added to a solution of Intermediate 6d(225 mg, 0.32 mmol) in MeOH (0.5 mL) at RT and stirred for 8 h. Thesolution was loaded on to a SCX-2 (10 g) cartridge, eluting with MeOHfollowed by 2M NH₃ in MeOH, to give a brown foam. Further purificationby HPLC (50-85% MeCN in H₂O (0.1% NH₃)) gave the title compound as anoff-white powder after freeze drying (7 mg, 4%). LCMS (Method 5): Rt3.73 min, m/z 605 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.29 (9H, s),1.84-2.07 (5H, m), 2.18-2.31 (3H, m), 2.35 (3H, s), 2.96-3.07 (2H, m),4.64 (1H, t, J 7.5), 5.01-5.08 (1H, m), 5.19 (1H, t, J 4.0), 5.27 (1H,d, J 8.8), 6.24 (2H, s), 7.02 (1H, dd, J 2.2, 10.0), 7.19-7.28 (6H, m),7.37 (2H, d, J 8.4), 7.58 (1H, d, J 10.0), 7.98 (1H, m).

Example 71-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperazin-1-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.4-[N′-(5-fluoro-pyridin-2-yl)-hydrazinocarbonylmethyl]-piperazine-1-carboxylicacid tert-butyl ester (Intermediate 7a)

EDC (543 mg, 2.83 mmol) was added portionwise to a solution of2-(4-Boc-1-piperazinyl)acetic acid (576 mg, 2.36 mmol),5-fluoro-2-hydrazinyl-pyridine (for reference procedure see WO2010/022076, which is incorporated herein by reference in its entirety;0.30 g, 2.36 mmol) and HOBt (32 mg, 0.24 mmol) in dry DCM (15 mL) at RTand stirred for 16 h. The solution was diluted with DCM (20 mL), washedwith water (2×20 mL) and dried (Na₂SO₄). The solvent was evaporated togive the title compound as an off-white solid (667 mg, 80%). LCMS(Method 1): Rt 1.99 min, m/z 354 [MH⁺].

b.4-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-piperazine-1-carboxylicacid tert-butyl ester (Intermediate 7b)

Hexachloroethane (893 mg, 3.77 mmol) was added portionwise to a solutionof Intermediate 7a (667 mg, 1.89 mmol), triphenylphosphine (990 mg, 3.77mmol) and triethylamine (1.05 mL, 7.55 mmol) in dry THF (20 mL) at RTand stirred for 4 h. The resulting precipitate was filtered off and thefiltrate evaporated. The residue was purified by SCX-2, eluting withMeOH followed by 2M NH₃ in MeOH, to give an off-white solid. This wastriturated (diethyl ether) to give the title compound as a colourlesssolid LCMS (Method 1): Rt 2.33 min, m/z 336 [MH⁺].

c.4-[6-((1S,4R)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl]-piperazine-1-carboxylicacid tert-butyl ester. (Intermediate 7c)

The title compound was prepared with Intermediate 7b and Intermediate Ausing an analogous procedure to that described in Example 6 step c. LCMS(Method 1): Rt 1.98 min, m/z 479 [MH⁺].

d.4-(6-{(1S,4R)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-piperazine-1-carboxylicacid tert-butyl ester. (Intermediate 7d)

The title compound was prepared starting from Intermediate 7c and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety) byusing an analogous procedure to that described in Example 1 step d. LCMS(Method 1): Rt 3.59 min, m/z 734 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperazin-1-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 7).

HCl (4M in dioxane; 1 mL) was added to a solution of Intermediate 7d (92mg, 0.12 mmol) in MeOH (1 mL) at Rt and stirred for 4.5 h. The solutionwas loaded on to a SCX-2 cartridge, eluting with MeOH followed by 2M NH₃in MeOH, to give a pale yellow foam. Further purification by HPLC(40-80% MeCN in H₂O (0.1% NH3)) gave the title compound as an off-whitepowder after freeze drying (28 mg, 35%). LCMS (Method 5): Rt 3.59 min,m/z 634 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.33 (9H, s), 1.89-1.98 (1H, m),2.06-2.14 (2H, m), 2.25-2.32 (1H, m), 2.38 (3H, s), 2.38-2.48 (4H, m),2.80-2.83 (4H, m), 4.03 (2H, s), 5.06-5.12 (1H, m), 5.20-5.24 (2H, m),6.28 (1H, s), 6.34 (1H, br s), 7.08 (1H, dd, J 9.8, 2.0), 7.23-7.36 (6H,m), 7.40 (2H, d, J 7.7), 7.63 (1H, d, J 9.5), 8.14 (1H, m).

Example 81-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-isopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 2-(5-Fluoropyridin-2-yl)-N-(propan-2-yl)hydrazinecarboxamide(Intermediate 8a)

Isopropyl isocyanate (0.25 mL, 2.60 mmol) was added dropwise, over 2min, to a solution of 5-fluoro-2-hydrazinyl-pyridine (for referenceprocedure see WO 2010/022076, which is incorporated herein by referencein its entirety; 0.30 g, 2.36 mmol) in dry DCM (10 mL) at RT and stirredfor 3 h. The solvent was evaporated and the residue triturated (diethylether) and filtered to give the title compound as a colourless solid(464 mg, 93%). LCMS (Method 1): Rt 1.92 min, m/z 213 [MH⁺].

b. (6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-isopropyl-amine.(Intermediate 8b)

Hexachloroethane (1.77 g, 7.75 mmol) was added portionwise to a solutionof Intermediate 8a 822 mg, 3.87 mmol), triphenylphosphine (2.03 g, 7.75mmol) and triethylamine (2.2 mL, 15.49 mmol) in dry THF (15 mL) at RTand stirred for 16 h. The resulting precipitate was filtered off and thefiltrate evaporated. The residue was purified by SCX-2, eluting withMeOH followed by 2M NH₃ in MeOH, to give the title compound as abuff-coloured foam (618 mg, 82%). LCMS (Method 1): Rt 1.55 min, m/z 195[MH⁺].

c. (6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-isopropyl-carbamic acidtert-butyl ester (Intermediate 8c)

Di-tert-butyl dicarbonate (472 mg, 2.16 mmol) in dry DCM (1 mL) wasadded to a solution of Intermediate 8b (168 mg, 0.86 mmol) in DCM (2mL). 4-(1-pyrrolidinyl)pyridine (ca. 5 mg) was then added at RT andstirred for 5 h. The solvent was evaporated and the residue purified bySCX-2, eluting with MeOH then 2M NH₃ in MeOH, affording a dark colouredfoam. Further purification by FCC, using 0-10% [2M NH₃ in MeOH] in DCM,afforded the title compound (112 mg). LCMS (Method 4): Rt 2.90 min, m/z295 [MH⁺]/589 [2MH⁺]

d.[6-((1S,4R)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy-[1,2,4]triazolo[4,3-a]pyridin-3-yl]isopropyl-carbamicacid tert-butyl ester (Intermediate 8d)

Sodium hydride (60% in mineral oil, 45 mg, 1.14 mmol) was addedportionwise to a solution of Intermediate A (62 mg, 0.38 mmol) in dryDMF (1 mL) at RT and stirred for 15 min. Intermediate 8c (112 mg, 0.38mmol) was added and the mixture heated at 60° C. for 4 h. After cooling,the mixture was partitioned between water (10 mL) and EtOAc (3×10 mL)and the combined organic extracts washed with brine (2×15 mL), dried(Na₂SO₄) and evaporated. The residue was purified by SCX-2, eluting withMeOH then 2M NH₃ in MeOH, affording a dark gum. Further purification byFCC, using 0-10% [2M NH₃ in MeOH] in DCM, afforded the title compound(75 mg, 45%). LCMS (Method 1): Rt 2.20 min, m/z 438 [MH⁺].

e.(6-{(1S,4R)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-isopropyl-carbamicacid tert-butyl ester. (Intermediate 8e)

The title compound was prepared starting from Intermediate 8d and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety) byusing an analogous procedure to that described in Example 1 step d. LCMS(Method 4): Rt 3.98 min, ink 693 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-isopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 8).

HCl (4.0 M in dioxane; 1 mL) was added to a solution of Intermediate 8e(110 mg, 0.16 mmol) in MeOH (1 mL) at RT and stirred for 5 h. Thesolution was loaded on to a SCX-2 cartridge, eluting with MeOH then 2MNH₃ in MeOH, to afford a dark gum. Further purification by HPLC (elutingwith 50-90% MeCN in H₂O (0.1% NH3)) gave the title compound as acolourless powder after freeze drying (10 mg, 11%). LCMS (Method 5): Rt4.15 min, m/z 593 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.21-1.27 (15H, m),1.87 (1H, m), 2.00 (2H, m), 2.10 (1H, m), 2.31 (3H, s), 3.85 (1H, br s),3.94 (1H, m), 5.02 (1H, m), 5.11 (1H, t, J 4.13), 5.59 (1H, d), 6.24(1H, s), 6.54 (1H, s), 6.84 (1H, dd, J 9.93, 2.05), 7.14 (3H, d, J8.13), 7.20-7.26 (3H, m), 7.30-7.34 (3H, m).

Example 91-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(6-cyano-pyridin-3-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.5-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-pyridine-2-carbonitrile(Intermediate 9a)

Intermediate A (300 mg, 1.84 mmol) was added to an ice cold stirredsuspension of sodium hydride (60% in mineral oil, 221 mg, 5.52 mmol) inDMF (15 mL) and stirred for 15 min. 2-Cyano-5-fluoropyridine (224 mg,1.84 mmol) was added and the reaction warmed to RT. After 90 min, thereaction was quenched by dropwise addition of water and the mixturepartitioned between EtOAc (75 mL) and water (150 mL). The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was purified by FCC, using 0-5% [2M NH₃ in MeOH] in DCM, to givethe title compound (255 mg, 0.96 mmol, 52%). LCMS (Method 4): Rt 0.28,1.73, m/z 266.1 [MH⁺].

b.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(6-cyano-pyridin-3-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 9).

The title compound was prepared starting from Intermediate 9a and[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety)using an analogous procedure to that described in Example 1 step d. LCMS(Method 5): Rt 5.25 mins, m/z 521 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.29(9H, s), 1.76-1.88 (1H, m), 2.00-2.20 (3H, m), 2.36 (3H, s), 4.94-4.98(1H, d, J 8.8), 5.00-5.08 (1H, m), 5.38-5.42 (1H, t, J 3.6), 6.03 (1H,s), 6.22 (1H, s), 7.16-7.20 (1H, m), 7.21-7.26 (3H, m), 7.26-7.32 (3H,m), 7.34-7.38 (2H, d, J 8.3), 7.63-7.66 (1H, d, J 8.8), 8.36-8.38 (1H,d, J 2.7).

Example 10N-(4-{(1S,4S)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-pyridin-2-yl)-2-methoxy-acetamide

a. ((1S,4S)-4-Hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-carbamic acidtert-butyl ester (Intermediate 10a)

Intermediate B (1.62 g, 9.94 mmol) was suspended in acetonitrile (35 mL)then di-tert-butyl-dicarbonate (2.40 g, 11 mmol) was added. Mixturestirred at RT for 16 h. Some insoluble material was still present, somixture filtered through Celite, washing with DCM. Filtrate wasevaporated to give an off-white solid and then purified by FCC, elutingwith 0-80% ethyl acetate in cyclohexane, to give the title compound as awhite solid (2.38 g, 91%). ¹H NMR (300 MHz, d₆-DMSO): 1.42 (9H, s),1.54-1.70 (2H, m), 1.92-2.18 (2H, m), 4.46-4.73 (2H, m), 5.17 (1H, d, J6.3), 7.10-7.25 (4H, m), 7.39-7.46 (1H, m).

b.[(1S,4S)-4-(2-Chloro-pyridin-4-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-carbamicacid tert-butyl ester (Intermediate 10b)

Sodium hydride (60% in mineral oil, 0.32 g, 8.00 mmol) was suspended indry DMF (15 mL) under argon. To this was added Intermediate 10a (1.05 g,4.00 mmol) followed by 2-chloro-4-nitropyridine (0.64 g, 4.02 mmol). Thedark coloured mixture was stirred at RT under argon for 30 min. Thereaction mixture was diluted with water and extracted with DCM (3×30mL). The combined organic layers were washed with brine, dried (Na₂SO₄),filtered, concentrated in vacuo. Purification by FCC, eluting with 0-70%ethyl acetate in cyclohexane, gave the title compound as a white foam(1.43 g, 95%). LCMS (Method 3): Rt 4.22 min, m/z 373.1 [MH⁺].

c.{(1S,4S)-4-[2-(2-Methoxy-acetylamino)-pyridin-4-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-carbamicacid tert-butyl ester (Intermediate 10c)

Intermediate 10b (562 mg, 1.50 mmol), 2-methoxyacetamide (334 mg, 3.75mmol), Xantphos (173 mg, 0.30 mmol) and potassium carbonate (518 mg,3.75 mmol) were suspended in 1,4-dioxane (20 mL), warmed, degassed, andplaced under argon. To this mixture palladium acetate (34.0 mg, 0.15mmol) was added. The mixture was degassed and then heated at reflux for17 h. After cooling, the mixture was filtered through Celite, washingwith DCM, and evaporated to a yellow gum. Purification by FCC, elutingwith 0-100% ethyl acetate in cyclohexane, gave the title compound as awhite foam (281 mg, 44%). LCMS (Method 3): Rt 3.27 min, m/z 450.2[MNa⁺].

d.N-[4-((1S,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-pyridin-2-yl]-2-methoxy-acetamide(Intermediate 10d)

To a solution of Intermediate 10c (272 mg, 0.64 mmol) in DCM (6 mL) wasadded TFA (2 mL), and the mixture stirred at RT for 30 min. The mixturewas concentrated in vacuo. The residue was purified on an Isolute SCX-2cartridge, eluting with MeOH then 0.4-1M NH₃ in MeOH, to give the titlecompound as a colourless gum (208 mg, 100%). LCMS (Method 3): Rt 0.44min, m/z 350.2 [MNa⁺].

e.N-(4-{(1S,4S)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-pyridin-2-yl)-2-methoxy-acetamide(Example 10).

To a solution of Intermediate 10d (204 mg, 0.62 mmol) and DIPEA (0.127mL, 0.80 mmol) in 1,4-dioxane (6 mL),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;315 mg, 0.78 mmol) was added. The mixture was heated at 80° C. underargon for 17 h, and then evaporated to dryness. The residue was purifiedby FCC, eluting with 0-100% ethyl acetate in cyclohexane, to give theslightly impure product (0.262 g). Further purification by HPLC (Method6) gave the title compound as a white solid (102 mg, 28%). LCMS (Method5): Rt 4.51 min, m/z 583 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.26 (9H, s),1.69-1.81 (1H, m), 1.90-2.24 (3H, m), 2.36 (3H, s), 3.36 (3H, s), 4.05(2H, s), 4.86-4.94 (1H, m), 5.62-5.67 (1H, m), 6.32 (1H, s), 6.91 (1H,dd, J 2.5, 5.9), 7.03 (1H, d, J 8.4), 7.26-7.37 (8H, m), 7.60 (1H, br d,J 2.0), 8.01 (1H, s), 8.16 (1H, d, J 5.7), 9.90 (1H, s).

Example 111-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[1-(2-hydroxy-ethyl)-1H-indazol-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 6-Fluoro-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indazole(Intermediate 11a)

A mixture of 6-fluoro-1H-indazole (2.0 g, 14.7 mmol), and2-(2-bromo-ethoxy)-tetrahydro-pyran (3.38 g, 16.2 mmol) in DMF (25 mL)was treated with caesium carbonate (6.1 g, 18.7 mmol) and stirred at RTfor 18 h. The solvent volume was reduced in vacuo, and the residuepartitioned between EtOAc (100 mL) and water (100 mL). The aqueous layerwas extracted into EtOAc (3×). The combined organic layers were washedwith saturated aqueous sodium chloride solution, dried (MgSO₄) andevaporated in vacuo. The residue was purified by FCC, using 0-50%cyclohexane in EtOAc, to afford the title product and a yellow oil. LCMS(Method 1): Rt 3.42 min, m/z 181 [MH⁺] (M-THP). ¹H NMR (300 MHz; CDCl₃)1.52-1.56 (6H, m), 3.39-3.49 (1H, m), 3.57-3.68 (1H, m), 3.89-3.91 (1H,m), 4.19-4.21 (1H, m), 4.56-4.57 (3H, m), 6.88 (1H, td, J 9.15 and2.26), 7.30 (1H, m), 7.62 (1H, m), 8.04 (1H, s).

b.2-[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-indazol-1-yl]-ethanol(Intermediate 11b)

Intermediate A (212 mg, 1.3 mmol) was added portionwise to a suspensionof sodium hydride (60% in mineral oil, 120 mg, 3.0 mmol) in DMF (3 mL)at RT and stirred for 20 min. A solution of Intermediate 11a (264.3 mg,1.0 mmol) in DMF (1 mL) was then added dropwise and the resultingmixture stirred at 60° C. for 2.5 h. After cooling, the mixture wasdiluted with EtOAc (50 mL) and poured onto ice water. The organic layerwas washed with saturated aqueous sodium chloride solution, dried(MgSO₄), filtered and concentrated in vacuo. The residue was loaded onto a SCX-2 cartridge, eluting with MeOH then 2M NH₃ in MeOH. Furtherpurification by FCC, using 0-10% [2M NH₃ in MeOH] in DCM to give thetitle compound as a brown oil. LCMS (Method 1): Rt 1.80 min, m/z 323[MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[1-(2-hydroxy-ethyl)-1H-indazol-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 11).

The title compound was prepared starting from Intermediate 11b and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;315 mg, 0.78 mmol) by using an analogous procedure to that described inExample 1 step d. LCMS (Method 5): Rt 4.99 min, m/z 578 [MH⁺]. ¹H NMR(400 MHz, d₆-DMSO): 1.22 (9H, s), 1.81-1.92 (2H, m), 2.02-2.06 (2H, m),2.31 (3H, s), 3.74-3.75 (2H, m), 4.34 (2H, t, J 5.75), 4.78 (2H, m),5.53 (1H, t, J 4.8), 6.28 (1H, s), 6.74 (1H, dd, J 8.75 and 2.03), 7.08(1H, d, J 8.53), 7.27-7.28 (9H, m), 7.57 (1H, d, J 8.75), 7.89 (1H, s),7.96 (1H, s).

Example 121-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((R)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

The title compound was prepared starting fromN-tert-butylcarbonyl-D-proline using analogous procedures to thosedescribed in Example 6. LCMS (Method 5): Rt 3.69 min, m/z 605 [MH⁺]; ¹HNMR (400 MHz, CDCl₃): 1.33 (9H, s), 1.86-2.39 (8H, m), 2.36 (3H, s),2.96-3.08 (2H, m), 4.51 (1H, t, J 7.4 Hz), 5.04-5.10 (1H, m), 5.24 (1H,t, J 4.0 Hz), 5.52 (1H, d, J 8.1 Hz), 6.30 (1H, s), 6.57 (1H, br s),7.03 (1H, dd, J 2.2, 10.0 Hz), 7.20 (2H, d, J 7.9 Hz), 7.23-7.34 (4H,m), 7.38 (2H, d, J 7.4 Hz), 7.56 (1H, d, J 9.8 Hz), 7.92 (1H, m).

Example 13N-(4-{(1R,4S)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-pyridin-2-yl)-2-methoxy-acetamide

The title compound was prepared starting from Intermediate A by usinganalogous procedures to those described in Example 10. LCMS (Method 5):Rt 4.54 min, m/z 583 [MH⁺]; ¹H NMR (400 MHz, d₆-DMSO): 1.21 (9H, s),1.66-2.11 (4H, m), 2.31 (3H, s), 3.31 (3H, s), 4.0 (2H, s), 4.72-4.81(1H, m), 5.49-5.58 (1H, m), 6.26 (1H, s), 6.86 (1H, dd, J 5.8, 2.2 Hz),7.07 (1H, d, J 8.5 Hz), 7.19-7.33 (8H, m), 7.68 (1H, d, J 2.2 Hz), 7.96(1H, s), 8.12 (1H, d, J 5.8 Hz), 9.86 (1H, br s).

Example 141-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a. (4-Methyl-piperazin-1-yl)-acetic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 14a)

5-Fluoro-2-hydrazinyl-pyridine (for reference procedure see WO2010/022076, which is incorporated herein by reference in its entirety;500 mg, 3.94 mmol) and 4-methyl-1-piperazin-1-yl acetic acid (684 mg,4.33 mmol) were dissolved in DMF (10.0 mL). EDC (831 mg, 4.33 mmol) andHOBt (53.0 mg, 0.39 mmol) were added and the reaction stirred for 18 h.The mixture was loaded onto an SCX-2 cartridge, which was washed withMeOH then eluted with 2M NH₃ in MeOH. The resulting residue was purifiedby FCC, using 4-20% [2M NH₃ in MeOH] in DCM, to give the title compound(570 mg, 54%). ¹H NMR (400 MHz, CDCl₃): 2.32 (3H, s), 2.47-2.56 (4H, brs), 2.62-2.71 (4H, br s), 3.18 (2H, s), 6.56-6.61 (1H, br s), 6.60-6.66(1H, dd, J 8.9, 3.4 Hz), 7.26-7.32 (1H, m), 8.02-8.05 (1H, d, J 2.9 Hz),8.93 (1H, br s).

b.6-Fluoro-3-(4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 14b)

Intermediate 14a (570 mg, 2.13 mmol) was dissolved in THF (20.0 mL) andcooled in an ice/water bath. Triphenylphosphine (1.12 g, 4.27 mmol) wasadded followed by triethylamine (1.19 mL, 8.54 mmol) andhexachloroethane (1.01 g, 4.27 mmol). The reaction was stirred for 18 h.The mixture was loaded onto an SCX-2 cartridge, washing with MeOH andeluting with 2M NH₃ in MeOH. The residue was purified by FCC, using0-10% [2M NH₃ in MeOH] in DCM, to give the title compound (470 mg, 1.89mmol, 89%). LCMS (Method 1): Rt 0.36 min, m/z 250 [MH⁺].

c.(1S,4R)-4-[3-(4-Methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 14c)

Intermediate A (200 mg, 1.22 mmol) was added to a suspension of sodiumhydride (60% in mineral oil, 146 mg, 3.66 mmol) in DMF (6.0 mL) andstirred for 20 min. Intermediate 14b (305 mg, 1.22 mmol) was added andthe reaction heated to 60° C. for 90 min. The mixture was cooled andquenched by dropwise addition of MeOH. The solution was diluted withMeOH and loaded onto an SCX-2 cartridge, washing with MeOH and elutingwith 2M NH₃ in MeOH. The residue was purified by FCC, using 0-10% [2MNH₃ in MeOH] in DCM to give the title compound (240 mg, 0.61 mmol, 50%).LCMS (Method 4): Rt 0.29 min, m/z 393 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 14).

Intermediate 14c (120 mg, 0.31 mmol) was dissolved in 1,4-dioxane (2.0mL) and [5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;124 mg, 0.31 mmol) and diisopropylethylamine (106 μL, 0.61 mmol) wereadded. The reaction was heated to 60° C. for 20 h. After cooling, themixture was partitioned between EtOAc (50 mL) and water (50 mL), andextracted into EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄) and evaporated in vacuo. The residue was purifiedby FCC, using 0-10% [2M NH₃ in MeOH] in DCM, then further purified byHPLC (C18 X-select column, 20-70% MeCN in H₂O, 0.1% formic acid) to givethe title compound as the formic acid salt (103 mg, 0.16 mmol, 52%).LCMS (Method 5): Rt 3.63 min, m/z=648 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.30 (9H, s), 1.90-1.99 (1H, m), 1.99-2.07 (1H, m), 2.10-2.19 (1H, m),2.21-2.30 (1H, m), 2.37 (3H, s), 2.38 (3H, s), 2.52-2.67 (8H, br s),4.05-4.09 (1H, d, J 14.3 Hz), 4.11-4.15 (1H, d, J 14.3 Hz), 4.88-4.93(1H, dd, J 8.9, 5.6 Hz), 5.41-5.44 (1H, t, J 4.3 Hz), 6.33 (1H, s),7.22-7.36 (11H, m), 7.63-7.67 (1H, d, J 10.0 Hz), 8.21-8.22 (1H, d, J1.9 Hz), 8.44-8.45 (0.25H, s).

Example 151-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-morpholin-4-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureaformate salt

The title compound was prepared starting from 1-morpholinoacetic acid byusing analogous procedures to those described for Example 14. LCMS(Method 5): Rt 4.02 min, m/z=635 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.30(9H, s), 1.90-1.97 (1H, m), 1.97-2.07 (1H, m), 2.10-2.19 (1H, m),2.23-2.31 (1H, m), 2.38 (3H, s), 2.42-2.53 (4H, m), 3.60-3.64 (4H, m),4.01-4.05 (1H, d, J 14.3 Hz), 4.08-4.12 (1H, d, J 14.3 Hz), 4.88-4.93(1H, dd, J 9.0, 5.6 Hz), 5.42-5.45 (1H, t, J 4.3 Hz), 6.33 (1H, s),7.22-7.36 (11H, m), 7.63-7.66 (1H, d, J 10.0 Hz), 8.24-8.26 (1H, d, J2.0 Hz), 8.48-8.52 (0.25H, s).

Example 161-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

The title compound was prepared starting from 1-pyrrolidin-1-yl-aceticacid hydrochloride (for reference procedure see U.S. Pat. No. 5,756,533,which is incorporated herein by reference in its entirety) by usinganalogous procedures to those described for Example 14. LCMS (Method 5):Rt 3.72 min, m/z=619 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.30 (9H, s),1.80-1.85 (4H, m), 1.90-2.05 (2H, m), 2.07-2.15 (1H, m), 2.21-2.30 (1H,m), 2.38 (3H, s), 2.65-2.70 (4H, m), 4.21-4.26 (1H, d, J 14.3 Hz),4.26-4.31 (1H, d, J 14.3 Hz), 4.87-4.92 (1H, dd, J 8.9, 5.6 Hz),5.40-5.43 (1H, t, J 4.3 Hz), 6.33 (1H, s), 7.21-7.36 (11H, m), 7.63-7.67(1H, d, J 9.9 Hz), 8.23-8.24 (1H, d, J 1.9 Hz), 8.29-8.31 (0.3H, br s).

Example 171-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[6-(morpholine-4-carbonyl)-pyridin-3-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (5-Fluoro-pyridin-2-yl)-morpholin-4-yl-methanone (Intermediate 17a)

2-Cyano-5-fluoropyridine (1.00 g, 8.19 mmol) was dissolved inhydrochloric acid (37% aqueous, 1.0 mL) and heated to 60° C. for 18 hand then evaporated in vacuo. The residue was suspended in DMF (40.0 mL)and EDC (1.89 g, 9.83 mmol), HOBt (111 mg, 0.82 mmol), morpholine (787μL, 9.00 mmol) and triethylamine (1.25 mL, 9.00 mmol) were added and thereaction stirred for 18 h. The reaction was partitioned between water(200 mL) and EtOAc (100 mL), and extracted into EtOAc (3×). The combinedorganic layers were washed with brine, dried (MgSO₄) and evaporated invacuo. The residue was purified by FCC, using 0-8% [2M NH₃ in MeOH] inDCM, to give the title compound (350 mg), contaminated with a singleimpurity (˜10% by NMR integration). The product was used in the nextstep without further purification. LCMS (Method 1): Rt 1.88 min, m/z 211[MH⁺].

b.[5-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-pyridin-2-yl]-morpholin-4-yl-methanone(Intermediate 17b)

Intermediate A (150 mg, 0.92 mmol) was added to a suspension of sodiumhydride (60% in mineral oil, 147 mg, 3.66 mmol) in DMF (3.0 mL). Thereaction was stirred for 20 min, then Intermediate 17a (280 mg) in DMF(3.0 mL) was added and the reaction heated to 60° C. for 90 min. Themixture was cooled and quenched by dropwise addition of MeOH. Thesolution was diluted with MeOH and loaded onto an SCX-2 cartridge, whichwas washed sequentially with MeOH and 2M NH₃ in MeOH. The basicfractions were evaporated in vacuo then purified by FCC, using 0-10% [2MNH₃ in MeOH] in DCM, to give the title compound (234 mg, 0.66 mmol,72%). LCMS (Method 4): Rt 1.60 min, m/z 354 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[6-(morpholine-4-carbonyl)-pyridin-3-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 17).

Intermediate 17b (234 mg, 0.66 mmol) was dissolved in 1,4-dioxane (7.0mL) and [5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;268 mg, 0.66 mmol) and diisopropylethylamine (229 μL, 1.32 mmol) wereadded. The reaction mixture was heated to 60° C. for 20 h, then cooled,partitioned between EtOAc (50 mL) and water (50 mL), and extracted intoEtOAc (3×). The combined organic layers were washed with brine, dried(MgSO₄) and evaporated in vacuo. The residue was purified by FCC, using0-10% [2M NH₃ in MeOH] in DCM, to give the title compound (120 mg, 0.20mmol, 30%). LCMS (Method 5): Rt 4.76 min, m/z=609 [MH⁺]. ¹H NMR (400MHz, d₄-MeOD): 1.30 (9H, s), 1.85-2.05 (2H, m), 2.05-2.18 (2H, m), 2.38(3H, s), 3.57-3.76 (8H, br m), 4.86-4.92 (1H, dd, J 8.6, 5.5 Hz),5.54-5.57 (1H, t, J 4.3 Hz), 6.33 (1H, s), 7.20-7.34 (9H, m), 7.58-7.65(2H, m), 8.24-8.26 (1H, dd, J 2.4, 0.8 Hz).

Example 181-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 4-Morpholin-4-ylmethyl-benzoic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 18a)

HOBt (53 mg, 0.39 mmol) was added to (5-fluoro-pyridin-2-yl)-hydrazine(for reference procedure see WO 2010/022076, which is incorporatedherein by reference in its entirety; 500 mg, 3.94 mmol),4-morpholin-4-ylmethyl-benzoic acid (1.04 g, 4.72 mmol) and EDC (907 mg,4.72 mmol) in DCM (5.0 mL) and the reaction stirred for 4 h. Thereaction was partitioned between DCM (75 mL) and saturated aqueousNaHCO₃ (75 mL) and the aqueous layer extracted with DCM (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo then purified by FCC using [0.5-7.5% 2M NH₃ inMeOH] in DCM to give the title compound (980 mg, 2.97 mmol, 75%). LCMS(Method 4): Rt 0.27, m/z 331 [MH⁺].

b.6-Fluoro-3-(4-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 18b)

To an ice cold solution of Intermediate 18a (980 mg, 2.97 mmol) in THF(15 mL) was added triphenylphosphine (1.56 g, 5.94 mmol), triethylamine(1.65 mL, 11.9 mmol) and hexachloroethane (1.40 g, 5.94 mmol). Thereaction was stirred for 90 min then partitioned between EtOAc (75 mL)and water (75 mL) and the aqueous layer extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo then purified by SCX-2, washing with MeOH andeluting with 2M NH₃ in MeOH to give the title compound (640 mg, 2.05mmol, 69%). LCMS (Method 2): Rt 0.28, 1.32, m/z 313 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 18).

The title compound was prepared starting from Intermediate 18b usinganalogous procedures to those described for Example 14. LCMS (Method 5):Rt 3.79 mins, m/z=711 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.29 (9H, s),1.80-1.90 (1H, m), 1.96-2.08 (2H, m), 2.16-2.24 (1H, m), 2.33 (3H, s),2.44-2.49 (4H, t, J 4.2 Hz), 3.56 (2H, s), 3.68-3.71 (4H, t, J 4.6 Hz),5.00-5.06 (1H, td, J 8.8, 5.2 Hz), 5.11-5.17 (2H, m), 6.22 (2H, s),7.06-7.10 (1H, dd, J 9.9, 2.1 Hz), 7.17-7.22 (3H, m), 7.24-7.30 (3H, m),7.33-7.36 (2H, d, J 8.4 Hz), 7.49-7.53 (2H, d, J 8.1 Hz), 8.68-7.71 (2H,d, J 8.2 Hz), 7.71 (1H, s), 7.81-7.82 (1H, d, J 1.6 Hz).

Example 191-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from3-morpholin-4-ylmethyl-benzoic acid by using analogous procedures tothose described for Example 18. LCMS (Method 5): Rt 3.81 mins, m/z 711.3[MH⁺]; ¹H NMR (400 MHz, d₄-MeOD): 1.29 (9H, s), 1.89-2.10 (3H, m),2.20-2.28 (1H, m), 2.37 (3H, s), 2.45-2.50 (4H, t, J 4.3 Hz), 3.61 (2H,s), 3.61-3.65 (4H, t, J 4.6 Hz), 4.84-4.88 (1H, dd, J 8.9, 5.7 Hz),5.36-5.39 (1H, t, J 4.1 Hz), 6.31 (1H, s), 7.18-7.38 (9H, m), 7.53-7.59(2H, m), 7.70-7.74 (1H, dt, J 6.4, 2.3 Hz), 7.72-7.75 (1H, d, J 9.9 Hz),7.80 (1H, s), 8.02-8.04 (1H, d, J 1.7 Hz).

Example 201-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from2-morpholin-4-ylmethyl-benzoic acid by using analogous procedures tothose described for Example 18. LCMS (Method 5): Rt 4.00 mins, m/z 711.4[MH⁺]; ¹H NMR (400 MHz, d₄-MeOD): 1.30 (9H, s), 1.82-2.02 (3H, m),2.04-2.18 (5H, m), 2.38 (3H, s), 3.08-3.16 (4H, br s), 3.50-3.54 (1H, d,J 13.5 Hz), 3.54-3.58 (1H, d, J 13.5 Hz), 4.81-4.86 (1H, dd, J 8.8, 5.6Hz), 5.29-5.33 (1H, t, J 4.0 Hz), 6.31 (1H, s), 7.17-7.35 (9H, m),7.35-7.39 (1H, dd, J 9.9, 2.0 Hz), 7.49-7.59 (6H, m), 7.74-7.78 (1H, d,J 9.9 Hz).

Example 211-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(6-morpholin-4-ylmethyl-pyridin-3-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

Borane dimethylsulfide complex (2M in THF, 99 μL, 0.20 mmol) was addedto a solution of Example 17 (60.0 mg, 0.099 mmol) in THF (3.00 mL). Thereaction stirred for 20 min then heated to 60° C. overnight. Thereaction was cooled and further borane dimethylsulfide complex (2M inTHF, 99 μL, 0.20 mmol) added. After stirring for 20 min at RT thereaction was heated to 60° C. overnight. The reaction was cooled andfurther borane dimethylsulfide complex (2M in THF, 99 μL, 0.20 mmol)added. After stirring for 20 min at RT the reaction was heated to 60° C.overnight. The reaction was cooled and quenched by dropwise addition ofMeOH, then evaporated in vacuo. The residue was then partitioned betweenEtOAc and water. The aqueous layer was then extracted with EtOAc (3×).The combined organic layers were washed with brine, dried (MgSO₄),filtered and evaporated in vacuo. The residue was purified by HPLC (C18X-select column, 10-60% MeCN in H₂O, 0.1% HCO₂H) to give the titlecompound as a white powder after freeze-drying (11 mg, 19%). LCMS(Method 5): Rt 3.78 min, m/z 595.2 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.30 (9H, s), 1.86-2.15 (4H, m), 2.38 (3H, s), 2.46 (4H, t, J 9.3), 3.57(2H, s), 3.66 (4H, t, J 9.4), 4.89 (1H, dd, J 8.7, 5.7), 5.44 (1H, t, J8.7), 6.33 (1H, s), 7.19-7.34 (8H, m), 7.44 (1H, d, J 8.5), 7.51 (1H,dd, J 8.7, 2.9), 8.15 (1H, d, J 2.8).

Example 221-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-piperidin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.4-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 22a)

A dark brown solution of (5-fluoro-pyridin-2-yl)-hydrazine (549 mg, 4.32mmol) and N-Boc-4-piperidine acetaldehyde (Aldrich, 982 mg, 4.32 mmol)in EtOH (10 mL) was stirred at reflux for 30 min, then cooled to 0° C.,diluted with DCM (25 mL) and then (diacetoxyiodo)benzene (1.67 g, 5.18mmol) was added portionwise over 1 min. The purple solution was stirredat RT for 30 min, then aqueous NaOH (1M, 20 mL) was added and themixture shaken. The aqueous layer was extracted with DCM (2×20 mL), thenthe combined organics passed through a hydrophobic frit and concentratedin vacuo to leave an orange solid. FCC, using 3% MeOH in DCM, gave thetitle compound as a pale orange solid (1.53 g, 90%). LCMS (Method 3): Rt3.15, m/z 235 [M-CO₂C₄H₉+H⁺].

b.4-[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl]-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 22b)

To a solution of Intermediate A (392 mg, 2.40 mmol) in dry DMF (5 mL)was added NaH (60% dispersion in mineral oil, 240 mg, 6.00 mmol) and theresulting brown suspension was stirred at RT for 45 min (CARE: gasevolution). Intermediate 22a (669 mg, 2.00 mmol) was added and the darkbrown solution stirred at 60° C. for 2 h. The cooled solution wasconcentrated in vacuo, redissolved in MeOH (5 mL), applied to an SCX-2cartridge (20 g) and washed with MeOH (100 mL). The product was elutedwith 2M NH₃ in MeOH (75 mL); concentration in vacuo left a dark brownresidue. FCC, using 4-9% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a brown oil (421 mg, 44%). LCMS (Method 3): Rt 2.45 min, m/z478 [MH⁺].

c.4-(6-{(1R,4S)-4-[3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-ureido]-1,2,3,4-tetrahydro-naphthalen-1-yloxy}-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 22c)

A dark brown solution of(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;162 mg, 0.401 mmol), Intermediate 22b (174 mg, 0.364 mmol) and DIPEA(0.079 mL, 0.455 mmol) in DMF (5 mL) was stirred at 100° C. for 3 h. Thesolution was cooled to RT, concentrated in vacuo, suspended in water (10mL) and extracted with DCM (2×10 mL). The combined organics were passedthrough a hydrophobic frit and concentrated in vacuo to leave a browngum. FCC, using 2-6% MeOH in DCM, gave the title compound as anoff-white solid (155 mg, 58%). LCMS (Method 3): Rt 4.16 min, m/z 733[MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-4-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 22d)

An orange solution of Intermediate 22c (155 mg, 0.211 mmol) and TFA(0.157 mL, 2.11 mmol) in DCM (3 mL) was stirred at RT for 3 h. Thesolution was concentrated in vacuo, redissolved in MeOH (1 mL), appliedto an SCX-2 cartridge (2 g) and washed with MeOH (15 mL). The productwas eluted with 2M NH₃ in MeOH (15 mL); concentration in vacuo left thetitle compound as a pale brown solid (116 mg, 87%). LCMS (Method 3): Rt2.90 min, m/z 633 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-piperidin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 22).

To a suspension of Intermediate 22d (58 mg, 0.0917 mmol) andformaldehyde (37% wt in water, 0.074 mL, 0.917 mmol) in DCM-MeOH (4:1,2.5 mL), were added AcOH (0.0105 mL, 0.183 mmol) and NaBH(OAc)₃ (38.8mg, 0.183 mmol) sequentially, then the solution stirred at RT for 2.5 h.The solution was concentrated in vacuo to ˜0.5 mL volume, diluted withMeOH (0.5 mL), then applied to an SCX-2 cartridge and washed with MeOH(15 mL). The product was eluted with 2M NH₃ in MeOH (15 mL);concentration in vacuo left a pale brown solid. HPLC (XBridge C18,40-98% MeCN in H₂O, 0.1% NH₄OH) gave the title compound as a white solidafter freeze-drying (15.0 mg, 25%). LCMS (Method 5): Rt 3.66 min, m/z647 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.22 (9H, s), 1.26 (2H, m), 1.58(2H, d, J 12.6), 1.75 (2H, t, J 11.4), 1.78-1.92 (3H, m), 2.03 (2H, m),2.07 (3H, s), 2.31 (3H, s), 2.68 (2H, d, J 10.7), 2.97 (2H, d, J 7.0),4.78 (1H, m), 5.48 (1H, t, J 4.5), 6.27 (1H, s), 7.07 (1H, d, J 8.5),7.11 (1H, dd, J 9.5, 2.0), 7.23-7.35 (8H, m), 7.63 (1H, d, J 9.8), 8.03(1H, s), 8.17 (1H, s).

Example 231-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[1-(2,2-difluoro-ethyl)-piperidin-4-ylmethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea

To an orange solution of Intermediate 22d (58 mg, 0.0917 mmol) and DIPEA(0.0319 mL, 0.183 mmol) in DCM-MeOH (4:1, 2.5 mL), was added2,2-difluoroethyl trifluoromethane-sulfonate (Fluorochem, 29.4 mg, 0.138mmol) and the solution stirred at RT for 2 h. DIPEA (0.0319 mL, 0.183mmol) and 2,2-difluoroethyl trifluoromethanesulfonate (29.4 mg, 0.138mmol) were added sequentially, and the pale green solution stirred at RTfor 1 h. Water (2 mL) was added and the mixture extracted with DCM (2×3mL). The combined organics were passed through a hydrophobic frit andconcentrated in vacuo to leave a pale green-brown solid. HPLC (XBridgeC18, 50-98% MeCN in H₂O, 0.1% NH₄OH) gave the title compound as a whitesolid after freeze-drying (11.5 mg, 18%). LCMS (Method 5): Rt 3.75 min,m/z 697 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.22 (9H, s), 1.24-1.33 (2H,m), 1.59 (2H, d, J 13.0), 1.75-1.92 (3H, m), 2.01-2.10 (4H, m), 2.31(3H, s), 2.62 (2H, td, J 15.8, 4.8), 2.82 (2H, d, J 11.4), 2.98 (2H, d,J 7.2), 4.78 (1H, m), 5.48 (1H, t, J 4.7), 6.04 (1H, tt, J 55.7, 4.4),6.27 (1H, s), 7.07 (1H, d, J 8.9), 7.11 (1H, dd, J 10.0, 2.2), 7.21-7.35(8H, m), 7.63 (1H, d, J 9.8), 8.03 (1H, s), 8.17 (1H, d, J 2.0).

Example 241-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-(4-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 6-Fluoro-[1,2,4]triazolo[4,3-a]pyridine (Intermediate 24a)

(5-Fluoro-pyridin-2-yl)-hydrazine (500 mg, 3.93 mmol) in diethoxymethylacetate (5 mL) was stirred at RT for 2 h. The resulting precipitate wasdiluted with cyclohexane (5 ml) and filtered to give the title compound(379 mg, 70%). ¹H NMR (400 MHz, CDCl₃): 7.25 (1H, m), 7.84 (1H, m), 8.09(1H, t), 8.84 (1H, s).

b. 3-Chloro-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine (Intermediate 24b)

A solution of Intermediate 24a (789 mg, 5.98 mmol) andN-chlorosuccinimide (878 mg, 6.57 mmol) in chloroform (15 mL) was heatedat 65° C. overnight. The cooled mixture was washed with sat. aq. NaHCO₃solution (2×15 mL) and dried (Na₂SO₄). The solvent was evaporated, thenthe residue suspended in diethyl ether (10 mL) and filtered to give thetitle compound (730 mg, 76%). LCMS (Method 1): Rt 1.83 min, m/z 172[MH⁺].

c. 1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl-piperidin-4-ol(Intermediate 24c)

A brown solution of Intermediate 24b (855 mg, 4.98 mmol) and4-hydroxypiperidine (2.02 g, 19.9 mmol) in DMA (15 mL) was irradiated to175° C. in the microwave for 3 h. The cooled solution was concentratedin vacuo, then the residue diluted with water (20 mL) and brine (20 mL).The mixture was washed with diethyl ether (2×50 mL), then extracted withEtOAc (2×50 mL). The combined EtOAc layers were washed with brine (50mL), dried (Na₂SO₄), filtered and concentrated in vacuo to leave ayellow oil. The aqueous was further extracted with DCM (3×50 mL). Thecombined DCM layers were passed through a hydrophobic frit andconcentrated in vacuo to leave a brown oil. The two oils were combined.FCC, using 4-5% [2M NH₃ in MeOH] in DCM, gave the title compound as ayellow crystalline solid (514 mg, 44%). LCMS (Method 3): Rt 1.96 min,m/z 237 [MH⁺].

d.6-Fluoro-3-(4-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 24d)

Triisopropylsilyl trifluoromethanesulfonate (395 mg, 1.29 mmol) wasadded dropwise to a solution of Intermediate 24c (254 mg, 1.07 mmol) andEt₃N (0.20 mL, 1.40 mmol) in DMF (3 mL) at RT under N₂. The mixture wasstirred for 1 h then Et₃N (0.10 ml, 0.70 mmol) and triisopropylsilyltrifluoromethanesulfonate (200 mg, 0.65 mmol) were added sequentially,and the mixture stirred for 1 h. The solvent was evaporated, the residueapplied to an SCX-2 cartridge and washed with MeOH. The product waseluted with 2M NH₃ in MeOH; concentration in vacuo left the titlecompound (339 mg, 80%). LCMS (Method 1): Rt 4.74 min, m/z 393 [MH⁺].

e.(1S,4R)-4-[3-(4-Triisopropylsilanyloxy-piperidin-1-yl-[1,2,4]triazolo[4,3a]pyridin-6-yloxy]1,2,3,4-tetrahydro-naphthalen-1-ylamine.(Intermediate 24e)

Intermediate A (81 mg, 0.497 mmol) was added dropwise to a suspension ofNaH (60% dispersion in oil, 59 mg, 1.49 mmol) in DMF (3 mL) at RT underN₂. The mixture was stirred for 15 min then Intermediate 24d (150 mg,0.382 mmol) was added and the mixture stirred at 60° C. under N₂ for 3h. Sat. aq. NH₄Cl solution (0.2 mL) was added to the cooled mixturewhich was then diluted with water (15 mL) and extracted with EtOAc (3×15mL). The combined organics were washed with brine (15 mL) and dried(Na₂SO₄). The solvent was evaporated, the residue applied to an SCX-2cartridge and washed with MeOH. The product was eluted with 2M NH₃ inMeOH; concentration in vacuo left the title compound (180 mg, 90%). LCMS(Method 1): Rt 3.05 min, m/z 536 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-(4-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea.(Intermediate 24f)

A mixture of (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;140 mg, 0.346 mmol), Intermediate 24e (185 mg, 0.346 mmol) and DIPEA(0.18 mL, 1.03 mmol) in DMF (3 mL) was heated at 60° C. for 4 h underN₂. The cooled mixture was applied to an SCX-2 cartridge and washed withMeOH. The product was eluted with 2M NH₃ in MeOH; concentration in vacuoleft a brown gum. FCC, using 0.6-6% [2M NH₃ in MeOH] in DCM, gave thetitle compound (124 mg, 45%). LCMS (Method 4): Rt 5.15 min, m/z 791[MH⁺].

g.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-(4-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 24).

TBAF (1M in THF, 0.235 mL, 0.235 mmol) was added dropwise to a solutionof Intermediate 24f (124 mg, 0.157 mmol) in dry THF (3 mL) at −30° C.for 4 h under N₂. The mixture was allowed to warm to RT, then stirredfor 5 h. The solution was applied to an SCX-2 cartridge and washed withMeOH. The product was eluted with 2M NH₃ in MeOH; concentration in vacuoleft a brown foam. HPLC (Gemini C18; 40-90% MeCN in H₂O, 0.1% NH₄OH)gave the title compound as a white powder (77 mg, 77%). LCMS (Method 5):Rt 4.18 min, m/z 635 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.33 (9H, s),1.71-1.80 (2H, m), 1.87-1.96 (1H, m), 2.01-2.12 (4H, m), 2.25 (1H, m),2.36 (3H, s), 3.04-3.11 (2H, m), 3.37-3.44 (2H, m), 3.93 (1H, m), 5.09(1H, td, J 8.9, 5.3), 5.19 (1H, t, J 4.0), 5.44 (1H, d, J 8.8), 6.28(1H, s), 6.46 (1H, br s), 6.99 (1H, dd, J 9.9, 2.1), 7.21 (2H, d, J8.1), 7.25-7.33 (5H, m), 7.39 (2H, d, J 8.1), 7.49 (1H, d, J 9.9).

Example 251-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-{3-[(2-hydroxy-ethyl)-methyl-amino]-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]urea

a. 2-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-methyl-amino]ethanoland2-[(3-chloro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-methyl-amino]ethanol(Intermediate 25a)

A solution of Intermediate 24b (300 mg, 1.75 mmol) and 2-methylaminoethanol (660 mg, 8.77 mmol) in NMP (2 ml) was heated at 165° C. for 2 hin the microwave. The cooled mixture was applied to an SCX-2 cartridgeand washed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo left a brown gum. FCC, using 3-6% [2M NH₃ inMeOH] in DCM, gave a mixture of the title compounds (240 mg, 65%). LCMS(Method 4): Rt 1.05 min, m/z 211 [MH⁺] and Rt 1.76 min, m/z 227 [MH⁺].

b.(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-methyl-(2-triisopropylsilanyloxy-ethyl)-amine.(Intermediate 25b)

Triisopropylsilyl trifluoromethanesulfonate (454 mg, 1.48 mmol) wasadded dropwise to a solution of Intermediate 25a (240 mg, 1.14 mmol) andEt₃N (0.24 mL, 1.71 mmol) in DMF (2 mL) at RT under N₂ and the mixturewas stirred for 3 h. The solvent was evaporated, the residue applied toan SCX-2 cartridge and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo left a brown gum. FCC, using 0-3%[2M NH₃ in MeOH] in DCM, gave the title compound (160 mg, 38%). LCMS(Method 4): Rt 4.25 min, m/z 367 [MH⁺].

c.[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-methyl-(2-triisopropylsilanyloxy-ethyl)-amine.(Intermediate 25c)

Intermediate A (93 mg, 0.568 mmol) was added dropwise to a suspension ofNaH (60% dispersion in oil, 68 mg, 1.71 mmol) in DMF (3 mL) at RT underN₂. The mixture was stirred for 15 min then Intermediate 25b (160 mg,0.437 mmol) was added and the mixture stirred at 60° C. under N₂ for 3h. Sat. aq. NH₄Cl solution (0.2 mL) was added to the cooled mixturewhich was then diluted with water (15 mL) and extracted with EtOAc (3×15mL). The combined organics were washed with brine (15 mL) and dried(Na₂SO₄). The solvent was evaporated, the residue applied to an SCX-2cartridge and washed with MeOH. The product was eluted with 2M NH₃ inMeOH; concentration in vacuo left a brown foam. FCC, using 0-6% [2M NH₃in MeOH] in DCM, gave the title compound (64 mg, 29%). LCMS (Method 1):Rt 2.71 min, m/z 510 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-{3-[methyl-(2-triisopropylsilanyloxy-ethyl-amino]-1-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea.(Intermediate 25d)

A mixture of (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 71mg, 0.175 mmol), Intermediate 25c (64 mg, 0.125 mmol) and DIPEA (0.093mL, 0.524 mmol) in DMF (2 mL) was heated at 60° C. for 4 h under N₂. Thecooled mixture was applied to an SCX-2 cartridge and washed with MeOH.The product was eluted with 2M NH₃ in MeOH; concentration in vacuo lefta brown gum. FCC, using 3-6% [2M NH₃ in MeOH] in DCM, gave the titlecompound (65 mg, 68%). LCMS (Method 1): Rt 4.78 min, m/z 765 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-{3-[(2-hydroxy-ethyl)-methyl-amino]-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 25).

TBAF (1M in THF; 0.127 mL, 0.235 mmol) was added dropwise to a solutionof Intermediate 25d (65 mg, 0.085 mmol) in dry THF (0.3 mL) at −30° C.under N₂. The mixture was allowed to warm to RT, then stirred for 1 h.The solution was applied to an SCX-2 cartridge and washed with MeOH. Theproduct was eluted with 2M NH₃ in MeOH; concentration in vacuo left apale yellow oil. Further purification by HPLC (Gemini C18; 40-100% MeCNin H₂O, 0.1% NH₄OH) gave the title compound as a white powder (32 mg,62%). LCMS (Method 5): Rt 4.11 min, m/z 609 [MH⁺]. ¹H NMR (400 MHz,CDCl₃): 1.32 (9H, s), 1.90-1.99 (1H, m), 2.02-2.12 (2H, m), 2.23-2.30(1H, m), 2.37 (3H, s), 2.94 (3H, s), 3.11 (1H, ddd, J 14.3, 6.9, 3.5),3.18 (1H, ddd, J 14.3, 5.6, 3.2), 3.68-3.79 (2H, m), 5.06 (1H, td, J8.6, 5.5), 5.20 (1H, t, J 4.2), 5.50 (1H, d, J 8.7), 6.31 (1H, s), 6.42(1H, s), 6.98 (1H, dd, J 9.9, 2.0), 7.18-7.30 (6H, m), 7.39 (2H, d, J8.2), 7.49 (1H, d, J 9.9), 7.58 (1H, d, J 2.0).

Example 261-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-3-ol(Intermediate 26a)

A mixture of Intermediate 24b (300 mg, 1.74 mmol) and(S)-3-hydroxypyrrolidine (600 mg, 9.96 mmol) in NMP (6 mL) was heated inthe microwave at 160° C. for 2 h. The reaction mixture was applied to anSCX-2 cartridge (70 g) and washed with MeOH. The product was eluted with2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-8%[2M NH₃ in MeOH] in DCM, gave the title compound (150 mg, 38%). LCMS(Method 1): Rt 1.45 min, m/z 223 [MH⁺].

b.6-Fluoro-3-((S)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 26b)

Triisopropylsilyl trifluoromethanesulfonate (250 mg, 0.81 mmol) wasadded to a solution of Intermediate 26a (150 mg, 0.67 mmol) and Et₃N(101 mg, 1.00 mmol) in DMF (2 mL) and the mixture stirred at RT for 1 h.The reaction mixture was applied to an SCX-2 cartridge (5 g) and washedwith MeOH. The product was eluted with 2M NH₃ in MeOH; concentration invacuo gave the title compound (220 mg, 86%). LCMS (Method 4): Rt 4.15min, m/z 379 [MH⁺].

c.(1S,4R)-4-[3-((S)-3-Triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 26c)

To a solution of Intermediate A (104 mg, 0.640 mmol) in DMF (2 mL) wasadded NaH (60% in oil, 70 mg, 1.74 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 26b (220 mg, 0.582 mmol) was added. Thismixture was stirred thermally at 60° C. for 4 h, then at 60° C. in themicrowave for 3 h. The cooled reaction mixture was applied to an SCX-2cartridge (10 g) and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2MNH₃ in MeOH] in DCM gave the title compound as a yellow gum (70 mg,23%). LCMS (Method 1): Rt 2.89, m/z 522 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 26d)

A solution of Intermediate 26c (70 mg, 0.134 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 81mg, 0.201 mmol) and DIPEA (70 mg, 0.54 mmol) in DMF (2 mL) was stirredat 60° C. for 30 min. The reaction mixture was applied to an SCX-2cartridge (5 g) and washed with MeOH. The product was eluted with 2M NH₃in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃in MeOH] in DCM, gave the title compound as an off-white foam (19 mg,23%). LCMS (Method 1): Rt 4.70, m/z 777 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 26).

To a solution of Intermediate 26d (19 mg, 0.024 mmol) in THF (1 mL) at−30° C. was added TBAF (1M in THF, 36 μL, 0.036 mmol) and the mixturewas allowed to warm to RT over 1 h. The reaction mixture was applied toan SCX-2 cartridge (2 g) and washed with MeOH. The product was elutedwith 2M NH₃ in MeOH; concentration in vacuo gave a residue. Purificationby HPLC (C6-Ph column, 35-75% MeCN in H₂O, 0.1% HCO₂H) gave the titlecompound as an off-white powder after freeze-drying (10.0 mg, 60%). LCMS(Method 5): Rt 4.00 min, m/z 621 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.29(9H, s), 1.89-2.09 (4H, m), 2.13-2.29 (2H, m), 2.34 (3H, s), 3.35 (1H,td, J 9.2, 4.6), 3.45 (1H, d, J 11.1), 3.50 (1H, dd, J 11.1, 4.3), 3.60(1H, m), 4.51 (1H, m), 5.04 (1H, td, J 8.5, 5.3), 5.15 (1H, t, J 4.1),5.57 (1H, d, J 8.6), 6.26 (1H, s), 6.67 (1H, br s), 6.89 (1H, dd, J 9.9,1.7), 7.15 (2H, d, J 7.1), 7.24-7.29 (4H, m), 7.30-7.38 (4H, m).

Example 271-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.[(R)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-2-yl]-methanol(Intermediate 27a)

A mixture of Intermediate 24b (300 mg, 1.74 mmol) and(R)-(−)-2-(hydroxymethyl)-pyrrolidine (704 mg, 9.96 mmol) in NMP (6 mL)was heated in the microwave at 160° C. for 2 h. The reaction mixture wasapplied to an SCX-2 cartridge (75 g) and washed with MeOH. The productwas eluted with 2M NH₃ in MeOH; concentration in vacuo gave a residue.FCC, using 0-10% [2M NH₃ in MeOH] in DCM, gave the title compound (220mg, 53%). LCMS (Method 4): Rt 1.50, m/z 237 [MH⁺].

b.6-Fluoro-3-((S)-2-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 27b)

Triisopropylsilyl trifluoromethanesulfonate (430 mg, 1.40 mmol) wasadded to a solution of Intermediate 27a (220 mg, 0.93 mmol) and Et₃N(190 mg, 1.86 mmol) in a DMF (2 mL) and the mixture stirred at RT for 1h. The reaction mixture was applied to an SCX-2 cartridge (10 g) andwashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave the title compound (170 mg, 47%). LCMS(Method 1): Rt 4.45, m/z 393 [MH⁺].

c.(1S,4R)-4-[3-((R)-2-Triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 27c)

To a solution of Intermediate A (60 mg, 0.364 mmol) in DMF (2 mL) wasadded NaH (60% in oil, 40 mg, 0.99 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 27b (130 mg, 0.331 mmol) was added. Thismixture was heated at 60° C. in the microwave for 1.5 h. The reactionmixture was applied to an SCX-2 cartridge (5 g) and washed with MeOH.The product was eluted with 2M NH₃ in MeOH; concentration in vacuo gavea residue. FCC, using 0-7% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a brown oil (50 mg, 28%). LCMS (Method 4): Rt 2.36, m/z 536[MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 27d)

A solution of Intermediate 27c (50 mg, 0.093 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 56mg, 0.140 mmol) and DIPEA (70 mg, 0.54 mmol) in DMF (2 mL) was stirredat 60° C. for 1 h. The reaction mixture was applied to an SCX-2cartridge (5 g) and washed with MeOH. The product was eluted with 2M NH₃in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃in MeOH] in DCM, gave the title compound as an off-white foam (27 mg,36%). LCMS (Method 4): Rt 4.58, m/z 791 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 27).

To a solution of Intermediate 27d (27 mg, 0.034 mmol) in THF (1 mL) at−30° C. was added TBAF (1M in THF, 36 μL, 0.036 mmol) and the mixturewas allowed to warm to RT over 1 h. The reaction mixture was applied toan SCX-2 cartridge (2 g) and washed with MeOH. The product was elutedwith 2M NH₃ in MeOH; concentration in vacuo gave a residue. Purificationby HPLC (C6-Ph column, 10-70% MeCN in H₂O, 0.1% HCO₂H) gave the titlecompound as a white powder after freeze-drying (10.0 mg, 45%). LCMS(Method 5): Rt 4.18 min, m/z 635 [MH⁺]. ¹H NMR (400 MHz, CDCl₃): 1.25(9H, s), 1.63-1.75 (1H, m), 1.81-1.95 (3H, m), 1.97-2.01 (3H, m), 2.26(1H, m), 2.31 (3H, s), 3.17-3.26 (1H, m), 3.32-3.47 (2H, m), 3.57 (1H,dd, J 11.6, 3.2), 4.07-4.15 (1H, m), 4.99-5.07 (1H, m), 5.15 (1H, t, J4.1), 5.57 (1H, d, J 8.9), 6.25 (1H, s), 6.61 (1H, s), 6.91 (1H, d, J10.2), 7.16 (2H, d, J 8.3), 7.20-7.29 (4H, m), 7.32 (2H, d, J 8.0),7.35-7.41 (2H, m).

Example 281-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.[(S)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-2-yl]-methanol(Intermediate 28a)

A mixture of Intermediate 24b (300 mg, 1.74 mmol) and L-prolinol (704mg, 9.96 mmol) in NMP (4 mL) was heated in the microwave at 160° C. for2 h. The reaction mixture was applied to an SCX-2 cartridge (70 g) andwashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM, gave the title compound (210 mg, 50%). LCMS (Method 4): Rt 1.50min, m/z 237 [MH⁺].

b.6-Fluoro-3-((S)-2-triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 28b)

Triisopropylsilyl trifluoromethanesulfonate (327 mg, 1.06 mmol) wasadded to a solution of Intermediate 28a (210 mg, 0.89 mmol) and Et₃N(135 mg, 1.33 mmol) in a DMF (3 mL) and the mixture stirred at RT for 1h. The reaction mixture was applied to an SCX-2 cartridge (25 g) andwashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM, gave the title compound (110 mg, 31%). LCMS (Method 1): Rt 4.45min, m/z 393 [MH⁺].

c.(1S,4R)-4-[3-((S)-2-Triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 28c)

To a solution of Intermediate A (50 mg, 0.309 mmol) in DMF (2 mL) wasadded NaH (60% in oil, 33 mg, 0.80 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 28b (110 mg, 0.280 mmol) was added. Thismixture was heated at 60° C. in the microwave for 1.25 h. The reactionmixture was applied to an SCX-2 cartridge (25 g) and washed with MeOH.The product was eluted with 2M NH₃ in MeOH; concentration in vacuo gavea residue. FCC, using 0-7% [2M NH₃ in MeOH] in DCM gave the titlecompound as a viscous yellow oil (42 mg, 28%). LCMS (Method 4): Rt 2.55min, m/z 536 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 28d)

A solution of Intermediate 28c (40 mg, 0.074 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 45mg, 0.112 mmol) and DIPEA (38 mg, 0.296 mmol) in DMF (2 mL) was stirredat 60° C. for 30 min. The reaction mixture was applied to an SCX-2cartridge (5 g) and washed with MeOH. The product was eluted with 2M NH₃in MeOH; concentration in vacuo gave a residue. FCC, using 0-7% [2M NH₃in MeOH] in DCM, gave the title compound as a viscous yellow oil (38 mg,65%). LCMS (Method 1): Rt 4.72 min, m/z 791 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 28).

To a solution of Intermediate 28d (38 mg, 0.048 mmol) in THF (1 mL) at−30° C. was added TBAF (1M in THF, 72 μL, 0.072 mmol) and the mixturewas allowed to warm to RT over 1 h. The reaction mixture was applied toan SCX-2 cartridge (5 g) and washed with MeOH. The product was elutedwith 2M NH₃ in MeOH; concentration in vacuo gave a residue. Purificationby HPLC (C6-Ph column, 10-70% MeCN in H₂O, 0.1% HCO₂H) gave the titlecompound as a white powder after freeze-drying (12 mg, 39%). LCMS(Method 5): Rt 4.20 min, m/z 635 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOH): 1.29(9H, s), 1.78-2.28 (8H, m), 2.38 (3H, s), 3.36-3.46 (1H, m), 3.53 (2H,dd, J 5.0, 1.6), 3.64-3.73 (1H, m), 4.04-4.12 (1H, m), 4.85-4.91 (1H,m), 5.36 (1H, t, J 4.1), 6.32 (1H, s), 7.11 (1H, dd, J 10.0, 2.1),7.20-7.35 (8H, m), 7.44 (1H, d, J 9.9), 7.99-8.01 (1H, m).

Example 291-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 3-(5-Amino-3-tert-butyl-pyrazol-1-yl)-benzoic acid ethyl ester(Intermediate 29a)

A solution of 3-hydrazino benzoic acid (5.53 g, 36.4 mmol) and4,4-dimethyl-3-oxo pentanenitrile (5.00 g, 40.0 mmol) and concentratedsulfuric acid (2 mL) in EtOH (72 mL) was stirred at reflux for 19 h. Thecooled mixture was concentrated in vacuo, was diluted with 1N NaOHsolution (15 mL) and extracted with EtOAc. The combined organics weredried and concentrated in vacuo. The residue was purified by FCC, using0-40% EtOAc in cyclohexane, to give the title compound as an off-whitepowder (5.92 g, 56%). LCMS (Method 3): Rt 3.04 min, m/z 288 [MH⁺].

b. [3-(5-Amino-3-tert-butyl-pyrazol-1-yl)-phenyl]-methanol (Intermediate29b)

To a solution of Intermediate 29a (1.00 g, 3.48 mmol) and Et₃N (265 μL,1.91 mmol) in EtOH (35 mL) was added NaBH₄ (198 mg, 5.23 mmol) and thesuspension stirred at RT for 1.5 h. NaBH₄ (198 mg, 5.23 mmol) was addedand the suspension stirred for a further 19 h. NaBH₄ (1.31 g, 34.8 mmol)was added and the suspension stirred for a further 24 h, then dilutedwith water and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-10% [2MNH₃ in MeOH] in DCM, to give the title compound as a white solid (740mg, 87%). LCMS (Method 3): Rt 2.05 min, m/z 246 [MH⁺].

c. [5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 29c)

To a bi-phasic mixture of Intermediate 29b (737 mg, 3.00 mmol) in EtOAc(22.5 mL) and 1N NaOH solution (8.11 mL, 8.11 mmol) at 0° C. was added2,2,2-trichloroethyl chloroformate (0.45 mL, 3.30 mmol) and the mixturestirred for 1.25 h. The layers were separated and the organic layer waswashed with brine, dried and concentrated in vacuo to give the titlecompound as an off-white solid (1.26 g, 99%). LCMS (Method 3): Rt 4.00min, m/z 420, 422 [MH⁺].

d.1-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 29).

A solution of Intermediate 29c (509 mg, 1.21 mmol) and Intermediate 3c(400 mg, 1.10 mmol) and DIPEA (0.58 mL, 3.30 mmol) in THF (11 mL) wasstirred at reflux for 15 h. The cooled reaction mixture was diluted withwater and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-10% [2MNH₃ in MeOH] in DCM, to give the product. A 50 mg portion of this wasfurther purified by HPLC (XBridge C18 column, 10-98% MeCN in H₂O, 0.1%NH₄OH) to give the title compound as a white powder after freeze-drying(10 mg, 20%). LCMS (Method 5): Rt 4.23 min, m/z 635 [MH⁺]. ¹H NMR (400MHz, d₄-MeOH): 1.35 (9H, s), 1.57-1.74 (6H, m), 1.89 (1H, t, J 10.7),2.01-2.08 (2H, m), 2.14-2.22 (1H, m), 3.06 (4H, t, J 5.1), 4.56 (2H, s),5.09 (1H, m), 5.18 (1H, t, J 4.3), 5.92 (1H, d, J 8.6), 6.40 (1H, s),6.88 (1H, dd, J 9.9, 2.1), 7.14-7.17 (3H, m), 7.30-7.32 (5H, m), 7.42(1H, d, J 8.1), 7.50 (1H, s).

Example 303-[3-tert-Butyl-5-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzoicacid ethyl ester

a.3-[3-tert-Butyl-5-(2,2,2-trichloro-ethoxycarbonylamino)-pyrazol-1-yl]-benzoicacid ethyl ester (Intermediate 30a)

The title compound was prepared from Intermediate 29a using an analogousprocedure to that described for Intermediate 29c. LCMS (Method 3): Rt4.67 min, m/z 462, 464 [MH⁺].

b.3-[3-tert-Butyl-5-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzoicacid ethyl ester (Example 30).

A mixture of Intermediate 5c (163 mg, 0.45 mmol), Intermediate 30a (208mg, 0.45 mmol) in 1,4-dioxane (3 mL) and DIPEA (119 μL, 0.68 mmol) wasstirred at 90° C. for 3 h. The cooled mixture was concentrated in vacuo.The residue was purified by FCC, using 0-12% MeOH in DCM, to give theproduct (291 mg, 96%). A 64 mg portion of this was further purified byHPLC (C18 X-select column, 30-98% MeCN in H₂O, 0.1% HCO₂H) to give thetitle compound as a white powder after freeze-drying powder (38 mg).LCMS (Method 5): Rt 3.85 min, m/z 677.3 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.26-1.33 (12H, m), 1.80-2.27 (11H, m), 2.30-2.39 (1H, m),3.09-3.16 (1H, m), 3.99 (1H, br t, J 8.2), 4.32 (2H, q, J 7.1),4.74-4.83 (1H, m), 5.36-5.41 (1H, m), 6.33 (1H, s), 7.11 (1H, d, J 8.6),7.19-7.37 (5H, m), 7.66 (1H, t, J 7.9), 7.75 (1H, d, J 9.9), 7.80-7.84(1H, m), 7.93-7.98 (1H, m), 8.07-8.09 (1H, m), 8.22-8.28 (2H, m).

Example 311-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt

A solution of Example 30 (225 mg, 0.333 mmol) and sodium borohydride(31.5 mg, 0.833 mmol) in ethanol (3 mL) was stirred at RT for 2.5 h.Sodium borohydride (31.5 mg, 0.833 mmol) was added and the solutionstirred for 90 min. Sodium borohydride (31.5 mg, 0.833 mmol) was addedand the solution stirred for 2.5 h. Sodium borohydride (31.5 mg, 0.833mmol) was added and the solution stirred for a further 15.5 h. Water wasadded followed by sat. aq. NH₄Cl solution. The mixture was thenextracted with DCM (4×20 mL). The combined organic extracts were driedand concentrated in vacuo. The residue was purified by FCC, using 0-14%MeOH in DCM, to give the product (150 mg). This was further purified byHPLC (C18 X-select column, 30-98% MeCN in H₂O, 0.1% HCO₂H) to give thetitle compound as a white powder after freeze-drying (97 mg, 46%). LCMS(Method 5): Rt 3.29 min, m/z 635.2 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):1.28 (9H, s), 1.82-2.26 (11H, m), 2.30-2.39 (1H, m), 3.09-3.16 (1H, m),3.99 (1H, t, J 8.1), 4.57 (2H, s), 4.78-4.86 (1H, m), 5.39 (1H, t, J4.3), 6.33 (1H, s), 7.11 (1H, d, J 8.4), 7.24-7.38 (7H, m), 7.42-7.48(2H, m), 7.75 (1H, d, J 9.9), 8.1 (1H, s), 8.20 (0.5H, s), 8.24 (1H, m).

Example 321-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(2-morpholin-4-yl-ethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.2-((1S,4R)-4-Hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-isoindole-1,3-dione(Intermediate 32a)

A solution of Intermediate A (150 mg, 0.92 mmol) and phthalic anhydride(143 mg, 0.97 mmol) in toluene (9 mL) was stirred and heated at refluxfor 19.5 h. After cooling, the mixture was concentrated in vacuo. Theresidue was purified by FCC, using 0-50% EtOAc in cyclohexane, to givethe title compound as white powder (215 mg, 79%). LCMS (Method 3): Rt3.36 min, m/z 316 [MNa⁺].

b.2-[(1S,4R)-4-(2-Morpholin-4-yl-2-oxo-ethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-isoindole-1,3-dione(Intermediate 32b)

A solution of Intermediate 32a (115 mg, 0.39 mmol) in dry THF (4 mL) wasadded NaH (60% in mineral oil, 23 mg, 0.59 mmol) at RT and stirred for15 min. 4-(Chloroacetyl)morpholine (56 μL, 0.43 mmol) was then added andthe mixture heated at reflux for 3.5 h. After cooling, the dark brownmixture was diluted with water and extracted with DCM. The combinedorganics were dried and concentrated in vacuo. The residue was purifiedby FCC, using 0-5% MeOH in DCM, to give the title compound as lightbrown foam (103 mg, 62%). LCMS (Method 3): Rt 3.44 min, m/z 443 [MNa⁺].

c.2-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-1-morpholin-4-yl-ethanone(Intermediate 32c)

A solution of Intermediate 32b (100 mg, 0.23 mmol) and hydrazine hydrate(74 μL, 2.4 mmol) in dry MeOH (6 mL) was stirred at RT for 5 h. Thereaction mixture was concentrated in vacuo. The residue was purified byFCC, using 0-20% [2M NH₃ in MeOH] in DCM, to give the title compound asan off white foam (50 mg, 72%). LCMS (Method 3): Rt 1.70 min, m/z 291[MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(2-morpholin-4-yl-2-oxo-ethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 32d)

A stirred solution of Intermediate 32c (50 mg, 0.17 mmol) and5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 84mg, 0.21 mmol) and DIPEA (90 μL, 0.52 mmol) in THF (1.7 mL) was heatedat reflux for 21 h. The cooled reaction mixture was diluted with waterand extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-5% [2MNH₃ in MeOH] in DCM, to give impure product. This residue purified byHPLC (Gemini C18 column, 30-98% MeCN in H₂O, 0.1% HCO₂H) to give thetitle compound as a white powder after freeze-drying (37 mg, 39%). LCMS(Method 5): Rt 4.73 min, m/z 546 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(2-morpholin-4-yl-ethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 32).

To a solution of Intermediate 32d (50 mg, 62.3 μmol) in THF (1.7 mL) wasadded borane (1M in THF, 0.12 mL, 0.12 mmol) and the mixture stirred at60° C. After 23 h, further borane (1M in THF, 0.31 mL, 0.31 mmol) wasadded. After 26 h, further borane (1M in THF, 0.31 mL, 0.31 mmol) wasadded. After 3 d, the cooled reaction mixture was diluted with water andextracted with DCM. The combined organics were dried and concentrated invacuo. The residue was purified by HPLC (Gemini C18 column, 20-98% MeCNin H₂O, 0.1% HCO₂H) to give the title compound as a white powder afterfreeze-drying (15 mg, 47%). LCMS (Method 5): Rt 3.64 min, m/z 532 [MH⁺].¹H NMR (400 MHz, CDCl₃): 1.32 (9H, s), 1.93-1.96 (3H, m), 2.02-2.07 (1H,m), 2.32 (4H, t, J 4.5), 2.38 (3H, s), 2.47 (1H, dt, J 13.0, 5.3), 2.61(1H, ddd, J 13.0, 7.3, 5.4), 3.56-3.58 (5H, m), 3.67-3.68 (1H, m),4.35-4.37 (1H, m), 4.98-5.02 (1H, m), 5.50 (1H, d, J 8.8), 6.27 (2H, s),7.18-7.28 (5H, m), 7.30-7.32 (1H, m), 7.36 (2H, d, J 8.2).

Example 331-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea

a. [5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 33a)

To a suspension of[4-(5-amino-3-tert-butyl-pyrazol-1-yl)-phenyl]-methanol (WO 2011/070368,which is incorporated herein by reference in its entirety; 3.05 g, 12.4mmol) in aq. NaOH solution (1 M, 31 mL, 31 mmol) and EtOAc (30 mL) at RTwas added 2,2,2-trichloroethyl chloroformate (1.88 mL, 13.7 mmol) over 3min (CARE: exotherm to 35° C.) and the mixture stirred at RT for 1 h.The aqueous layer was extracted with EtOAc (20 mL), then the combinedorganics washed with brine (25 mL), dried (Na₂SO₄), filtered andconcentrated in vacuo to leave a pale orange solid. Recrystallisationfrom hot cyclohexane-EtOAc (3:1, 30 mL) and drying in vacuo gave thetitle compound as a flocculent off-white solid (3.87 g, 74%). LCMS(Method 3): Rt 4.00 min, m/z 420, 422 [MH⁺].

b.1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea(Example 33).

A mixture of Intermediate 5c (109 mg, 0.300 mmol) and Intermediate 33a(126 mg, 0.300 mmol) in 1,4-dioxane (3 mL) and DIPEA (78 μL, 0.45 mmol)was stirred at 80° C. for 3 h, and then at 95° C. for 2 h. The cooledmixture was concentrated in vacuo. The residue was purified by FCC,using 0-14% MeOH in DCM, to give the title compound as an off-whitepowder after freeze-drying (95 mg, 50%). LCMS (Method 5): Rt 3.26 min,m/z 635.3 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.81-2.26(11H, m), 2.31-2.40 (1H, m) 3.10-3.17 (1H, m), 3.99 (1H, br t, J 8.1),4.56 (2H, d, J 5.6), 4.78-4.87 (1H, m), 5.29 (1H, t, J 5.7), 5.37-5.42(1H, m), 6.33 (1H, s), 7.11 (1H, d, J 8.7), 7.24-7.47 (9H, m), 7.75 d, J9.7), 8.07 (1H, s), 8.24 (1H, br d).

Example 341-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

A mixture of Intermediate 3c (109 mg, 0.300 mmol) and Intermediate 33a(126 mg, 0.300 mmol) in 1,4-dioxane (3 mL) and DIPEA (78 μL, 0.45 mmol)was stirred at 80° C. for 3 h, and then at 95° C. for 2 h. The cooledmixture was concentrated in vacuo. The residue was purified by FCC,using 0-14% MeOH in DCM, to give the title compound as an off-whitepowder after freeze-drying (95 mg, 50%). LCMS (Method 5): Rt 4.21 min,m/z 635.2 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s), 1.56-2.17(10H, m), 3.11-3.17 (4H, m), 4.56 (2H, d, J 5.7), 4.77-4.86 (1H, m),5.29 (1H, t, J 5.7), 5.52-5.57 (1H, br t), 6.33 (1H, s), 7.09 (1H, d, J8.4), 7.16 (1H, dd, J 9.7, 2.2), 7.25-7.47 (8H, m), 7.58-7.64 (2H, m),8.07 (1H, s).

Example 351-{5-tert-Butyl-2-[3-(2-hydroxy-ethylsulfanyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. Di-tert-butyl1-{3-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)sulfanyl]phenyl}hydrazine-1,2-dicarboxylate(Intermediate 35a)

A mixture of 3-bromothiophenol (1.00 g, 5.29 mmol),bromoethoxydimethylsilyl ether (1.36 mL, 6.35 mmol) and K₂CO₃ (1.46 g,10.6 mmol) in acetone (15 mL) was stirred at RT overnight. The mixturewas filtered, evaporated, and the residue redissolved in dry THF (15 mL)and cooled to −78° C. nBuLi (1.6M in hexanes, 4.5 mL, 7.28 mmol) wasadded dropwise and the mixture stirred for 10 min. Di-tert-butylazodicarboxylate (1.54 g, 6.68 mmol) was added in one portion at −78° C.and the mixture stirred for 20 min. The mixture was then allowed to warmto RT over 2 h. The reaction was quenched with sat. aq. NH₄Cl solution(15 mL), then extracted with EtOAc (3×15 mL). The combined organicextracts were washed with brine (20 mL), dried (Na₂SO₄) and concentratedin vacuo. The residue was purified by FCC, using 0-20% EtOAc in pentane,to give the title compound as a pale yellow oil (1.68 g, 64%). ¹H NMR(400 MHz, CDCl₃): 0.04 (6H, s), 0.84 (9H, s), 1.48 (18H, m), 3.04 (2H,t), 3.79 (2H, t), 7.14-7.28 (3H, m), 7.42 (1H, s).

b. 2-[3-(5-Amino-3-tert-butyl-pyrazol-1-yl)phenylsulfanyl]-ethanol.(Intermediate 35b)

A mixture of Intermediate 35a (1.68 g, 3.37 mmol), pivaloyl acetonitrile(0.42 g, 3.37 mmol) and concentrated HCl solution (1.7 mL) in ethanol(10 mL) was heated under reflux for 3 h. After cooling, the pH wasadjusted to ˜7 (using sat. aq. NaHCO₃ solution) and the mixture dilutedwith water (20 mL) and extracted with EtOAc (3×20 mL). The combinedorganic extracts were washed with brine (20 mL), dried (Na₂SO₄) andconcentrated in vacuo. The residue was purified by FCC, eluting with20-80% EtOAc in pentane, to give the title compound as a pale yellow oil(458 mg, 47%). LCMS (Method 1): Rt 2.35 min, m/z 292 [MH⁺].

c.{5-tert-Butyl-2-[3-(2-hydroxy-ethylsulfanyl)-phenyl]-2H-pyrazol-3-yl}-carbamicacid 2,2,2-trichloro-ethyl ester. (Intermediate 35c)

2,2,2-Trichloroethyl chloroformate (0.10 mL, 0.78 mmol) was added to asolution of Intermediate 35b (176 mg, 0.60 mmol) and DIPEA (0.31 mL,1.81 mmol) in THF (10 mL) and the mixture stirred at RT for 3 h. Themixture was diluted with water (15 mL), extracted with EtOAc (3×20 mL),then the combined organic extracts dried (Na₂SO₄) and concentrated invacuo. The residue was suspended in cyclohexane, and filtered to givethe title compound as a yellow solid (280 mg, 100%). LCMS (Method 1): Rt3.93 min, m/z 466, 468 [MH⁺]

d.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethylsulfanyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 35).

A mixture of Intermediate 5c (109 mg, 0.3 mmol) and Intermediate 35c(140 mg, 0.3 mmol) in 1,4-dioxane (3 mL) and DIPEA (78 μL, 0.45 mmol)was stirred at 90° C. for 4 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 0-14% MeOH in DCM, to givethe title compound as an off-white powder after freeze-drying (115 mg,56%). LCMS (Method 5): Rt 3.47 min, m/z 681 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.28 (9H, s), 1.83-2.26 (11H, m), 2.31-2.39 (1H, m), 3.04 (2H,t, J 6.8), 3.09 (1H, m), 3.59 (2H, q, J 6.0), 3.99 (1H, t, J 8.2),4.78-4.86 (1H, m), 4.95 (1H, t, J 5.6), 5.36-5.41 (1H, m), 6.33 (1H, s),7.08 (1H, d, J 8.4), 7.24-7.46 (9H, m), 7.75 (1H, d, J 9.6), 8.12 (1H,s), 8.25 (1H, br d).

Example 361-[5-(2-Hydroxy-1,1-dimethyl-ethyl)-2-p-tolyl-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

The title compound was prepared as an off-white solid (120 mg, 68%)using Intermediate 3c (100 mg, 0.28 mmol) and[5-(2-hydroxy-1,1-dimethyl-ethyl)-2-p-tolyl-2H-pyrazol-3-yl]-carbamicacid 2,2,2-trichloro-ethyl ester (WO 2009/015000, which is incorporatedherein by reference in its entirety; 138 mg, 0.34 mmol) in a similarmanner to Example 34. LCMS (Method 5): Rt 4.02 min, m/z 635 [MH⁺]. ¹HNMR (400 MHz, d₆-DMSO): 1.21 (6H, s), 1.58-1.64 (2H, m), 1.69-1.75 (4H,m), 1.81-1.97 (2H, m), 2.00-2.16 (2H, m), 2.36 (3H, s), 3.14 (4H, t, J5.4), 3.43 (2H, s), 4.55 (1H, br s), 4.79-4.85 (1H, m), 5.54 (1H, t, J4.3), 6.32 (1H, s), 7.08 (1H, d, J 8.6), 7.16 (1H, dd, J 4.9, 2.3),7.26-7.39 (8H, m), 7.59-7.63 (2H, m), 8.07 (1H, s).

Example 371-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,3S)-3-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-indan-1-yl}-urea

a.(1S,3S)-3-[3-((S)-1-Methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-indan-1-ylamine(Intermediate 37a)

(1S,3S)-3-Amino-indan-1-ol (110 mg, 0.74 mmol) was added to a suspensionof NaH (60% in mineral oil, 87 mg, 2.17 mmol) in anhydrous DMF (5 mL) atRT and stirred for 20 min. Intermediate 5b (160 mg, 0.72 mmol) was thenadded in one portion and the mixture heated at 60° C. for 3 h. Aftercooling the mixture was diluted with water (20 mL) and extracted withEtOAc (3×50 mL). The combined organics were washed with brine (50 mL),dried (MgSO₄) and evaporated in vacuo. The residue was purified by FCC,using 0-10% MeOH in DCM, to give the title compound as give a foam (132mg, 52%). LCMS (Method 1): Rt 0.34 min, m/z 350 [MH⁺]. ¹H NMR (300 MHz,CDCl₃): 1.95-2.16 (6H, m), 2.24 (3H, s), 2.26-2.45 (2H, m), 2.77 (1H,ddd, J 14.1, 7.0, 2.0), 3.23-3.30 (1H, m), 4.02-4.09 (1H, m), 4.71 (1H,t, J 6.8), 5.68 (1H, dd, J 6.2, 1.9), 7.04 (1H, dd, J 9.9, 2.2),7.29-7.50 (4H, m), 7.64 (1H, dd, J 9.9, 0.9), 8.35 (1H, d, J 2.2).

b.1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,3S)-3-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-indan-1-yl}-urea(Example 37).

A solution of Intermediate 33a (190 mg, 0.454 mmol), Intermediate 37a(132 mg, 0.378 mmol) and DIPEA (132 μL, 0.756 mmol) in anhydrous DMF (3mL) was stirred at 100° C. for 3 h. After cooling, the mixture waspartitioned between EtOAc (50 mL) and water (50 mL), and then extractedinto EtOAc (3×50 mL). The combined organics were washed with brine (50mL), dried (MgSO₄) and evaporated in vacuo. The residue was purified byFCC, using 0-10% MeOH in DCM, to give the title compound as give anoff-white solid after freeze-drying (143 mg, 61%). LCMS (Method 5): Rt3.23, m/z 621 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.22 (9H, s), 1.95-1.97(3H, m), 2.07 (3H, s), 2.20-2.23 (3H, m), 2.52-2.53 (1H, m), 3.10 (1H,m), 3.92 (1H, t, J 8.1), 4.51 (2H, d, J 5.6), 5.25-5.27 (2H, m), 5.83(1H, d, J 5.8), 6.25 (1H, s), 6.99 (1H, d, J 7.9), 7.18 (1H, dd, J 9.9,2.2), 7.24-7.32 (2H, m), 7.35-7.41 (6H, m), 7.67 (1H, d, J 9.9), 8.10(1H, s), 8.20 (1H, s).

Example 381-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (R)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-3-ol(Intermediate 38a)

A mixture of Intermediate 24b (300 mg, 1.74 mmol) and(R)-3-hydroxypyrrolidine (607 mg, 9.96 mmol) in NMP (4 mL) was heated inthe microwave at 160° C. for 2 h. The reaction mixture was applied to anSCX-2 cartridge (70 g) and washed with MeOH. The product was eluted with2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-10%[2M NH₃ in MeOH] in DCM, gave the title compound (170 mg, 44%). LCMS(Method 1): Rt 0.39 min, m/z 223 [MH⁺].

b.6-Fluoro-3-((R)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 38b)

Triisopropylsilyl trifluoromethanesulfonate (280 mg, 0.919 mmol) wasadded to a solution of Intermediate 38a (170 mg, 0.766 mmol) and Et₃N(116 mg, 1.14 mmol) in a DMF (3 mL) and the mixture stirred at RT for 1h. The reaction mixture was applied to an SCX-2 cartridge (10 g) andwashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM, gave the title compound (260 mg, 90%). LCMS (Method 3): Rt 4.26min, m/z 379 [MH⁺].

c.(1S,4R)-4-[3-((R)-3-Triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 38c)

To a solution of Intermediate A (123 mg, 0.755 mmol) in DMF (4 mL) wasadded NaH (60% in oil, 82 mg, 2.06 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 38b (260 mg, 0.687 mmol) was added. Thismixture was heated at 60° C. in the microwave for 3 h. The reactionmixture was applied to an SCX-2 cartridge (25 g) and washed with MeOH.The product was eluted with 2M NH₃ in MeOH; concentration in vacuo gavea residue. FCC, using 0-7% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a viscous yellow oil (100 mg, 23%). LCMS (Method 1): Rt 2.90min, m/z 522 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 38d)

A solution of Intermediate 38c (100 mg, 0.191 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;115 mg, 0.286 mmol) and DIPEA (100 mg, 0.764 mmol) in DMF (2 mL) wasstirred at 60° C. for 1 h. The reaction mixture was applied to an SCX-2cartridge (10 g) and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2MNH₃ in MeOH] in DCM, gave the title compound as a viscous yellow oil (80mg, 53%). LCMS (Method 4): Rt 4.55 min, m/z 777 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 38).

To a solution of Intermediate 38d (80 mg, 0.10 mmol) in THF (1 mL) at−30° C. was added TBAF (1M in THF, 150 μL, 0.150 mmol) and the mixturewas allowed to warm to RT over 1 h. The reaction mixture was applied toan SCX-2 cartridge (5 g) and washed with MeOH. The product was elutedwith 2M NH₃ in MeOH; concentration in vacuo gave a residue. Purificationby HPLC (C6-Ph column, 35-75% MeCN in H₂O, 0.1% HCO₂H) gave the titlecompound as a white powder after freeze-drying (22 mg, 35%). LCMS(Method 5): Rt 4.01 min, m/z 621 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOH): 1.29(9H, s), 1.86-2.13 (4H, m), 2.14-2.28 (2H, m), 2.38 (3H, s), 3.40-3.45(1H, m), 3.49-3.56 (1H, m), 3.66-3.71 (1H, m), 3.74-3.81 (1H, m),4.50-4.55 (1H, m), 4.85-4.91 (1H, m), 5.37 (1H, t J 4.2), 6.33 (1H, s),7.10 (1H, dd, J 9.8, 2.2), 7.19-7.36 (8H, m), 7.43 (1H, d, J 9.8), 7.76(1H, d, J 1.6).

Example 391-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-ylamine(Intermediate 39a)

DIAD (847 μL, 4.32 mmol) was added slowly to a solution of3-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)phenol (US 2006/35922, which isincorporated herein by reference in its entirety; 500 mg, 2.16 mmol),2-(tetrahydro-pyran-2-yloxy)-ethanol (439 μL, 3.25 mmol) and Ph₃P (1.13g, 4.32 mmol) in THF (10.0 mL) and the mixture stirred for 72 h. Thereaction mixture was partitioned between EtOAc (75 mL) and H₂O (75 mL)and the aqueous layer extracted with EtOAc (3×). The combined organiclayers were dried (MgSO₄), filtered and evaporated in vacuo.Purification by FCC, using 5-60% EtOAc in cyclohexane, gave the titlecompound (1.26 g). LCMS (Method 4): Rt 2.77, m/z 360 [MH⁺].

b.(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 39b)

The title compound was prepared starting from2,2,2-trichloroethylchloroformate and Intermediate 39a by using ananalogous procedure to that described for Intermediate 35c. LCMS (Method4): Rt 3.85, m/z 536 [MH⁺].

c.1-(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 39c)

A solution of Intermediate 39b (287 mg, 0.53 mmol), Intermediate 3c (177mg, 0.49 mmol) and DIPEA (256 μL, 1.46 mmol) in THF (5 ml) was stirredat 60° C. for 16.5 h. Water was added and the mixture extracted with DCM(3×20 mL). The combined organics were dried and concentrated in vacuo.The residue was purified by FCC, using 0-5% [2M NH₃ in MeOH] in DCM, togive the title compound as an off-white powder (361 mg, 99%). LCMS(Method 3): Rt 4.05 min, m/z 749 [MH⁺].

d.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 39).

Pyridinium p-toluenesulfonate (362 mg, 1.44 mmol) was added to asolution of Intermediate 39c (360 mg, 0.48 mmol) in MeOH (5 mL). Thesolution was stirred at 40° C. for 19 h, then diluted with water andextracted with DCM (3×20 mL). The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-7.5% [2MNH₃ in MeOH] in DCM, to give the title compound as a white powder afterfreeze-drying (218 mg, 68%). LCMS (Method 5): Rt 4.22 min, m/z 665[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s), 1.60-1.63 (2H, m),1.70-1.75 (4H, m), 1.86-1.92 (2H, m), 2.01-2.06 (1H, m), 2.10-2.16 (1H,m), 3.14 (4H, t, J 5.2), 3.71 (2H, q, J 5.1), 4.03 (2H, t, J 5.0),4.79-4.82 (1H, m), 4.87 (1H, t, J 5.5), 5.54 (1H, t, J 4.3), 6.33 (1H,s), 6.96 (1H, m), 7.11-7.22 (4H, m), 7.34-7.46 (5H, m), 7.61-7.64 (2H,m), 8.11 (1H, s).

Example 401-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureapartial formate salt

a. Methanesulfonic acid2-[3-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-phenoxy]-ethylester (Intermediate 40a)

Methane sulfonylchloride (46.0 μL, 0.59 mmol) was added to an ice coldsolution of Example 39 (187 mg, 0.28 mmol) and DIPEA (122 μL, 0.70 mmol)in DCM (3.0 mL). After 2.5 h the reaction was partitioned between DCMand water. The aqueous layer was then extracted with DCM (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo to give the title compound (208 mg, 99%). LCMS(Method 2): Rt 3.38 min, m/z 743 [MH⁺].

b.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea,partial formate salt (Example 40).

Dimethylamine (2M in MeOH, 1.12 mL, 2.24 mmol) was added to a solutionof Intermediate 40a (208 mg, 0.28 mmol) in THF (3.0 mL). The reactionwas heated to 50° C. in a sealed environment overnight. Furtherdimethylamine (2M in MeOH, 250 μL, 0.50 mmol) was added and heatingcontinued for 8 h then the mixture was cooled and partitioned betweenEtOAc and water. The aqueous layer was then extracted with EtOAc (3×).The combined organic layers were washed with brine, dried (MgSO₄),filtered and evaporated in vacuo. The residue was purified by FCC, using0-10% [2M NH₃ in MeOH] in DCM. Further purification by HPLC (C18X-select column, 20-98% MeCN in H₂O, 0.1% HCO₂H) gave the title compoundas a white powder after freeze-drying (110 mg, 57%). LCMS (Method 5): Rt3.47 min, ink 692.5 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.30 (9H, s),1.63-1.69 (2H, m), 1.73-1.80 (4H, m), 1.88-2.04 (2H, m), 2.04-2.14 (1H,m), 2.22-2.32 (1H, m), 2.60 (6H, s), 3.08-3.14 (4H, m), 3.17 (2H, t, J5.4), 4.23 (2H, t, J 5.4), 4.89 (1H, dd, J 8.7, 5.8), 5.41 (1H, t, J8.2), 6.34 (1H, s), 7.03-7.07 (1H, ddd, J 8.5, 2.4, 0.6), 7.09-7.13 (2H,m), 7.18-7.25 (3H, m), 7.26-7.31 (2H, m), 7.39-7.44 (1H, t, J 7.8),7.50-7.54 (2H, m), 8.45 (0.7H, br s).

Example 411-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

To a solution of Example 29 (100 mg, 0.15 mmol) and Et₃N (65 μL, 0.47mmol) in THF (7 mL) at 0° C. was added mesyl chloride (19 μL, 0.19mmol), and the mixture stirred for 30 min. To the solution was added1-methyl piperazine (52 μL, 0.47 mmol) and the solution heated at refluxfor 35 min. Water was added and the mixture extracted with DCM. Thecombined organics were dried and concentrated in vacuo. The residue waspurified by HPLC (Gemini C18 column, 30-98% MeCN in H₂O, 0.1% HCO₂H) togive the title compound as a white powder after freeze-drying (32 mg,28%). LCMS (Method 5): Rt 3.52 min, m/z 717 [MH⁺]. ¹H NMR (400 MHz,CDCl₃): 1.34 (9H, s), 1.66 (2H, q, J 5.4), 1.72-1.76 (4H, m), 1.90-1.99(1H, m), 2.04-2.13 (3H, m), 2.23 (3H, s), 2.39-2.55 (10H, m), 3.16 (4H,t, J 5.2), 3.60 (1H, d, J 13.4), 3.62 (1H, d, J 13.4), 5.13 (1H, td, J8.7, 5.3), 5.21 (1H, t, J 4.4), 6.00 (1H, br s), 6.37 (1H, s), 6.91 (1H,br s), 6.97-6.98 (1H, m), 7.23 (1H, d, J 7.5), 7.29-7.54 (9H, m).

Example 421-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.1-(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 42a)

A mixture of Intermediate 5c (150 mg, 0.410 mmol) and Intermediate 39b(230 mg, 0.430 mmol) in 1,4-dioxane (4 mL) and DIPEA (113 μL, 0.65 mmol)was stirred at 90° C. for 4.5 h. The mixture was concentrated in vacuo.The residue was purified by FCC twice, using 0-10% MeOH in DCM, to givethe title compound as a pale yellow foam (234 mg, 76%). LCMS (Method 3):Rt 3.03 min, m/z 749.2 [MH⁺].

b.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 42).

A mixture of Intermediate 42a (230 mg, 0.300 mmol) and pyridiniump-toluenesulfonate (226 mg, 0.900 mmol) in MeOH (3 mL) was stirred at RTfor 15 h. Pyridinium p-toluenesulfonate (113 mg, 0.450 mmol) was addedand the mixture stirred at 50-55° C. for 8 h. The cooled mixture wasdiluted with sat. aq. NaHCO₃ solution and extracted with DCM (3×15 mL).The combined organics were dried and concentrated in vacuo. The residuewas purified by FCC, using 0-14% MeOH in DCM, to give the title compoundas a white powder after freeze-drying (163 mg, 82%). LCMS (Method 5): Rt3.33 min, m/z 665.3 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s),1.82-2.27 (11H, m), 2.31-2.39 (1H, m), 3.10-3.17 (1H, m), 3.71 (2H, q, J5.1), 3.96-4.05 (3H, m), 4.79-4.89 (2H, m), 5.37-5.41 (1H, m), 6.34 (1H,s), 6.95-6.99 (1H, m), 7.05-7.15 (3H, m), 7.24-7.43 (6H, m), 7.75 (1H,d, J 9.9), 8.11 (1H, s), 8.25 (1H, br d).

Example 431-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(2-dimethylamino-ethyl)-methyl-amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea

a.N-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-N,N′,N′-trimethyl-ethane-1,2-diamine(Intermediate 43a)

A mixture of Intermediate 24b (300 mg, 1.74 mmol) andN,N′,N′-trimethylethane-1,2-diamine (900 mg, 8.77 mmol) in NMP (2 mL)was heated in the microwave at 170° C. for 2 h. The reaction mixture wasapplied to an SCX-2 cartridge (25 g) and washed with MeOH. The productwas eluted with 2M NH₃ in MeOH; concentration in vacuo gave a residue.FCC, using 0-10% [2M NH₃ in MeOH] in DCM, gave the title compound as abrown oil (190 mg, 46%). LCMS (Method 4): Rt 0.38 min, m/z 238 [MH⁺].

b.N-[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-N,N′,N′-trimethyl-ethane-1,2-diamine(Intermediate 43b)

To a solution of Intermediate A (143 mg, 0.88 mmol) in DMF (3 mL) wasadded NaH (60% in oil, 96 mg, 2.4 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 43a (190 mg, 0.80 mmol) was added. Thismixture was heated at 60° C. in the microwave for 1 h. The reactionmixture was applied to an SCX-2 cartridge and washed with MeOH. Theproduct was eluted with 2M NH₃ in MeOH; concentration in vacuo gave aresidue. FCC, using 0-20% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a pale brown oil (140 mg, 46%). LCMS (Method 1): Rt 1.34min, ink 381 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(2-dimethylamino-ethyl)-methyl-amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Example 43).

A solution of Intermediate 43b (140 mg, 0.36 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;218 mg, 0.54 mmol) and DIPEA (186 mg, 1.44 mmol) in DMF (6 mL) wasstirred at 60° C. for 1 h. The reaction mixture was applied to an SCX-2cartridge (25 g) and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2MNH₃ in MeOH] in DCM, gave a viscous yellow gum. HPLC (C6-Ph column,10-40% MeCN in H₂O, 0.1% HCO₂H) gave the title compound as an off-whitepowder after freeze-drying (80 mg, 35%). LCMS (Method 5): Rt 3.67 min,m/z 636.3 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOH): 1.30 (9H, s), 1.86-2.15 (3H,m), 2.19-2.30 (1H, m), 2.38 (3H, s), 2.57 (6H, s), 2.92 (3H, s), 3.00(2H, t J 6.2), 3.46-3.60 (2H, m), 4.89 (1H, m), 5.42 (1H, t, J 3.9),6.33 (1H, s), 7.16-7.36 (9H, m), 7.52 (1H, d, J 10.1), 7.90 (1H, s).

Example 441-[5-tert-Butyl-2-(3-piperidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

To a solution of Example 29 (100 mg, 0.15 mmol) and Et₃N (65 μL, 0.47mmol) in THF (7 mL) at 0° C. was added mesyl chloride (19 μL, 0.19mmol), and the mixture stirred for 0.5 h. To the solution was addedpiperidine (47 μL, 0.47 mmol), and the mixture heated at reflux for 16h. NaI (24 mg, 0.15 mmol) was added and the solution heated at refluxfor 1 h. The cooled reaction mixture was diluted with water andextracted with DCM. The combined organics were dried and concentrated invacuo. The residue was purified by HPLC (XBridge C18 column, 20-98% MeCNin H₂O, 0.1% HCO₂H) to give the impure product. The residue wasre-purified by HPLC (Gemini C18 column, 20-98% MeCN in H₂O, 0.1% HCO₂H),the product containing fractions were partitioned between DCM andsaturated NaHCO₃ solution. The combined organics were dried andconcentrated in vacuo to give the title compound as a white powder (14mg, 12%). LCMS (Method 5): Rt 3.60 min, m/z 702 [MH⁺]. ¹H NMR (400 MHz,d₄-MeOH): 1.34 (9H, s), 1.39-1.44 (2H, m), 1.52-1.55 (4H, m), 1.67-1.71(2H, m), 1.77-1.80 (4H, m), 2.03-2.08 (3H, m), 2.24-2.33 (1H, m), 3.20(4H, t, J 5.3), 3.55 (2H, s), 4.93 (1H, dd, J 8.6, 5.6), 5.44 (1H, t, J4.2), 6.38 (1H, s), 7.21-7.33 (5H, m), 7.40-7.56 (6H, m).

Example 451-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[methyl-(2-morpholin-4-yl-ethyl)-amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea

a. (2-Morpholin-4-yl-ethyl)-carbamic acid tert-butyl ester (Intermediate45a)

4-(2-Aminoethyl)morpholine (5.00 g, 38.5 mmol) was added to a stirredmixture of di-tert-butyl dicarbonate (8.38 g, 38.5 mmol) andindium(III)chloride (85 mg, 0.39 mmol). This mixture was stirred for 1min before being diluted with EtOAc (200 mL) and washed with water (×2).The organic layer was dried (MgSO₄) and was evaporated in vacuo to givethe title compound as a clear oil (8.14 g, 92%). ¹H NMR (400 MHz,CDCl₃): 1.45 (9H, s), 2.40-2.50 (6H, m), 3.23 (2H, q, J 5.9), 3.70 (4H,t, J 4.7), 4.96 (1H, br s).

b. Methyl-(2-morpholin-4-yl-ethyl)-amine (Intermediate 45b)

To a solution of Intermediate 45a (6.0 g, 24.6 mmol) in THF (123 mL) wasadded lithium aluminium hydride (2.33 g, 61.5 mmol) portionwise, thenthe mixture was stirred at reflux for 4 h. A further portion of lithiumaluminium hydride (1.28 g, 33.6 mmol) was added to the cooled solution,then the mixture was stirred at reflux for a further 8 h. Water (3.75mL) was added dropwise, followed by 4N aqueous NaOH (11.3 mL) and water(3.75 ml). The mixture was filtered, washed with diethyl ether, dried(MgSO₄) and concentrated in vacuo to give the title compound as a yellowoil (3.67 g, 99%). ¹H NMR (400 MHz, CDCl₃): 2.40-2.52 (9H, m), 2.67 (2H,t, J 2.7), 3.70 (4H, t, J 4.5).

c.(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-methyl-(2-morpholin-4-yl-ethyl)-amine(Intermediate 45c)

A mixture of Intermediate 24b (300 mg, 1.74 mmol) and Intermediate 45b(1.26 g, 8.77 mmol) in NMP (2 mL) was heated in the microwave at 170° C.for 2 h. The reaction mixture was applied to an SCX-2 cartridge (25 g)and washed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM, gave the title compound as an orange oil (350 mg, 71%). ¹H NMR(400 MHz, CDCl₃): 2.41-2.52 (4H, m), 2.58 (2H, t, J 5.6), 3.03 (3H, s),3.27 (2H, t, J 6.0), 3.62 (4H, t, J 5.2), 7.04-7.08 (1H, m), 7.58-7.65(1H, m), 8.39 (1H, t, J 2.4).

d.[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-methyl-(2-morpholin-4-yl-ethyl)-amine(Intermediate 45d)

To a solution of Intermediate A (225 mg, 1.38 mmol) in DMF (3 mL) wasadded NaH (60% in oil, 150 mg, 3.75 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 45c (350 mg, 1.25 mmol) was added. Thismixture was stirred at 60° C. for 7 h. The reaction mixture was appliedto an SCX-2 cartridge (25 g) and washed with MeOH. The product waseluted with 2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC,using 0-20% [2M NH₃ in MeOH] in DCM, gave the title compound as anorange oil (270 mg, 51%). LCMS (Method 4): Rt 0.22 min, m/z 423 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[methyl-(2-morpholin-4-yl-ethyl)-amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Example 45).

A solution of Intermediate 45d (270 mg, 0.63 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;380 mg, 0.95 mmol) and DIPEA (325 mg, 2.52 mmol) in DMF (8 mL) wasstirred at 60° C. for 1 h. The reaction mixture was applied to an SCX-2cartridge (25 g) and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2MNH₃ in MeOH] in DCM, gave a stiff yellow gum which was further purifiedby HPLC (C18 column, 10-45% MeCN in H₂O, 0.1% HCO₂H). The residue wasrecrystallized from boiling EtOAc to give the title compound as a whitepowder (60.0 mg, 14%). LCMS (Method 5): Rt 3.65 min, m/z 678.3 [MH⁺]. ¹HNMR (400 MHz, d₄-MeOH): 1.30 (9H, s), 1.87-2.15 (3H, m), 2.18-2.27 (1H,m), 2.32 (4H, t, J 4.4), 2.38 (3H, s), 2.55 (2H, t, J 5.6), 2.96 (3H,s), 3.31-3.40 (6H, m), 4.89 (1H, m), 5.40 (1H, t, J 4.2), 6.33 (1H, s),7.19-7.36 (9H, m), 7.53 (1H, d, J 10.0), 7.92 (1H, d, J 1.6).

Example 461-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaand1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(1:1 mixture of diastereomers)

a. 2-Morpholin-4-yl-propionic acid N′-(5-fluoro-pyridin-2-yl)-hydrazide(Intermediate 46a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (1.62 g, 12.8 mmol),2-(morpholin-4-yl)propanoic acid (Enamine, 2.50 g, 12.8 mmol), HOBt.H₂O(196 mg, 1.28 mmol) and Et₃N (2.14 mL, 15.3 mmol) in DCM (50 mL) wasadded EDC (2.94 g, 15.3 mmol) and the brown solution stirred at RT for16 h. Water (20 mL) and brine (20 mL) were added, and the mixtureshaken. The aqueous layer was extracted with DCM (20 mL), then thecombined organics were passed through a hydrophobic frit andconcentrated in vacuo to give the title compound as a brown foam (3.43g, >99%). LCMS (Method 3): Rt 0.44 min, m/z 269 [MH⁺].

b. 6-Fluoro-3-(1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 46b)

To a solution of Intermediate 46a (3.43 g, 12.8 mmol), Ph₃P (6.71 g,25.6 mmol) and Et₃N (7.14 mL, 51.2 mmol) in THF (75 mL) at 0° C. wasadded hexachloroethane (6.06 g, 25.6 mmol) and the solution stirred atRT for 4 h. The brown suspension was filtered and the solid washed withTHF (10 mL). The combined organics were applied to an SCX-2 cartridge,which was washed with DCM-MeOH (1:1, 100 mL) and MeOH (100 mL). Theproduct was eluted with 2M NH₃ in MeOH; concentration in vacuo gave anoff-white solid. FCC, using 1-5% [2M NH₃ in MeOH] in DCM, gave the titlecompound as an off-white solid (1.70 g, 53%). ¹H NMR (300 MHz, CDCl₃):1.66 (3H, d, J 6.8), 2.45-2.60 (4H, m), 3.63-3.76 (4H, m), 4.28 (1H, q,J 6.8), 7.21 (1H, ddd, J 10.0, 7.5, 2.3), 7.76 (1H, ddd, J 10.0, 4.9,0.9), 8.50 (1H, ddd, J 3.9, 2.3, 0.9).

c.(1S,4R)-4-[3-((R)-1-Morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamineand(1S,4R)-4-[3-((S)-1-Morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylam(1:1 mixture diastereomers, Intermediate 46c)

A suspension of Intermediate A (343 mg, 2.10 mmol) and NaH (60%dispersion in oil, 240 mg, 6.00 mmol) in dry DMF (10 mL) at RT under Arwas stirred for 30 min (CARE: gas evolution), then Intermediate 46b (501mg, 2.00 mmol) was added and the brown mixture stirred at 60° C. underAr for 1 h. The solution was concentrated in vacuo, redissolved in MeOH(4 mL) and AcOH (0.60 mL, 10.0 mmol), then applied to an SCX-2 cartridge(20 g) and washed with MeOH (100 mL). The product was eluted with 2M NH₃in MeOH (50 mL); concentration in vacuo gave a dark brown foam. FCC,using 2-8% [2M NH₃ in MeOH] in DCM, gave the title compounds as a lightbrown foam (558 mg, 71%). LCMS (Method 3): Rt 0.44 min, m/z 394 [MH⁺]

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaand1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(1:1 mixture of diastereomers) (Example 46).

A yellow solution of (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;223 mg, 0.550 mmol), Intermediate 46c (197 mg, 0.500 mmol) and DIPEA(0.109 mL, 0.625 mmol) in dioxane (10 mL) was stirred at 60° C. for 18h. The cooled solution was concentrated in vacuo, suspended in water (10ml) and extracted with DCM (2×10 mL). The combined organics were passedthrough a hydrophobic fit and concentrated in vacuo to leave ayellow-brown gum. FCC, using 2-7% [2M NH₃ in MeOH] in DCM, gave thetitle compounds as a pale yellow solid (192 mg, 59%). LCMS (Method 5):two peaks in 1:1 ratio, Rt 4.13 and 4.15 min, m/z 649 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 1.27 (9H, s), 1.52 (1.5H, d, J 6.8), 1.53 (1.5H, d, J6.8), 1.83-1.99 (2H, m), 2.10-2.17 (2H, m), 2.36 (3H, s), 2.43 (2H, t, J4.5), 2.51-2.55 (2H, m), 3.47-3.55 (4H, m), 4.46 (0.5H, q, J 6.8), 4.49(0.5H, q, J 6.8), 4.83 (1H, m), 5.45 (0.5H, t, J 4.5), 5.52 (0.5H, t, J4.5), 6.33 (1H, s), 7.10 (1H, d, J 8.5), 7.21-7.44 (9H, m), 7.73 (1H,dd, J 9.9, 2.6), 8.03 (1H, s), 8.32 (0.5H, d, J 2.1), 8.37 (0.5H, d, J2.1).

Example 471-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,2-dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1,2-Dimethyl-pyrrolidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 47a)

To a suspension of (S)-1,2-dimethyl-pyrrolidine-2-carboxylic acid (660mg, 4.61 mmol), (5-fluoro-pyridin-2-yl)-hydrazine (488 mg, 3.84 mmol)and Et₃N (1.1 mL, 7.7 mmol) in DCM (20 mL) were added HOBt.H₂O (51 mg,0.38 mmol) and EDCI.HCl (884 mg, 4.61 mmol) and the mixture stirred atRT overnight. The mixture was partitioned between EtOAc/water andextracted with EtOAc. The combined organics were dried (Na₂SO₄),filtered and concentrated in vacuo. FCC, using 0-10% MeOH in DCM, gavethe title compound as a brown solid (668 mg, 69%). LCMS (Method 4): Rt0.40, m/z 253 [MH⁺].

b.3-((S)-1,2-Dimethyl-pyrrolidin-2-yl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 47b)

To a solution of Intermediate 47a (668 mg, 2.64 mmol), Et₃N (1.5 mL, 11mmol) and Ph₃P (1.4 g, 5.3 mmol) in THF (20 mL) at 0° C. was addedhexachloroethane (1.25 g, 5.29 mmol). The mixture was stirred at 0° C.for 10 min, then at RT for 1 h. The mixture was partitioned betweenEtOAc/water and the aqueous extracted with EtOAc. The combined organicswere dried (Na₂SO₄), filtered and concentrated in vacuo. Purification byFCC, using 0-10% MeOH in EtOAc, gave the title compound as a pale brownsolid (300 mg, 49%). LCMS (Method 4): Rt 0.39, m/z 235 [MH⁺].

c.(1S,4R)-4-[3-((S)-1,2-Dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 47c)

To a solution of Intermediate 47b (150 mg, 0.64 mmol) and Intermediate A(126 mg, 0.64 mmol) in DMF (3 mL) was added NaH (60% in mineral oil, 90mg, 2.24 mmol) portionwise. The mixture was stirred at 60° C. for 1.5 hthen allowed to cool to RT. The mixture was carefully quenched bypouring into MeOH (10 mL), then applied to an SCX-2 cartridge and washedwith MeOH. The product was eluted with 2M NH₃ in MeOH; concentration invacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH] in DCM, gave thetitle compound as a brown solid (180 mg, 75%). LCMS (Method 4): Rt 0.49,m/z 378 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,2-dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 47).

The title compound was prepared as an off-white solid (80 mg, 53%) using(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 80mg, 0.20 mmol) and Intermediate 47c (90 mg, 0.24 mmol) in a similarmanner to Example 1, step d. LCMS (Method 5): Rt 3.83 min, m/z 633[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.51 (3H, s), 1.78-1.99(5H, m), 2.02 (3H, s), 2.03-2.22 (3H, m), 2.36 (3H, s), 2.65 (1H, q, J8.6), 3.11-3.17 (1H, m), 4.79-4.86 (1H, m), 5.32 (1H, t, J 4.2), 6.32(1H, s), 7.11 (1H, d, J 8.6), 7.25-7.39 (9H, m), 7.75 (1H, d, J 9.8),8.05 (1H, s), 8.43 (1H, d, J 2.2).

Example 481-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxymethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

To a solution of Example 29 (204 mg, 0.32 mmol) and Et₃N (134 μL, 0.97mmol) in DCM (3.2 mL) at 0° C. was added mesyl chloride (39 μL, 0.39mmol), and the mixture stirred for 1 h. The solution was washed withwater, dried, and concentrated in vacuo to give methanesulfonic acid3-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-benzylester. This was immediately dissolved in dioxane (1.5 mL) and ethyleneglycol (1.5 mL) and the solution stirred at 85° C. for 1 h. The cooledreaction mixture was suspended in water and filtered to leave a solid.Purification by HPLC (XBridge C18 column, 40-98% MeCN in H₂O, 0.1%NH₄OH) gave the title compound as a white powder after freeze-drying (59mg, 27%). LCMS (Method 5): Rt 4.27 min, m/z 679 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.28 (9H, s), 1.60-1.64 (2H, m), 1.70-1.75 (4H, m), 1.86-1.93(2H, m), 2.03 (1H, m), 2.11 (1H, m), 3.14 (4H, t, J 5.2), 3.54-3.48 (4H,m), 4.56 (2H, s), 4.64 (1H, s), 4.80 (1H, m), 5.54 (1H, t, J 4.3), 6.34(1H, s), 7.07 (1H, d, J 8.6), 7.16 (1H, dd, J 9.8, 2.2), 7.37-7.49 (8H,m), 7.60-7.63 (2H, m), 8.11 (1H, s).

Example 491-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-[1,4]oxazepan-4-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 6-Fluoro-3-[1,4]oxazepan-4-yl-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 49a)

A solution of Intermediate 24b (429 mg, 2.50 mmol) and homomorpholine(939 mg, 9.30 mmol) in NMP (10 mL) was heated in the microwave at 170°C. for 10 h. The cooled mixture was applied to an SCX-2 cartridge (70g), washing with methanol then eluting basic components with 0.4-2 M NH₃in MeOH. Product containing fractions were combined and concentrated invacuo. The residue was purified by FCC, using 0-12% [2M NH₃ in MeOH] inDCM, to give impure product. Further purified by FCC, using 0-12% MeOHin EtOAc gave the title compound as a pale brown gum (147 mg, 25%). LCMS(Method 3): Rt 2.11 min, m/z 237 [MH⁺].

b.(1S,4R)-4-(3-[1,4]Oxazepan-4-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 49b)

To a solution of Intermediate A (145 mg, 0.614 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 74 mg, 1.84 mmol). The mixture wasstirred at RT for 15 min, then a solution of Intermediate 49a (100 mg,0.614 mmol) in DMF (3 mL) was added and the mixture stirred at 60° C.for 2.25 h. The cooled mixture was diluted with water and extracted withDCM (4×25 mL). The combined organics were dried and concentrated invacuo. The residue was purified by FCC, using 0-12% [2M NH₃ in MeOH] inDCM, to give the title compound as a pale brown gum (93 mg, 40%). LCMS(Method 3): Rt 0.43 min, m/z 380 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-[1,4]oxazepan-4-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 49).

A solution of Intermediate 49b (90.0 mg, 0.237 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety; 97mg, 0.24 mmol) in 1,4-dioxane (3 mL) and DIPEA (63 μL, 0.36 mmol) wasstirred at 90° C. for 4 h, then more DIPEA (63 μL, 0.36 mmol) was addedand mixture stirred at 100-110° C. for 3.5 h. The cooled mixture wasconcentrated in vacuo. The residue was purified by FCC, using 0-12% [2MNH₃ in MeOH] in DCM, to give the product (31 mg, 21%). This was furtherpurified by HPLC (C18 X-select column, 35-98% MeCN in H₂O, 0.1% HCO₂H)to give the title compound as a white powder after freeze-drying (20 mg,13%). LCMS (Method 5): Rt 4.40 min, m/z 635.2 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.27 (9H, s), 1.80-2.18 (6H, m), 2.36 (3H, s), 3.44-3.51 (4H,m), 3.78-3.85 (4H, m), 4.77-4.85 (1H, m), 5.51 (1H, t, J 4.4), 6.32 (1H,s), 7.10-7.16 (2H, m), 7.25-7.40 (8H, m), 7.60 (1H, d, J 9.6), 7.65 (1H,d, J 1.5), 8.10 (1H, s).

Example 501-(5-tert-Butyl-2-{3-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-phenyl}-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

To a solution of Example 29 (150 mg, 0.24 mmol) and Et₃N (98 μL, 0.71mmol) in DCM (7 mL) at 0° C. was added mesyl chloride (28 μL, 0.28mmol), and the mixture stirred for 1 h. The solution was washed withwater, dried, and concentrated in vacuo to give methanesulfonic acid3-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-benzylester. This was immediately dissolved in THF (2.5 mL) and DIPEA (83 μL,0.47 mmol) then 1-(2-hydroxyethyl)piperazine (87 μL, 0.71 mmol) addedand the solution stirred at reflux for 1 h. Water was added and themixture extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by HPLC (XBridge C18column, 20-98% MeCN in H₂O, 0.1% NH₄OH) to give the title compound as awhite powder after freeze-drying (45 mg, 25%). LCMS (Method 5): Rt 3.42min, m/z 747 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s), 1.60-1.64(2H, m), 1.69-1.75 (4H, m), 1.83-1.94 (2H, m), 2.03-2.12 (2H, m),2.29-2.45 (8H, m), 2.33 (2H, t, J 6.4), 3.14 (4H, t, J 5.2), 3.44 (2H,m), 3.49 (2H, s), 4.31 (1H, s), 4.80 (1H, m), 5.54 (1H, t, J 4.4), 6.33(1H, s), 7.03 (1H, d, J 8.6), 7.16 (1H, dd, J 9.8, 2.2), 7.34-7.46 (8H,m), 7.60-7.63 (2H, m), 8.10 (1H, s).

Example 511-(2-tert-Butyl-5-p-tolyl-3H-imidazol-4-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 2-tert-Butyl-5-p-tolyl-1H-imidazole (Intermediate 51a)

A red suspension of 2,2-dimethylpropionamide hydrochloride (Atlantic,1.00 g, 7.32 mmol), 2-bromo-4′-methylacetophenone (Aldrich, 1.56 g, 7.32mmol) and K₂CO₃ (1.52 g, 11.0 mmol) in DMF (20 mL) was stirred at 75° C.for 3 h. The mixture was cooled to RT, concentrated in vacuo, suspendedin water (25 mL) and extracted with DCM (2×25 mL). The combined organicswere passed through a hydrophobic frit, concentrated in vacuo,redissolved in MeOH (5 mL), applied to an SCX-2 cartridge (20 g) andwashed with MeOH (100 mL). The product was eluted with 2M NH₃ in MeOH(60 mL); concentration in vacuo left a yellow foam (1.26 g). FCC, using1-5% MeOH in DCM, gave the title compound as a pale yellow solid (770mg, 49%). LCMS (Method 3): Rt 2.26 min, m/z 215 [MH⁺].

b. 2-tert-Butyl-4-nitroso-5-p-tolyl-1H-imidazole (Intermediate 51b)

A yellow solution of Intermediate 51a (390 mg, 1.82 mmol) and isopentylnitrite (0.294 mL, 2.18 mmol) in THF (10 mL) was stirred at 50° C. for 8h, then cooled to RT and concentrated in vacuo to leave a dark greenoil. FCC, using 0-25% EtOAc in cyclohexane, gave the title compound as agreen solid (154 mg, 35%). LCMS (Method 3): Rt 3.82 min, m/z 244 [MH⁺].

c. 2-tert-Butyl-5-p-tolyl-1H-imidazol-4-ylamine (Intermediate 51c)

A suspension of Intermediate 51b (150 mg, 0.617 mmol) and Pd/C (10%, 15mg) in EtOH (10 mL) was stirred at RT under H₂ for 2 h. The flask wasevacuated and purged with N₂ thrice, then the mixture filtered throughCelite, and the filter-cake washed with EtOH (10 mL). The combinedorganics were concentrated in vacuo to leave a red-brown gum. FCC, using1-6% MeOH in DCM, gave the title compound as a yellow-orange gum (96.3mg, 68%). LCMS (Method 3): Rt 2.26 min, m/z 230 [MH⁺].

d. (2-tert-Butyl-5-p-tolyl-1H-imidazol-4-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Intermediate 51d)

To a solution of Intermediate 51c (45.3 mg, 0.197 mmol) in EtOAc (1 mL)and aqueous NaOH (1M, 0.49 mL) was added 2,2,2-trichloroethylchloroformate (0.0326 mL, 0.237 mmol) and the resulting mixture stirredat RT for 45 min. The layers were separated and the aqueous extractedwith EtOAc (2 mL). The combined organics were washed with brine (2 mL),dried (Na₂SO₄), filtered and concentrated in vacuo to leave anorange-red gum. FCC, using 0-50% EtOAc in cyclohexane, gave the titlecompound as a pale orange film (44.1 mg, 55%). LCMS (Method 3): Rt 2.87min, m/z 404, 406 [MH⁺].

e.1-(2-tert-Butyl-5-p-tolyl-3H-imidazol-4-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 51).

An orange solution of Intermediate 51d (65.4 mg, 0.162 mmol),Intermediate 3c (55.9 mg, 0.153 mmol) and DIPEA (0.042 mL, 0.242 mmol)in dioxane (2 mL) was stirred at 60° C. for 18 h. After cooling, themixture was concentrated in vacuo, suspended in water (5 ml) andextracted with DCM (2×5 mL). The combined organics were passed through ahydrophobic frit and concentrated in vacuo to leave an orange-brown gum.FCC, using 2-8% MeOH in DCM, gave a pale yellow solid (50.5 mg). Furtherpurification by HPLC (C18 XBridge column, 25-75% MeCN in H₂O, 0.1%NH₄OH) gave the title compound as a white solid after freeze-drying(33.3 mg, 33%). LCMS (Method 5): Rt 3.35 min, m/z 619 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 3:1 ratio of tautomers: 1.30 (6.75H, s), 1.31 (2.25H, s),1.61 (2H, m), 1.72 (4H, m), 1.83-2.00 (2H, m), 2.05 (1H, m), 2.15 (1H,m), 2.30 (0.75H, s), 2.32 (2.25H, s), 3.13 (4H, q, J 5.2), 4.87 (1H, m),5.54 (1H, t, J 4.3), 7.14-7.19 (2.5H, m), 7.21 (1.5H, d, J 8.2),7.25-7.40 (4H, m), 7.54 (1.5H, d, J 8.3), 7.60-7.71 (3.5H, m), 11.56(0.75H, s), 11.68 (0.25H, s).

Example 521-{5-tert-Butyl-2-[3-(4-hydroxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

To a solution of Example 29 (150 mg, 0.24 mmol) and Et₃N (98 μL, 0.71mmol) in DCM (7 mL) at 0° C. was added mesyl chloride (28 μL, 0.28mmol), and the mixture stirred for 1 h. The solution was washed withwater, dried, and concentrated in vacuo to give methanesulfonic acid3-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-benzylester. This was immediately dissolved in THF (2.5 mL) and DIPEA (83 μL,0.47 mmol) then 4-hydroxypiperidine (83 μL, 0.71 mmol) added and thesolution stirred at reflux for 1 h. Water was added and the mixtureextracted with DCM. The combined organics were dried and concentrated invacuo. The residue was purified by FCC, using 0-10% [2M NH₃ in MeOH] inDCM, to give the product. This was purified further by HPLC (XBridge C18column, 20-98% MeCN in H₂O, 0.1% NH₄OH) to give the title compound as awhite powder after freeze-drying (30 mg, 18%). LCMS (Method 5): Rt 3.41min, m/z 718 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s), 1.34-1.40(2H, m), 1.60-1.75 (7H, m), 1.81-1.96 (3H, m), 2.00-2.15 (4H, m),2.64-2.69 (2H, m), 3.14 (4H, t, J 5.2), 3.40-3.45 (1H, m), 3.47 (2H, s),4.51 (1H, d, J 3.9), 4.82 (1H, m), 5.54 (1H, t, J 4.4), 6.33 (1H, s),7.04 (1H, d, J 8.5), 7.16 (1H, dd, J 9.8, 2.2), 7.26-7.33 (4H, m),7.35-7.46 (4H, m), 7.60-7.63 (2H, m), 8.10 (1H, s).

Example 531-{5-tert-Butyl-2-[3-(2-hydroxy-ethylsulfanyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

A solution of Intermediate 3c (107 mg, 0.29 mmol) and Intermediate 53c(151 mg, 0.32 mmol) in THF (3 mL) and DIPEA (169 μL, 0.97 mmol) wasstirred at reflux for 20.5 h. The cooled reaction mixture was dilutedwith water and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-5% [2MNH₃ in MeOH] in DCM, to give the product. This residue purified furtherby HPLC (XBridge C18 column, 30-98% MeCN in H₂O, 0.1% NH₄OH) to give thetitle compound as a white powder after freeze-drying (21 mg, 10%). LCMS(Method 5): Rt 4.42 min, m/z 681 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28(9H, s), 1.60-1.63 (2H, m), 1.69-1.74 (4H, m), 1.86-1.93 (2H, m), 2.03(1H, m), 2.13 (1H, m), 3.09 (2H, t, J 6.8), 3.14 (4H, t, J 5.2), 3.59(2H, q, J 6.2), 4.80 (1H, m), 4.95 (1H, t, J 5.6), 5.54 (1H, t, J 4.3),6.33 (1H, s), 7.07 (1H, d, J 8.6), 7.16 (1H, dd, J 9.8, 2.1), 7.35-7.47(8H, m), 7.60-7.64 (2H, m), 8.14 (1H, s).

Example 541-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.[1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidin-4-yl]-methanol(Intermediate 54a)

A solution of Intermediate 24b (593 mg, 3.45 mmol) and4-piperidinemethanol (1.59 g, 13.8 mmol) in NMP (10 mL) was heated inthe microwave at 170° C. for 3 h. The cooled mixture was applied to anSCX-2 cartridge (70 g), washing with methanol then eluting basiccomponents with 0.4-2 M NH₃ in MeOH. Product containing fractions werecombined and concentrated in vacuo. The residue was purified by FCC,using 0-15% MeOH in EtOAc, to give the title compound as a brown gum(481 mg, 56%). LCMS (Method 3): Rt 2.12 min, m/z 251 [MH⁺].

b.6-Fluoro-3-(4-triisopropylsilanyloxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin(Intermediate 54b)

To a solution of Intermediate 54a (470 mg, 1.88 mmol) and Et₃N (390 μL,2.82 mmol) in DCM (5 mL) was added triisopropylsilyltrifluoromethanesulfonate (607 μL, 2.26 mmol) and the mixture stirred at RT for 0.5 h.The mixture was washed with sat. aq. NaHCO₃ solution, dried andconcentrated in vacuo. The residue was purified by FCC, using 0-100%EtOAc in cyclohexane, then 10% MeOH in EtOAc, to give the title compoundas a pale yellow solid (565 mg, 74%). LCMS (Method 3): Rt 5.21 min, m/z407 [MH⁺].

c.(1S,4R)-4-[3-(4-Triisopropylsilanyloxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 54c)

To a solution of Intermediate A (223 mg, 1.37 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 168 mg, 4.20 mmol) and the mixturestirred at RT for 15 min. A solution of Intermediate 54b (555 mg, 1.37mmol) in DMF (3 mL) was added and the mixture stirred at 60° C. for 1.75h. The cooled mixture was diluted with water and extracted with DCM(5×20 mL). The combined organics were dried and concentrated in vacuo.The residue was purified by FCC, using 0-14% [2M NH₃ in MeOH] in DCM, togive the title compound as a brown gum (344 mg, 46%). LCMS (Method 3):Rt 3.29 min, m/z 550 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-triisopropylsilanyloxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 54d)

A solution of Intermediate 54c (171 mg, 0.311 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;132 mg, 0.327 mmol) in 1,4-dioxane (3 mL) and DIPEA (87 μL, 0.50 mmol)was stirred at 90° C. for 3 h, and then at 100° C. for 2.5 h. The cooledmixture was concentrated in vacuo. The residue was purified by FCC,using 0-8% MeOH in DCM, to give the title compound as a pale brown solid(215 mg, 86%). LCMS (Method 3): Rt 5.70 min, m/z 805.4 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 54).

A solution of Intermediate 54d (210 mg, 0.261 mmol) and TBAF (1M in THF,0.31 mL, 0.31 mmol) in THF (5 mL) was stirred at RT for 1.25 h. Themixture was diluted with water and extracted with DCM (3×15 mL). Thecombined organics were dried and concentrated in vacuo. The residue waspurified by FCC, using 0-16% MeOH in DCM, to give the title compound asan off-white powder after freeze-drying (134 mg, 79%). LCMS (Method 5):Rt 4.24 min, m/z 649.2 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.38-2.16 (9H, m), 2.36 (3H, s), 2.85-2.97 (2H, m), 3.28-3.49 (4H, m),4.52 (1H, t, J 5.2), 4.78-4.85 (1H, m), 5.55 (1H, t, J 4.3), 6.32 (1H,s), 7.07 (1H, d, J 8.6), 7.15 (1H, dd, J 9.7, 2.1), 7.25-7.41 (8H, m),7.60 (1H, d, J 9.7), 7.64 (1H, d, J 1.6), 8.04 (1H, s).

Example 551-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4S)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.(1S,4S)-4-(3-Piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 55a)

Intermediate B (74.0 mg, 454 μmol) was added to a mixture of NaH (60% inmineral oil, 27.2 mg, 681 μmol) in DMF (2.5 mL) at RT and stirred for 15min. Intermediate 3b (100 mg, 454 μmol) was then added and the resultingmixture heated to 60° C. for 1 h. After cooling, the reaction wasquenched with sat. aq. NH₄Cl solution. The mixture was diluted withwater and extracted with EtOAc. The combined organic extracts wereconcentrated in vacuo. The resulting residue was purified by FCC, using0 to 10% [2M NH₃ in MeOH] in DCM, to afford the title compound as anorange residue (122 mg, 74%). LCMS (Method 3): Rt 2.13 min, m/z 364[MH⁺].

b.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4S)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 55).

A mixture of Intermediate 55a (120 mg, 0.33 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;147 mg, 0.36 mmol), DIPEA (86.0 μL, 110.50 mmol) and 1,4-dioxane (2.5mL) were heated to 60° C. for 18 h. After cooling the solvent wasevaporated in vacuo. The residue was purified by FCC, using 0-10% MeOHin DCM, to give a pale yellow foam. This was lyophilised to provide thetitle compound as an off-white solid (28 mg, 20%). LCMS (Method 5) Rt4.76 min, m/z 619 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.26 (9H, s), 1.61(2H, m), 1.72 (5H, m), 2.02-2.17 (3H, m), 2.35 (3H, s), 3.13 (4H, m),4.90 (1H, m), 5.58 (1H, m), 6.31 (1H, s), 6.99 (1H, d, J 7.8), 7.19 (1H,dd, J 9.7, 2.2), 7.26-7.43 (8H, m), 7.58-7.64 (2H, m), 7.98 (1H, s).

Example 561-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-hydroxymethyl-4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (3-Hydroxymethyl-4-methyl-piperazin-1-yl)-acetic acid ethyl ester(Intermediate 56a)

A mixture of (1-methyl-2-piperazinyl)methanol dihydrochloride (500 mg,2.46 mmol), ethyl bromoacetate (410 mg, 2.46 mmol), K₂CO₃ (1.02 g, 7.38mmol) and MeCN (15 mL) were heated to reflux for 18 h. After cooling,the mixture was filtered and concentrated in vacuo. The title compoundwas isolated as a colourless oil (525 mg, 98%) and used without furtherpurification. ¹H NMR (300 MHz, CDCl₃): 1.25 (3H, t, J 7.0), 2.35 (3H,s), 2.35-2.59 (4H, m), 2.76-2.90 (3H, m), 3.19 (2H, m), 3.44 (1H, dd, J11.3, 2.0), 3.87 (1H, dd, J 11.3, 4.0), 4.15 (2H, q, J 7.1).

b. Sodium(4-methyl-3-triisopropylsilanyloxymethyl-piperazin-1-yl)-acetate(Intermediate 56b)

To a mixture of Intermediate 56a (520 mg, 2.40 mmol), Et₃N (485 mg, 4.80mmol) and DCM (15 mL), triisopropylsilyl trifluoromethanesulfonate (774μL, 2.88 mmol) was added. The mixture was stirred for 1 h. The mixturewas diluted with DCM and washed with water, sat. aq. NaHCO₃ solution andbrine, and concentrated in vacuo. The title compound was isolated as apale yellow oil (882 mg, quant.) and used without further purification.A mixture of crude silyl-protected product (440 mg, 1.18 mmol), NaOH(47.0 mg, 1.18 mmol), water (10 mL) and THF (10 mL) were stirred for 18h. The mixture was concentrated in vacuo to give the title compound as apink solid (393 mg, 91%). LCMS (Method 3): Rt 2.81 min, m/z 345[M-Na+2H⁺].

c. (4-Methyl-3-triisopropylsilanyloxymethyl-piperazin-1-yl)-acetic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 56c)

To a mixture of Intermediate 56b (390 mg, 1.06 mmol),(5-fluoro-pyridin-2-yl)-hydrazine (135 mg, 1.06 mmol) and HOBt.H₂O (14.4mg, 106 μmol) in DCM (15 mL) was added EDC (245 mg, 1.27 mmol) andstirred for 18 h. The mixture was washed with water, sat. aq. NaHCO₃ andbrine, and concentrated in vacuo to leave the title compound as a brownresidue (412 mg, 86%). LCMS (Method 3): Rt 3.00 min, m/z 454 [MH⁺].

d.6-Fluoro-3-(4-methyl-3-triisopropylsilanyloxymethyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 56d)

Hexachloroethane (426 mg, 1.80 mmol) was added portion-wise to a stirredmixture of Intermediate 56c (410 mg, 0.90 mmol), Ph₃P (472 mg, 1.80mmol) and Et₃N (500 μL, 3.60 mmol) in THF (15 mL) at RT. The reactionmixture was stirred for 18 h, then filtered and concentrated in vacuo.The resulting residue was purified by FCC, using 0-25% MeOH in EtOAc, togive the title compound (237 mg, 60%). LCMS (Method 3): Rt 2.95 min, m/z436 [MH⁺].

e.(1S,4R)-4-[3-(4-Methyl-3-triisopropylsilanyloxymethyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 56e)

Intermediate A (115.4 mg, 0.71 mmol) was added to a mixture of NaH (60%in mineral oil, 87.2 mg, 2.18 mmol) in DMF (4 mL) at RT and stirred for15 min. Intermediate 56d (237 mg, 0.54 mmol) was then added and theresulting mixture heated to 60° C. for 2 h. After cooling, the reactionwas quenched with sat. aq. NH₄Cl solution. The mixture was diluted withwater and extracted with EtOAc. The combined organic extracts werewashed with sat. aq. NaHCO₃ solution and brine, and concentrated invacuo. The resulting residue was loaded onto an SCX-2 cartridge, washedwith MeOH then eluted with 1M NH₃ in MeOH; concentration in vacuo gavethe title compound as a brown residue (91 mg, 29%). LCMS (Method 3): Rt3.08 min, m/z 579 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-3-triisopropylsilanyloxymethyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 56f)

A mixture of Intermediate 56e (87.0 mg, 0.15 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009; 66.8 mg, 0.17 mmol), DIPEA (39.2 μL, 0.23 mmol) and1,4-dioxane (2.5 mL) were heated to 60° C. for 18 h. After cooling thesolvent was evaporated in vacuo and the residue purified by FCC, using0-10% MeOH in DCM, to provide the title compound as a pale yellow foam(64 mg, 51%). LCMS (Method 3): Rt 3.63 min, m/z 834 [M⁺].

g.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-hydroxymethyl-4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 56).

A mixture of Intermediate 56f (60.0 mg, 72.0 μmol) and TBAF (1M in THF,144 μL, 144 μmol) in THF (3 mL) was stirred at RT for 1 h. The mixturewas diluted with water and extracted with EtOAc (3×). The combinedorganic extracts were washed with brine, and concentrated in vacuo. Theresidue was purified by FCC, using 0-20% MeOH in DCM, to afford thetitle compound as an off-white solid (24.9 mg, 51%). LCMS (Method 5): Rt3.54 min, m/z 678 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.82-2.01 (4H, m), 2.01-2.25 (7H, m), 2.53-2.88 (3H, m), 3.21 (1H, m),3.54 (1H, m), 3.96-4.11 (2H, m), 4.37 (1H, dt, J 12.5, 5.4), 4.84 (1H,m), 5.47 (1H, m), 6.32 (1H, s), 7.10 (1H, d, J 8.4), 7.22-7.44 (9H, m),7.72 (1H, d, J 10.3), 8.02 (1H, s), 8.30 (1H, m).

Example 571-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(4-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 3-(4-Allyloxy-piperidin-1-yl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 57a)

To an opaque pale yellow solution of Intermediate 24c (510 mg, 2.16mmol) in dry THF at 0° C. under Ar was added NaH (60% dispersion in oil,216 mg, 5.40 mmol) (CARE: gas evolution) and the resulting suspensionwas stirred at 0° C. for 30 min. Allyl bromide (0.467 mL, 5.40 mmol) wasadded and the suspension stirred at RT under Ar for 1 h and at 70° C.for 18 h. Water (25 mL) was added to the cooled solution, then themixture extracted with EtOAc (3×25 mL). The combined organics werewashed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated invacuo to leave a dark brown oil. FCC, using 0-8% MeOH in EtOAc, gave thetitle compound as a brown oil (171 mg, 29%). LCMS (Method 3): Rt 2.81min, m/z 277 [MH⁺].

b.(1S,4R)-4-[3-(4-Allyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 57b)

A suspension of Intermediate A (108 mg, 0.661 mmol) and NaH (60%dispersion in oil, 72.1 mg, 180 mmol) in dry DMF (5 mL) at RT under Arwas stirred for 1 h (CARE: gas evolution). A solution of Intermediate57a (166 mg, 0.601 mmol) in dry DMF (3 mL) was added and the dark brownsolution stirred at 60° C. for 90 min. The solution was concentrated invacuo, and the residue redissolved in MeOH (5 mL) and AcOH (0.171 mL,3.00 mmol). The solution was applied to an SCX-2 cartridge (10 g) andwas washed with MeOH (100 mL). The product was eluted with 2M NH₃ inMeOH (75 mL); concentration in vacuo left a dark brown solid. FCC, using2-8% [2M NH₃ in MeOH] in DCM, gave the title compound as a dark brownoil (204 mg, 81%). LCMS (Method 3): Rt 2.34 min, m/z 420 [MH⁺].

c.1-{(1S,4R)-4-[3-(4-Allyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-[5-tert-butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-urea(Intermediate 57c)

A yellow-brown solution of Intermediate 33a (99.6 mg, 0.237 mmol),Intermediate 57b (90.3 mg, 0.215 mmol) and DIPEA (0.047 mL, 0.269 mmol)in dioxane (3 mL) was stirred at 60° C. for 18 h. The solution wasconcentrated in vacuo, then the residue suspended in water (5 mL) andextracted with DCM (2×5 mL). The combined organics were passed through ahydrophobic fit and concentrated in vacuo. The residue was purified byFCC, using 2-8% [2M NH₃ in MeOH] in DCM, to give the title compound as apale yellow solid (96.4 mg, 65%). LCMS (Method 3): Rt 3.54 min, m/z 691[MH⁺].

d.1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(4-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 57).

Ar was bubbled through a solution of Intermediate 57c (93.0 mg, 0.135mmol) and 1,3-dimethyl barbituric acid (63.0 mg, 0.404 mmol) in DCM (5mL) at RT under Ar for 30 min, then Pd(PPh₃)₄ (15.6 mg, 0.0135 mmol) wasadded and the orange solution was stirred at RT for 1 h, and then atreflux for 17 h. The suspension was concentrated in vacuo, the residueredissolved in DCE (10 mL) and Ar bubbled through the mixture for 30min. Pd(PPh₃)₄ (15.6 mg, 0.0135 mmol) was added and the opaqueorange-red solution stirred at 75° C. under Ar for 2 h. The cooledsolution was concentrated in vacuo to ˜3 mL volume, then applied to anSCX-2 cartridge (5 g) and washed with MeOH (25 mL). The product waseluted with 2M NH₃ in MeOH (20 mL); concentration in vacuo left anorange solid. FCC, using 5-15% MeOH in DCM, gave a pale orange solid(46.0 mg). Further purification by HPLC (XBridge C18 column, 20-80% MeCNin H₂O, 0.1% NH₄OH) gave the title compound as a white powder afterfreeze-drying (27.1 mg, 31%). LCMS (Method 5): Rt 3.59 min, m/z 651[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.23 (9H, s), 1.56-1.67 (2H, m),1.76-1.92 (4H, m), 1.95-2.11 (2H, m), 2.91-2.97 (2H, m), 3.31-3.35 (2H,m), 3.64-3.71 (1H, m), 4.51 (2H, d, J 4.2), 4.70 (1H, d, J 3.9), 4.77(1H, m), 5.25 (1H, t, J 5.3), 5.50 (1H, t, J 4.4), 6.29 (1H, s), 7.05(1H, d, J 8.5), 7.10 (1H, dd, J 9.9, 2.1), 7.21-7.25 (2H, m), 7.28-7.34(2H, m), 7.39 (2H, d, J 9.1), 7.40 (2H, d, J 9.1), 7.56 (1H, dd, J 9.9,0.8), 7.61 (1H, dd, J 2.1, 0.9), 8.04 (1H, s).

Example 581-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt

a. (S)-1-Isopropyl-pyrrolidine-2-carboxylic acidAr-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 58a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (200 mg, 1.57 mmol)in DMF (15.0 mL) was added (S)-1-isopropyl-pyrrolidine-2-carboxylic acid(Chem. Commun. 2006, 14, 1482, which is incorporated herein by referencein its entirety; 247 mg, 1.57 mmol), EDC (332 mg, 1.73 mmol) andHOBt.H₂O (20.0 mg, 0.16 mmol). The reaction was stirred overnight thenpartitioned between EtOAc and water. The aqueous layer was thenextracted with EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC, using 0-10% MeOH in DCM, to give the title compound(346 mg, 83%). LCMS (Method 1): Rt 0.37 min, m/z 267.1 [MH⁺].

b.6-Fluoro-3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 58b)

To a solution of Intermediate 58a (346 mg, 1.30 mmol), Ph₃P (681 mg,2.60 mmol) and Et₃N (723 μL, 5.20 mmol) in THF (10.0 mL) at 0° C. wasadded hexachloroethane (616 mg, 2.60 mmol). The reaction was stirred atRT overnight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was dissolved in MeOH and loaded onto an SCX-2 cartridge, whichwas washed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave the title compound (220 mg, 68%). LCMS(Method 4): Rt 0.32 min, m/z 249.1 [MH⁺].

c.(1S,4R)-4-[3-((S)-1-Isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 58c)

To a suspension of NaH (60% in mineral oil, 142 mg, 3.56 mmol) in DMF(2.00 mL) was added (1R,4S)-4-amino-1,2,3,4-tetrahydro-naphthalen-1-olIntermediate A (145 mg, 0.88 mmol) and the reaction stirred for 20 min.A solution of Intermediate 58b (220 mg, 0.88 mmol) in DMF (2.00 mL) wasadded and the reaction heated to 60° C. for 1 h. The reaction was cooledand quenched by dropwise addition of methanol, before being diluted withmethanol and loaded onto an SCX-2 cartridge, which was washed with MeOH.The product was eluted with 2M NH₃ in MeOH; concentration in vacuo gavea residue. FCC, using 2-10% [2M NH₃ in MeOH] in DCM, gave the titlecompound (145 mg, 44%). LCMS (Method 4): Rt 0.29 min, m/z 392.2 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt (Example 58).

To a solution of Intermediate 58c (140 mg, 0.37 mmol) in 1,4-dioxane(3.00 mL) was added DIPEA (130 μL, 0.75 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;151 mg, 0.37 mmol). The reaction was heated to 60° C. overnight thencooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-5% MeOH in DCM. Further purification byHPLC (C18 X-select column, 10-98% MeCN in H₂O, 0.1% HCO₂H) gave thetitle compound as a white powder after freeze-drying (60 mg, 25%). LCMS(Method 5): Rt 3.84 min, m/z 647.3 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):0.99 (6H, d, J 6.5), 1.29 (9H, s), 1.90-2.06 (5H, m), 2.11 (1H, m),2.22-2.36 (2H, m), 2.38 (3H, s), 2.73-2.84 (2H, m), 3.25 (1H, m), 4.59(1H, t, J 7.3), 4.90 (1H, dd, J 9.1, 5.7), 5.29 (1H, t, J 4.1), 6.33(1H, s), 7.20-7.36 (9H, m), 7.65 (1H, d, J 10.0), 8.25 (0.5H, br s),8.42 (1H, d, J 1.8).

Example 591-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-dimethylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 2-(5-Fluoropyridin-2-yl)-N,N-dimethylhydrazine carboxamide(Intermediate 59a)

A solution of (5-fluoro-pyridin-2-yl)-hydrazine (500 mg, 3.93 mmol),dimethylcarbamyl chloride (505 mg, 4.72 mmol) and DIPEA (1.01 g, 7.86mmol) in DCM (20 mL) was stirred at reflux for 16 h. The reactionmixture was applied to an SCX-2 cartridge (25 g) and washed with MeOH.The product was eluted with 2M NH₃ in MeOH; concentration in vacuo andthen trituration with diethyl ether gave the title compound (600 mg,77%). ¹H NMR (400 MHz, CDCl₃): 2.99 (6H, s), 6.46 (2H, m), 6.75 (1H, dd,J 9.1, 3.5), 7.22-7.32 (1H, m), 8.03 (1H, d, J 2.7).

b. (6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-dimethyl-amine(Intermediate 59b)

To a solution of Intermediate 59a (590 mg, 2.98 mmol), Ph₃P (1.56 g,5.96 mmol) and Et₃N (1.20 g, 11.9 mmol) in THF (40 mL) was addedhexachloroethane (1.41 g, 5.96 mmol) and the mixture stirred at 60° C.for 9 h. The mixture was diluted with EtOAc (100 mL), washed with water,brine, dried (MgSO₄) and then concentrated in vacuo. The residue waspurified by FCC, using 0-10% (2M NH₃ in MeOH) in DCM, then trituratedwith diethyl ether to give the title compound (78 mg, 14%). LCMS (Method1): Rt 2.24 min, m/z 181 [MH⁺].

c.[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-dimethyl-amine(Intermediate 59c)

To a solution of Intermediate A (75 mg, 0.458 mmol) in DMF (2 mL) wasadded NaH (60% in oil, 50 mg, 1.25 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 59b (75 mg, 0.416 mmol) was added. Thismixture was stirred at 60° C. for 1 h. The reaction mixture was appliedto an SCX-2 cartridge (10 g) and washed with MeOH. The product waseluted with 2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC,using 0-10% [2M NH₃ in MeOH] in DCM gave the title compound as a yellowgum (82 mg, 61%). LCMS (Method 4): Rt 1.49 min, m/z 324 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-dimethylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]urea(Example 59).

A solution of Intermediate 59c (80 mg, 0.25 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;150 mg, 0.370 mmol) and DIPEA (129 mg, 1.00 mmol) in DMF (2 mL) wasstirred at 60° C. for 30 min. The reaction mixture was applied to anSCX-2 cartridge (10 g) and washed with MeOH. The product was eluted with2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-5%[2M NH₃ in MeOH] in DCM, gave the title compound as an off-white solid(75 mg, 52%). LCMS (Method 5): Rt 4.39 min, m/z 579.1 [MH⁺]. ¹H NMR (400MHz, d₄-MeOH): 1.29 (9H, s), 1.83-2.17 (3H, m), 2.17-3.00 (1H, m), 2.38(3H, s), 2.92 (6H, s), 4.88 (1H, dd, J 8.5, 5.4), 5.41 (1H, t, J 3.0),6.33 (1H, s), 7.14-7.36 (9H, m), 7.50 (1H, d, J 9.7), 7.70 (1H, d, J1.4).

Example 601-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.6-Fluoro-3-((R)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 60a)

A mixture of (5-fluoro-pyridin-2-yl)-hydrazine (889 mg, 7.00 mmol),N-methyl-D-proline hydrochloride (1.274 g, 7.7 mmol) and HOBt.H₂O (95mg, 0.70 mmol) in DCM (20 mL) was treated with EDC (1.494 g, 7.8 mmol),and the mixture stirred at RT for 6.5 h. The mixture was then dilutedwith sat. aq. NaHCO₃ solution, NaCl added, and the mixture extractedwith DCM (8×20 mL). The combined organics were dried and concentrated invacuo to give (R)-1-methyl-pyrrolidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide as a pale orange solid (1.09 g).This was dissolved in THF (20 mL) then Ph₃P (2.40 g, 9.16 mmol), Et₃N(2.6 mL, 18.3 mmol), and hexachloroethane (2.17 g, 9.16 mmol) addedsequentially. The mixture was stirred at RT for 4 h, then was filtered,the filter-cake washed with diethyl ether, and the combined organicsconcentrated in vacuo. The residue was purified on a SCX-2 cartridge (50g), washing with methanol then eluting basic components with 0.2-2 Mammonia in methanol. Product containing fractions were combined andconcentrated in vacuo. The residue was further purified by FCC, using0-100% EtOAc in cyclohexane, then 8-10% MeOH in EtOAc, to give the titlecompound as a pale red oil (876 mg, 57%). LCMS (Method 3): Rt 0.55 min,m/z 221 [MH⁺].

b.(1S,4R)-4-[3-((R)-1-Methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 60b)

To a solution of Intermediate A (245 mg, 1.50 mmol) in DMF (4 mL) wasadded NaH (60% dispersion in oil, 180 mg, 4.50 mmol) and the mixturestirred at RT for 0.5 h. A solution of Intermediate 60a (330 mg, 1.50mmol) in DMF (5 mL) was added and the mixture stirred at 60° C. for 2 h.The cooled solution was diluted with water and extracted with DCM (5×20mL). The combined organics were dried and concentrated in vacuo. Theresidue was purified by FCC, using 0-15% [2M NH₃ in MeOH] in DCM, togive the title compound as a brown solid after freeze-drying (408 mg,74%). LCMS (Method 3): Rt 0.44 min, m/z 364 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 60).

A solution of Intermediate 60b (123 mg, 0.339 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;140 mg, 0.346 mmol) in 1,4-dioxane (4 mL) and DIPEA (91 μL, 0.52 mmol)was stirred at 93° C. for 3.25 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 0-20% MeOH in DCM, to givethe impure product. Further purification by HPLC (C18 X-select column,25-70% MeCN in H₂O, 0.1% formic acid) gave the title compound as a whitepowder after freeze-drying (118 mg, 56%). LCMS (Method 5): Rt 3.67 min,m/z 619.2 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.80-2.27(11H, m), 2.31-2.40 (4H, m), 3.11-3.18 (1H, m), 3.98 (1H, t, J 8.2),4.78-4.86 (1H, m), 5.42 (1H, t, J 4.3), 6.32 (1H, s), 7.09 (1H, d, J8.5), 7.26-7.42 (9H, m), 7.75 (1H, dd, J 9.7, 1.0), 8.03 (1H, s), 8.28(1H, d, J 1.0).

Example 611-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-ethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1-Ethyl-pyrrolidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 61a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (178 mg, 1.39 mmol)in DMF (10.0 mL) was added (S)-1-ethyl-pyrrolidine-2-carboxylic acid(200 mg, 1.39 mmol), EDC (293 mg, 1.53 mmol) and HOBt.H₂O (18.0 mg, 0.14mmol). The reaction was stirred for 4 h then partitioned between EtOAcand water. The aqueous layer was then extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The residue was purified by FCC, using 0-10%[2M NH₃ in MeOH] in DCM, to give the title compound (190 mg, 54%). LCMS(Method 4): Rt 0.29 min, ink 253.1 [MH⁺].

b.6-Fluoro-3-((S)-1-ethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 61b)

To a solution of Intermediate 61a (190 mg, 0.75 mmol), Ph₃P (395 mg,1.51 mmol) and Et₃N (419 μL, 3.01 mmol) in THF (6.00 mL) at 0° C. wasadded hexachloroethane (357 mg, 1.51 mmol). The reaction was stirred atRT overnight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was dissolved in MeOH and loaded onto an SCX-2 cartridge, whichwas washed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM, gave the title compound (157 mg, 89%). LCMS (Method 2): Rt 0.28min, m/z 235.2 [MH⁺].

c.(1S,4R)-4-[3-((S)-1-Ethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 61c)

To a suspension of NaH (60% in mineral oil, 107 mg, 2.68 mmol) in DMF(2.00 mL) was added Intermediate A (110 mg, 0.67 mmol) and the reactionstirred for 20 min. Intermediate 61b (150 mg, 0.67 mmol) was added inDMF (2.00 mL) and the reaction heated to 60° C. for 1 h. The reactionwas cooled and quenched by dropwise addition of methanol, before beingdiluted with methanol and loaded onto an SCX-2 cartridge, which waswashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 2-10% [2M NH₃ in MeOH]in DCM, gave the title compound (72.0 mg, 28%). LCMS (Method 4): Rt 0.29min, m/z 378.2 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-ethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 61).

To a solution of Intermediate 61c (72.0 mg, 0.19 mmol) in 1,4-dioxane(2.00 mL) was added DIPEA (66 μL, 0.38 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;77.0 mg, 0.19 mmol). The reaction was heated to 60° C. overnight thencooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-7.5% MeOH in DCM. Further purification byHPLC (C18 X-select column, 20-70% MeCN in H₂O, 0.1% HCO₂H) gave thetitle compound as a white powder after freeze-drying (37 mg, 31%). LCMS(Method 5): Rt 3.73 min, m/z 633.2 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):0.94 (3H, t, J 7.2), 1.30 (9H, s), 1.89-2.16 (6H, m), 2.22-2.31 (2H, m),2.31-2.38 (2H, m), 2.38 (3H, s), 2.49 (1H, m), 3.32 (1H, m), 4.11 (1H,t, J 8.0), 4.90 (1H, dd, J 9.0, 5.6), 5.28 (1H, t, J 4.1), 6.33 (1H, s),7.19-7.36 (9H, m), 7.65 (1H, dd, J 10.0, 0.7), 8.37 (1H, d, J 1.9).

Example 621-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1-Methyl-piperidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 62a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (250 mg, 1.96 mmol)in DMF (20.0 mL) was added (S)-1-methyl-piperidine-2-carboxylic acid(281 mg, 1.96 mmol), EDC (416 mg, 2.16 mmol) and HOBt.H₂O (25.0 mg, 0.20mmol). The reaction was stirred overnight then partitioned between EtOAcand water. The aqueous layer was then extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The residue was taken up in MeOH and loadedonto an SCX-2 cartridge, which was washed with MeOH. The product waseluted with 2M NH₃ in MeOH; concentration in vacuo gave residue. FCC,using 0-10% [2M NH₃ in MeOH] in DCM, gave the title compound (331 mg,67%). LCMS (Method 1): Rt 0.35 min, m/z 253.2 [MH⁺].

b.6-Fluoro-3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 62b)

To a solution of Intermediate 62a (331 mg, 1.31 mmol), Ph₃P (688 mg,2.63 mmol) and Et₃N (731 μL, 5.25 mmol) in THF (13.0 mL) at 0° C. wasadded hexachloroethane (622 mg, 2.63 mmol). The reaction was stirred atRT overnight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was taken up in MeOH and loaded onto an SCX-2 cartridge, whichwas washed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave the title compound (250 mg, 81%). LCMS(Method 4): Rt 0.31 min, m/z 235.1 [MH⁺].

c.(1S,4R)-4-[3-((S)-1-Methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 62c)

To a suspension of NaH (60% in mineral oil, 171 mg, 4.27 mmol) in DMF(4.00 mL) was added Intermediate A (175 mg, 1.07 mmol) and the reactionstirred for 20 min. Intermediate 62b (250 mg, 1.07 mmol) was added inDMF (2.00 mL) and the reaction heated to 60° C. for one hour. Thereaction was cooled and quenched by dropwise addition of methanol,before being diluted with methanol and loaded onto an SCX-2 cartridge,which was washed with MeOH and product eluted with 2M NH₃ in MeOH. Theresulting residue was purified by FCC, using 2-10% [2M NH₃ in MeOH] inDCM, to give the title compound (287 mg, 71%). LCMS (Method 1): Rt 1.64,m/z 378.2 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 62).

To a solution of Intermediate 62c (140 mg, 0.37 mmol) in 1,4-dioxane(4.00 mL) was added DIPEA (129 μL, 0.74 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;150 mg, 0.37 mmol). The reaction was heated to 60° C. overnight thencooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-7.5% MeOH in DCM. Further purification byHPLC (C18 X-select column, 10-98% MeCN in H₂O, 0.1% HCO₂H) gave thetitle compound as a white powder after freeze-drying (73 mg, 31%). LCMS(Method 5): Rt 3.75 min, m/z 633.2 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.30 (9H, s), 1.45 (1H, m), 1.60-1.83 (3H, m), 1.83-1.93 (2H, m),1.93-2.07 (5H, m), 2.11 (1H, m), 2.20-2.33 (2H, m), 2.38 (3H, s), 3.05(1H, dt, J 11.8, 2.8), 3.79 (1H, dd, J 10.9, 2.8), 4.91 (1H, dd, J 9.0,5.7), 5.32 (1H, t, J 4.0), 6.33 (1H, s), 7.19-7.36 (9H, m), 7.64 (1H, d,J 10.0), 8.43 (1H, d, J 1.7).

Example 631-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidin-3-ol(Intermediate 63a)

A mixture of Intermediate 24b (394 mg, 2.30 mmol),(S)-3-hydroxypiperidine hydrochloride (1.00 g, 7.27 mmol) and DIPEA(1.27 mL, 7.30 mmol) in DMA (8 mL) was heated in the microwave at170-180° C. for 9.5 h. The cooled mixture was concentrated in vacuo andapplied to an SCX-2 cartridge (70 g), washing with methanol then elutingbasic components with 0.4-2 M ammonia in methanol. Product containingfractions were combined and concentrated in vacuo. The residue waspurified by FCC, using 0-20% MeOH in DCM, to give the title compound asa pale brown solid (204 mg, 38%). LCMS (Method 3): Rt 2.02 min, m/z 237[MH⁺].

b.6-Fluoro-3-((S)-3-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 63b)

To a solution of Intermediate 63a (204 mg, 0.864 mmol) and Et₃N (180 μL,1.3 mmol) in DCM (5 mL) was added triisopropylsilyltrifluoromethanesulfonate (279 μL, 1.04 mmol) and the mixture stirred at RT for 1 h. Themixture was washed with sat. aq. NaHCO₃ solution, dried and concentratedin vacuo. The residue was purified by FCC, using 0-100% EtOAc incyclohexane, then 10% MeOH in EtOAc, to give the title compound as apale brown gum (290 mg, 86%). LCMS (Method 3): Rt 4.99 min, m/z 393[MH⁺].

c.(1S,4R)-4-[3-((S)-3-Triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 63c)

To a solution of Intermediate A (116 mg, 0.714 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 44 mg, 1.1 mmol) and the mixturestirred at RT for 20 min. A solution of Intermediate 63b (280 mg, 0.714mmol) in DMF (3 mL) was added and the mixture was stirred at 60° C. for25 min, and up to 150° C. over 20 min. The cooled mixture was dilutedwith water and extracted with DCM (4×20 mL). The combined organics weredried and concentrated in vacuo. The residue was purified twice by FCC,using 0-12% [2M NH₃ in MeOH] in DCM, to give the title compound as adark brown gum (141 mg, 37%). LCMS (Method 3): Rt 3.12 min, m/z 536[MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 63d)

A solution of Intermediate 63c (140 mg, 0.261 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;106 mg, 0.261 mmol) in 1,4-dioxane (3 mL) and DIPEA (70 μL, 0.4 mmol)was stirred at 90° C. for 3 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 0-10% MeOH in DCM, to givethe title compound as a pale brown gum (124 mg, 60%). LCMS (Method 3):Rt 5.43 min, m/z 791 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 63).

A solution of Intermediate 63d (123 mg, 0.156 mmol) and TBAF (1M in THF,195 μL, 0.195 mmol) in THF (4 mL) was stirred at RT for 1 h. The mixturewas diluted with water and extracted with DCM (4×15 mL). The combinedorganics were dried and concentrated in vacuo. The residue was purifiedby FCC, using 0-12% [2M NH₃ in MeOH] in DCM, to give the title compoundas a white powder after freeze-drying (82 mg, 83%). LCMS (Method 5): Rt4.27 min, m/z 635.2 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.38-1.47 (1H, m), 1.62-1.74 (1H, m), 1.79-1.98 (4H, m), 1.99-2.16 (2H,m), 2.36 (3H, s), 2.78-2.86 (1H, m), 2.89-2.98 (1H, m), 3.20-3.36 (2H,m, under water signal), 3.77-3.86 (1H, m), 4.77-4.86 (1H, m), 4.90 (1H,d, J 5.2), 5.53 (1H, t, J 4.3), 6.32 (1H, s), 7.08 (1H, d, J 8.7), 7.16(1H, dd, J 10.1, 2.1), 7.26-7.41 (8H, m), 7.61 (1H, d, J 10.0), 7.69(1H, d, J 1.4), 8.03 (1H, s).

Example 641-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from (R)-3-hydroxypiperidinehydrochloride using analogous procedures to those described for Example63. LCMS (Method 5): Rt 4.27 min, m/z 635.2 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.27 (9H, s), 1.36-1.47 (1H, m), 1.65-1.76 (1H, m), 1.77-1.98(4H, m), 1.99-2.17 (2H, m), 2.36 (3H, s), 2.78-2.85 (1H, m), 2.87-2.95(1H, m), 3.20-3.37 (2H, m, under water signal), 3.75-3.84 (1H, m),4.78-4.85 (1H, m), 4.90 (1H, d, J 5.0), 5.51 (1H, t, J 4.3), 6.32 (1H,s), 7.08 (1H, d, J 8.4), 7.17 (1H, dd, J 10.0, 2.2), 7.26-7.41 (8H, m),7.61 (1H, d, J 10.0), 7.69 (1H, d, J 1.4), 8.03 (1H, s).

Example 651-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt

To a solution of Intermediate 62c (117 mg, 0.31 mmol) in 1,4-dioxane(3.00 mL) was added DIPEA (108 μL, 0.62 mmol) and Intermediate 33a (130mg, 0.31 mmol). The reaction was heated to 60° C. overnight then cooledand partitioned between EtOAc and water. The aqueous layer was thenextracted with EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC, using 0-10% MeOH in DCM. Further purification by HPLC(C18X-select column, 10-98% MeCN in H₂O, 0.1% HCO₂H) gave the titlecompound as a white powder after freeze-drying (80 mg, 39%). LCMS(Method 5): Rt 3.31 min, m/z 649.3 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.31 (9H, s), 1.49 (1H, m), 1.60-2.05 (7H, m), 2.05 (3H, s), 2.10 (1H,m), 2.25-2.35 (2H, m), 3.09 (1H, m), 3.87 (1H, dd, J 10.9, 2.4), 4.65(2H, s), 4.91 (1H, m), 5.33 (1H, t, J 4.0), 6.34 (1H, s), 7.19-7.33 (5H,m), 7.42-7.51 (4H, m), 7.65 (1H, d, J 9.6), 8.26 (0.5H, br s), 8.43 (1H,d, J 1.7).

Example 661-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxyethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.[1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidin-4-yl]-ethanol(Intermediate 66a)

A mixture of Intermediate 24b (542 mg, 3.17 mmol) and4-piperidine-ethanol (1.54 g, 11.9 mmol) in DMA (10 mL) was heated inthe microwave at 170° C. for 3 h. The cooled mixture was applied to anSCX-2 cartridge (50 g), washing with methanol then eluting basiccomponents with 0.4-2 M ammonia in methanol. Product containingfractions were combined and concentrated in vacuo. The residue waspurified by FCC, using 0-20% MeOH in DCM, to give the title compound asa pale brown solid (324 mg, 41%). LCMS (Method 3): Rt 2.28 min, m/z 265[MH⁺].

b.6-Fluoro-3-(4-triisopropylsilanyloxyethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin(Intermediate 66b)

To a solution of Intermediate 66a (319 mg, 1.21 mmol) and Et₃N (252 μL,1.82 mmol) in DCM (10 mL) was added triisopropylsilyltrifluoromethanesulfonate (319 μL, 1.45 mmol) and the mixture stirred at RT for 1.5 h.The mixture was washed with sat. aq. NaHCO₃ solution, dried andconcentrated in vacuo. The residue was purified by FCC, using 0-10% MeOHin DCM, to give the title compound as an orange solid (465 mg, 92%).LCMS (Method 3): Rt 5.35 min, m/z 421 [MH⁺].

c.(1S,4R)-4-[3-(4-Triisopropylsilanyloxyethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 66c)

To a solution of Intermediate A (122 mg, 0.75 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 60 mg, 1.5 mmol) and the mixturestirred at RT for 25 min. A solution of Intermediate 66b (315 mg, 0.75mmol) in DMF (2.5 mL) was added and the mixture stirred at 60° C. for1.5 h. The cooled mixture was diluted with water and extracted with DCM(5×25 mL). The combined organics were dried and concentrated in vacuo.The residue was purified by FCC, using 0-14% [2M NH₃ in MeOH] in DCM, togive the title compound as a dark brown gum (180 mg, 42%). LCMS (Method3): Rt 3.35 min, m/z 564 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-triisopropylsilanyloxyethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 66d)

A mixture of Intermediate 66c (178 mg, 0.316 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;128 mg, 0.316 mmol) in 1,4-dioxane (3 mL) and DIPEA (83 μL, 0.474 mmol)was stirred at 95° C. for 4 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 0-10% MeOH in DCM, to givethe title compound as a brown foam (208 mg, 81%). LCMS (Method 3): Rt5.96 min, m/z 819 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxyethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 66).

A solution of Intermediate 66d (207 mg, 0.253 mmol) and TBAF (1M in THF,0.303 mL, 0.303 mmol) in THF (4 mL) was stirred at RT for 2.25 h. Themixture was diluted with water and extracted with DCM (4×15 mL). Thecombined organic extracts were dried and concentrated in vacuo. Theresidue was purified by FCC, using 0-15% MeOH in DCM, to give theproduct. This was further purified by HPLC (C18 X-select column, 30-98%MeCN in H₂O, 0.1% formic acid) to give the title compound as anoff-white powder after freeze-drying (114 mg, 68%). LCMS (Method 5): Rt4.29 min, m/z 663.3 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.38-1.51 (4H, m), 1.57-1.68 (1H, m), 1.72-1.97 (4H, m), 1.99-2.16 (2H,m), 2.36 (3H, s), 2.85-2.95 (2H, m), 3.30-3.52 (4H, m, under watersignal), 4.38 (1H, s), 4.77-4.85 (1H, m), 5.55 (1H, t, J 4.3), 6.32 (1H,s), 7.09 (1H, d, J 8.6), 7.16 (1H, dd, J 9.9, 2.2), 7.26-7.40 (8H, m),7.61 (1H, d, J 9.9), 7.65 (1H, d, J 1.4), 8.06 (1H, s).

Example 671-[(1S,4R)-4-(3-Azepan-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea

a. 6-Fluoro-3-azepan-1-yl-[1,2,4]triazolo[4,3-a]pyridine (Intermediate67a)

A solution of Intermediate 24b (451 mg, 2.50 mmol) and azapane (990 mg,10.0 mmol) in DMA (10 mL) was heated in the microwave at 175-180° C. for6 h. The mixture was concentrated in vacuo. The residue was purified byFCC, using 0-20% MeOH in DCM, to give impure product. Furtherpurification by FCC, using 0-12% MeOH in DCM, gave impure product.Further purification by FCC, using 0-6% MeOH in EtOAc, gave the titlecompound as a green gum (260 mg, 44%). LCMS (Method 3): Rt 2.76 min, m/z235 [MH⁺].

b.(1S,4R)-4-(3-Azepan-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 67b)

To a solution of Intermediate A (137 mg, 0.84 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 68 mg, 1.7 mmol) and the mixturestirred at RT for 25 min. A solution of Intermediate 67a (197 mg, 0.84mmol) in DMF (3 mL) was added and the mixture stirred at 60° C. for 1.25h. The cooled mixture was diluted with water and extracted with DCM(5×20 mL). The combined organics were dried and concentrated in vacuo.The residue was purified by FCC, using 0-14% [2M NH₃ in MeOH] in DCM, togive the title compound as a dark brown gum (175 mg, 55%). LCMS (Method3): Rt 2.22 min, m/z 378 [MH⁺].

c.1-[(1S,4R)-4-(3-Azepan-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea(Example 67).

A solution of Intermediate 67b (173 mg, 0.458 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;186 mg, 0.458 mmol) in 1,4-dioxane (3 mL) and DIPEA (122 μL, 0.700 mmol)was stirred at 95° C. for 3.5 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 0-14% [2M NH₃ in MeOH] inDCM. Further purification by FCC, using 0-10% MeOH in DCM, gave impureproduct. This was further purified by HPLC (C18X-select column, 30-98%MeCN in H₂O, 0.1% HCO₂H) to give impure product. Further purified byHPLC (XBridge column, 35-98% MeCN in H₂O, 0.1% NH₄OH) to give anoff-white powder after freeze-drying (50 mg). This material was furtherpurified by MDAP (Method 7) to give the title compound as a white solid(28 mg, 10%). LCMS (Method 5): Rt 4.77 min, m/z 633.2 [MH⁺]. ¹H NMR (400MHz, d₅-DMSO): 1.27 (9H, s), 1.64-1.71 (4H, m), 1.74-1.97 (6H, m),1.99-2.18 (2H, m), 2.36 (3H, s), 3.38-3.43 (4H, m, under water signal),4.77-4.85 (1H, m), 5.47 (1H, t, J 4.3), 6.32 (1H, s), 7.07-7.14 (2H, m),7.25-7.40 (8H, m), 7.55-7.59 (2H, m), 8.06 (1H, s).

Example 681-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 6-Fluoro-3-(4-methyl-piperazin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 68a)

A solution of Intermediate 24b (451 mg, 2.50 mmol) andN-methyl-piperazine (1.11 mL, 10.0 mmol) in DMA (10 mL) was heated inthe microwave at 170° C. for 8 h. The mixture was concentrated in vacuo.The residue was purified by FCC, using 0-20% [2M NH₃ in MeOH] in DCM, togive the title compound as an orange gum (190 mg, 32%). LCMS (Method 3):Rt 0.43 min, m/z 236 [MH⁺].

b.(1S,4R)-4-[3-(4-Methyl-piperazin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 68b)

To a solution of Intermediate A (125 mg, 0.766 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 62 mg, 1.54 mmol) and the mixturestirred at RT for 0.5 h. A solution of Intermediate 68a (180 mg, 0.766mmol) in DMF (3 mL) was added and the mixture stirred at 60° C. for 1.75h. The cooled mixture was diluted with water and extracted with DCM(5×25 mL). The combined organics were dried and concentrated in vacuo.The residue was purified by FCC, using 0-20% [2M NH₃ in MeOH] in DCM, togive the title compound as a pale brown gum (225 mg, 78%). LCMS (Method3): Rt 0.44 min, m/z 379 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazine-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea(Example 68).

A solution of Intermediate 68b (215 mg, 0.560 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;226 mg, 0.560 mmol) in 1,4-dioxane (3 mL) and DIPEA (146 μL, 0.840 mmol)was stirred at 65° C. for 18 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 10% MeOH in DCM, then0-14% (2M NH₃ in MeOH) in DCM, to give impure product. Furtherpurification by HPLC (XBridge C18 column, 35-95% MeCN in H₂O, 0.1%NH₄OH) gave the title compound as a white powder after freeze-drying(205 mg, 58%). LCMS (Method 5): Rt 3.58 min, m/z 634.2 [MH⁺]. ¹H NMR(400 MHz, d₆-DMSO): 1.27 (9H, s), 1.79-1.98 (2H, m), 1.99-2.15 (2H, m),2.26 (3H, s), 2.36 (3H, s), 2.52-2.57 (4H, m), 3.15-3.24 (4H, m),4.78-4.85 (1H, m), 5.56 (1H, t, J 4.4), 6.33 (1H, s), 7.07 (1H, d, J8.6), 7.15 (1H, dd, J 9.9, 2.1), 7.26-7.40 (8H, m), 7.62 (1H, d, J 9.9),7.68 (1H, d, J 1.8), 8.04 (1H, s).

Example 691-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-[1,4]diazepan-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea

a.6-Fluoro-3-(4-methyl-[1,4]diazepan-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 69a)

A solution of Intermediate 24b (451 mg, 2.50 mmol) and1-methyl-[1,4]diazepane (1.14 g, 10.0 mmol) in DMA (10 mL) was heated inthe microwave at 175° C. for 6 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 0-20% (2M NH₃ in MeOH) inDCM, to give the title compound as a brown oil (480 mg, 77%). LCMS(Method 3): Rt 0.44 min, m/z 250 [MH⁺].

b.(1S,4R)-4-[3-(4-Methyl-[1,4]diazepan-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 69b)

To a solution of Intermediate A (183 mg, 1.12 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 149 mg, 2.24 mmol) and the mixturestirred at RT for 0.5 h. A solution of Intermediate 69a (400 mg, 1.12mmol) in DMF (3 mL) was added and the mixture stirred at 60° C. for 1.5h. The cooled mixture was diluted with water and extracted with DCM(3×20 mL) and DCM-MeOH (4:1, 2×25 mL). The combined organics were driedand concentrated in vacuo. The residue was purified by FCC, using 0-25%[2M NH₃ in MeOH] in DCM, to give the title compound as a dark brown gum(179 mg, 41%). LCMS (Method 3): Rt 0.44 min, m/z 393 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-[1,4]diazepan-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}urea(Example 69).

A solution of Intermediate 69b (170 mg, 0.43 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;174 mg, 0.43 mmol) in 1,4-dioxane (3 mL) and DIPEA (113 μL, 0.65 mmol)was stirred at 65° C. for 18 h. The cooled mixture was concentrated invacuo. The residue was purified by FCC, using 10% MeOH in DCM, then0-15% (2M NH₃ in MeOH) in DCM, to give impure product. Furtherpurification by HPLC (XBridge C18 column, 35-95% MeCN in H₂O, 0.1%NH₄OH) gave the title compound as a white powder after freeze-drying(186 mg, 67%). LCMS (Method 5): Rt 3.57 min, m/z 648.2 [MH⁺]. ¹H NMR(400 MHz, d₆-DMSO): 1.27 (9H, s), 1.79-1.98 (4H, m), 2.00-2.18 (2H, m),2.31 (3H, s), 2.36 (3H, s), 2.62-2.67 (2H, m), 2.68-2.73 (2H, m),3.44-3.52 (4H, m), 4.78-4.85 (1H, m), 5.49 (1H, t, J 4.4), 6.32 (1H, s),7.08 (1H, d, J 8.5), 7.11 (1H, dd, J 9.7, 2.0), 7.26-7.40 (8H, m), 7.58(1H, d, J 9.7), 7.63 (1H, d, J 1.9), 8.03 (1H, s).

Example 701-[5-tert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.1-{5-tert-Butyl-2-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 70a)

The title compound was synthesised from5-tert-butyl-2-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2H-pyrazol-3-ylamine(ref: US 2006/035922, which is incorporated herein by reference in itsentirety) and Intermediate 3c using analogous procedures to those usedin the preparation of Example 30. Beige solid. LCMS (Method 3) Rt 4.78min, m/z 735 [MH⁺].

b.1-[5-tert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 70).

A mixture of Intermediate 70a (124 mg, 169 μmol) and TBAF (1M in THF,0.34 mL, 0.34 mmol) in THF (5 mL) was stirred for 1 h. The mixture wasdiluted with water and extracted with EtOAc (3×). The combined organicextracts were washed with brine, and concentrated in vacuo. The residuewas purified by FCC, using 0-20% MeOH in DCM, then further purified byHPLC (30-98% MeCN in H₂O, 0.1% HCO₂H) to give the title compound as anoff-white solid (18.4 mg, 18%). LCMS (Method 5) Rt 4.22 min, m/z 621[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.25 (9H, s), 1.61 (2H, m), 1.72 (4H,m), 1.79-1.98 (2H, m), 1.99-2.15 (2H, m), 3.13 (4H, m), 4.81 (1H, m),5.54 (1H, t, J 4.5), 6.29 (1H, s), 6.85 (2H, m), 7.09 (1H, d, J 8.7),7.14 (1H, dd, J 9.7, 2.0), 7.20-7.39 (6H, m), 7.59-7.64 (2H, m), 7.95(1H, s), 9.77 (1H, br s).

Example 711-[5-tert-Butyl-2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 4-(5-Amino-3-tert-butyl-pyrazol-1-yl)-benzonitrile (Intermediate 71a)

A cream suspension of 4-cyanophenylhydrazine hydrochloride (1.70 g, 10.0mmol) and 4,4-dimethyl-3-oxopentanenitrile (1.31 g, 10.5 mmol) in EtOH(25 mL) was stirred at reflux for 4 h, then at RT for 64 h, and again atreflux for 24 h. The solution was cooled to RT, concentrated in vacuo,and partitioned between water (50 mL) and EtOAc (75 mL). The organicswere washed with brine (50 mL), dried (Na₂SO₄), filtered andconcentrated in vacuo to leave an orange solid (2.28 g, 95%). LCMS(Method 3): Rt 3.45 min, m/z 241 [MH⁺].

b. [5-tert-Butyl-2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Intermediate 71b)

To a suspension of Intermediate 71a (2.28 g, 9.49 mmol) in EtOAc (25 mL)and aqueous NaOH (1M, 23.7 mL, 23.7 mmol) was added 2,2,2-trichloroethylchloroformate (1.57 mL, 11.4 mmol) dropwise over 2 min. A precipitateformed which redissolved after 15 min, then the orange solution wasstirred at RT for 90 min. 2,2,2-Trichloroethyl chloroformate (0.391 mL,2.85 mmol) was added and the orange mixture stirred at RT for 16 h. Thelayers were separated and the aqueous extracted with EtOAc (25 mL). Thecombined organics were washed with brine (25 mL), dried (Na₂SO₄),filtered and concentrated in vacuo to leave an orange-red oil.Recrystallisation from cyclohexane gave an off-white solid (3.12 g,79%). LCMS (Method 3): Rt 4.46 min, m/z 415, 417 [MH⁺].

c.1-[5-tert-Butyl-2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 71).

A brown solution of Intermediate 71b (114 mg, 0.275 mmol), Intermediate3c (91.0 mg, 0.250 mmol) and DIPEA (0.054 mL, 0.313 mmol) in dioxane (3mL) was stirred at 60° C. for 16 h. The cooled solution was concentratedin vacuo, the residue suspended in water (4 mL) and extracted with DCM(2×4 mL). The combined organics were passed through a hydrophobic fritand concentrated in vacuo. FCC, using 3% [2M NH₃ in MeOH] in DCM, gave apale yellow solid (99.5 mg, 63%). LCMS (Method 5): Rt 4.63 min, m/z 630[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.29 (9H, s), 1.60-1.64 (2H, m),1.70-1.76 (4H, m), 1.86-1.94 (2H, m), 1.99-2.07 (1H, m), 2.11-2.18 (1H,m), 3.14 (4H, t, J 5.2), 4.79 (1H, m), 5.54 (1H, t, J 4.3), 6.38 (1H,s), 7.12 (1H, d, J 8.6), 7.16 (1H, dd, J 9.8, 2.2), 7.25 (1H, d, J 7.7),7.27-7.37 (2H, m), 7.39 (1H, d, J 7.6), 7.60-7.63 (2H, m), 7.78 (2H, d,J 8.6), 7.98 (2H, d, J 8.6), 8.30 (1H, s).

Example 721-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4S)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.(1S,4S)-4-[3-((S)-1-Methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine.(Intermediate 72a)

A solution of Intermediate B (179 mg, 1.10 mmol) in dry DMF (2.5 mL) wasadded NaH (60% in mineral oil, 333 mg, 5.00 mmol) at RT and stirred for15 min. Intermediate 5b (220 mg, 1.00 mmol) in DMF (2.5 mL) was thenadded and the mixture heated at 60° C. for 1 h. After cooling, theresulting dark brown mixture was diluted with water and extracted withDCM. The combined organics were dried and concentrated in vacuo. Theresidue was purified by FCC, using 0-10% MeOH in DCM, to give a residue.FCC, using 0-10% [2M NH₃ in MeOH] in DCM, gave the title compound aslight brown powder after freeze drying (224 mg, 61%). LCMS (Method 3):Rt 1.34 min, m/z 364 [MH⁺].

b.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4S)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 72).

A stirred solution of Intermediate 72a (219 mg, 0.60 mmol) and5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;269 mg, 0.66 mmol) and DIPEA (317 μL, 1.14 mmol) in THF (6 mL) washeated at reflux for 23 h. The cooled reaction mixture was diluted withwater and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-5% [2MNH₃ in MeOH] in DCM, to give impure product. This residue was purifiedfurther by HPLC (ChiralPak IC column, 50% IPA in heptanes) to give thetitle compound as a white powder after freeze-drying (225 mg, 60%). LCMS(Method 5): Rt 3.65 min, m/z 619 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.26(9H, s), 1.74 (1H, m), 1.93-1.99 (3H, m), 2.08 (3H, s), 2.13-2.20 (4H,m), 2.32 (1H, m), 2.36 (3H, s), 3.14 (1H, td, J 8.1, 2.5), 3.95 (1H, t,J 8.1), 4.90 (1H, m), 5.48 (1H, t, J 4.0), 6.32 (1H, s), 7.00 (1H, d, J8.2), 7.33-7.45 (9H, m), 7.74 (1H, dd, J 9.9, 0.8), 7.98 (1H, s), 8.24(1H, d, J 2.1).

Example 731-[5-tert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.1-{5-tert-Butyl-2-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 73a)

The title compound was synthesised from5-tert-butyl-2-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2H-pyrazol-3-ylamine(ref: US 2006/035922, which is incorporated herein by reference in itsentirety) and Intermediate 5c using analogous procedures to those usedin the preparation of Example 30. Yellow powder. LCMS (Method 3): Rt3.59 min, m/z 735 [MH⁺].

b.1-[5-tert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 73).

A solution of Intermediate 73a (160 mg, 0.21 mmol) and TBAF (1M in THF,0.26 mL, 0.26 mmol) in THF (2 mL) was stirred at RT for 30 min, thendiluted with water and extracted with DCM (3×20 mL). The combinedorganics were dried and concentrated in vacuo. The residue was purifiedby FCC, using 0-5% [2M NH₃ in MeOH] in DCM, to give the title compoundas a white powder after freeze-drying (107 mg, 79%). LCMS (Method 5): Rt3.24 min, m/z 621 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.26 (9H, s),1.81-2.25 (11H, m), 2.34-2.36 (1H, m), 3.12-3.14 (1H, m), 3.99 (1H, t, J8.2), 4.81-4.84 (1H, m), 5.39 (1H, t, J 4.3), 6.29 (1H, s), 6.85-6.88(2H, m), 7.09 (1H, d, J 8.6), 7.28-7.39 (7H, m), 7.75 (1H, dd, J 9.9,0.8), 7.92 (1H, s), 8.24 (1H, d, J 2.1), 9.72 (1H, s).

Example 741-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(1-hydroxy-1-methyl-ethyl)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea

a.2-[1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidin-4-yl]-propan-2-ol(Intermediate 74a)

A brown solution of Intermediate 24b (666 mg, 3.88 mmol) and2-piperidinyl propan-2-ol (TCI, 1.39 g, 9.71 mmol) in DMA (10 mL) wasirradiated to 175° C. for 3 h in the microwave. The cooled solution wasconcentrated in vacuo, suspended in water (10 mL) and brine (10 mL),then extracted with DCM (2×20 mL). The combined organics were passedthrough a hydrophobic fit and concentrated in vacuo to leave a brown oil(1.3 g). FCC, using 5% MeOH in DCM, gave the title compound as a paleyellow solid (484 mg, 45%). LCMS (Method 3): Rt 2.42 min, m/z 279 [MH⁺].

b.6-Fluoro-3-[4-(1-methyl-1-triisopropylsilanyloxy-ethyl)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 74b)

A solution of Intermediate 74a (480 mg, 1.72 mmol), triisopropylsilyltrifluoromethane-sulfonate (0.579 mL, 2.16 mmol) and Et₃N (0.361 mL,2.59 mmol) in dry DCM (5 mL) under N₂ was stirred at reflux for 2 h. Themixture was cooled to RT, then Et₃N (0.361 mL, 2.59 mmol) andtriisopropylsilyl trifluoromethanesulfonate (0.579 mL, 2.16 mmol) wereadded and the orange solution stirred at reflux for 3 h. To the cooledsolution, water (5 mL) was added and the mixture shaken. The aqueous wasextracted with DCM (5 mL), then the combined organics passed through ahydrophobic frit and concentrated in vacuo to leave an orange oil. FCC,using 1-3% MeOH in DCM, gave the title compound as a pale yellow solid(592 mg, 79%). LCMS (Method 3): Rt 5.66 min, m/z 435 [MH⁺].

c.(1S,4R)-4-{3-[4-(1-Methyl-1-triisopropylsilanyloxy-ethyl)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 74c)

To a solution of Intermediate A (129 mg, 0.788 mmol) in dry DMF (2 mL)at RT under Ar was added NaH (60% dispersion in oil, 45.0 mg, 1.13 mmol)(CARE: gas evolution) and the resulting opaque brown solution stirred atRT for 45 min. A solution of Intermediate 74b (326 mg, 0.750 mmol) indry DMF (2 mL) was added and the resulting dark brown solution stirredat 60° C. for 2.5 h. The solution was concentrated in vacuo, redissolvedin MeOH (2 mL) and AcOH (0.100 mL), applied to an SCX-2 cartridge andwashed with MeOH (100 mL). The product was eluted with 2M NH₃ in MeOH(75 mL); concentration in vacuo gave a viscous dark brown oil. FCC,using 1-6% [2M NH₃ in MeOH] in DCM, gave the title compound as a viscousbrown oil (131 mg, 30%). LCMS (Method 3): Rt 3.53 min, m/z 578 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(1-hydroxy-1-methyl-ethyl)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Example 74).

A brown solution of (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;89.6 mg, 0.221 mmol), Intermediate 74c (128 mg, 0.221 mmol) and DIPEA(0.048 mL, 0.277 mmol) in dioxane (3 mL) was stirred at 60° C. for 16 h,and at 80° C. for 6 h. The cooled solution was concentrated in vacuo,suspended in water (4 mL) and extracted with DCM (2×4 mL). The combinedorganics were passed through a hydrophobic frit and concentrated invacuo to leave a viscous brown oil. FCC, using 1-4% [2M NH₃ in MeOH] inDCM) gave1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(1-methyl-1-triisopropylsilanyloxy-ethyl)-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-ureaas a yellow solid (125 mg). The solid was dissolved in THF (3 mL),treated with TBAF (1M in THF, 0.161 mL, 0.161 mmol) and the solutionstirred at RT for 2 h, and then at reflux for 1 h. The solution wascooled to ˜40° C., then TBAF (1M in THF, 0.161 mL, 0.161 mmol) added andthe solution stirred at reflux for 16 h. The cooled solution wasconcentrated in vacuo, suspended in water (10 mL) and extracted withEtOAc-MeOH (19:1, 2×10 mL). The combined organics were washed with brine(10 mL), dried (Na₂SO₄), filtered and concentrated in vacuo to leave adark green residue. FCC, using 2-7% MeOH in DCM, gave the title compoundas a pale yellow solid (60.6 mg, 41%). LCMS (Method 5): Rt 4.42 min, m/z677 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.09 (6H, s), 1.27 (9H, s),1.37-1.44 (1H, m), 1.49-1.61 (2H, m), 1.80 (2H, d, J 12.6), 1.83-1.96(2H, m), 2.01-2.10 (2H, m), 2.36 (3H, s), 2.81-2.90 (2H, m), 3.49 (2H,t, J 11.2), 4.16 (1H, s), 4.81 (1H, td, J 8.5, 5.5), 5.56 (1H, t, J4.4), 6.32 (1H, s), 7.08 (1H, d, J 8.6), 7.14 (1H, dd, J 9.9, 2.1),7.27-7.40 (8H, m), 7.61 (1H, d, J 9.9), 7.66 (1H, d, J 2.0), 8.04 (1H,s).

Example 751-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 6-Fluoro-3-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 75a)

A mixture of Intermediate 24b (515 mg, 3.00 mmol), pyrrolidine (0.85 g,12.0 mmol) and DMA (10 mL) was heated to 175° C. for 4 h using microwaveirradiation. After cooling, the solvent was removed in vacuo and theresulting residue purified by FCC, using 0 to 15% MeOH in DCM, toprovide the title compound as a brown gum (285 mg, 26%). LCMS (Method3): Rt 1.95 min, m/z 207 [MH⁺].

b.(1S,4R)-4-(3-Pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 75b)

Intermediate A (222 mg, 1.36 mmol) was added to a mixture of NaH (60% inmineral oil, 163 mg, 4.08 mmol) in DMF (15 mL) at RT and stirred for 30min. Intermediate 75a (280 mg, 1.36 mmol) was then added and theresulting mixture heated to 60° C. for 1 h. After cooling, the reactionwas quenched with sat. aq. NH₄Cl solution. The mixture was diluted withwater and extracted with EtOAc. The combined organic extracts werewashed with sat. aq. NaHCO₃ solution and brine, and concentrated invacuo. The resulting residue was purified by FCC, using 0 to 15% [2M NH₃in MeOH] in DCM, to afford the title compound as a brown solid (65.0 mg,14%). LCMS (Method 3): Rt 1.89 min, m/z 350 [MH⁺].

c.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 75).

A mixture of Intermediate 75b (62.0 mg, 0.18 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009; 78.9 mg, 0.195 mmol), DIPEA (46.3 μL, 0.27 mmol) and1,4-dioxane (2.5 mL) were heated to 60° C. for 18 h. After cooling thesolvent was evaporated in vacuo. The residue was purified by FCC, using0-10% MeOH in DCM, then further purified by HPLC (30-98% MeCN in H₂O,0.1% HCO₂H) to give the title compound as an off-white solid (22 mg,20%). LCMS (Method 5) Rt 4.30 min, m/z 605 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.27 (9H, s), 1.79-2.15 (8H, m), 2.36 (3H, s), 3.49 (4H, m),4.81 (1H, m), 5.51 (1H, t, J 4.5), 6.30 (1H, s), 7.03 (1H, dd, J 10.1,2.2), 7.09 (1H, d, J 8.5), 7.25-7.40 (8H, m), 7.51 (1H, m), 7.83 (1H,m), 8.07 (1H, s).

Example 761-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-1-methyl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

a. 2-Dimethylamino-2-methyl-propionic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 76a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (200 mg, 1.57 mmol)in DMF (10.0 mL) was added 2-dimethylamino-2-methyl-propionic acid (206mg, 1.57 mmol), EDC (332 mg, 1.73 mmol) and HOBt.H₂O (21.0 mg, 0.16mmol). The reaction was stirred overnight then partitioned between EtOAcand water. The aqueous layer was then extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The residue was purified by FCC, using 0-10%[2M NH₃ in MeOH] in DCM, to give the title compound (195 mg, 51%). ¹HNMR (300 MHz, CDCl₃): 1.25 (6H, s), 2.28 (6H, s), 6.44 (1H, br s), 6.62(1H, dd, J 9.1, 3.6), 7.27 (1H, ddd, J 9.1, 8.0, 3.1), 8.03 (1H, d, J2.9), 9.04 (1H, br s).

b.[1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1-methyl-ethyl]-dimethyl-amine(Intermediate 76b)

To a solution of Intermediate 76a (195 mg, 0.81 mmol), Ph₃P (426 mg,1.62 mmol) and Et₃N (452 □L, 3.25 mmol) in THF (9.00 mL) at 0° C. wasadded hexachloroethane (385 mg, 1.62 mmol). The reaction was stirred atRT overnight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was dissolved in MeOH and loaded onto an SCX-2 cartridge, whichwas washed with MeOH and eluted with 2M NH₃ in MeOH. The reaction showed50% conversion so was re-submitted to the reaction conditions overnightat 50° C. The workup and purification procedures were repeated to givethe title compound (153 mg, 85%). ¹H NMR (300 MHz, CDCl₃): 1.60 (6H, s),2.20 (6H, s), 7.16 (1H, ddd, J 9.9, 7.4, 2.4), 7.71 (1H, ddd, J 9.9,5.0, 0.8), 8.89 (1H, ddd, J 4.4, 2.4, 0.8).

c.(1S,4R)-4-[3-(1-Dimethylamino-1-methyl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 76c)

To a suspension of NaH (60% in mineral oil, 112 mg, 2.80 mmol) in DMF(2.50 mL) was added Intermediate A (114 mg, 0.70 mmol) and the reactionstirred for 20 min. Intermediate 76b (153 mg, 0.70 mmol) was added inDMF (2.50 mL) and the reaction heated to 60° C. for 1 h. The reactionwas cooled and quenched by dropwise addition of methanol, before beingdiluted with methanol and loaded onto an SCX-2 cartridge, which waswashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 2-10% [2M NH₃ in MeOH]in DCM, gave the title compound (120 mg, 47%). LCMS (Method 4): Rt 0.31,m/z 366 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-1-methyl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt (Example 76).

To a solution of Intermediate 76c (120 mg, 0.33 mmol) in 1,4-dioxane(3.00 mL) was added DIPEA (117 μL, 0.66 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;133 mg, 0.33 mmol). The reaction was heated to 60° C. overnight thencooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-8% MeOH in DCM. Further purification byHPLC (C18 X-select column, 25-60% MeCN in H₂O, 0.1% HCO₂H) gave thetitle compound as a white powder after freeze-drying (21 mg, 10%). LCMS(Method 5): Rt 3.86 min, m/z 621.1 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.30 (9H, s), 1.55 (3H, s), 1.56 (3H, s), 1.88-2.04 (2H, m), 2.10 (1H,m), 2.17 (6H, s), 2.26 (1H, m), 2.38 (3H, s), 4.90 (1H, dd, J 5.7, 8.7),5.30 (1H, t, J 4.1), 6.33 (1H, s), 7.20-7.36 (9H, m), 7.60-7.64 (1H, d,J 9.9), 8.51 (0.5H, br s), 8.66 (1H, d, J 1.9).

Example 771-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.[(R)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidin-3-yl]-methanol(Intermediate 77a)

A brown solution of Intermediate 24b (565 mg, 3.29 mmol) andR-3-hydroxymethyl piperidine (Chess GmbH, 948 mg, 8.23 mmol) in DMA (10mL) was irradiated at 175° C. for 3 h in the microwave. The cooledsolution was concentrated in vacuo, suspended in water (10 mL) and brine(10 mL), and then extracted with DCM (2×20 mL). The combined organicswere passed through a hydrophobic frit and concentrated in vacuo toleave a brown oil. FCC, using 4-5% MeOH in DCM, gave the title compoundas a viscous yellow oil (237 mg, 29%). LCMS (Method 3): Rt 2.11 min, m/z251 [MH⁺].

b.6-Fluoro-3-((R)-3-triisopropylsilanyloxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 77b)

To a solution of Intermediate 77a (233 mg, 0.931 mmol) and Et₃N (0.195mL, 1.40 mmol) in dry DCM (5 mL) at RT under N₂, was addedtriisopropylsilyl trifluoromethanesulfonate (0.313 mL, 1.16 mmol) andthe yellow solution stirred at RT for 30 min. Water (5 mL) was added andthe mixture shaken. The aqueous was extracted with DCM (5 mL), then thecombined organics passed through a hydrophobic frit and concentrated invacuo to leave a yellow oil. FCC, using 1-5% MeOH in DCM, gave the titlecompound as a yellow oil (333 mg, 88%). LCMS (Method 3): Rt 5.23 min,m/z 407 [MH⁺].

c.(1S,4R)-4-[3-((R)-3-Triisopropylsilanyloxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 77c)

To a solution of Intermediate A (140 mg, 0.860 mmol) in dry DMF (2 mL)at RT under Ar was added NaH (60% dispersion in oil, 49.0 mg, 1.23 mmol)(CARE: gas evolution) and the resulting brown suspension was stirred atRT for 45 min. A solution of Intermediate 77b (333 mg, 0.819 mmol) indry DMF (2 mL) was added and the resulting dark brown solution stirredat 60° C. under Ar for 2.5 h. The solution was concentrated in vacuo,redissolved in MeOH (2 mL) and AcOH (0.100 mL), then applied to andSCX-2 cartridge, and washed with MeOH (100 ml). The product was elutedwith 2M NH₃ in MeOH (75 mL); concentration in vacuo left a viscous darkbrown oil. FCC, using 2-7% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a yellow-brown viscous oil (257 mg, 57%). LCMS (Method 3):Rt 3.27 min, m/z 550 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-triisopropylsilanyloxy-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 77d)

An orange-brown solution of(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;103 mg, 0.255 mmol), Intermediate 77c (140 mg, 0.255 mmol) and DIPEA(0.055 mL, in dioxane (3 mL) was stirred at 60° C. for 16 h and then at80° C. for 2 h. The cooled solution was concentrated in vacuo, suspendedin water (4 mL) and extracted with DCM (2×4 mL). The combined organicswere passed through a hydrophobic frit and concentrated in vacuo to ˜0.5mL volume. FCC, using 2-3% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a yellow solid (136 mg, 66%). LCMS (Method 3): Rt 5.65 min,m/z 805 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 77).

A brown solution of Intermediate 77d (135 mg, 0.168 mmol) and TBAF (1Min THF, 0.184 mL, 0.184 mmol) in THF (3 mL) was stirred at RT for 1 h.The solution was concentrated in vacuo, suspended in water (10 mL) andextracted with EtOAc-MeOH (19:1, 2×10 mL). The combined organics werewashed with brine (10 mL), dried (Na₂SO₄), filtered and concentrated invacuo to leave a brown solid. FCC, using 5-9% MeOH in DCM, gave a palebrown solid. Further purification by HPLC (XBridge C18 column, 25-75%MeCN in H₂O, 0.1% NH₄OH) gave the title compound as a white powder afterfreeze-drying (63.9 mg, 59%). LCMS (Method 5): Rt 4.33 min, m/z 649[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.29-1.35 (1H, m),1.71-1.77 (3H, m), 1.82-1.96 (3H, m), 2.01-2.17 (2H, m), 2.36 (3H, s),3.02-3.07 (2H, m), 3.20 (1H, dd, J 11.9, 3.3), 3.25-3.28 (1H, m), 3.42(1H, dt, J 10.5, 5.0), 3.52-3.58 (1H, m), 4.69 (1H, t, J 5.1), 4.81 (1H,td, J 8.6, 5.4), 5.48 (1H, t, J 4.3), 6.32 (1H, s), 7.09 (1H, d, J 8.3),7.12 (1H, dd, J 9.9, 2.1), 7.27-7.39 (8H, m), 7.60 (1H, d, J 9.9), 7.80(1H, d, J 2.1), 8.04 (1H, s).

Example 781-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from (S)-3-hydroxymethylpiperidine (Chess GmbH) using analogous procedures to those described inExample 77. LCMS (Method 5): Rt 4.33 min, m/z 649 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 1.27 (9H, s), 1.27 (1H, m), 1.69-1.79 (3H, m), 1.82-1.96(3H, m), 2.03-2.14 (2H, m), 2.36 (3H, s), 2.96 (1H, dd, J 11.9, 8.2),3.02-3.08 (1H, m), 3.24 (1H, dd, J 11.9, 3.3), 3.29 (1H, m), 3.43 (1H,dt, J 10.6, 5.1), 3.47-3.54 (1H, m), 4.65 (1H, t, J 5.2), 4.81 (1H, td,J 8.5, 5.4), 5.50 (1H, t, J 4.4), 6.32 (1H, s), 7.09 (1H, d, J 8.5),7.13 (1H, dd, J 9.9, 2.1), 7.27-7.40 (8H, m), 7.60 (1H, d, J 9.9), 7.78(1H, s), 8.05 (1H, s).

Example 791-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxy-4-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester(Intermediate 79a)

To a solution of 1-Boc-4-piperidone (10.0 g, 50.0 mmol) in diethyl ether(100 mL) at 0° C. was added methylmagnesium bromide (3.0 M in Et₂O, 22.3mL, 67.0 mmol) maintaining the temperature below +10° C. The reactionmixture was allowed to warm to RT over 1 h. The reaction was quenched byaddition of sat. aq. NH₄Cl solution, then the mixture was extracted withdiethyl ether (2×). The combined organic layers were washed with brine,dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC, using 0-100% EtOAc in cyclohexane, to give the titlecompound (6.76 g, 62%). ¹H NMR (400 MHz, CDCl₃): 1.26 (3H, s), 1.45 (9H,s), 1.48-1.62 (4H, m), 3.15-3.32 (2H, m), 3.70 (2H, d, J 12.5).

b. 4-Methyl-piperidin-4-ol (Intermediate 79b)

A solution of Intermediate 79a (5.50 g, 25.6 mmol) in TFA (20 mL) andDCM (40 mL) was stirred at RT for 1 h. The reaction mixture was appliedto SCX-2 cartridges (2×70 g) and washed with MeOH. The product waseluted with 2M NH₃ in MeOH; concentration in vacuo gave the titlecompound (3.19 g, 99%). ¹H NMR (400 MHz, CDCl₃): 1.24 (3H, s), 1.51-1.61(4H, m), 2.75-2.87 (2H, m), 2.89-3.02 (2H, m).

c.1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-methyl-piperidin-4-ol(Intermediate 79c)

A mixture of Intermediate 24b (400 mg, 2.32 mmol) and Intermediate 79b(1.33 g, 11.6 mmol) in NMP (5 mL) was heated in the microwave at 170° C.for 3 h. The reaction mixture was applied to an SCX-2 cartridge (25 g)and washed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-8% [2M NH₃ in MeOH]in DCM, gave the title compound (190 mg, 32%). LCMS (Method 1): Rt 2.01min, m/z 251 [MH⁺].

d.6-Fluoro-3-(4-methyl-4-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 79d)

Triisopropylsilyl trifluoromethanesulfonate (550 mg, 1.81 mmol) wasadded to a solution of Intermediate 79c (150 mg, 0.60 mmol) and Et₃N(242 mg, 2.40 mmol) in a DCM (5 mL) and the mixture stirred at refluxfor 1 h. The reaction mixture was diluted with DCM (30 mL), washed withwater (2×), brine, dried (MgSO₄), and then concentrated in vacuo. Theresidue was purified by FCC, using 0-10% MeOH in DCM, to give the titlecompound (235 mg, 96%). ¹H NMR (400 MHz, CDCl₃): 1.00-1.20 (21H, m),1.40 (3H, s), 1.76-1.93 (4H, m), 3.18-3.29 (2H, m), 3.44-3.58 (2H, m),7.03-7.12 (1H, m), 7.58-7.69 (2H, m).

e.(1S,4R)-4-[3-(4-Methyl-4-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 79e)

To a solution of Intermediate A (111 mg, 0.680 mmol) in DMF (2 mL) wasadded NaH (60% in oil, 68 mg, 1.70 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 79d (230 mg, 0.566 mmol) was added. Thismixture was stirred at 60° C. for 1 h. The cooled reaction mixture wasdiluted with EtOAc (100 mL), washed with water (2×), brine, dried(MgSO₄) and concentrated in vacuo. The residue was purified by FCC,using 0-10% [2M NH₃ in MeOH] in DCM, to give the title compound (160 mg,51%). LCMS (Method 1): Rt 3.06 min, m/z 550 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-4-triisopropylsilanyloxy-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 79f)

A solution of Intermediate 79e (160 mg, 0.291 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;176 mg, 0.437 mmol) and DIPEA (150 mg, 1.16 mmol) in DMF (4 mL) wasstirred at 50° C. for 1 h. The reaction mixture was diluted with EtOAcand washed with water (2×), brine, dried (MgSO₄), filtered andconcentrated in vacuo. The residue was purified by FCC, using 0-10% (2MNH₃ in MeOH) in DCM, to give the title compound (210 mg, 93%). LCMS(Method 4): Rt 5.32 min, m/z 805 [MH⁺].

g.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxy-4-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 79).

To a solution of Intermediate 79f (210 mg, 0.260 mmol) in THF (4 mL) at−30° C. was added TBAF (1M in THF, 390 μL, 0.390 mmol) and the mixturewas allowed to warm to RT over 1 h. The reaction mixture was applied toan SCX-2 cartridge (10 g) and washed with MeOH. The product was elutedwith 2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC, using0-10% [2M NH₃ in MeOH] in DCM, and then recrystallisation from boilingEtOAc (˜40 mL) gave the title compound as a white powder (67 mg, 40%).LCMS (Method 5): Rt 4.31 min, m/z 649.1 [MH⁺]. ¹H NMR (400 MHz,d₄-MeOH): 1.30 (3H, s), 1.33 (9H, s), 1.71-1.77 (2H, m), 1.84-1.93 (2H,m), 1.95-2.17 (3H, m), 2.25-2.32 (1H, m), 2.41 (3H, s), 3.20-3.28 (2H,m), 3.36-3.45 (2H, m), 4.72-4.92 (1H, m), 5.47 (1H, t, J 4.4), 6.36 (1H,s), 6.88 (1H, d, J 9.3), 7.21-7.40 (8H, m), 7.58 (1H, d, J 9.7), 7.62(1H, d, J 1.7).

Example 801-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-1-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 2-Methyl-2-pyrrolidin-1-yl-propionic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 80a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (200 mg, 1.57 mmol)in DMF (10.0 mL) was added 2-methyl-2-pyrrolidin-1-yl-propionic acid(246 mg, 1.57 mmol), EDC (332 mg, 1.73 mmol) and HOBt.H₂O (21.0 mg, 0.16mmol). The reaction was stirred overnight then partitioned between EtOAcand water. The aqueous layer was then extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The residue was purified by FCC, using 0-10%[2M NH₃ in MeOH] in DCM, to give the title compound (260 mg, 62%). ¹HNMR (300 MHz, CDCl₃): 1.30 (6H, s), 1.76-1.84 (4H, m), 2.64-2.72 (4H,m), 6.46 (1H, br s), 6.62 (1H, dd, J 9.0, 3.6), 7.28 (1H, ddd, J 9.0,8.0, 2.9), 8.03 (1H, d, J 2.9), 9.06 (1H, br s).

b.6-Fluoro-3-(1-methyl-1-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 80b)

To a solution of Intermediate 80a (260 mg, 0.98 mmol), Ph₃P (511 mg,1.95 mmol) and Et₃N (544 μL, 3.91 mmol) in THF (10.0 mL) at 0° C. wasadded hexachloroethane (462 mg, 1.95 mmol). The reaction was stirred atRT overnight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was taken up in MeOH and loaded onto an SCX-2 cartridge, whichwas washed with MeOH and eluted with 2M NH₃ in MeOH. The reaction showed50% conversion so was re-submitted to the reaction conditions overnightat 50° C. The workup and purification procedures were repeated to givethe title compound (209 mg, 86%). ¹H NMR (300 MHz, CDCl₃): 1.64 (6H, s),1.74-1.82 (4H, m), 2.52-2.57 (4H, m), 7.16 (1H, ddd, J 9.8, 7.4, 2.3),7.69 (1H, m), 8.93 (1H, ddd, J 4.5, 2.3, 0.7).

c.(1S,4R)-4-[3-(1-Methyl-1-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 80c)

To a suspension of NaH (60% in mineral oil, 135 mg, 3.37 mmol) in DMF(4.50 mL) was added Intermediate A (137 mg, 0.84 mmol) and the reactionstirred for 20 min. Intermediate 80b (209 mg, 0.84 mmol) was added inDMF (1.50 mL) and the reaction heated to 60° C. for 1 h. The reactionwas cooled and quenched by dropwise addition of methanol, before beingdiluted with methanol and loaded onto an SCX-2 cartridge, which waswashed with MeOH and product eluted with 2M NH₃ in MeOH. The resultingresidue was purified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, togive the title compound (180 mg, 55%). LCMS (Method 4): Rt 0.31, m/z392.2 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-1-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 80).

To a solution of Intermediate 80c (180 mg, 0.46 mmol) in 1,4-dioxane(5.00 mL) was added DIPEA (160 μL, 0.92 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;185 mg, 0.46 mmol). The reaction was heated to 60° C. overnight thencooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-8% MeOH in DCM. Further purification byHPLC (C18 X-select column, 10-98% MeCN in H₂O, 0.1% HCO₂H) gave thetitle compound as a white powder after freeze-drying (58 mg, 20%). LCMS(Method 5): Rt 3.84 min, m/z 647.2 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.30 (9H, s), 1.60 (6H, s), 1.70-1.76 (4H, m), 1.86-2.06 (2H, m), 2.11(1H, m), 2.20 (1H, m), 2.38 (3H, s), 2.45-2.52 (2H, m), 2.55-2.62 (2H,m), 4.89 (1H, dd, J 5.6, 8.9), 5.29 (1H, t, J 4.2), 6.33 (1H, s),7.20-7.36 (9H, m), 7.62 (1H, d, J 9.9), 8.77 (1H, d, J 2.0).

Example 811-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-2-Methyl-piperidine-1-carbonyl chloride (Intermediate 81a)

To a pale yellow solution of triphosgene (742 mg, 2.50 mmol) andpyridine (0.404 mL, 5.00 mmol) in dry DCM (10 mL) at 10° C. under N₂ wasadded (S)-2-methyl piperidine (Aldrich, 0.603 mL, 5.00 mmol) cautiouslyover 2 min. The vivid orange solution was stirred at RT for 18 h, thenpyridine (0.404 mL, 5.00 mmol) and triphosgene (742 mg, 2.50 mmol) wereadded sequentially (CARE: exotherm on addition of triphosgene) and theorange solution stirred at RT for 4 h. Aqueous HCl solution (1M, 10 mL)was added and the mixture stirred vigorously until gas evolution ceased(30 min). The aqueous layer was extracted with DCM (10 mL), then thecombined organics passed through a hydrophobic fit and concentrated invacuo to leave the title compound as a dark red oil (745 mg, 92%). ¹HNMR (300 MHz, CDCl₃): 1.25 (3H, d, J 7.0), 1.42-1.77 (6H, m), 3.07 (1H,br s), 4.17 (1H, dd, J 13.8, 4.0), 4.62 (1H, apparent quin, J 6.3).

b. (S)-2-Methyl-piperidine-1-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 81b)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (582 mg, 4.58 mmol)and DIPEA (0.997 mL, 5.72 mmol) in dry DCM (20 mL) was addedIntermediate 81a (740 mg, 4.58 mmol) and the resulting red solutionstirred at RT for 66 h, and at reflux for 4 h. To the cooled solutionwas added water (20 mL) and the mixture shaken. The aqueous wasextracted with DCM (20 mL), then the combined organics passed through ahydrophobic frit and concentrated in vacuo to leave a pale brown solid.FCC, using 0-5% MeOH in DCM, gave the title compound as a pale yellowsolid (657 mg, 57%). ¹H NMR (300 MHz, CDCl₃): 1.22 (3H, d, J 6.9),1.40-1.77 (6H, m), 2.96 (1H, td, J 13.0, 2.9), 3.85 (1H, ddd, J 13.3,4.5, 2.2), 4.31 (1H, m), 6.50 (1H, s), 6.59 (1H, br s), 6.75 (1H, ddd, J9.0, 3.6, 0.7), 7.27 (1H, ddd, J 9.1, 8.1, 3.1), 8.02 (1H, d, J 2.9).

c.6-Fluoro-3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 81c)

To a solution of Intermediate 81b (657 mg, 2.60 mmol), Ph₃P (1.37 g,5.21 mmol) and Et₃N (1.45 mL, 10.4 mmol) in THF (20 mL) at 0° C. wasadded hexachloroethane (1.23 g, 5.21 mmol) and the resulting yellowsuspension was stirred at RT for 2 h, and at reflux for 19 h. The cooledsolution was filtered and concentrated in vacuo. The brown oil wasredissolved in MeOH (3 mL) and applied to an SCX-2 cartridge (20 g),washing with MeOH (100 mL). The product was eluted with 2M NH₃ in MeOH(75 mL); concentration in vacuo gave a brown oil. FCC, using 1-5% [2MNH₃ in MeOH] in DCM, gave the title compound as a brown oil (542 mg,89%). LCMS (Method 3): Rt 3.00 min, m/z 235 [MH⁺].

d.(1S,4R)-4-[3-((S)-2-Methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 81d)

To a solution of Intermediate A (374 mg, 2.29 mmol) in dry DMF (3 mL)under N₂ was added NaH (60% dispersion in oil, 183 mg, 4.58 mmol) andthe resulting opaque brown solution was stirred at RT for 45 min (CARE:gas evolution). A solution of Intermediate 81c (537 mg, 2.29 mmol) indry DMF (7 mL) was added and the dark brown solution stirred at 60° C.under N₂ for 90 min. The cooled solution was concentrated in vacuo,redissolved in MeOH (3 mL) and AcOH (0.10 mL) and then applied to anSCX-2 cartridge (20 g), washing with MeOH (50 mL). The product waseluted with 2M NH₃ in MeOH (50 mL); concentration in vacuo gave a darkbrown solid. FCC, using 2-7% [2M NH₃ in MeOH] in DCM, gave the titlecompound as a pale brown foam (505 mg, 58%). LCMS (Method 3): Rt 2.29min, m/z 378 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 81).

An orange-brown solution of(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;106 mg, 0.263 mmol), Intermediate 81d (94.4 mg, 0.250 mmol) and DIPEA(0.054 mL, 0.313 mmol) in dry dioxane (3 mL) was stirred at 70° C. for16 h. The cooled solution was concentrated in vacuo, suspended in water(5 mL) and extracted with DCM (2×5 mL). The combined organics werepassed through a hydrophobic frit and concentrated in vacuo to leave abrown gum. FCC, using 2-6% MeOH in DCM, gave a pale yellow solid (123mg). Further purification by HPLC (XBridge C18 column, 40-90% MeCN inH₂O, 0.1% NH₄OH) gave the title compound as a white powder afterfreeze-drying (72.4 mg, 46%). LCMS (Method 5): Rt 5.04 min, m/z 633[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J 6.3), 1.27 (9H, s),1.48-1.55 (2H, m), 1.63-1.71 (2H, m), 1.75-1.97 (4H, m), 2.00-2.16 (2H,m), 2.36 (3H, s), 2.90 (1H, ddd, J 12.1, 9.0, 3.9), 3.16 (1H, dt, J12.1, 4.3), 3.29 (1H, m), 4.82 (1H, td, J 8.6, 5.5), 5.51 (1H, t, J4.4), 6.32 (1H, s), 7.08 (1H, d, J 8.6), 7.19 (1H, dd, J 9.9, 2.2),7.25-7.38 (8H, m), 7.64 (1H, dd, J 9.8, 0.8), 7.69 (1H, d, J 2.1), 8.04(1H, s).

Example 821-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from (R)-2-methyl piperidine(ABCR) using analogous procedures to those described in Example 81. LCMS(Method 5): Rt 5.03 min, ink 633 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.88(3H, d, J 6.3), 1.27 (9H, s), 1.48-1.55 (2H, m), 1.65-1.71 (2H, m),1.76-1.98 (4H, m), 2.01-2.14 (2H, m), 2.36 (3H, s), 2.94 (1H, ddd, J12.2, 8.1, 4.8), 3.17 (1H, dt, J 12.1, 4.3), 3.26-3.30 (1H, m), 4.82(1H, td, J 8.6, 5.4), 5.54 (1H, t, J 4.4), 6.32 (1H, s), 7.08 (1H, d, J8.6), 7.18 (1H, dd, J 9.8, 2.2), 7.26-7.38 (8H, m), 7.64 (1H, d, J 9.9),7.70 (1H, d, J 2.1), 8.04 (1H, s).

Example 831-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-4-methyl-morpholin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt

a.(R)-3-[N′-(5-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-morpholine-4-carboxylicacid tert-butyl ester (Intermediate 83a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (143 mg, 1.13 mmol)in DCM (10.0 mL) was added (R)-morpholine-3,4-dicarboxylic acid4-tert-butyl ester (260 mg, 1.13 mmol), EDC (238 mg, 1.24 mmol) andHOBt.H₂O (15.0 mg, 0.11 mmol). The reaction was stirred overnight thenpartitioned between EtOAc and water. The aqueous layer was thenextracted with EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, to give the titlecompound (375 mg, 98%). LCMS (Method 1): Rt 2.69, m/z 341.2 [MH⁺].

b.(S)-3-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-morpholine-4-carboxylicacid tert-butyl ester (Intermediate 83b)

To a solution of Intermediate 83a (375 mg, 1.10 mmol), Ph₃P (578 mg,2.20 mmol) and Et₃N (614 μL, 4.41 mmol) in THF (11.0 mL) at 0° C. wasadded hexachloroethane (523 mg, 2.20 mmol). The reaction was stirred atRT overnight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was taken up in MeOH and loaded onto an SCX-2 cartridge, whichwas washed with MeOH and eluted with 2M NH₃ in MeOH; concentration invacuo gave the title compound (297 mg, 84%). LCMS (Method 1): Rt 2.73,m/z 323.2 [MH⁺].

c.6-Fluoro-3-((S)-4-methyl-morpholin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 83c)

To a solution of Intermediate 83b (297 mg, 0.92 mmol) in DCM (8.0 mL) at0° C. was added TFA (400 μL) and the reaction stirred at RT overnight.Further TFA (600 μL) was added and the reaction stirred for 1 h thenpartitioned between DCM and sat. aq. NaHCO₃ solution. The aqueous layerwas then extracted with DCM (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was taken up in DCM (4.0 ml) and MeOH (3 drops) added.Formaldehyde solution (37 wt % in water, 162 μL, 2.00 mmol) was addedfollowed by sodium triacetoxyborohydride (372 mg, 2.40 mmol). Thereaction was stirred overnight then loaded onto an SCX-2 cartridge,which was washed with MeOH and eluted with 2M NH₃ in MeOH; concentrationin vacuo gave the title compound (75.0 mg, 34%). ¹H NMR (400 MHz,d₄-MeOD): 2.09 (3H, s), 2.49 (1H, td, J 11.4, 3.8), 2.98 (1H, dt, J11.9, 2.0), 3.79-3.90 (3H, m), 3.94 (1H, m), 4.01 (1H, dd, J 10.1, 4.0),7.50 (1H, ddd, J 10.0, 7.7, 2.2), 7.81 (1H, ddd, J 10.1, 4.9, 0.8), 8.98(1H, ddd, J 4.0, 2.3, 0.8).

d.(1S,4R)-4-[3-((S)-4-Methyl-morpholin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 83d)

To a suspension of NaH (60% in mineral oil, 51.0 mg, 1.27 mmol) in DMF(1.50 mL) was added Intermediate A (51.0 mg, 0.32 mmol) and the reactionstirred for 20 min. Intermediate 83c (75.0 mg, 0.32 mmol) was added inDMF (1.50 mL) and the reaction heated to 60° C. for 1 h. The reactionwas cooled and quenched by dropwise addition of methanol, before beingdiluted with methanol and loaded onto an SCX-2 cartridge, which waswashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM, gave the title compound (31 mg, 26%). LCMS (Method 4): Rt 0.32,m/z 380.0 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-4-methyl-morpholin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea,partial formate salt (Example 83).

To a solution of Intermediate 83d (31.0 mg, 0.082 mmol) in 1,4-dioxane(2.00 mL) was added DIPEA (28.0 μL, 0.16 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;33.0 mg, 0.082 mmol). The reaction was heated to 60° C. overnight thencooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-10% MeOH in DCM. Further purification byHPLC (C18 X-select column, 10-98% MeCN in H₂O, 0.1% HCO₂H) gave thetitle compound as a white powder after freeze-drying (10 mg, 19%). LCMS(Method 5): Rt 3.90 min, m/z 635.2 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD):1.30 (9H, s), 1.86-2.06 (3H, m), 2.11 (1H, m), 2.08 (3H, s), 2.25 (1H,m), 2.38 (3H, s), 2.46 (1H, td, J 11.7, 3.5), 2.92 (1H, dt, J 11.8,1.7), 3.73-3.91 (3H, m), 3.97 (1H, dd, J 9.9, 4.0), 4.90 (1H, dd, J 8.6,5.6), 5.39 (1H, t, J 4.1), 6.33 (1H, s), 7.21-7.36 (9H, m), 7.65 (1H, d,J 9.9), 8.24 (0.4H, br s), 8.55 (1H, d, J 1.4).

Example 841-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(S)-1-(3-hydroxy-propyl)-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea

a. (S)-1-(2-tert-Butoxycarbonyl-ethyl)-pyrrolidine-2-carboxylic acidbenzyl ester (Intermediate 84a)

Tert-butyl acrylate (5.00 mL) was added to a solution of L-prolinebenzyl ester hydrochloride salt (1.10 g, 4.54 mmol) and Et₃N (632 μL,4.54 mmol) in tert-butanol (5.00 mL). The reaction was heated to 80° C.for 3 h then and evaporated in vacuo. The residue was purified by FCC,using 0-50% EtOAc in cyclohexane, to give the title compound (1.20 g,79%). ¹H NMR (300 MHz, CDCl₃): 1.43 (9H, s), 1.72-2.00 (3H, m), 2.08(1H, m), 2.39-2.48 (3H, m), 2.72 (1H, ddd, J 12.2, 8.4, 6.7), 3.00 (1H,dt, J 12.3, 7.8), 3.13 (1H, m), 3.28 (1H, dd, J 8.6, 5.4), 5.13 (1H, d,J 12.3), 5.18 (1H, d, J 12.3), 7.29-7.39 (5H, m).

b. (S)-1-(2-tert-Butoxycarbonyl-ethyl)-pyrrolidine-2-carboxylic acid(Intermediate 84b)

A solution of Intermediate 84a (1.10 g, 3.29 mmol) in IMS (25.0 mL) wasadded to palladium on charcoal (10 wt %, 110 mg) and the reactionstirred under H₂ for 1 h. The mixture was filtered through Celite andevaporated in vacuo to give the title compound (840 mg, 99%). ¹H NMR(300 MHz, d₄-MeOD): 1.48 (9H, s), 1.91 (1H, m), 2.02-2.24 (2H, m), 2.41(1H, m), 2.74 (2H, t, J 7.1), 3.13 (1H, ddd, J 11.1, 10.2, 7.0),3.32-3.53 (2H, m), 3.72 (1H, ddd, J 11.0, 7.2, 3.5), 3.89 (1H, dd, J9.5, 5.3).

c.3-{(S)-2-[N′-(5-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-pyrrolidin-1-yl}-propionicacid tert-butyl ester (Intermediate 84c)

HOBt.H₂O (695 mg, 3.62 mmol) was added to a suspension of(5-fluoro-pyridin-2-yl)-hydrazine (418 mg, 3.29 mmol), Intermediate 84b(840 mg, 3.29 mmol), and EDC (44.0 mg, 0.33 mmol) in DMF (25.0 mL). Thereaction was stirred overnight then partitioned between EtOAc and water.The aqueous layer was then extracted with EtOAc (3×). The combinedorganic layers were washed with brine, dried (MgSO₄), filtered andevaporated in vacuo. The residue was purified by FCC, using 0-10% [2MNH₃ in MeOH] in DCM, to give the title compound (1.16 g, 99%). LCMS(Method 1): Rt 2.06 mins, m/z 353.3 [MH⁺].

d.3-[(S)-2-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-1-yl]-propionicacid tert-butyl ester (Intermediate 84d)

Hexachloroethane (1.56 g, 6.58 mmol) was added to a solution ofIntermediate 84c (1.16 g, 3.29 mmol), Ph₃P (1.72 g, 6.58 mmol) and Et₃N(1.80 mL, 13.1 mmol) in THF (30.0 mL) at 0° C. The reaction was stirredovernight then partitioned between EtOAc and water. The aqueous layerwas then extracted with EtOAc (3×). The combined organic layers werewashed with brine, dried (MgSO₄), filtered and evaporated in vacuo. Theresidue was purified by FCC, using EtOAc then 10% [2M NH₃ in MeOH] inDCM, to give the title compound (1.06 g, 99%). LCMS (Method 4): Rt 1.97min, m/z 335.1 [MH⁺].

e.3-[(S)-2-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-1-yl]-propan-1-ol(Intermediate 84e)

Lithium aluminium hydride solution (2M in THF, 1.64 mL, 3.28 mmol) wasadded to a solution of Intermediate 84d (550 mg, 1.64 mmol) in THF (15.0mL) at −10° C. The reaction was stirred for 1 h then quenched bydropwise addition of water (125 μL), sodium hydroxide (3M aqueous, 125μL) and water (375 μL). The reaction was stirred for 10 min thenpartitioned between EtOAc and water. The aqueous layer was thenextracted with EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC, using 2-10% (2M NH₃ in MeOH) in DCM, to give the titlecompound (145 mg, 33%). LCMS (Method 4): Rt 0.32 mins, m/z 265.2 [MH⁺].

f.6-Fluoro-3-[(S)-1-(3-triisopropylsilanyloxy-propyl)-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 84f)

Triisopropylsilyl chloride (266μ□L, 1.24 mmol) was added to a solutionof Intermediate 84e (218 mg, 0.82 mmol) and Et₃N (26μ□L, 1.24 mmol) inDCM (8.00 mL). The reaction was stirred overnight then4-(dimethylamino)pyridine (10.0 mg, 0.082 mmol) added. The reaction wasstirred for 3 h then partitioned between EtOAc and water. The aqueouslayer was then extracted with EtOAc (3×). The combined organic layerswere washed with brine, dried (MgSO₄), filtered and evaporated in vacuo.The residue was purified by FCC, using 0-7.5% [2M NH₃ in MeOH] in DCM,to give the title compound (317 mg, 92%). ¹H NMR (300 MHz, CDCl₃): 0.92(21H, s), 1.56-1.68 (2H, m), 1.89-2.10 (3H, m), 2.21-2.40 (3H, m), 2.56(1H, dt, J 12.1, 7.9), 3.40 (1H, m), 3.46-3.64 (2H, m), 4.22 (1H, t, J8.4), 7.16 (1H, ddd, J 9.9, 7.5, 2.3), 7.71 (1H, ddd, J 10.0, 4.9, 0.6),8.64 (1H, m).

g.(1S,4R)-4-{3-[(S)-1-(3-Triisopropylsilanyloxy-propyl)-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 84g)

To a suspension of NaH (60% in mineral oil, 121 mg, 3.02 mmol) in DMF(2.00 mL) was added Intermediate A (122 mg, 0.75 mmol) and the reactionstirred for 20 min. Intermediate 84f (317 mg, 0.75 mmol) was added inDMF (2.00 mL) and the reaction heated to 60° C. for 1 h. The cooledreaction was quenched by dropwise addition of methanol, before beingdiluted with methanol and loaded onto an SCX-2 cartridge, which waswashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 2-10% [2M NH₃ in MeOH]in DCM, gave the title compound (140 mg, 33%). LCMS (Method 4): Rt 2.37,m/z 564.2 [MH⁺].

h.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(S)-1-(3-triisopropylsilanyloxy-propyl)-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Intermediate 84h)

To a solution of Intermediate 84g (140 mg, 0.25 mmol) in 1,4-dioxane(3.00 mL) was added DIPEA (86.0 μL, 0.50 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;100 mg, 0.25 mmol). The reaction was heated to 60° C. overnight thenfurther (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (50.0 mg, 0.12 mmol) was added and heatingat 60° C. continued overnight. The reaction was cooled and partitionedbetween EtOAc and water. The aqueous layer was then extracted with EtOAc(3×). The combined organic layers were washed with brine, dried (MgSO₄),filtered and evaporated in vacuo. The residue was purified by FCC, using0-10% [2M NH₃ in MeOH] in DCM, to give the title compound (70.0 mg,34%). LCMS (Method 1): Rt 3.46, m/z 820.4 [MH⁺].

i.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(S)-1-(3-hydroxy-propyl)-pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Example 84).

TBAF (1M in THF, 100 μL, 0.10 mmol) was added to a solution ofIntermediate 84h (70.0 mg, 0.085 mmol) in THF (2.00 mL). The reactionwas stirred for 2 h then partitioned between EtOAc and water. Theaqueous layer was then extracted with EtOAc (3×). The combined organiclayers were washed with brine, dried (MgSO₄), filtered and evaporated invacuo. The residue was purified by FCC, using 0-10% [2M NH₃ in MeOH] inDCM. Further purification by HPLC (C18 X-select column, 10-98% MeCN inH₂O, 0.1% HCO₂H) gave the title compound as a white powder afterfreeze-drying (29 mg, 52%). LCMS (Method 5): Rt 3.63 min, m/z 663.3[MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.30 (9H, s), 1.54-1.62 (2H, quin, J7.0), 1.88-2.15 (6H, m), 2.20-2.37 (4H, m), 2.38 (3H, s), 2.55 (1H, dt,J 12.0, 8.1), 3.32-3.48 (3H, m), 4.11 (1H, t, J 8.0), 4.90 (1H, dd, J9.1, 5.7), 5.31 (1H, t, J 4.0), 6.33 (1H, s), 7.20-7.36 (9H, m), 7.65(1H, d, J 9.9), 8.32 (1H, d, J 1.7).

Example 851-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (3R,7aS)-3-Trichloromethyl-tetrahydro-pyrrolo[1,2-c]oxazol-1-one(Intermediate 85a)

A suspension of L-proline (10.0 g, 87.0 mmol) and chloral hydrate (21.6g, 130 mmol) in chloroform (100 mL) was heated at reflux for 6 h under asoxlet adapter charged with sodium sulfate. The cooled mixture waswashed with water (2×), dried (MgSO₄) and concentrated in vacuo. Theproduct was recrystallised from boiling absolute ethanol to give thetitle compound as white needles (13.3 g, 63%). ¹H NMR (400 MHz, CDCl₃):1.65-1.83 (1H, m), 1.86-2.01 (1H, m), 2.04-2.31 (2H, m), 3.06-3.18 (1H,m), 3.36-3.49 (1H, m), 4.12 (1H, dd, J 4.6, 4.0), 5.16 (1H, s).

b.(3R,7aR)-7a-Benzyloxymethyl-3-trichloromethyl-tetrahydro-pyrrolo[1,2-c]oxazol-1-one(Intermediate 85b)

To a solution of LDA (531 mL, 0.109M, 58.1 mmol) at −78° C. was added asolution of Intermediate 85a (10.0 g, 41.2 mmol) in THF (200 mL) over 30min maintaining the temperature below −70° C. The mixture was stirred at−78° C. for 2 h, then a solution of benzyloxymethyl chloride (11.6 g,74.1 mmol) in THF (50 mL) added, maintaining the temperature below −70°C. The mixture was allowed to warm to −30° C. over 3 h before beingquenched with dropwise addition of water (300 mL). The aqueous wasextracted with EtOAc (2×). The combined organic layers were dried(MgSO₄) and concentrated in vacuo. The residue was purified by FCC,using 0-60% diethyl ether in cyclohexane, to give the title compound asa clear oil (6.39 g, 42%). ¹H NMR (400 MHz, CDCl₃): 1.63-1.77 (1H, m),1.94-2.04 (1H, m), 2.08-2.17 (1H, m), 2.26-2.36 (1H, m), 3.22-3.29 (1H,m), 3.30-3.38 (1H, m), 3.74, (2H, s), 4.62 (2H, s), 4.99 (1H, s),7.26-7.37 (5H, m).

c. (R)-2-Benzyloxymethyl-pyrrolidine-2-carboxylic acid methyl ester(Intermediate 85c)

A solution of Intermediate 85b (6.39 g, 17.9 mmol) and sodium methoxide(580 mg, 10.8 mmol) in MeOH (100 mL) was stirred at RT for 18 h. Themixture was cooled to 0° C., then acetyl chloride (28.4 g, 359 mmol)added. This mixture was stirred at reflux for 1 h, then cooled andconcentrated in vacuo. The residue was divided, applied to SCX-2cartridges (3×70 g) and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo gave the title compound as a paleyellow oil (3.92 g, 87%). ¹H NMR (400 MHz, CDCl₃): 1.62-1.86 (3H, m),1.07-2.13 (1H, m), 2.48 (1H, br s), 2.93-3.11 (2H, m), 3.69-3.78 (4H,m), 4.53 (1H, d, J 12.9), 4.55 (1H, d, J 12.9), 7.21-7.37 (5H, m).

d. (R)-2-Benzyloxymethyl-1-methyl-pyrrolidine-2-carboxylic acid methylester (Intermediate 85d)

A solution of Intermediate 85c (3.37 g, 13.5 mmol) and formaldehyde (37%aqueous, 4.38 mL, 54.1 mmol) in DCM (140 mL) was stirred at RT for 30min, then sodium triacetoxyborohydride (5.74 g, 27.1 mmol) was added.This mixture was stirred at RT for 18 h then washed with sat. aq. NaHCO₃solution, dried (MgSO₄) and concentrated in vacuo. The residue waspurified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, to give the titlecompound as a clear oil (2.59 g, 72%). LCMS (Method 4): Rt 1.85 min, m/z263 [MH⁺].

e. (R)-2-Hydroxymethyl-1-methyl-pyrrolidine-2-carboxylic acid methylester (Intermediate 85e)

A suspension of Intermediate 85d (2.59 g, 9.84 mmol), palladiumhydroxide on charcoal (10%, 250 mg) and glacial acetic acid (1 mL) inIMS (20 mL) under an atmosphere of hydrogen (1 atm) was stirred at RTfor 5 d. The mixture was filtered and concentrated in vacuo to give thetitle compound as a clear oil (1.70 g, 99%), as a mixture of methyl andethyl esters. Data for major product, methyl ester: ¹H NMR (400 MHz,CDCl₃): 1.75-1.95 (2H, m), 2.01-2.18 (2H, m), 2.36 (3H, s), 2.86-2.99(2H, m), 3.65 (3H, s), 4.19 (2H, m), 4.91 (1H, br s).

f. (R)-1-Methyl-2-triisopropylsilanyloxymethyl-pyrrolidine-2-carboxylicacid methyl ester (Intermediate 85f)

Triisopropylsilyl trifluoromethanesulfonate (11.7 g, 38.1 mmol) wasadded to a solution of Intermediate 85e (2.20 g, 12.7 mmol) and Et₃N(12.8 g, 127 mmol) in DCM (100 mL) at 0° C., then the mixture stirred atRT for 30 min. The mixture was diluted with DCM and washed with 10% aq.K₂CO₃ solution, water, brine, dried (MgSO₄) and concentrated in vacuo.The residue was purified by FCC, using 0-5% [2M NH₃ in MeOH] in DCM, togive the title compound as a pale yellow solid (2.51 g, 65%). ¹H NMR(400 MHz, CDCl₃): 0.97-1.15 (21H, m), 1.72-1.96 (2H, m), 2.23-2.35 (2H,m), 2.46 (3H, s), 2.89-2.99 (2H, m), 3.69 (3H, m), 4.12-4.22 (2H, m).

g. (R)-1-Methyl-2-triisopropylsilanyloxymethyl-pyrrolidine-2-carboxylicacid (Intermediate 85g)

A solution of Intermediate 85f (2.50 g, 7.93 mmol) and lithium hydroxidemonohydrate (3.33 g, 79.3 mmol) in MeOH and water (50 mL) was stirred atreflux for 2 h. The cooled solution was acidified with 1M HCl to pH 5.The MeOH was removed in vacuo and the resulting aqueous layer wasextracted with EtOAc (3×). The combined organic layers were dried(MgSO₄) and concentrated in vacuo to give the title compound as a whitefoam (2.21 g, 92%). ¹H NMR (400 MHz, CDCl₃): 1.00-1.21 (21H, m),1.93-2.04 (2H, m), 2.32-2.42 (1H, m), 2.43-2.56 (1H, m), 2.96-3.09 (4H,m), 3.90-4.00 (1H, m), 4.20 (1H, d, J 10.9), 4.22 (1H, d, J 10.9).

h. (R)-1-Methyl-2-triisopropylsilanyloxymethyl-pyrrolidine-2-carboxylicacid N′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 85h)

To a solution of Intermediate 85g (1.08 g, 3.58 mmol),(5-fluoro-pyridin-2-yl)-hydrazine (500 mg, 3.93 mmol) and DIPEA (1.38 g,10.7 mmol) in DCM (120 mL) was added HATU (2.04 g, 5.37 mmol) and themixture stirred at RT for 2 h. The solution was washed with 10% aq.K₂CO₃ solution, brine, dried (MgSO₄), and concentrated in vacuo. Theresidue was purified by FCC, using 0-6% [2M NH₃ in MeOH] in DCM, to givethe title compound as a pale yellow oil (1.37 g, 90%). LCMS (Method 4):Rt 2.74 min, m/z 425 [MH⁺].

i.6-Fluoro-3-((S)-1-methyl-2-triisopropylsilanyloxymethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 85i)

To a solution of Intermediate 85h (1.37 g, 2.08 mmol), Ph₃P (1.09 g,4.16 mmol) and Et₃N (840 mg, 8.32 mmol) in THF (60 mL) was addedhexachloroethane (980 mg, 4.16 mmol) and the mixture stirred at RT for20 h. The mixture was diluted with DCM, washed with 10% aq. K₂CO₃solution, brine, dried (MgSO₄) and concentrated in vacuo. The residuewas purified by FCC, using 0-100% EtOAc in cyclohexane, to give thetitle compound as a clear oil (350 mg, 41%). LCMS (Method 4): Rt 3.07min, m/z 407 [MH⁺].

j.(1S,4R)-4-[3-((S)-1-Methyl-2-triisopropylsilanyloxymethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine (Intermediate 85j)

To a solution of Intermediate A (170 mg, 1.03 mmol) in DMF (4 mL) wasadded NaH (60% in oil, 103 mg, 2.59 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 85i (350 mg, 0.862 mmol) was added. Thismixture was stirred at 60° C. for 4 h. The cooled mixture was dilutedwith EtOAc, washed with water (3×), brine, dried (MgSO₄) andconcentrated in vacuo. The residue was purified by FCC, using 0-10% [2MNH₃ in MeOH] in DCM, to give the title compound as a clear viscous oil(230 mg, 48%). LCMS (Method 1): Rt 2.28 min, m/z 550 [MH⁺].

k.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-2-triisopropylsilanyloxymethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 85k)

A solution of Intermediate 85j (230 mg, 0.418 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009. which is incorporated herein by reference in its entirety;253 mg, 0.628 mmol) and DIPEA (215 mg, 1.67 mmol) in DMF (4 mL) wasstirred at 50° C. for 1 h. The mixture was diluted with EtOAc, washedwith water (2×), brine, dried (MgSO₄) and concentrated in vacuo. Theresidue was purified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, togive the title compound as a white foam (250 mg, 48%). LCMS (Method 3):Rt 3.70 min, m/z 805 [MH⁺].

l.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 85).

To a solution of Intermediate 85k (250 mg, 0.310 mmol) in THF (10 mL) at−30° C. was added TBAF (1M in THF, 620 μL, 0.620 mmol) and the mixturewas allowed to warm to RT over 2 h. The reaction mixture was applied toan SCX-2 cartridge (10 g) and washed with MeOH. The product was elutedwith 2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC, using0-10% [2M NH₃ in MeOH] in DCM, gave a crude product. Recrystallisationfrom hot diethyl ether (50 mL), EtOAc (10 mL) and cyclohexane (20 mL)gave the title compound as a white powder (113 mg, 56%). LCMS (Method5): Rt 3.68 min, m/z 649.1 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOD): 1.29 (9H,s), 1.86-2.34 (11H, m), 2.38 (3H, s), 3.02 (1H, m), 3.09 (1H, dt, J 8.8,3.5), 4.07 (1H, d, J 11.0), 4.25 (1H, d, J 4.3), 4.52 (1H, br s), 4.90(1H, m), 5.25 (1H, t, J 4.3), 6.33 (1H, s), 7.18-7.36 (9H, m), 7.62 (1H,d J 7.6), 8.44 (1H, s).

Example 861-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1,4-dimethyl-piperazin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.2-[N′-(5-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-piperazine-1,4-dicarboxylicacid di-tert-butyl ester (Intermediate 86a)

To a solution of piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butylester (780 mg, 2.4 mmol) and (5-fluoro-pyridin-2-yl)-hydrazine (250 mg,2.0 mmol) and Et₃N (0.83 mL, 6 mmol) in DCM (20 mL) were added HOBt.H₂O(27 mg, 0.2 mmol) and EDC (542 mg, 2.4 mmol) sequentially, and then themixture stirred at RT overnight. The mixture was partitioned betweenEtOAc/water and extracted with EtOAc. The combined organics were driedover Na₂SO₄, filtered and concentrated in vacuo. The residue waspurified by FCC, using 0-10% MeOH in DCM, to give the title compound asa brown solid (550 mg, 63%). LCMS (Method 4): Rt 3.28, m/z 440 [MH⁺].

b. 6-Fluoro-3-piperazin-2-yl-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 86b)

To a solution of Intermediate 86a (550 mg, 1.25 mmol), Et₃N (0.69 mL, 5mmol) and Ph₃P (657 mg, 2.5 mmol) in THF (20 mL) at 0° C. was addedhexachloroethane (590 mg, 2.5 mmol) and the mixture stirred for 10 min.The solution was allowed to warm to RT, stirred for 1 h, thenpartitioned between EtOAc/water and extracted with EtOAc. The combinedorganics were dried over Na₂SO₄, filtered and concentrated in vacuo. Theresidue was purified by FCC, using 0-100% EtOAc in cyclohexane, to givecrude2-(6-fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperazine-1,4-dicarboxylicacid di-tert-butyl ester, contaminated with triphenylphosphine oxide, asa pale brown solid (500 mg). The solid (500 mg) was treated with a 4MHCl solution in dioxane (30 mL) and the mixture stirred at RT for 2 h.The suspension was diluted with MeOH, then applied onto an SCX-2cartridge and washed with MeOH. The product was eluted with 2M NH₃ inMeOH; concentration in vacuo gave the title compound as a pale yellowsolid (100 mg, 23% over 2 steps). LCMS (Method 4): Rt 0.26, m/z 222[MH⁺].

c.3-(1,4-Dimethyl-piperazin-2-yl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 86c)

To a suspension of Intermediate 86b (100 mg) in 1,2-dichloroethane (10mL) were added formaldehyde (30% in water, 104 μL, 1.13 mmol) andNaBH(OAc)₃ (240 mg, 1.13 mmol) sequentially. The mixture was stirred atRT for 2 h, then applied to an SCX-2 cartridge and washed with MeOH. Theproduct was eluted with 2M NH₃ in MeOH; concentration in vacuo gave thetitle compound as a pale yellow solid (100 mg, 89%). LCMS (Method 4): Rt0.49, m/z 250 [MH⁺].

d.(1S,4R)-4-[3-(1,4-Dimethyl-piperazin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 86d)

To a solution of Intermediate 86c (100 mg, 0.40 mmol) and Intermediate A(79 mg, 0.40 mmol) in DMF (3 mL) was added NaH (60% in mineral oil, 56mg, 1.4 mmol) portion-wise. The mixture was stirred at 60° C. for 1.5 hthen allowed to cool to RT. The mixture was carefully quenched bypouring into MeOH (10 mL) then applied to an SCX-2 cartridge and washedwith MeOH. The product was eluted with 2M NH₃ in MeOH; concentration invacuo gave a residue. FCC, using 0-20% [2M NH₃ in MeOH] in DCM, gave thetitle compound as a brown oil (104 mg, 66%). LCMS (Method 4): Rt 0.26,m/z 393 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1,4-dimethyl-piperazin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 86).

The title compound was prepared as an off white solid (70 mg, 42%) using(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;107 mg, 0.26 mmol) and Intermediate 86d (104 mg, 0.26 mmol) in a similarmanner to Example 1, step d. LCMS (Method 5): Rt 3.64 min, m/z 648[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.83-1.98 (5H, m),2.05-2.25 (6H, m), 2.30-2.42 (5H, m), 2.75 (2H, d, J 10.7), 2.89-2.94(1H, m), 3.92-3.95 (1H, m), 4.80-4.86 (1H, m), 5.38-5.46 (1H, m), 6.32(1H, s), 7.10 (1H, d, J 8.6), 7.26-7.42 (9H, m), 7.75 (1H, d, J 9.7),8.04 (1H, s), 8.16 (1H, s), 8.46-8.50 (1H, m).

Example 871-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,4,4-trimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1,4,4-Trimethyl-pyrrolidine-2-carboxylic acid (Intermediate 87a)

A suspension of 4,4-dimethyl-L-proline hydrochloride (900 mg, 5.00mmol), formaldehyde (37% aqueous, 450 μL), DIPEA (645 mg, 5.00 mmol) andpalladium on carbon (10%, 400 mg) in IMS (50 mL) was stirred under anatmosphere of hydrogen (1 atm) for 4 h. The suspension was filtered andconcentrated in vacuo to give the title compound as a viscous pink oil(780 mg, 99%). ¹H NMR (400 MHz, CDCl₃): 1.47 (3H, s), 1.49 (3H, s),2.04-2.16 (1H, m), 2.23-2.34 (1H, m), 2.93 (3H, s), 3.10 (2H, m),3.78-3.89 (1H, m), 4.86 (1H, br s).

b. (S)-1,4,4-Trimethyl-pyrrolidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 87b)

To a solution of Intermediate 87a (1.70 g, 5.00 mmol),(5-fluoro-pyridin-2-yl)-hydrazine (600 mg, 5.00 mmol) and DIPEA (1.29 g,10.0 mmol) in DCM was added HATU (2.28 g, 6.00 mmol) and the mixturestirred at RT for 1 h. The reaction mixture was applied to an SCX-2cartridge (70 g) and washed with MeOH. The product was eluted with 2MNH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-10% [2MNH₃ in MeOH] in DCM, gave the title compound as a yellow oil (950 mg,71%). ¹H NMR (400 MHz, CDCl₃): 1.13 (3H, s), 1.15 (3H, s), 1.74 (1H, dd,J 12.5, 6.2), 2.12 (1H, dd, J 11.6, 10.0), 2.29 (1H, d, J 8.9), 2.46(3H, s), 2.88 (1H, d, J 8.9), 3.15 (1H, dd, J 9.7, 6.5), 6.56-6.65 (2H,m), 7.28 (1H dt, J 8.6, 2.9), 8.03 (1H, d, J 2.5), 9.09 (1H, br s).

c.6-Fluoro-3-((S)-1,4,4-trimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 87c)

To a solution of Intermediate 87b (950 mg, 3.57 mmol), Ph₃P (1.87 g,7.14 mmol) and Et₃N (1.44 g, 14.28 mmol) in THF (40 mL) was addedhexachloroethane (1.65 g, 7.14 mmol) and the mixture stirred at RT for20 h. The reaction mixture was applied to an SCX-2 cartridge (70 g) andwashed with MeOH. The product was eluted with 2M NH₃ in MeOH;concentration in vacuo gave a residue. FCC, using 0-10% [2M NH₃ in MeOH]in DCM gave the title compound as a clear oil (750 mg, 84%). ¹H NMR (400MHz, CDCl₃): 1.22 (3H, s), 1.24 (3H, s), 1.84 (1H, dd, J 12.7, 10.8),2.04 (1H, dd, J 12.4, 7.4), 2.16 (3H, s), 2.25 (1H, d J, 9.1), 3.04 (1H,d, J 9.3), 4.22 (1H, dd, J 10.0, 7.6), 7.14-7.23 (1H, m), 7.69-7.77 (1H,m), 8.75-8.80 (1H, m).

d.(1S,4R)-4-[3-((S)-1,4,4-Trimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 87d)

To a solution of Intermediate A (552 mg, 3.89 mmol) in DMF (25 mL) wasadded NaH (60% in oil, 338 mg, 8.46 mmol) and the mixture stirred at RTfor 20 min, before Intermediate 87c (700 mg, 2.82 mmol) was added. Thismixture was stirred at 60° C. for 1 h. The cooled reaction mixture wasapplied to an SCX-2 cartridge (70 g) and washed with MeOH. The productwas eluted with 2M NH₃ in MeOH; concentration in vacuo gave a residue.FCC, using 0-10% (2M NH₃ in MeOH) in DCM gave the title compound (820mg, 74%). LCMS (Method 4): Rt 1.53 min, m/z 392 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,4,4-trimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 87).

A solution of Intermediate 87d (150 mg, 0.383 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;232 mg, 0.575 mmol) and DIPEA (198 mg, 1.53 mmol) in DMF (4 mL) wasstirred at 50° C. for 1 h. The cooled reaction mixture was applied to anSCX-2 cartridge (10 g) and washed with MeOH. The product was eluted with2M NH₃ in MeOH; concentration in vacuo gave a residue. FCC, using 0-6%[2M NH₃ in MeOH] in DCM, then trituration with diethyl ether gave thetitle compound as an off-white powder (170 mg, 68%). LCMS (Method 5): Rt3.80 min, m/z 647.5 [MH⁺]. ¹H NMR (400 MHz, d₄-MeOH): 1.15 (3H, s), 1.24(3H, s), 1.30 (9H, s), 1.85-2.05 (4H, m), 2.14 (3H, s), 2.19-2.31 (2H,m), 2.38 (3H, s), 2.97 (1H, d, J 10.3), 3.45 (1H, dd, J 7.5, 6.1), 4.06(1H, t, J 9.3), 4.90 (1H, m), 5.30 (1H, t, J 4.2), 6.33 (1H, s),7.20-7.36 (9H, m), 7.65 (1H, d, J 10.8), 8.46 (1H, d, J 1.1).

Example 881-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.(S)-3-[N′-(5-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 88a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (1.27 g, 10.0 mmol),(S)-1-BOC piperidine-3-carboxylic acid (Alfa Aesar, 2.29 g, 10.0 mmol)and HOBt.H₂O (153 mg, 1.00 mmol) in DCM (50 mL) was added EDC (2.30 g,12.0 mmol) and the resulting orange solution stirred at RT for 16 h.Water (25 mL) was added and the mixture shaken. The aqueous wasextracted with DCM (25 mL) then the combined organics were passedthrough a hydrophobic frit and concentrated in vacuo to leave a palebrown foam. FCC, using 0-5% MeOH in DCM, gave the title compound as apale orange foam (3.21 g, 95%). LCMS (Method 3): Rt 3.14 min, m/z 361[MNa⁺].

b.(S)-3-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperidine-1-carboxylicacid tert-butyl ester (Intermediate 88b)

To a solution of Intermediate 88a (3.21 g, 9.49 mmol), Ph₃P (4.98 g,19.0 mmol) and Et₃N (5.29 mL, 37.9 mmol) in THF (100 mL) at 0° C. wasadded hexachloroethane (4.49 g, 19.0 mmol) and the resulting opaqueorange solution stirred vigorously at RT for 2 h. The suspension wasfiltered, and the filter-cake washed with THF (20 mL). The combinedorganics were concentrated in vacuo, redissolved in MeOH (5 mL), appliedto an SCX-2 cartridge (70 g) and washed with MeOH (150 mL). The productwas eluted with 2M NH₃ in MeOH (150 mL); concentration in vacuo gave apale orange solid (2.62 g). FCC, using 2-5% MeOH in DCM, gave the titlecompound as a pale yellow solid (2.01 g, 66%). LCMS (Method 3): Rt 3.09min, m/z 221 [M-C₅H₉O₂+H⁺].

c. 6-Fluoro-3-(S)-piperidin-3-yl-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 88c)

A yellow solution of Intermediate 88b (2.01 g, 6.27 mmol) and TFA (11.0mL, 148 mmol) in DCM (50 mL) was stirred at reflux for 30 min. Thecooled solution was concentrated in vacuo, redissolved in MeOH (3 mL),applied to an SCX-2 cartridge (50 g) and washed with MeOH (150 mL). Theproduct was eluted with 2M NH₃ in MeOH (100 mL); concentration in vacuoleft the title compound as a pale orange solid (1.26 g, 91%). LCMS(Method 3): Rt 0.35 min, m/z 221 [MH⁺].

d.6-Fluoro-3-((S)-1-methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 88d)

To a yellow solution of Intermediate 88c (220 mg, 1.00 mmol),formaldehyde (37% in water, 0.811 mL, 10.0 mmol) and AcOH (0.057 mL,1.00 mmol) in DCM-MeOH (5:1, 12 mL) was added NaBH(OAc)₃ (424 mg, 2.00mmol) (CARE: gas evolution) and the solution stirred at RT for 2 h. Thesolution was concentrated in vacuo to 5 mL volume, then applied to anSCX-2 cartridge (10 g) and washed with MeOH (50 mL). The product waseluted with 2M NH₃ in MeOH (50 mL); concentration in vacuo gave thetitle compound as a pale yellow gum, that became a white solid onstanding (234 mg, quant.). LCMS (Method 3): Rt 0.45 min, m/z 235 [MH⁺].

e.(1S,4R)-4-[3-((S)-1-Methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 88e)

To a solution of Intermediate A (196 mg, 1.20 mmol) in dry DMF (3 mL) atRT under N₂ was added NaH (60% dispersion in oil, 80 mg, 2.00 mmol) andthe resulting opaque brown solution stirred for 45 min. A solution ofIntermediate 88d (234 mg, 1.00 mmol) in dry DMF (2 mL) was added and theresulting dark brown solution stirred at 60° C. for 90 min. The cooledsolution was concentrated in vacuo, redissolved in MeOH (2 mL) and AcOH(0.1 mL), applied to and SCX-2 cartridge and washed with MeOH (75 mL).The product was eluted with 2M NH₃ in MeOH (60 mL); concentration invacuo left a dark brown solid. FCC, using 3-13% [2M NH₃ in MeOH] in DCM,gave the title compound as a light brown solid after freeze-drying (280mg, 74%). LCMS (Method 3): Rt 0.44 min, m/z 378 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 88).

An orange-brown solution(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;243 mg, 0.600 mmol), Intermediate 88e (151 mg, 0.400 mmol) and DIPEA(0.122 mL, 0.700 mmol) in dry dioxane (5 mL) was stirred at 65° C. for15 h. The cooled solution was concentrated in vacuo, redissolved in MeOH(2 mL), applied to an SCX-2 cartridge (10 g) and washed with MeOH (50mL). The product was eluted with 2M NH₃ in MeOH (30 mL); concentrationin vacuo left a brown solid. FCC, using 2-7% [2M NH₃ in MeOH] in DCM,gave the title compound as a pale yellow solid (188 mg, 74%). LCMS(Method 5): Rt 3.63 min, m/z 633 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27(9H, s), 1.55 (1H, qd, J 11.9, 5.3), 1.68-1.79 (2H, m), 1.83-2.03 (4H,m), 2.06-2.14 (2H, m), 2.22 (1H, t, J 10.9), 2.22 (3H, s), 2.36 (3H, s),2.83 (1H, br d, J 10.9), 3.01 (1H, ddd, J 11.1, 3.6, 1.6), 3.54 (1H, tt,J 11.1, 3.7), 4.83 (1H, td, J 8.4, 5.5), 5.57 (1H, t, J 4.5), 6.33 (1H,s), 7.09 (1H, d, J 8.5), 7.15 (1H, dd, J 9.8, 2.0), 7.27-7.42 (8H, m),7.68 (1H, d, J 9.9), 8.03 (1H, s), 8.32 (1H, d, J 2.0).

Example 891-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-piperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from(R)-1-BOC-piperidine-3-carboxylic acid (Alfa Aesar) using analogousprocedures to those described in Example 88. LCMS (Method 5): Rt 3.62min, m/z 633 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.55 (1H,qd, J 12.0, 5.5), 1.67-1.79 (2H, m), 1.82-2.16 (6H, m), 2.22 (3H, s),2.23 (1H, t, J 11.0), 2.36 (3H, s), 2.83 (1H, br d, J 11.0), 2.99 (1H,br d, J 11.2), 3.53 (1H, tt, J 11.1, 3.7), 4.83 (1H, td, J 8.4, 5.5),5.57 (1H, t, J 4.5), 6.33 (1H, s), 7.09 (1H, d, J 8.5), 7.16 (1H, dd, J9.8, 2.1), 7.35-7.33 (8H, m), 7.68 (1H, d, J 9.9), 8.04 (1H, s), 8.29(1H, d, J 2.0).

Example 901-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-pyrrolidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.(R)-3-[N′-(5-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-pyrrolidine-1-carboxylicacid tert-butyl ester (Intermediate 90a)

To a brown solution of (5-fluoro-pyridin-2-yl)-hydrazine (590 mg, 4.64mmol), (R)-1-N—BOC-beta proline (Manchester Organics, 1.00 g, 4.64 mmol)and HOBt.H₂O (71.1 mg, 0.464 mmol) in DCM (20 mL) at RT was added EDC(1.07 g, 5.57 mmol) (CARE: exotherm to ˜35° C.) and the resultingsolution stirred at RT for 4 h. Water (20 mL) was added and the mixtureshaken. The aqueous was extracted with DCM (20 mL), then the combinedorganics were passed through a hydrophobic frit and concentrated invacuo to ˜1 mL volume. FCC, using 1-10% MeOH in DCM, gave the titlecompound as a pale brown foam (1.37 g, 91%). LCMS (Method 3): Rt 2.93min, ink 347 [MNa⁺].

b.(R)-3-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester (Intermediate 90b)

To a brown solution Intermediate 90a (1.37 g, 4.22 mmol), Ph₃P (2.22 g,8.45 mmol) and Et₃N (2.35 mL, 16.9 mmol) in THF (25 mL) at 0° C. wasadded hexachloroethane (2.00 g, 8.45 mmol) in 3 portions at 1 minintervals. The solution was stirred at 0° C. for 30 min and at RT for3.5 h. The suspension was filtered and the filter-cake washed with THF(10 mL). The combined organics were applied to an SCX-2 cartridge (50g), then washed with DCM-MeOH (1:1, 50 mL) and MeOH (50 mL). The productwas eluted with 2M NH₃ in MeOH (75 mL); concentration in vacuo gave abrown oil that solidified on standing. The solid was dissolved in DCM(10 mL) then Et₃N (0.580 mL, 4.16 mmol) and BOC anhydride (454 mg, 2.08mmol) added sequentially. The solution was stirred at RT for 45 min,then water (10 mL) was added and the aqueous extracted with DCM (5 mL).The combined organics were passed through a hydrophobic frit andconcentrated in vacuo to leave a brown gum. FCC, using 2.5-3% MeOH inDCM, gave the title compound as a pale brown solid (933 mg, 73%). LCMS(Method 3): Rt 2.94 min, m/z 207 [MH⁺-C₅H₉O₂].

c. 6-Fluoro-3-(R)-pyrrolidin-3-yl-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 90c)

A mixture of Intermediate 90b (335 mg, 1.09 mmol) and TFA (0.812 mL,10.9 mmol) in DCM (5 mL) was stirred at reflux for 45 min. The cooledsolution was concentrated in vacuo, redissolved in MeOH (2 mL), appliedto an SCX-2 cartridge (10 g) and washed with MeOH (50 mL). The productwas eluted with 2M NH₃ in MeOH; concentration in vacuo left the titlecompound as a pale yellow solid (225 mg, >99%). LCMS (Method 3): Rt 0.44min, m/z 207 [MH⁺].

d.6-Fluoro-3-((R)-1-methyl-pyrrolidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 90d)

To a solution of Intermediate 90c (225 mg, 1.09 mmol), formaldehyde (37%in water, 0.885 mL, 10.9 mmol) and AcOH (0.0625 mL, 1.09 mmol) in DCM(20 mL) and MeOH (1 mL) was added NaBH(OAc)₃ (462 mg, 2.18 mmol) (CARE:gas evolution) and the pale yellow solution stirred at RT for 16 h. Thesolution was concentrated to 2 mL volume, then was applied to an SCX-2cartridge and was washed with MeOH (25 mL). The product was eluted with2M NH₃ in MeOH (25 mL); concentration in vacuo left the title compoundas a pale brown viscous oil (228 mg, 95%). LCMS (Method 3): Rt 0.44 min,m/z 221 [MH⁺].

e.(1S,4R)-4-[3-((R)-1-Methyl-pyrrolidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 90e)

To a solution of Intermediate A (203 mg, 1.24 mmol) in dry DMF (3 mL)under N₂ was added NaH (60% dispersion in oil, 83.0 mg, 2.07 mmol)(CARE: gas evolution) and the resulting opaque brown solution stirred atRT for 45 min. A solution of Intermediate 90d (228 mg, 1.03 mmol) in dryDMF (2 mL) was added and the dark brown solution stirred at 60° C. underN₂ for 90 min. The cooled solution was concentrated in vacuo,redissolved in MeOH (2 mL) and AcOH (0.1 mL), applied to and SCX-2cartridge (20 g) and washed with MeOH (75 mL). The product was elutedwith 2M NH₃ in MeOH (50 mL); concentration in vacuo gave a dark brownsolid. FCC, using 5-15% (2M NH₃ in MeOH) in DCM, gave the title compoundas a light brown powder after freeze-drying (299 mg, 80%). LCMS (Method3): Rt 0.44 min, m/z 364 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methyl-pyrrolidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 90).

A brown solution of (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;227 mg, 0.560 mmol), Intermediate 90e (145 mg, 0.400 mmol) and DIPEA(0.111 mL, 0.640 mmol) in dry dioxane (5 mL) was stirred at 65° C. for15 h. The cooled solution was concentrated in vacuo, redissolved in MeOH(2 mL), applied to an SCX-2 cartridge (10 g) and washed with MeOH (50mL). The product was eluted with 2M NH₃ in MeOH (30 mL); concentrationin vacuo gave a brown solid. FCC, using 2-7% [2M NH₃ in MeOH] in DCM,gave a pale brown solid (195 mg). Further purification by MDAP (Method8) gave the title compound as a white powder after freeze-drying (10.0mg, 4%). LCMS (Method 5): Rt 3.62 min, m/z 619 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.27 (9H, s), 1.83-1.98 (2H, m), 2.08-2.20 (3H, m), 2.32 (3H,s), 2.33-2.40 (1H, m), 2.36 (3H, s), 2.59-2.70 (2H, m), 2.75 (1H, dd, J9.2, 6.1), 2.96 (1H, t, J 8.7), 3.93-4.01 (1H, m), 4.83 (1H, td, J 8.4,5.4), 5.46 (1H, t, J 4.6), 6.32 (1H, s), 7.10 (1H, d, J 8.5), 7.18 (1H,dd, J 9.9, 2.1), 7.27-7.40 (8H, m), 7.69 (1H, dd, J 9.9, 0.8), 8.04 (1H,s), 8.44 (1H, d, J 2.0).

Example 911-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,4R)-4-fluoro-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (2S,4R)-4-Fluoro-1-methyl-pyrrolidine-2-carboxylic acid (Intermediate91a)

A solution of (2S,4R)-4-fluoropyrrolidine-2-carboxylic acid (1.00 g,7.52 mmol), formaldehyde (37% wt in water, 1.00 mL, 30.8 mmol), 12N HCl(0.5 mL) in IMS (38 mL) was purged with argon. To the solution was addedPd/C (100 mg), then the flask was evacuated and filled with H₂ theresulting suspension was stirred at RT for 3 d. The reaction mixture waspassed through a pad of Celite and the mixture was concentrated in vacuoto give the title compound as a pale yellow gum (600 mg, 54%). ¹H NMR(300 MHz, d₆-DMSO): 2.29-2.37 (1H, m), 2.63-2.67 (1H, m), 2.97 (3H, s),3.44-3.53 (1H, m), 4.00-4.04 (1H, m), 4.58 (1H, dd, J 11.6, 7.11),5.41-5.45 (1H, m).

b. (2S,4R)-4-Fluoro-1-methyl-pyrrolidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 91b)

A solution of (5-fluoro-pyridin-2-yl)-hydrazine (378 mg, 2.98 mmol),Intermediate 91a (600 mg, 4.08 mmol) and HOBt.H₂O (44 mg, 0.12 mmol) inDCM (10 mL) and DMF (3 mL) was added EDC (628 mg, 3.28 mmol) portionwiseat RT and the mixture stirred at RT for 17 h. The solution was dilutedwith water and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-7.5% [2MNH₃ in MeOH] in DCM, to give the title compound as light orange powder(366 mg, 35%). LCMS (Method 3): Rt 0.56 min, m/z 257 [MH⁺].

c.6-Fluoro-3-((2S,4R)-4-fluoro-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 91c)

A solution of Intermediate 91b (189 mg, 0.79 mmol), Ph₃P (416 mg, 1.59mmol) and Et₃N (0.44 mL, 3.17 mmol) in THF (10 mL) at RT was addedhexachloroethane (375 mg, 1.59 mmol) portion wise and the mixturestirred for 4 h. The solution was diluted with water and extracted withDCM. The combined organics were dried and concentrated in vacuo. Theresidue was purified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, togive the title compound as light yellow powder (214 mg, 63%). LCMS(Method 3): Rt 0.42 min, m/z 239 [MH⁺].

d.(1S,4R)-4-[3-((2S,4R)-4-Fluoro-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine.(Intermediate 91d)

To a solution of Intermediate A (161 mg, 0.99 mmol) in dry DMF (2.5 mL)at RT was added NaH (60% in mineral oil, 108 mg, 2.70 mmol) and themixture stirred for 15 min. Intermediate 91c (214 mg, 0.89 mmol) in DMF(2.5 mL) was then added and the mixture heated at 60° C. for 1 h. Aftercooling, the resulting dark brown mixture was diluted with water andextracted with DCM. The combined organics were dried and concentrated invacuo. The residue was purified by FCC, using 0-10% MeOH in DCM, to givecrude product. FCC, using 0-10% (2M NH₃ in MeOH) in DCM, gave the titlecompound as light brown foam (175 mg, 51%). LCMS (Method 3): Rt 0.43min, m/z 382 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,4R)-4-fluoro-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 91).

A solution of Intermediate 91d (164 mg, 0.43 mmol) and5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;191 mg, 0.47 mmol) and DIPEA (225 μL, 1.14 mmol) in THF (5 mL) wasstirred at reflux for 18.5 h. The cooled reaction mixture was dilutedwith water and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-5% [2MNH₃ in MeOH] in DCM, to give impure product. This residue was purifiedfurther by HPLC (XBridge C18 column, 30-98% MeCN in H₂O, 0.1% NH₄OH) togive the title compound as a white powder after freeze-drying (63 mg,23%). LCMS (Method 5): Rt 3.88 min, m/z 637 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.27 (9H, s), 1.88-1.93 (2H, m), 2.06-2.10 (2H, m), 2.17 (3H,s), 2.30-2.41 (2H, m), 2.36 (3H, s), 2.61-2.64 (2H, m), 3.49 (1H, ddd, J25.6, 11.5, 5.5), 4.54 (1H, t, J 7.7), 4.80-4.83 (1H, m), 5.49 (1H, t, J4.3), 6.32 (1H, s), 7.10 (1H, d, J 8.5), 7.30-7.42 (9H, m), 7.75 (1H,dd, J 9.9, 0.8), 8.05 (1H, s), 8.35 (1H, d, J 2.1).

Example 921-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.[(S)-1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-3-yl]-methanol(Intermediate 92a)

A solution of Intermediate 24b (485 mg, 2.83 mmol) and(S)-3-(hydroxymethyl)pyrrolidine (1.00 g, 9.90 mmol) in DMA (10 mL) washeated in the microwave at 175° C. for 2.5 h. The cooled mixture wasconcentrated in vacuo. The residue was purified by FCC, using 0-20% [2MNH₃ in MeOH] in DCM, to give the title compound as a brown gum (670 mg,quant.). LCMS (Method 3): Rt 0.44 min, m/z 237 [MH⁺].

b.6-Fluoro-3-((S)-3-triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 92b)

To a solution of Intermediate 92a (667 mg, 2.83 mmol) and Et₃N (630 μL,4.53 mmol) in DCM (5 mL) was added triisopropylsilyltrifluoromethanesulfonate (950 μL, 3.54 mmol) and the mixture was stirred at RT for 1 h.The mixture was washed with sat. sodium hydrogen carbonate solution thenbrine, dried and concentrated in vacuo. The residue was purified by FCC,2-6% MeOH in DCM, to give the title compound as a pale green viscous oil(1.11 g, quant.). LCMS (Method 3): Rt 4.76 min, m/z 393 [MH⁺].

c.(1S,4R)-4-[3-((S)-3-Triisopropylsilanyloxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 92c)

To a solution of Intermediate A (179 mg, 1.10 mmol) in DMF (3 mL) wasadded NaH (60% dispersion in oil, 120 mg, 3.00 mmol) and the mixturestirred at RT for 25 min. A solution of Intermediate 92b (958 mg, 1.10mmol) in DMF (3 mL) was added and the mixture stirred at 60° C. for 1.5h. The solution was cooled, water added, and the mixture extracted withDCM (4×25 mL). The combined organics were dried and concentrated invacuo. The residue was purified by FCC, using 0-16% MeOH in DCM, to givethe title compound as a brown gum (216 mg, 37%). LCMS (Method 3): Rt3.08 min, m/z 536 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-triisopropylsilanyloxy-methyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 92d)

A solution of Intermediate 92c (210 mg, 0.39 mmol) and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;159 mg, 0.390 mmol) in 1,4-dioxane (4 mL) and DIPEA (105 μL, 0.600 mmol)was stirred at 65° C. for 15.5 h and at 90° C. for 1.5 h. The cooledmixture was concentrated in vacuo. The residue was purified by FCC,using 0-10% MeOH in DCM, to give the title compound as a pale brownsolid (242 mg, 79%). LCMS (Method 3): Rt 5.18 min, m/z 791 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 92).

To a solution of Intermediate 92d (240 mg, 0.300 mmol) and TBAF (1M inTHF, 0.400 mL, 0.400 mmol) in THF (3 mL) was stirred at RT for 1 h.Water was added and the mixture extracted with DCM (4×20 mL). Thecombined organics were dried and concentrated in vacuo. The residue waspurified by FCC, using 0-14% MeOH in DCM, to give the title compound asan off-white powder after freeze-drying (154 mg, 81%). LCMS (Method 5):Rt 4.01 min, m/z 635.3 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.68-1.79 (1H, m), 1.79-1.97 (2H, m), 1.98-2.14 (3H, m), 2.36 (3H, s),2.40-2.48 (1H, m), 3.23-3.30 (1H, m), 3.41-3.64 (5H, m), 4.71 (1H, t, J5.3), 4.77-4.85 (1H, m), 5.51 (1H, br t, J 4.4), 6.33 (1H, s), 7.03-7.10(2H, m), 7.25-7.40 (8H, m), 7.53 (1H, d, J 9.9), 7.82 (1H, d, J 1.8),8.03 (1H, s).

Example 931-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from(R)-3-(hydroxymethyl)pyrrolidine using analogous procedures to thosedescribed in Example 92. LCMS (Method 5): Rt 4.01 min, m/z 635.3 [MH⁺].¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.67-1.77 (1H, m), 1.79-1.97(2H, m), 1.98-2.15 (3H, m), 2.37 (3H, s), 2.40-2.48 (1H, m), 3.25-3.30(1H, m), 3.41-3.62 (5H, m), 4.71 (1H, t, J 5.3), 4.77-4.85 m), 5.51 (1H,br t, J 4.3), 6.33 (1H, s), 7.04-7.10 (2H, m), 7.25-7.40 (8H, m), 7.53(1H, d, J 9.9), 7.82 (1H, d, J 1.6), 8.04 (1H, s).

Example 941-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea

a.2-[4-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-piperazin-1-yl]-ethanol(Intermediate 94a)

A solution of Intermediate 24b (485 mg, 2.82 mmol) and1-(2-hydroxylethyl)-piperazine (1.39 mL, 11.3 mmol) in DMA (10 mL) washeated in the microwave at 170° C. for 8 h. The cooled mixture wasconcentrated in vacuo. The residue was purified by FCC, using 0-20% (2MNH₃ in MeOH) in DCM, to give impure product. Further purified by FCC,using 0-7% (2M NH₃ in MeOH) in DCM gave the title compound as a palebrown gum (175 mg, 23%). LCMS (Method 3): Rt 0.43 min, m/z 266 [MH⁺].

b.6-Fluoro-3-[4-(2-triisopropylsilanyloxy-ethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 94b)

To a solution of Intermediate 94a (169 mg, 0.64 mmol) and Et₃N (265 μL,1.91 mmol) in DCM (6 mL) was added triisopropylsilyltrifluoromethanesulfonate (189 μL, 0.70 mmol). The solution was stirredfor 2.5 h, then diluted with water and extracted with DCM. The combinedorganics were dried and concentrated in vacuo. The residue was purifiedby FCC, using 0-5% (2M NH₃ in MeOH) in DCM, to give the title compoundas a pale brown gum (242 mg, 90%). LCMS (Method 3): Rt 2.93 min, m/z 422[MH⁺].

c.(1S,4R)-4-{3-[4-(2-Triisopropylsilanyloxy-ethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 94c)

To a solution of Intermediate A (102 mg, 0.63 mmol) in DMF (1.5 mL) wasadded NaH (60% dispersion in oil, 68 mg, 1.71 mmol). The mixture wasstirred at RT for 5 min, then a solution of Intermediate 94b (240 mg,0.57 mmol) in DMF (1.5 mL) was added and the mixture stirred at 60° C.for 1.25 h. The cooled mixture was diluted with water and extracted withDCM (4×25 mL). The combined organics were dried and concentrated invacuo. The residue was purified by FCC, using 0-10% (2M NH₃ in MeOH) inDCM, to give the title compound as a pale brown gum (219 mg, 68%). LCMS(Method 3): Rt 2.65 min, m/z 565 [MH⁺].

d.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(2-triisopropylsilanyloxy-ethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Intermediate 94d)

A solution of Intermediate 94c (170 mg, 0.42 mmol),5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Synthetic Communications, 2009, 39,3999-4009, which is incorporated herein by reference in its entirety;170 mg, 0.42 mmol) and DIPEA (199 μL, 1.14 mmol) in THF (4 mL) wasstirred at reflux for 15.5 h. The cooled reaction mixture was dilutedwith water and extracted with DCM. The combined organics were dried andconcentrated in vacuo. The residue was purified by FCC, using 0-7.5% (2MNH₃ in MeOH) in DCM, to give the title compound as a yellow powder (293mg, 93%). LCMS (Method 3): Rt 3.70 min, m/z 820 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydro-naphthalen-1-yl)-urea(Example 94).

A solution of Intermediate 94d (243 mg, 0.29 mmol) and TBAF (1M in THF,0.53 mL, 0.53 mmol) in THF (3.5 mL) was stirred at RT for 45 min, thendiluted with water and extracted with DCM (3×20 mL). The combinedorganics were dried and concentrated in vacuo. The residue was purifiedby FCC, using 0-7.5% (2M NH₃ in MeOH) in DCM, to give the title compoundas a white powder after freeze-drying (135 mg, 58%). LCMS (Method 5): Rt3.52 min, m/z 664 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.86-1.92 (2H, m), 2.04-2.11 (2H, m), 2.36 (3H, s), 2.48 (2H, q, J 5.8),2.66 (4H, t, J 4.8), 3.19 (4H, t, J 4.5), 3.55 (2H, q, J 5.8), 4.44 (1H,t, J 5.4), 4.79-4.82 (1H, m), 5.57 (1H, t, J 4.4), 6.32 (1H, s), 7.07(1H, d, J 8.5), 7.15 (1H, dd, J 9.9, 2.1), 7.32-7.44 (8H, m), 7.60-7.63(1H, m), 7.68 (1H, d, J 2.0), 8.04 (1H, s).

Example 951-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea

a. 3-(5-Amino-3-tert-butyl-pyrazol-1-yl-phenol (Intermediate 95a)

A mixture of 5-tert-butyl-2H-pyrazol-3-ylamine (1 g, 7.18 mmol),3-iodophenol (1.74 g, 7.90 mmol), copper (I) iodide (68 mg, 0.36 mmol),(1S,2S)—N,N′-dimethyl cyclohexane-1,2-diamine (204 mg, 1.44 mmol) andpotassium carbonate (2.08 g, 15.09 mmol) in toluene (8 mL) was de-gassedand flushed with argon (3×). The reaction mixture was then treated withmicrowave irradiation, at 150° C. for 1 h. The mixture was diluted withEtOAc (20 mL) and washed with water (20 mL). The aqueous layer wasextracted with a further 20 mL EtOAc and the combined organic layerswere washed with brine (20 mL), dried (MgSO₄), filtered and concentratedin vacuo. The residue obtained was purified by FCC, using 0-100% EtOAcin cyclohexane to afford the title compound as a brown gum (1.42 g,86%). LCMS (Method 3): Rt 2.21 min, m/z 232 [MH⁺].

b.5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-ylamine(Intermediate 95b)

A solution of intermediate 95a (1.42 g, 6.15 mmol) and triphenylphosphine (3.22 g, 12.29 mmol) in THF (50 mL), under an atmosphere ofargon was treated with 2-(tetrahydro-pyran-2-yloxy)-ethanol (1.25 mL,9.22 mmol), followed by the dropwise addition of diethylazodicarboxylate (1.94 mL, 12.29 mmol). The reaction mixture was thenstirred at RT for 1 h. Water (0.5 mL) was added and the mixture wasconcentrated in vacuo. The residue was taken up in EtOAc (8 mL) andcyclohexane was added until triphenylphosphine oxide had precipitatedout of solution. This was filtered and the filtrate was concentrated invacuo. The residue was purified by FCC, using 0-100% EtOAc incyclohexane to afford the title compound as an orange/brown oil (2.98g, >100%). LCMS (Method 3): Rt 3.20 min, m/z 360 [MH⁺].

c.(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 95c)

A solution of intermediate 95b (2.21 g, 6.16 mmol) in EtOAc (20 mL) wastreated with aqueous NaOH (1M, 11.08 mmol), followed by2,2,2-trichloroethyl chloroformate (1.01 mL, 7.39 mmol) and the reactionmixture was stirred at RT for 1 h. The mixture was partitioned betweenEtOAc (50 mL) and water (50 mL). The layers were separated and theaqueous layer was extracted with a further 50 mL EtOAc. The combinedorganic layers were dried (MgSO4), filtered and concentrated in vacuo.The residue was purified by FCC, using 0-100% EtOAc in cyclohexane toafford the title compound as a dark orange oil (2.39 g, 73%). LCMS(Method 3): Rt 4.70 min, m/z 534/536 [MH⁺].

d.1-(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 95d)

A mixture of intermediate 95c (200 mg, 0.37 mmol), intermediate 81d (141mg, 0.37 mmol) and DIPEA (98 μL, 0.56 mmol) in dioxane (1.5 mL) washeated at 70° C. for 20 h. The reaction mixture was cooled to RT,diluted with DCM (5 mL) and washed with water (2×5 mL). The organiclayer was passed through a hydrophobic fit and concentrated in vacuo.The residue was purified by FCC, using 0-10% (2M NH₃ in MeOH) in DCM toafford the title compound as a yellow glass (158 mg, 55%). LCMS (Method3): Rt 4.25 min, m/z 763 [MH⁺].

e.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 95e)

A mixture of intermediate 95d (158 mg, 0.21 mmol) and pyridiniump-toluene sulfonate (156 mg, 0.62 mmol) in methanol was heated at 45° C.for 18 h. The mixture was cooled to RT and was partitioned between DCM(5 mL) and saturated aqueous NaHCO₃ (5 mL). The layers were separatedand the organic layer was passed through a hydrophobic frit andconcentrated in vacuo. The residue was purified by FCC, using 0-10% (2MNH₃ in MeOH) in DCM to afford the title compound as a beige solid (105mg, 74%). LCMS (Method 3): Rt 3.64 min, m/z 679 [MH⁺].

f.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea(Example 95).

To a solution of intermediate 95e (105 mg, 0.15 mmol) and DIPEA (81 μL,0.46 mmol) in DCM (2 mL) was added methanesulfonyl chloride (16 μL, 0.20mmol). The reaction mixture was stirred at RT for 30 min. The mixturewas diluted with DCM (5 mL) and washed with water (2×5 mL). The organiclayer was passed through a hydrophobic frit and concentrated in vacuo.The residue was taken up in THF (2 mL) and dimethylamine solution in THF(2M, 1.55 mL) was added. The reaction mixture was heated at 60° C. in asealed tube for 20 h. The reaction mixture was cooled to RT andconcentrated in vacuo. The residue was triturated with Et₂O (1 mL) andthe solid obtained was purified by MDAP to afford the title compound asa glassy solid (44 mg, 40%). LCMS (Method 5): Rt 3.64 min, m/z 706.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J 6.7 Hz), 1.28 (9H, s),1.46-1.54 (2H, m), 1.63-1.72 (2H, m), 1.75-1.76 (4H, m), 2.00-2.18 (2H,m), 2.22 (6H, s), 2.66 (2H, t, J 5.8 Hz), 2.85-2.95 (1H, m), 3.12-3.20(1H, m, obscured by water), 3.27-3.35 (1H, m, obscured by water), 4.10(2H, t, J 5.4 Hz), 4.78-4.86 (1H, m), 5.52 (1H, t, J 4.0 Hz), 6.33 (1H,s), 6.95-6.99 (1H, m), 7.06-7.14 (3H, m), 7.19 (1H, dd, J 10.0 Hz),7.25-7.43 (5H, m), 7.64 (1H, d, J 10.6 Hz), 7.69 (1H, d, J 1.8 Hz), 8.12(1H, s).

Example 961-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-(cis-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a. cis-2,6-Dimethyl-piperidine-1-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 96a)

Pyridine (2.40 mL, 29.7 mmol) was added dropwise to an ice coldsuspension of triphosgene (4.42 g, 14.9 mmol) in DCM (30.0 mL).cis-2,6-Dimethylpiperidine (2.00 mL, 14.9 mmol) was added and thereaction stirred for 3 hours, then quenched by dropwise addition of HCl(1M aqueous, 30 mL). The mixture was extracted into DCM (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The product was used in the next reactionwithout purification. cis-2,6-Dimethylpiperidine-carbamoylchloride (1.79g, 10.2 mmol) was dissolved in DCM (90.0 mL) and DIPEA (2.42 mL, 13.9mmol) was added followed by (5-fluoro-pyridin-2-yl)-hydrazine (WO 2010022076, which is incorporated herein by reference in its entirety, 1.18g, 9.30 mmol) and the reaction heated to 45° C. overnight. The reactionwas cooled and quenched into water. The mixture was extracted into DCM(3×). The combined organic layers were washed with brine, dried (MgSO₄),filtered and evaporated in vacuo. The residue was purified by FCC using0-6% [2M NH₃ in MeOH] in DCM to give the title compound (1.38 g, 56%).¹H NMR (300 MHz, CDCl₃): 1.29 (6H, d, J 7.1 Hz), 1.48-1.90 (6H m), 4.26(2H, qn, J 6.9 Hz), 6.39 (1H, d, J 2.3 Hz), 6.50 (1H, d, J 2.3 Hz), 6.74(1H, dd, J 9.0, 3.6 Hz), 7.27 (1H, ddd, J 8.9, 8.0, 2.9 Hz), 8.03 (1H,d, J 2.9 Hz).

b.3-(cis-2,6-Dimethyl-piperidin-1-yl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 96b)

To an ice cold solution of Intermediate 96a (1.38 g, 5.19 mmol) in THF(50.0 mL) was added sequentially triphenylphosphine (2.72 g, 10.4 mmol),Et₃N (2.89 mL, 20.8 mmol) and hexachloroethane (2.46 g, 10.4 mmol). Thecooling bath was removed and the reaction was heated to 55° C.overnight. The reaction was cooled and partitioned between EtOAc andwater. The aqueous layer was then extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The residue was taken up in MeOH and loadedonto an SCX-2 cartridge, which was washed with MeOH and eluted with 2MNH₃ in MeOH. The residue was concentrated in vacuo then resubmitted tothe reaction conditions overnight. After analogous workup the residuewas concentrated in vacuo to give the title compound (1.03 g, 80%). ¹HNMR (300 MHz, CDCl₃): 0.68 (6H, d, J 6.2 Hz), 1.36-1.68 (3H m),1.74-1.90 (3H, m), 3.35 (2H, m), 7.14 (1H, ddd, J 9.8, 7.5, 2.3 Hz),7.65 (1H, ddd, J 9.9, 4.7, 0.8 Hz), 8.02 (1H, ddd, J 3.2, 2.3, 0.8 Hz).

c.(1S,4R)-4-[3-(cis-2,6-Dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 96c)

To a suspension of sodium hydride (60% in mineral oil, 323 mg, 8.06mmol) in DMF (10.0 mL) was added(1R,4S)-4-amino-1,2,3,4-tetrahydro-naphthalen-1-ol (329 mg, 2.02 mmol)and the reaction stirred for 20 min. Intermediate 96b (500 mg, 2.02mmol) was added in DMF (2.00 mL) and the reaction heated to 60° C. for 1h. The reaction was cooled and quenched by dropwise addition ofmethanol, before being diluted with methanol and loaded onto an SCX-2cartridge, which was washed with MeOH. The product was eluted with 2MNH₃ in MeOH. The residue was purified by FCC, using 0-10% (2M NH₃ inMeOH) in DCM, to give the title compound (453 mg, 57%). LCMS (Method 4):Rt 2.13, m/z 392 [MH⁺].

d.1-(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(cis-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 96d)

To a solution of Intermediate 96c (100 mg, 0.25 mmol) in 1,4-dioxane(3.00 mL) was added DIPEA (89.0 μL, 0.51 mmol) and Intermediate 39b (133mg, 0.25 mmol). The reaction was heated to 70° C. overnight then cooledand partitioned between EtOAc and water. The aqueous layer was thenextracted with EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC using 0-8% MeOH in DCM to give the title compound. LCMS(Method 4): Rt 4.09 min, m/z 777 [MH⁺].

e.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-(cis-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 96e)

Pyridinium p-toluenesulfonate (65.0 mg, 0.26 mmol) was added to asolution of Intermediate 96d in MeOH (2.0 mL). The reaction was heatedto 60° C. for 3.5 h then cooled and solvent volume reduced in vacuo. Theresidue was partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo to give thetitle compound (89.0 mg, 99%). LCMS (Method 4): Rt 3.49 min, m/z 693[MH⁺].

f. Methanesulfonic acid2-{3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-phenoxy}-ethylester (Intermediate 96f)

Methane sulfonylchloride (11.0 μL, 0.13 mmol) was added to an ice coldsolution of Intermediate 96e (89.0 mg, 0.13 mmol) and DIPEA (27.0 μL,0.15 mmol) in DCM (1.5 mL). After 1 hour additional DIPEA (27.0 μL, 0.15mmol) and methane sulfonylchloride (11.0 μL, 0.13 mmol) was added. Aftera further 1 hour additional DIPEA (27.0 μL, 0.15 mmol) and methanesulfonylchloride (11.0 μL, 0.13 mmol) was added. After 1 hour thereaction was partitioned between DCM and water. The aqueous layer wasthen extracted with DCM (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo to give thetitle compound (100 mg, 99%). LCMS (Method 1): Rt 3.73 min, m/z 771[MH⁺].

g.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-(cis-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 96).

Dimethylamine (2M in MeOH, 520 μL, 1.04 mmol) was added to a solution ofIntermediate 96f (100 mg, 0.13 mmol) in THF (1.5 mL). The reaction washeated to 50° C. in a sealed environment overnight. The mixture wascooled and partitioned between EtOAc and water. The aqueous layer wasthen extracted with EtOAc (3×). The combined organic layers were washedwith brine, dried (MgSO₄), filtered and evaporated in vacuo. The residuewas purified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM. Furtherpurification by HPLC (C18 X-select column, 10-98% MeCN in H₂O, 0.1%HCO₂H) gave the title compound as a white powder after freeze-drying (50mg, 54%). LCMS (Method 5): Rt 3.79 min, m/z 720.5 [MH⁺]. ¹H NMR (400MHz, d₄-MeOD): 0.65 (3H, d, J 6.0 Hz), 0.68 (3H, d, J 6.0 Hz), 1.31 (9H,s), 1.40-1.50 (2H, m), 1.53-1.65 (1H, m), 1.73-1.87 (3H, m), 1.92-2.05(2H, m), 2.05-2.15 (1H, m), 2.19-2.26 (1H, m), 2.43 (6H, s), 2.92 (2H,t, J 5.2 Hz), 3.24 (2H, m), 4.18 (2H, t, J 5.3 Hz), 4.90 (1H, dd, J 8.7,5.8), 5.42 (1H, t, J 8.2), 6.34 (1H, s), 7.02-7.06 (1H, ddd, J 8.5, 2.4,0.6), 7.08-7.13 (2H, m), 7.17-7.25 (3H, m), 7.26-7.31 (2H, m), 7.38-7.44(1H, t, J 7.8), 7.56-7.60 (1H, dd, J 9.8, 0.7 Hz), 7.86 (1H, d, J 1.8Hz), 8.45 (0.3H, br s).

Example 971-[5-tert-Butyl-2-(3-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.1-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 97a)

A brown solution of Intermediate 29c (177 mg, 0.420 mmol), Intermediate81d (151 mg, 0.400 mmol) and DIPEA (0.087 mL, 0.50 mmol) in dry dioxane(5 mL) was stirred at 100° C. for 3 h. The cooled solution wasconcentrated in vacuo, suspended in water (10 mL) and extracted with DCM(2×10 mL). The combined organics were passed through a hydrophobic fritand concentrated under vacuum to leave a dark brown gum. FCC, using 3-8%MeOH in DCM, gave the title compound as an orange solid (188 mg, 72%).LCMS (Method 4): Rt 3.63 min, m/z 649 [MH⁺].

b. Methanesulfonic acid3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzylester and1-[5-tert-Butyl-2-(3-chloromethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(1:1 mixture). (Intermediate mixture 97b)

To a solution of Intermediate 97a (187 mg, 0.288 mmol) and DIPEA (0.151mL, 0.865 mmol) in DCM (5 mL) at 0° C. was added mesyl chloride (0.056mL, 0.721 mmol) and the resulting orange solution stirred at 0° C. for 1h. Water (5 mL) was added and the mixture shaken. The aqueous layer wasextracted with DCM (5 mL), then the combined organics passed through ahydrophobic frit and concentrated in vacuo to leave the mixture of titlecompounds as a brown gum. LCMS (Method 4): 1:1 ratio, Rt 3.87 min, m/z727 [MH⁺] and Rt 4.11, m/z 667 [MH⁺].

c.1-[5-tert-Butyl-2-(3-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 97).

A brown solution of Intermediate mixture 97b (0.144 mmol) and morpholine(0.063 mL, 0.72 mmol) in dry DMF (3 mL) was stirred at 75° C. for 2 h.The cooled solution was concentrated in vacuo, suspended in water (10mL) and extracted with DCM (2×10 mL). The combined organics were passedthrough a hydrophobic frit and concentrated in vacuo to leave a browngum. FCC, 3-7% MeOH in DCM, gave a pale yellow solid (58.6 mg). MDAP(Method 7) gave the title compound as a pale yellow solid (31 mg, 28%).LCMS (Method 5): Rt 3.59 min, m/z 718.6 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 0.91 (3H, d, J 6.3), 1.28 (9H, s), 1.48-1.55 (2H, m),1.63-1.71 (2H, m), 1.75-1.97 (4H, m), 2.00-2.16 (2H, m), 2.37 (4H, t, J4.2), 2.90 (1H, ddd, J 12.2, 9.0, 4.0), 3.15 (1H, dt, J 12.0, 4.2), 3.51(2H, s), 3.55 (4H, t, J 4.4), 4.82 (1H, td, J 8.6, 5.6), 5.51 (1H, t, J4.3), 6.33 (1H, s), 7.04 (1H, d, J 8.6), 7.19 (1H, dd, J 9.9, 2.2),7.25-7.29 (2H, m), 7.31-7.48 (6H, m), 7.64 (1H, dd, J 9.8, 0.8), 7.69(1H, d, J 2.1), 8.10 (1H, s), 8.16 (1H, s). One 1H signal under solventpeak.

Example 981-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

The title compound was prepared starting from N-methyl piperazine usinganalogous procedures to those described in Example 97. LCMS (Method 5):Rt 3.61 min, m/z 731.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J6.3), 1.28 (9H, s), 1.48-1.56 (2H, m), 1.63-1.71 (2H, m), 1.75-1.96 (4H,m), 2.00-2.16 (2H, m), 2.12 (3H, s), 2.26-2.43 (8H, m), 2.90 (1H, ddd, J11.8, 9.2, 4.2), 3.16 (1H, dt, J 12.0, 4.2), 3.28-3.34 (1H, m), 3.50(2H, s), 4.82 (1H, td, J 8.6, 5.5), 5.52 (1H, t, J 4.3), 6.33 (1H, s),7.04 (1H, d, J 8.6), 7.19 (1H, dd, J 9.9, 2.2), 7.25-7.47 (8H, m), 7.64(1H, dd, J 9.8, 0.8), 7.69 (1H, d, J 2.1), 8.11 (1H, s), 8.18 (1H, s).

Example 991-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-cyclopentyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 1-Dimethylamino-cyclopentanecarboxylic acid (Intermediate 99a)

A solution of 1-amino-cyclopentanecarboxylic acid (2.0 g, 15.5 mmol) andformaldehyde (37% aqueous solution, 3 mL) in formic acid (4 mL) washeated at 80° C. for 2.5 h. The volatiles were concentrated in vacuo andthe resulting residue was loaded onto an SCX cartridge. The cartridgewas washed with MeOH and the product eluted with 2M NH₃ in MeOH toafford the title compound (1.82 g, 75%). ¹H NMR (400 MHz, CD₃OD):1.71-2.02 (6H, m), 2.16-2.29 (2H, m), 2.77 (6H, s).

b. 1-Dimethylamino-cyclopentanecarboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 99b)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (for referenceprocedure see WO 2010/022076, which is incorporated herein by referencein its entirety; 200 mg, 1.57 mmol) in DMF (10 mL) were addedIntermediate 99a (247 mg, 1.57 mmol), EDC (333 mg, 1.73 mmol) and HOBt(21 mg, 0.16 mmol). The reaction mixture was stirred at RT for 18 h andthen partitioned between EtOAc and water. The aqueous phase was furtherextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-8% (2M NH₃in MeOH) in DCM, to give the title compound (282 mg, 67%). ¹H NMR (400MHz, CDCl₃): 1.54-1.73 (4H, m), 1.76-2.04 (4H, m), 2.25 (6H, s), 6.46(1H, s), 6.64 (1H, dd, J=9.0, 3.5 Hz), 7.23-7.33 (1H, m), 8.04 (1H, d,J=3.0 Hz), 8.94 (1H, s).

c.[1-(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-cyclopentyl]-dimethyl-amine(Intermediate 99c)

Hexachloroethane (503 mg, 2.12 mmol) was added portionwise over 5minutes at RT to a stirred mixture of Intermediate 99b (282 mg, 1.06mmol), triethylamine (590 μL, 4.24 mmol) and triphenylphosphine (555 mg,2.12 mmol) in THF (11 mL). The reaction mixture was stirred at 50° C.for 2.5 h and then partitioned between EtOAc and water. The aqueousphase was extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC using SCX-2 cartridge. Thecartridge was washed with MeOH and the product was eluted with 2M NH₃ inMeOH to give the title compound (207 mg, 79%). ¹H NMR (400 MHz, CDCl₃):1.67-1.78 (4H, m), 2.10-2.22 (8H, m), 2.24-2.34 (2H, m), 7.15 (1H, ddd,J=10.0, 7.4, 2.3 Hz), 7.69 (1H, dd, J=10.0, 5.0 Hz), 8.65-8.68 (1H, m).

d.(1S,4R)-4-[3-(1-Dimethylamino-cyclopentyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 99d)

To a suspension of sodium hydride (60% in mineral oil, 133 mg, 3.34mmol) in DMF (5 mL) was added Intermediate A (136 mg, 0.83 mmol) and thereaction mixture was stirred for 20 min. A solution of Intermediate 99c(207 mg, 0.83 mmol) in DMF (3 mL) was added and the reaction mixture washeated at 60° C. for 90 min. After cooling, the reaction mixture wasquenched by careful addition of MeOH and then loaded onto an SCXcartridge. The cartridge was washed with MeOH and the product elutedwith 2M NH₃ in MeOH. The product containing fractions were concentratedin vacuo and the resultant residue was purified by FCC on silica, usinga gradient of 0-10% (2M NH₃ in MeOH) in DCM, to give the title compound(211 mg, 65%). LCMS (Method 4): Rt 1.49 min, m/z 392 [MH⁺].

e.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-cyclopentyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 99).

A mixture of Intermediate 99d (108 mg, 0.27 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (for reference procedure see SyntheticCommunications, 2009, 39, 3999-4009, which is incorporated herein byreference in its entirety; 105 mg, 0.27 mmol) and DIPEA (93 μL, 0.54mmol) in dioxane (3 mL) was stirred at 60° C. for 18 h and then at 80°C. for 4 h. The reaction mixture was diluted with EtOAc and then pouredinto water. The aqueous phase was extracted with EtOAc (×3) and thecombined organic layers were washed with brine, dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by MDAP(Method 7) to afford the title compound (23 mg, 13%). LCMS (Method 5):Rt 3.90 min, m/z 647 [MH⁺]. ¹H NMR (400 MHz, CD₃OD): 1.34 (9H, s),1.59-1.85 (4H, m), 1.91-2.15 (3H, m), 2.18 (6H, s), 2.21-2.36 (5H, m),2.42 (3H, s), 4.91-4.96 (1H, m), 5.34 (1H, t, J=4.1 Hz), 6.37 (1H, s),7.22-7.40 (9H, m), 7.65 (1H, d, J=9.9 Hz), 8.46 (1H, d, J=2.2 Hz).

Example 1001-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from Intermediate 96c and(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (for reference procedure see SyntheticCommunications, 2009, 39, 3999-4009, which is incorporated herein byreference in its entirety) using analogous procedures to those describedin Example 3. LCMS (Method 5): Rt 5.33 min, m/z 647 [MH⁺]. ¹H NMR (400MHz, CD₃OD): 0.64-0.74 (6H, m), 1.34 (9H, s), 1.41-1.72 (3H, m),1.75-2.19 (6H, m), 2.21-2.31 (1H, m), 2.42 (3H, s), 3.22-3.35 (2H, m),4.90-4.98 (1H, m), 5.45 (1H, t, J=4.1 Hz), 6.37 (1H, s), 7.19-7.40 (9H,m), 7.62 (1H, dd, J=9.9, 0.8 Hz), 7.89 (1H, d, J=2.1 Hz).

Example 1011-[(1S,4R)-4-(3-Amino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea

a. 2-(5-Fluoropyridin-2-yl)-N,N-di(prop-2-en-1-yl)hydrazinecarboxamide(Intermediate 101a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (for referenceprocedure see WO 2010/022076, which is incorporated herein by referencein its entirety; 2.54 g, 20.0 mmol) in DCM (150 mL) and DIPEA (3.87 g,30.0 mmol) was added N,N-di-2-propen-1-yl-carbamic chloride (forreference procedure see for example Tetrahedron 1996, 52, 13739-13750,which is incorporated herein by reference in its entirety; 4.13 g, 26.0mmol) and the reaction mixture was stirred at RT for 18 h. The reactionmixture was diluted with MeOH (50 mL) and loaded onto an SCX cartridge.The cartridge was washed with MeOH and the product eluted with 2M NH₃ inMeOH. The compound containing fractions were concentrated in vacuo andthe resulting residue was purified by FCC on silica, using a gradient of0-6% [2M NH₃ in MeOH] in DCM, to afford the title compound (2.30 g, 46%)as a yellow solid. LCMS (Method 1): Rt 2.26 min, m/z 251 [MH⁺].

b. Diallyl-(6-fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-amine(Intermediate 101b)

Hexachloroethane (4.34 g, 18.4 mmol) was added portionwise over 5 min atRT to a stirred mixture of Intermediate 101a (2.30 g, 9.2 mmol),triethylamine (3.71 g, 36.8 mmol) and triphenylphosphine (4.82 g, 18.4mmol) in THF (90 mL). The reaction mixture was stirred at RT for 1 h,then diluted with MeOH and purified by FCC using SCX-2 cartridge. Thecartridge was washed with MeOH and the product was eluted with 2M NH₃ inMeOH. The compound containing fractions were combined and concentratedin vacuo. The resultant residue was subjected to the follow purificationprocedure; FCC on silica (0-6% [2M NH₃ in MeOH] in DCM), then SCX-2cartridge (conditions described above) and finally further FCC on silica(0-2% MeOH in EtOAc), to afford the title compound (1.34 g, 62%). ¹H NMR(400 MHz, CDCl₃): 3.87 (4H, d, J=6.2 Hz), 5.16-5.35 (4H, m), 5.85-6.02(2H, m), 7.11 (1H, ddd, J=10.0, 7.6, 2.3 Hz), 7.58-7.67 (1H, m),7.75-7.80 (1H, m).

c. [6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-bis-((E)-propenyl)-amine(Intermediate 101c)

To a suspension of sodium hydride (40% in mineral oil, 690 mg, 17.31mmol) in DMF (20 mL) was added Intermediate A (1.12 g, 6.92 mmol) andthe reaction mixture was stirred for 20 min at RT. A solution ofIntermediate 101b (1.34 g, 5.77 mmol) in DMF (20 mL) was added and thereaction mixture was stirred at RT for 1 h. The reaction mixture wasquenched by careful addition of MeOH and then loaded onto an SCXcartridge. The cartridge was washed with MeOH and the product elutedwith 2M NH₃ in MeOH. The product containing fractions were concentratedin vacuo and the resultant residue was purified by FCC on silica, usinga gradient of 0-10% [2M NH₃ in MeOH] in DCM, to give the title compound(1.33 g, 61%) as an orange gum. ¹H NMR (400 MHz, CDCl₃): 0.92-1.13 (1H,m), 1.39 (6H, dd, J=7.2, 1.7 Hz), 1.82-2.16 (4H, m), 2.26-2.38 (1H, m),3.93-3.99 (1H, m), 4.99-5.10 (2H, m), 5.18 (1H, t, J=4.4 Hz), 6.10 (2H,dd, J=8.2, 2.0 Hz), 7.09 (1H, dd, J=9.9, 2.2 Hz), 7.25-7.44 (3H, m),7.48-7.53 (1H, m), 7.57-7.66 (2H, m).

d.1-[(1S,4R)-4-(3-Amino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea(Example 101).

A mixture of Intermediate 101c (1.33 g, 3.54 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (for reference procedure see SyntheticCommunications, 2009, 39, 3999-4009, which is incorporated herein byreference in its entirety; 2.0 g, 4.96 mmol) and DIPEA (1.82, 14.16mmol) in DMF (20 mL) was stirred at RT for 20 h. The reaction mixturewas diluted with MeOH and loaded onto an SCX cartridge. The cartridgewas washed with MeOH and the product eluted with 2M NH₃ in MeOH. Theproduct containing fractions were concentrated in vacuo and theresultant residue was purified by FCC on silica, using a gradient of0-10% [2M NH₃ in MeOH] in DCM, followed by recrystallization from 5%MeOH in DCM (few drops of cyclohexane added to start recrystallization),to give the title compound (760 mg, 39%) as an off white dust. LCMS(Method 5): Rt 3.81 min, m/z 551 [MH⁺]. ¹H NMR (400 MHz, CD₃OD): 1.34(9H, s), 1.86-2.08 (2H, m), 2.09-2.19 (1H, m), 2.22-2.34 (1H, m), 2.42(3H, s), 4.89-4.96 (1H, m), 5.32 (1H, t, J=4.4 Hz), 6.37 (1H, s), 7.05(1H, dd, J=10.0, 2.1 Hz), 7.23-7.44 (9H, m), 7.83 (1H, d, J=2.0 Hz).

Example 1021-[5-tert-Butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. [5-tert-Butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 102a)

To a mixture of5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-ylamine (forreference procedure see for example WO2003072569, which is incorporatedherein by reference in its entirety; 833 mg, 3.62 mmol) in NaOH (1M inwater, 5.4 mL, 4.4 mmol) and EtOAc (5 mL) was added 2,2,2-trichloroethylchloroformate (548 μL, 3.98 mmol) and the reaction mixture was stirredat RT for 1 h. Additional NaOH (1M in water, 5.4 mL) and2,2,2-trichloroethyl chloroformate (548 μL) were added and stirring atRT was continued for 1 h. Additional NaOH (1M in water, 5.4 mL) and2,2,2-trichloroethyl chloroformate (548 μL) were added and stirring atRT was continued for 2 h. Additional NaOH (1M in water, 10.8 mL) and2,2,2-trichloroethyl chloroformate (1.10 mL) were added and stirring atRT was continued for 24 h. The aqueous layer was extracted with EtOAc(×3) and the combined organic layers were washed with brine, dried(Na₂SO₄) and concentrated in vacuo. The resultant residue was purifiedby FCC on silica, using a gradient of 10-50% EtOAc in cyclohexane, toafford the title compound (550 mg, 37%) as a white foam. LCMS (Method3): Rt 3.87 min, m/z 405 [MH⁺].

b.1-[5-tert-Butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 102).

A mixture of Intermediate 102a (84 mg, 0.206 mmol), Intermediate 3c (75mg, 0.206 mmol) and DIPEA (45 μL, 0.258 mmol) in dioxane (3 mL) wasstirred at 65° C. for 16 h. After cooling, the volatiles wereconcentrated in vacuo and the resultant residue was partitioned betweenwater and DCM. The organic layer was dried through a separator phase andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 2-7% MeOH in DCM followed by HPLC (XBridgeC18 column, 25-75% MeCN in H₂O, 0.1% NH₄OH), to afford the titlecompound (41 mg, 32%) as a white solid. LCMS (Method 5): Rt 4.06 min,m/z 620 [MH⁺]. H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s), 1.56-1.66 (2H,m), 1.67-1.77 (4H, m), 1.79-1.96 (2H, m), 1.96-2.20 (2H, m), 2.53 (3H,s), 3.13 (4H, t, J=5.2 Hz), 4.75-4.84 (1H, m), 5.54 (1H, t, J=4.3 Hz),6.35 (1H, s), 7.06 (1H, d, J=8.6 Hz), 7.16 (1H, dd, J=9.8, 2.2 Hz),7.23-7.43 (5H, m), 7.58-7.64 (2H, m), 7.81 (1H, dd, J=8.3, 2.6 Hz), 8.18(1H, s), 8.59 (1H, d, J=2.6 Hz).

Example 1031-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 2-(5-Fluoropyridin-2-yl)-N,N-di(propan-2-yl)hydrazinecarboxamide(Intermediate 103a)

To a solution of (5-fluoro-pyridin-2-yl)-hydrazine (for referenceprocedure see WO2010022076; 200 mg, 1.57 mmol) in DCM (15 mL) was addedtriethylamine (328 μL, 2.35 mmol) followed by N,N-diisopropylcarbamoylchloride (282 mg, 1.73 mmol). The reaction mixture was heated at 45° C.for 4 h then poured into water and extracted with DCM (×3). The combinedorganic layers were washed with brine, dried (MgSO₄) and concentrated invacuo. The resultant residue was purified by FCC on silica, using agradient of 0-100% EtOAc in cyclohexane, to afford the title compound(200 mg, 50%). ¹H NMR (400 MHz, CDCl₃): 1.30 (12H, d, J=6.8 Hz),3.80-4.03 (2H, m), 6.17 (1H, s), 6.53 (1H, s), 6.67-6.81 (1H, m),7.24-7.36-(1H, m), 8.02 (1H, d, J=3.0 Hz).

b. (6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-diisopropyl-amine(Intermediate 103b)

The title compound was prepared starting from Intermediate 103a usinganalogous procedures to those described in Intermediate 99c. ¹H NMR (400MHz, CDCl₃): 1.09 (12H, d, J=6.5 Hz), 3.60-3.79 (2H, m), 7.11-7.24 (1H,m), 7.44-7.62 (1H, m), 7.98-8.05 (1H, m).

c.[6-((1R,4S)-4-Amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]-diisopropyl-amine(Intermediate 103c)

To a suspension of sodium hydride (60% in mineral oil, 136 mg, 3.39mmol) in DMF (5 mL) was added Intermediate A (138 mg, 0.85 mmol) and thereaction mixture was stirred for 15 min at RT. A solution ofIntermediate 103b (200 mg, 0.85 mmol) in DMF (3 mL) was added and thereaction mixture was heated at 60° C. for 1 h. The reaction mixture wasquenched by careful addition of MeOH and then loaded onto an SCXcartridge. The cartridge was washed with MeOH and the product elutedwith 2M NH₃ in MeOH. The product containing fractions were concentratedin vacuo and the resultant residue was purified by FCC on silica, usinga gradient of 0-10% [2M NH₃ in MeOH] in DCM, to give the title compound(220 mg, 68%). LCMS (Method 4): Rt 2.07 min, m/z 380 [MH⁺].

d.1-(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 103d)

The title compound was prepared starting from Intermediate 103c andIntermediate 95c using analogous procedures to those described inIntermediate 95d. LCMS (Method 4): Rt 3.92 min, m/z 765 [MH⁺].

e.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 103e)

To a solution of Intermediate 103d (100 mg, 0.13 mmol) in MeOH (2 mL)was added pyridinium p-toluenesulfonate (65 mg, 0.26 mmol) and thereaction mixture was heated to reflux temperature for 3 h. The volatileswere concentrated in vacuo and the resultant residue was partitionedbetween EtOAc and water. The aqueous phase was extracted with EtOAc (×3)and the combined organic layers were washed with brine, dried (MgSO₄)and concentrated in vacuo to afford the title compound (97 mg, 99%).LCMS (Method 2): Rt 3.39 min, m/z 681 [MH⁺].

f. Methanesulfonic acid2-[3-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-phenoxy]-ethylester (Intermediate 103f)

To an ice-bath cooled solution of Intermediate 103e (97 mg, 0.13 mmol)in DCM (2 mL) was added DIPEA (58 μL, 0.32 mmol) followed bymethanesulfonyl chloride (22 μL, 0.27 mmol). The reaction mixture wasstirred for 2 h then partitioned between DCM and water. The aqueousphase was extracted with DCM (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo to afford thetitle compound (130 mg, quantitative). LCMS (Method 1): Rt 3.69 min, m/z759 [MH⁺].

g.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 103).

To a solution of Intermediate 103f (130 mg, 0.13 mmol) in THF (1.5 mL)was added dimethylamine (2M in MeOH, 520 μL, 1.04 mmol). The reactionmixture was heated at 50° C. for 18 h, then cooled and partitionedbetween EtOAc and water. The aqueous phase was extracted with EtOAc (×3)and the combined organic layers were washed with brine, dried (MgSO₄)and concentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-10% [2M NH₃ in MeOH] in DCM followed byHPLC (C18 X-select column, 10-98% gradient MeCN in H₂O, 0.1% HCO₂H), togive the title compound (37 mg, 40%). LCMS (Method 5): Rt 3.70 min, m/z708 [MH⁺]. ¹H NMR (400 MHz, CD₃OD): 1.05 (12H, dd, J=6.4, 1.8 Hz), 1.33(9H, s), 21.89-2.30 (4H, m), 2.43 (6H, s), 2.91 (2H, t, J=5.2 Hz),3.62-3.74 (2H, m), 4.19 (2H, t, J=5.3 Hz), 4.88-4.97 (1H, m), 5.42 (1H,t, J=4.1 Hz), 6.37 (1H, s), 7.04-7.13 (3H, m), 7.19-7.34 (5H, m), 7.44(1H, t, J=8.3 Hz), 7.60 (1H, d, J=9.8 Hz), 7.87 (1H, d, J=2.1 Hz).

Example 104N-(5-tert-Butyl-2-methoxy-3-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide

a. (5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-carbamic acid2,2,2-trichloro-ethyl ester (Intermediate 104a)

NaOH (199 mg, 4.97 mmol) was added to an ice-bath cooled solution ofN-[3-amino-5-(1,1-dimethylethyl)-2-methoxyphenyl]-methanesulfonamide(for reference procedure see for example WO2010026096, which isincorporated herein by reference in its entirety; 500 mg, 1.84 mmol).The ice bath was removed and complete dissolution of reagents occurred.2,2,2-trichloroethyl chloroformate (380 μL, 2.76 mmol) was added and thereaction mixture was warmed to RT and stirred for 90 min. The reactionmixture was partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-60% EtOAcin cyclohexane, to afford the title compound (620 mg, 75%) as a whitesolid. LCMS (Method 1): Rt 3.98 min, m/z 445, 447, 449 [MH⁺].

b.N-(5-tert-Butyl-2-methoxy-3-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide(Example 104).

A mixture of Intermediate 3c (50 mg, 0.14 mmol), Intermediate 104a (62mg, 0.14 mmol) and DIPEA (48 μL, 0.27 mmol) in dioxane (1.5 mL) wasstirred at 70° C. for 18 h and then at 80° C. for 48 h. The reactionmixture was diluted with EtOAc and then poured into water. The aqueousphase was extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of1-8% MeOH in DCM and then by HPLC (C18X-select column, 10-98% gradientMeCN in H₂O, 0.1% HCO₂H), to afford the title compound (19 mg, 21%).LCMS (Method 5): Rt 4.47 min, m/z 662 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):1.25 (9H, s), 1.57-1.66 (2H, m), 1.69-1.78 (4H, m), 1.83-1.95 (1H, m),1.98-2.24 (3H, m), 3.05 (3H, s), 3.15 (4H, t, J=5.3 Hz), 3.69 (3H, s),4.87-4.96 (1H, m), 5.59 (1H, t, J=4.5 Hz), 6.94 (1H, d, J=2.3 Hz), 7.19(1H, dd, J=9.9, 2.1 Hz), 7.31 (1H, dd, J=8.2, 6.7 Hz), 7.35-7.45 (4H,m), 7.60-7.69 (2H, m), 8.07 (1H, s), 8.19 (1H, d, J=2.4 Hz).

Example 1051-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[8-methyl-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. N-Benzhydrylidene-N′-(5-fluoro-3-methyl-pyridin-2-yl)-hydrazine(Intermediate 105a)

A mixture of 2-bromo-5-fluoro-3-methyl-pyridine (190 mg, 1.0 mmol),benzhydrylidene-hydrazine (216 mg, 1.1 mmol), phenylboronic acid (5 mol%, 6 mg) and potassium tert-butoxide (157 mg, 1.4 mmol) in anhydroustoluene (6 mL) was degassed with a stream of argon, treated withPd(OAc)₂ (2 mol %, 5 mg) and racemic(1,1′-binaphthalene-2,2′-diyl)bis(diphenylphosphine) (2 mol %, 12 mg)and stirred at 80° C. for 1 h. After cooling to RT, the reaction mixturewas diluted with EtOAc and washed with water followed by a saturatedaqueous solution of NaHCO₃. The organic layer was dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 1-10% MeOH in DCM followed by 100% DCM, toafford the title compound (196 mg, 64%). LCMS (Method 4): Rt 3.44 min,m/z 306 [MH⁺].

b. (5-Fluoro-3-methyl-pyridin-2-yl)-hydrazine (Intermediate 105b)

A solution of Intermediate 105a (194 mg, 0.635 mmol) in toluene (13 mL)was treated with HCl (37%, 3.5 mL) and heated at 110° C. for 1.5 h.After cooling to RT, the reaction mixture was diluted with water andextracted with toluene (×3). The aqueous layer was cooled to 0° C.,neutralised with 5N NaOH and extracted with DCM (×3). The combinedorganic layers were dried (MgSO₄) and concentrated in vacuo to affordthe title compound (78 mg, 86%) as a silver/green solid. LCMS (Method4): Rt 0.29 min, m/z 142 [MH⁺].

c. (S)-1-Methyl-pyrrolidine-2-carboxylic acidN′-(5-fluoro-3-methyl-pyridin-2-yl)-hydrazide (Intermediate 105c)

A solution of Intermediate 105b (76 mg, 0.537 mmol),(S)-1-methyl-pyrrolidine-2-carboxylic acid (55 mg, 0.72 mmol) and HOBT(8 mg, 0.72 mmol) in anhydrous DCM (5 mL) was treated with EDC (138 mg,0.717 mmol) and stirred at RT under a nitrogen atmosphere for 18 h. Thereaction mixture was diluted with DCM and washed with brine. The organiclayer was dried (MgSO₄) and concentrated in vacuo. The resultant residuewas purified by FCC on silica, using a gradient of 1-10% MeOH in DCM, toafford the title compound (76 mg, 56%). ¹H NMR (400 MHz, CDCl₃):1.74-2.05 (3H, m), 2.15-2.33 (4H, m), 2.34-2.46 (1H, m), 2.52 (3H, s),3.02-3.12 (1H, m), 3.15-3.25 (1H, m), 6.70 (1H, s), 7.08-7.18 (1H, m),7.90 (1H, d, J=2.8 Hz), 9.52 (1H, br s).

d.6-Fluoro-8-methyl-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 105d)

Hexachloroethane (141 mg, 0.587 mmol) was added portionwise at RT to astirred mixture of Intermediate 105c (74 mg, 0.293 mmol), triethylamine(166 μL, 1.17 mmol) and triphenylphosphine (154 mg, 0.587 mmol) in THF(5 mL). The reaction mixture was stirred at 80° C. for 2 h, then cooledto RT and filtered. The filtrate was concentrated in vacuo and theresultant residue was purified by SCX cartridge. The cartridge waswashed with 10% MeOH in DCM and the product eluted with 10% (2M NH₃ inMeOH) in DCM. The product containing fractions were concentrated invacuo and the resultant residue was purified by FCC on silica, using agradient of 1-10% MeOH in DCM, to afford the title compound (59 mg, 86%)as a colourless oil. ¹H NMR (400 MHz, CDCl₃): 1.88-2.12 (3H, m),2.15-2.53 (5H, m), 2.69 (3H, s), 3.28 (1H, t, J=7.8 Hz), 4.01-4.15 (1H,m), 6.97 (1H, d, J=8.4 Hz), 8.50 (1H, s).

e.(1S,4R)-4-[8-Methyl-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 105e)

A mixture of Intermediate A (44 mg, 0.267 mmol) and sodium hydride (60%in mineral oil, 29 mg, 0.729 mmol) in anhydrous DMF (1 mL) was stirredat RT for 20 min under argon atmosphere. To the reaction mixture wasadded a solution of Intermediate 105d (57 mg, 0.243 mmol) in anhydrousDMF (2 mL) and stirring at 60° C. was continued for 2.5 h. After coolingto RT, the reaction mixture was diluted with EtOAc and poured intoice-water. The aqueous phase was extracted with EtOAc (×3) and thecombined organic layers were dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by SCX cartridge by washing thecartridge with 10% MeOH in DCM and eluting the product with 10% (2M NH₃in MeOH) in DCM and then by FCC on silica, using 10% MeOH in DCMfollowed by 10% [2M NH₃ in MeOH] in DCM, to give the title compound (53mg, 58%). LCMS (Method 1): Rt 0.38, 1.54 min, m/z 378 [MH⁺].

f.1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[8-methyl-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 105).

A mixture of Intermediate 105e (53 mg, 0.14 mmol),(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (for reference procedure see SyntheticCommunications, 2009, 39, 3999-4009, which is incorporated herein byreference in its entirety; 67 mg, 0.168 mmol) and DIPEA (49 μL, 4, 0.28mmol) in DMF (2 mL) was stirred at 100° C. for 1.5 h under argonatmosphere. After cooling to RT, the reaction mixture was diluted withEtOAc and washed with brine. The organic layer was dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-100% EtOAc in cyclohexane followed by 10%[2M NH₃ in MeOH] in EtOAc. The product containing fractions wereconcentrated in vacuo and the resultant residue was purified by HPLC(C18 Phenomenex Gemini column, 5-98% gradient MeCN in H₂O, 0.1% NH₄OH),to afford the title compound (52 mg, 74%). LCMS (Method 5): Rt 3.76 min,m/z 633 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.23 (9H, s), 1.75-2.30 (13H,m), 2.32 (3H, s), 2.48 (3H, s), 3.19 (1H, br s), 4.72-4.83 (1H, m),5.30-5.38 (1H, m), 6.28 (1H, s), 7.03-7.11 (2H, m), 7.20-7.36 (8H, m),8.00 (1H, s), 8.11 (1H, s).

Example 1061-{5-tert-Butyl-2-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]urea(Intermediate 106a)

A mixture of Intermediate 3c (100 mg, 0.28 mmol), Intermediate 33a (116mg, 0.28 mmol) and DIPEA (96 μL, 0.55 mmol) in dioxane (3 mL) wasstirred at 80° C. for 16 h. After cooling, the reaction mixture waspartitioned between water and EtOAc. The aqueous phase was extractedwith EtOAc (×3) and the combined organic layers were washed with brine,dried (MgSO₄) and concentrated in vacuo. The resultant residue waspurified by FCC on silica, using a gradient of 1-10% MeOH in DCM, toafford the title compound (156 mg, 88%). LCMS (Method 4): Rt 3.07 min,m/z 635 [MH⁺].

b.1-[5-tert-Butyl-2-(4-chloromethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 106b)

To an ice-bath cooled solution of Intermediate 106a (150 mg, 0.25 mmol)in DCM (3 mL) was added DIPEA (107 μL, 0.61 mmol) followed bymethanesulfonyl chloride (29 μL, 0.37 mmol). The reaction mixture wasstirred for 2 h. After warming to RT, additional amount of DIPEA (65 μL)and methanesulfonyl chloride (30 μL) were added and stirring wascontinued for 2 h. The reaction mixture was partitioned between DCM andwater. The aqueous phase was extracted with DCM (×3) and the combinedorganic layers were washed with brine, dried (MgSO₄) and concentrated invacuo to afford the title compound (Quantitative). Product used in thefollowing step without further purification. LCMS (Method 4): Rt 3.59min, m/z 653 [MH⁺].

c.1-{5-tert-Butyl-2-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 106).

To a solution of Intermediate 106b (0.25 mmol) in THF (2.5 mL) was addedDIPEA (130 μL, 0.75 mmol) followed by N-methylpiperazine (83 μL, 0.75mmol). The reaction mixture was heated at 50° C. for 18 h in a sealedtube, then cooled and partitioned between EtOAc and water. The aqueousphase was extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-10% [2M NH₃ in MeOH] in DCM followed by HPLC (C18 X-select column,10-98% gradient MeCN in H₂O, 0.1% HCO₂H), to give the title compound (13mg, 7%). LCMS (Method 5): Rt 3.44 min, m/z 717 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 1.27 (9H, s), 1.57-1.66 (2H, m), 1.68-1.77 (4H, m), 1.79-1.95(2H, m), 1.98-2.19 (5H, m), 2.22-2.46 (8H, m), 3.14 (4H, t, J=5.3 Hz),3.49 (2H, s), 4.76-4.85 (1H, m), 5.54 (1H, t, J=4.4 Hz), 6.33 (1H, s),7.09 (1H, d, J=8.6 Hz), 7.17 (1H, dd, J=9.8, 2.2 Hz), 7.25-7.47 (8H, m),7.59-7.65 (2H, m), 8.11 (1H, s).

Example 1071-(3-tert-Butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

To a solution of Intermediate 3c (100 mg, 0.27 mmol) in dioxane (3 mL)was added DIPEA (90 μL, 0.55 mmol) followed by(3-tert-butyl-1′-methyl-1′H-[1,4]bipyrazolyl-5-yl)-carbamic acid2,2,2-trichloro-ethyl ester (for reference procedure see for exampleU.S. Pat. No. 6,492,529, which is incorporated herein by reference; 109mg, 0.27 mmol). The reaction mixture was heated at 60° C. for 18 h, thencooled and poured into water. The aqueous phase was extracted with EtOAc(×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resultant residue was purified byFCC on silica, using a gradient of 0-10% MeOH in DCM followed by MDAP(Method 7) purification, to give the title compound (100 mg, 61%). LCMS(Method 5): Rt 4.05 min, ink 609 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.24(9H, s), 1.54-1.66 (2H, m), 1.67-1.76 (4H, m), 1.81-2.18 (4H, m), 3.13(4H, t, J=5.2 Hz), 3.86 (3H, s), 4.78-4.87 (1H, m), 5.55 (1H, t, J=4.1Hz), 6.26 (1H, s), 7.10-7.18 (2H, m), 7.25-7.41 (4H, m), 7.58-7.64 (3H,m), 7.98-8.02 (2H, m).

Example 1081-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a.3-tert-Butyl-1′-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1′H-[1,4′]bipyrazolyl-5-ylamine(Intermediate 108a)

To a mixture of4-iodo-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazole (for referenceprocedure see for example WO 2010/139731, which is incorporated hereinby reference; 1.54 g, 4.81 mmol), 5-tert-butyl-2H-pyrazol-3-ylamine (668mg, 4.81 mmol), copper (I) iodide (45 mg, 0.24 mmol) and K₂CO₃ (1.39 g,10.1 mmol) was added a solution of toluene (5 mL), previously degassedby using a stream of argon.(R,R)-(−)-N,N′-Dimethyl-1,2-cyclohexanediamine (151 μL, 0.96 mmol) wasthen added and the reaction mixture was heated at 150° C. for 2.5 hunder microwave irradiation. The crude reaction mixture was poured intowater and extracted with EtOAc (×3). The combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-100% EtOAc in cyclohexane, to give the title compound (1.29 g, 81%).LCMS (Method 1): Rt 2.31 min, m/z 334 [MH⁺].

b.{3-tert-Butyl-1′-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1′H-[1,4′]bipyrazolyl-5-yl}-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 108b)

To a mixture of Intermediate 108a (1.29 g, 3.87 mmol) in water (5 mL)and EtOAc (13 mL) was added NaOH (310 mg, 7.74 mmol). After 10 minstirring, 2,2,2-trichloroethyl chloroformate (640 μL, 4.65 mmol) wasadded and the reaction mixture was stirred at RT for 1 h. The aqueouslayer was extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-75% EtOAc in cyclohexane, to afford the title compound (1.24 g, 63%).LCMS (Method 4): Rt 3.92 min, m/z 508, 510 [MH⁺].

c.1-{3-tert-Butyl-1′-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1′H-[1,4′]bipyrazolyl-5-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 108c)

The title compound was prepared starting from Intermediate 3c andIntermediate 108b using analogous procedures to those described inIntermediate 106a. LCMS (Method 4): Rt 3.27 min, m/z 723.5 [MH⁺].

d.1-[3-tert-Butyl-1′-(2-hydroxy-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 108d)

To a solution of Intermediate 108c (170 mg, 0.23 mmol) in MeOH (2.5 mL)was added pyridinium p-toluenesulfonate (118 mg, 0.47 mmol) and thereaction mixture was heated at 60° C. for 2 h. The resultant mixture waspoured into water and a saturated aqueous solution of NaHCO₃ was added.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of0-10% MeOH in DCM, to give the title compound (105 mg, 72%). LCMS(Method 1): Rt 2.96 min, m/z 639 [MH⁺].

e. Methanesulfonic acid2-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-[1,4′]bipyrazolyl-1′-yl)-ethylester (Intermediate 108e)

To an ice-bath cooled solution of Intermediate 108d (105 mg, 0.16 mmol)in DCM (2 mL) was added DIPEA (43 μL, 0.25 mmol) followed bymethanesulfonyl chloride (15 μL, 0.20 mmol). The reaction mixture wasstirred for 2 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the following step withoutfurther purification. LCMS (Method 4): Rt 3.09 min, m/z 717 [MH⁺].

f.1-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 108).

To a solution of Intermediate 108e (0.20 mmol) in THF (2 mL) was addeddimethylamine (2M in MeOH, 0.8 mL, 1.6 mmol) and stirring at RT wascontinued for 48 h. The crude reaction mixture was partitioned betweenEtOAc and water. The aqueous phase was extracted with EtOAc (×3) and thecombined organic layers were washed with brine, dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-10% [2M NH₃ in MeOH] in DCM followed byMDAP (Method 7) purification, to give the title compound (20 mg, 15%).LCMS (Method 5): Rt 3.34 min, m/z 666 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):1.24 (9H, s), 1.54-1.65 (2H, m), 1.67-1.77 (4H, m), 1.81-2.13 (4H, m),2.16 (6H, s), 2.67 (2H, t, J=6.5 Hz), 3.13 (4H, t, J=5.3 Hz), 4.20 (2H,t, J=6.5 Hz), 4.79-4.87 (1H, m), 5.55 (1H, t, J=4.5 Hz), 6.26 (1H, s),7.11-7.19 (2H, m), 7.26-7.41 (4H, m), 7.58-7.64 (3H, m), 7.99-8.05 (2H,m).

Example 109N-[5-tert-Butyl-2-methoxy-3-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamideformate salt

A mixture of Intermediate 5c (122 mg, 0.33 mmol), Intermediate 104a (150mg, 0.33 mmol) and DIPEA (87 μL, 0.50 mmol) in dioxane (2 mL) wasstirred at 60° C. for 18 h and then at 85° C. for 48 h. The volatileswere concentrated in vacuo and the resultant residue was purified byMDAP (Method 7) to afford the title compound (88 mg, 40%). LCMS (Method5): Rt 3.41 min, m/z 662 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.24 (9H, s),1.81-2.27 (10H, m), 2.28-2.40 (1H, m), 3.04 (3H, s), 3.11-3.18 (2H, m),3.67 (3H, s), 3.99 (1H, t, J=8.3 Hz), 4.83-4.99 (1H, m), 5.43 (1H, t,J=4.5 Hz), 6.93 (1H, d, J=2.3 Hz), 7.25-7.44 (7H, m), 7.76 (1H, d,J=10.3 Hz), 8.05 (1H, s), 8.15 (1H, s), 8.18 (1H, d, J=2.8 Hz), 8.27(1H, d, J=2.1 Hz).

Example 1101-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 2-(5-Amino-3-tert-butyl-pyrazol-1-yl)-ethanol (Intermediate 110a)

2-Hydrazino-ethanol (2.98 mL, 44.0 mmol) was added to a stirred solutionof 4,4-dimethyl-3-oxo-pentanenitrile (5.0 g, 40.0 mmol) in EtOH (IMSgrade, 40 mL) at RT followed by concentrated HCl (0.4 mL). The reactionmixture was heated at reflux temperature for 18 h then cooled andconcentrated in vacuo. The resultant residue was triturated with pentaneto give the title compound (7.4 g, quantitative) as a yellow solid. LCMS(Method 3): Rt 0.81 min, m/z 184 [MH⁺].

b. [5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-carbamic acid2,2,2-trichloro-ethyl ester (Intermediate 110b)

2,2,2-Trichloroethyl chloroformate (3.24 mL, 23.5 mmol) was addeddropwise over 5 min to a solution of Intermediate 110a (4.11 g, 22.4mmol) in NaOH (1M in water, 33.6 mL, 33.6 mmol) and EtOAc (35 mL) cooledat 0° C. under argon atmosphere. The reaction mixture was stirred at RTfor 5 h. Additional 2,2,2-trichloroethyl chloroformate (462 μL) wasadded and stirring at RT was continued for 16 h. Additional NaOH (1M inwater, 15 mL) and 2,2,2-trichloroethyl chloroformate (462 μL) were addedand stirring at RT was continued for 1 h. The aqueous layer wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (Na₂SO₄) and concentrated in vacuo. The resultantresidue was dissolved in cyclohexane (100 mL) and left to stand for 5days. The resulting suspension was filtered and the solid collected byfiltration washing with additional cyclohexane affording the titlecompound (3.64 g, 45%) as a white solid. The filtrate was concentratedin vacuo and the resultant residue was purified by FCC on silica, usinga mixture of 50% EtOAc in cyclohexane, then partitioned between DCM andwater. The organic layer was dried through a phase separator andconcentrated in vacuo to afford additional title compound (1.43 g, 18%)as an orange gum. LCMS (Method 3): Rt 3.72 min, m/z 358 [MH⁺].

c.1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 110).

A mixture of Intermediate 110b (143 mg, 0.40 mmol), Intermediate 81d(1151 mg, 0.40 mmol) and DIPEA (82 μL, 0.50 mmol) in dioxane (5 mL) wasstirred at 100° C. for 4 h. After cooling, the reaction mixture wasconcentrated in vacuo and then partitioned between water and DCM. Theaqueous phase was extracted with DCM (×3) and the combined organiclayers were washed with brine, dried through a phase separator andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 3-15% MeOH in DCM followed by MDAP (Method7) purification, to afford the title compound (36 mg, 15%) as a glassywhite solid. LCMS (Method 5): Rt 4.02 min, m/z 587 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 0.92 (3H, d, J=6.3 Hz), 1.21 (9H, s), 1.44-1.57 (2H, m),1.60-1.74 (2H, m), 1.74-1.87 (2H, m), 1.88-2.22 (4H, m), 2.86-2.96 (1H,m), 3.12-3.20 (2H, m), 3.63-3.71 (2H, m), 3.95 (2H, t, J=6.0 Hz),4.82-4.91 (1H, m), 5.00 (1H, br s), 5.54 (1H, t, J=4.3 Hz), 6.07 (1H,s), 7.10 (1H, d, J=8.6 Hz), 7.22 (1H, dd, J=9.8, 2.2 Hz), 7.26-7.32 (1H,m), 7.35-7.42 (3H, m), 7.65 (1H, d, J=10.8 Hz), 7.71 (1H, d, J=2.1 Hz),8.19-8.23 (1H, m).

Example 1111-(5-tert-Butyl-isoxazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

The title compound was prepared starting from Intermediate 81d and(5-tert-butyl-isoxazol-3-yl)-carbamic acid 2,2,2-trichloro-ethyl ester(for reference procedure see WO 2006/091671, which is incorporatedherein by reference in its entirety) using analogous procedures to thosedescribed in Example 110 step c. LCMS (Method 5): Rt 4.67 min, m/z 544[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.28 (9H, s),1.44-1.57 (2H, m), 1.60-1.73 (2H, m), 1.74-1.86 (2H, m), 1.88-2.22 (4H,m), 2.86-2.94 (1H, m), 3.12-3.20 (2H, m), 4.86-4.95 (1H, m), 5.54 (1H,t, J=4.2 Hz), 6.40 (1H, s), 7.00 (1H, d, J=8.6 Hz), 7.21-7.26 (1H, m),7.27-7.33 (1H, m), 7.34-7.42 (3H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz), 7.71(1H, d, J=2.10 Hz), 9.31 (1H, s).

Example 1121-[3-tert-Butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureaformate salt

The title compound was prepared starting from Intermediate 108e andmorpholine using analogous procedures to those described in Example 108.LCMS (Method 5): Rt 3.37 min, m/z 708 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):1.24 (9H, s), 1.55-1.65 (2H, m), 1.67-1.76 (4H, m), 1.79-2.19 (4H, m),2.41 (4H, d, J=4.7 Hz), 2.72 (2H, t, J=6.7 Hz), 3.13 (4H, t, J=5.3 Hz),3.53 (4H, t, J=4.6 Hz), 4.23 (2H, t, J=6.6 Hz), 4.78-4.87 (1H, m), 5.55(1H, t, J=4.4 Hz), 6.25 (1H, s), 7.11-7.18 (2H, m), 7.25-7.41 (4H, m),7.58-7.64 (3H, m), 8.00 (1H, s), 8.05 (1H, s), 8.16 (1H, s).

Example 1131-[3-tert-Butyl-1′-(3-dimethylamino-propyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureaformate salt

a. 4-Iodo-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-pyrazole(Intermediate 113a)

To a mixture of 4-iodo-1H-pyrazole (2.0 g, 10.3 mmol) and Cs₂CO₃ (5.04g, 15.5 mmol) in MeCN (28 mL) was added2-(3-bromopropoxy)tetrahydro-2H-pyran (1.84 mL, 10.8 mmol) and themixture stirred overnight. The crude reaction mixture was poured intowater and extracted with EtOAc (×3). The combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-80% EtOAc in cyclohexane, to give the title compound (2.95 g, 81%). ¹HNMR (300 MHz, CDCl₃): 150-1.58 (4H, m), 1.65-1.90 (2H, m), 2.12 (2H, qn,J=6.4 Hz), 3.35 (1H, dt, J=10.2, 5.9 Hz), 3.46-3.54 (1H, m), 3.73 (1H,dt, J=10.2, 5.9 Hz), 3.80-3.88 (1H, m), 4.26 (2H, td, J=6.9, 1.5 Hz),4.54 (1H, dd, J=4.5, 3.1 Hz), 7.46 (1H, s), 7.50 (1H, s).

b.3-tert-Butyl-1′-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1′H-[1,4′]bipyrazolyl-5-ylamine(Intermediate 113b)

To a mixture of intermediate 113a (1.50 g, 4.46 mmol),5-tert-butyl-2H-pyrazol-3-ylamine (620 mg, 4.46 mmol), copper (I) iodide(42 mg, 0.22 mmol) and K₂CO₃ (1.29 g, 9.37 mmol) was added a solution oftoluene (4.6 mL), previously degassed by using a stream of argon.(R,R)-(−)-N,N′-Dimethyl-1,2-cyclohexanediamine (141 μL, 0.89 mmol) wasthen added and the reaction mixture was heated at 140° C. for 2.5 hunder microwave irradiation. The crude reaction mixture was poured intowater and extracted with EtOAc (×3). The combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-100% EtOAc in cyclohexane, to give the title compound (1.14 g, 73%).LCMS (Method 4): Rt 2.34 min, m/z 348 [MH⁺].

c.3-tert-Butyl-1′-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1′H-[1,4′]bipyrazolyl-5-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 113c)

To a stirred mixture of Intermediate 113b (1.14 g, 3.28 mmol) in water(6 mL) and EtOAc (12 mL) was added NaOH (263 mg, 6.57 mmol). After 10min, 2,2,2-trichloroethyl chloroformate (543 μL, 3.94 mmol) was addedand the reaction mixture was stirred at RT for 1 h. The aqueous layerwas extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-100% EtOAc in cyclohexane, to afford the title compound (1.57 g, 91%).LCMS (Method 4): Rt 3.99 min, m/z 522, 524 [MH⁺].

d.1-{3-tert-Butyl-1′-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1′H-[1,4′]bipyrazolyl-5-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 113d)

The title compound was prepared starting from Intermediate 3c andIntermediate 113c using analogous procedures to those described inIntermediate 106a. LCMS (Method 4): Rt 3.34 min, m/z 737 [MH⁺].

e.1-[3-tert-Butyl-1′-(3-hydroxy-propyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 113e)

To a solution of Intermediate 113d (263 mg, 0.36 mmol) in MeOH (2.5 mL)was added pyridinium p-toluenesulfonate (179 mg, 0.71 mmol) and thereaction mixture was heated at 60° C. for 3 h. The resultant mixture waspoured into water and a saturated aqueous solution of NaHCO₃ was added.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of3-10% MeOH in DCM, to give the title compound (163 mg, 70%). LCMS(Method 4): Rt 3.00 min, rink 653 [MH⁺].

f. Methanesulfonic acid3-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-[1,4′]bipyrazolyl-1′-yl)-propylester (Intermediate 113f)

To an ice-bath cooled solution of Intermediate 113e (163 mg, 0.25 mmol)in DCM (3 mL) was added DIPEA (174 μL, 1.0 mmol) followed bymethanesulfonyl chloride (39 μL, 0.50 mmol). The reaction mixture wasstirred for 1 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the following step withoutfurther purification. LCMS (Method 4): Rt 3.12 min, ink 731 [MH⁺].

g.1-[3-tert-Butyl-1′-(3-dimethylamino-propyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureaformate salt (Example 113).

To a solution of Intermediate 113f (0.125 mmol) in THF (1.5 mL) wasadded dimethylamine (2M in MeOH, 0.5 mL, 1.0 mmol) and the reactionstirred at 50° C. for 24 h. The crude reaction mixture was cooled andpartitioned between EtOAc and water. The aqueous phase was extractedwith EtOAc (×3) and the combined organic layers were washed with brine,dried (MgSO₄) and concentrated in vacuo. The resultant residue waspurified by FCC on silica, using a gradient of 0-10% [2M NH₃ in MeOH] inDCM, followed by MDAP (Method 7) purification, to give the titlecompound (10 mg, 12%). LCMS (Method 5): Rt 3.36 min, m/z 680 [MH⁺]. ¹HNMR (400 MHz, d₆-DMSO): 1.21 (9H, s), 1.54-1.65 (2H, m), 1.67-1.77 (4H,m), 1.81-1.95 (4H, m), 1.99-2.07 (4H, m) 2.08 (6H, s), 2.16 (2H, t,J=6.9 Hz), 3.10 (4H, t, J=5.2 Hz), 4.09 (2H, t, J=7.1 Hz), 4.79 (1H, td,J=8.4, 5.5 Hz), 5.51 (1H, t, J=4.5 Hz), 6.21 (1H, s), 7.09-7.14 (2H, m),7.22-7.37 (4H, m), 7.55-7.62 (3H, m), 7.97-8.01 (2H, m), 8.22 (0.4H, brs).

Example 1141-[3-tert-Butyl-1′-(3-morpholin-4-yl-propyl)-1′H-[1,4]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureaformate salt

The title compound was prepared starting from Intermediate 113f andmorpholine using analogous procedures to those described in Example 113.LCMS (Method 5): Rt 3.36 min, m/z 722 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):1.20 (9H, s), 1.54-1.60 (2H, m), 1.65-1.72 (4H, m), 1.80-1.96 (4H, m),1.98-2.10 (4H, m) 2.22 (2H, t, J=7.0 Hz), 2.24-2.30 (4H, m), 3.10 (4H,t, J=5.2 Hz), 3.50 (4H, t, J=4.6 Hz), 4.09 (2H, t, J=7.0 Hz), 4.79 (1H,td, J=8.4, 5.5 Hz), 5.51 (1H, t, J=4.5 Hz), 6.21 (1H, s), 7.10-7.15 (2H,m), 7.22-7.36 (4H, m), 7.55-7.62 (3H, m), 7.97-8.01 (2H, m), 8.22 (0.3H,br s).

Example 1151-{(1S,4R)-4-[3-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-(3-fluoro-5-morpholin-4-yl-phenyl)-urea

a. (3-Fluoro-5-morpholin-4-yl-phenyl)-carbamic acid2,2,2-trichloro-ethyl ester (Intermediate 115a)

2,2,2-Trichloroethyl chloroformate (1.05 mL, 7.65 mmol) was added to anice cold solution of 3-fluoro-5-morpholin-4-ylaniline (referenceprocedure see EP1102743; 1.0 g, 5.10 mmol) and triethylamine (1.77 mL,10.2 mmol) in THF (25 mL). The reaction mixture was stirred at RT for1.5 h, then quenched with water. The aqueous layer was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo to afford the title compound (1.89 g,99%) as a clear oil. LCMS (Method 3): Rt 3.75 min, m/z 371, 373 [MH⁺].

b.1-{(1S,4R)-4-[3-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-(3-fluoro-5-morpholin-4-yl-phenyl)-urea(Example 115).

The title compound was prepared starting from Intermediate 96c andintermediate 115a using analogous procedures to those described inExample 99. LCMS (Method 5): Rt 4.70 min, ink 614 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 0.55 (3H, d, J=6.3 Hz), 0.59 (3H, d, J=6.3 Hz), 1.35-1.53(3H, m), 1.63-1.69 (2H, m), 1.72-1.78 (1H, m), 1.82-1.99 (2H, m),2.00-2.13 (2H, m), 3.03 (4H, t, J=4.8 Hz), 3.08-3.20 (2H, m), 3.65-3.69(2H, t, J=4.8 Hz), 4.80-4.88 (1H, td, J=8.7, 5.5 Hz), 5.50 (1H, t, J=4.0Hz), 6.31 (1H, dt, J=12.4, 2.0 Hz), 6.68 (1H, br s), 6.71 (1H, d, J=8.9Hz), 6.81 (1H, dt, J=11.3, 1.9 Hz), 7.18-7.25 (2H, m), 7.29-7.37 (3H,m), 7.62 (1H, dd, J=9.8, 0.6 Hz), 7.86 (1H, d, J=2.0 Hz), 8.51 (1H, s).

Example 1161-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

A solution of Example 110 (80 mg, 0.136 mmol), DIPEA (71 μL, 0.409 mmol)and methanesulfonyl chloride (26 μL, 0.34 mmol) in DCM (3 mL) wasstirred at RT for 90 min. Additional DIPEA (71 μL) and methanesulfonylchloride (26 μL) were added and stirring was continued for 1 h. Water (1mL) and a saturated aqueous solution of NaHCO₃ (2 mL) were added and thereaction mixture was vigorously stirred for 30 min. The aqueous phasewas extracted with DCM (×3) and the combined organic layers were driedthrough a phase separator and concentrated in vacuo. The resultantresidue was dissolved in DMF (2 mL) and morpholine (36 μL, 0.41 mmol)and heated at 75° C. for 18 h. After cooling, the volatiles wereconcentrated in vacuo and the resultant residue was loaded onto an SCXcartridge. The cartridge was washed with MeOH and the product elutedwith 2M NH₃ in MeOH. The product containing fractions were combined andconcentrated in vacuo and the resultant residue was purified by MDAP(Method 7) to afford the title compound (23 mg, 26%) as a white solid.LCMS (Method 5): Rt 3.48 min, m/z 656 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.92 (3H, d, J=6.3 Hz), 1.21 (9H, s), 1.46-1.58 (2H, m), 1.63-1.73 (2H,m), 1.74-1.87 (2H, m), 1.89-2.02 (2H, m), 2.02-2.24 (2H, m), 2.35-2.43(4H, m), 2.63 (2H, t, J=7.1 Hz), 2.87-2.97 (1H, m), 3.14-3.22 (2H, m),3.55 (4H, t, J=4.5 Hz), 4.01 (2H, t, J=7.1 Hz), 4.82-4.92 (1H, m),5.51-5.57 (1H, m), 6.04 (1H, s), 7.10 (1H, d, J=8.6 Hz), 7.23 (1H, dd,J=9.8, 2.2 Hz), 7.27-7.42 (4H, m), 7.65 (1H, d, J=9.9 Hz), 7.72 (1H, s),8.37-8.45 (1H, m).

Example 1171-Cyclopropyl-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

The title compound was prepared starting from Intermediate 96c and4-nitrophenyl cyclopropylcarbamate (for reference procedure see WO2007/72158, which is incorporated herein by reference in its entirety)using analogous procedures to those described in Example 99. LCMS(Method 5): Rt 4.70 min, m/z 614 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.31-0.35 (2H, m), 0.52-0.60 (8H, m), 1.33-1.56 (3H, m), 1.63-1.70 (2H,m), 1.73-1.88 (3H, m), 1.94-2.11 (2H, m), 3.08-3.20 (2H, m), 4.78 (1H,td, J=8.6, 6.8 Hz), 5.47 (1H, t, J=3.8 Hz), 6.07 (1H, d, J=2.1 Hz), 6.24(1H, d, J=8.9 Hz), 7.15-7.22 (2H, m), 7.27-7.32 (3H, m), 7.62 (1H, d,J=9.8 Hz), 7.84 (1H, d, J=1.7 Hz), 8.12 (0.6H, br s).

Example 1181-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

A mixture of Intermediate 96c (160 mg, 0.41 mmol), Intermediate 110b(142 mg, 0.41 mmol) and DIPEA (142 μL, 0.82 mmol) in dioxane (5 mL) wasstirred at 80° C. overnight. After cooling, the reaction mixture waspartitioned between water and DCM. The aqueous phase was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resultant residue was purified byFCC on silica, using a gradient of 1-8% MeOH in DCM followed by MDAP(Method 7) purification, to afford the title compound (86 mg, 32%) as aglassy white solid. LCMS (Method 5): Rt 4.32 min, m/z 601 [MH⁺]. ¹H NMR(400 MHz, d₆-DMSO): 0.55 (3H, d, J=6.2 Hz), 0.58 (3H, d, J=6.2 Hz), 1.17(9H, s), 1.35-1.55 (3H, m), 1.63-1.69 (2H, m), 1.73-1.79 (1H, m),1.82-2.00 (2H, m), 2.00-2.13 (2H, m), 3.09-3.19 (2H, m), 3.62 (2H, brs), 3.90 (2H, t, J=5.9 Hz), 4.82 (1H, td, J=8.6, 5.7 Hz), 4.92-4.98 (1H,br s), 5.50 (1H, t, J=4.2 Hz), 6.02 (1H, s), 7.04 (1H, d, J=8.6 Hz),7.18 (1H, dd, J=9.8, 2.3 Hz), 7.20-7.25 (1H, m), 7.30-7.36 (3H, m), 7.62(1H, dd, J=9.7, 0.6 Hz), 7.86 (1H, d, J=2.1 Hz), 8.14 (1H, s).

Example 1191-{5-tert-Butyl-2-[1-(2-dimethylamino-ethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea

a. 4-Iodo-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-imidazole and5-Iodo-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-imidazole (Intermediate119a)

To an ice cold mixture of 4-iodo-1H-imidazole (1.0 g, 5.13 mmol) andsodium hydroxide (226 mg, 5.64 mmol) in DMF (10 mL) was added2-(2-bromothoxy)tetrahydro-2H-pyran (1.18 mL, 5.64 mmol) and the mixturestirred overnight. The crude reaction mixture was poured into water andextracted with EtOAc (×3). The combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo. The resultant residuewas purified by FCC on silica, using a gradient of 20-100% EtOAc incyclohexane, to give the title compound (1.50 g, 91%) as a 2:1 mixtureof regioisomers. LCMS (Method 4): Rt 2.03 min, ink 323 [MH⁺].

b.5-tert-Butyl-2-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-imidazol-4-yl}-2H-pyrazol-3-ylamine(Intermediate 119b)

To a mixture of Intermediate 119a (1.50 g, 4.66 mmol),5-tert-butyl-2H-pyrazol-3-ylamine (648 mg, 4.66 mmol), copper(I)iodide(44 mg, 0.23 mmol) and K₂CO₃ (1.35 g, 9.78 mmol) was added a solution oftoluene (10 mL), previously degassed by using a stream of argon.(R,R)-(−)-N,N′-Dimethyl-1,2-cyclohexanediamine (147 μL, 0.93 mmol) wasthen added and the reaction mixture was heated at 150° C. for 3 h undermicrowave irradiation. The crude reaction mixture was poured into waterand extracted with EtOAc (×3). The combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-100% EtOAcin cyclohexane, to give a product consisting of the title compound (550mg) in mixture with the un-reacted5-iodo-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-imidazole isomer. LCMS(Method 4): Rt 2.32 min, m/z 334 [MH⁺].

c.(5-tert-Butyl-2-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-imidazol-4-yl}-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 119c)

To a mixture of Intermediate 119b (550 mg) in water (3 mL) and EtOAc (6mL) was added NaOH (132 mg, 3.30 mmol). After 10 min stirring,2,2,2-trichloroethyl chloroformate (273 μL, 1.98 mmol) was added and thereaction mixture was stirred at RT for 2 h. The aqueous layer wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-80% EtOAcin cyclohexane, to afford the title compound (175 mg). LCMS (Method 4):Rt 4.54 min, m/z 508, 510 [MH⁺].

d.1-(5-tert-Butyl-2-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-imidazol-4-yl}-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 119d)

The title compound was prepared starting from Intermediate 3c andIntermediate 119c using analogous procedures to those described inIntermediate 106a. LCMS (Method 4): Rt 5.52 min, m/z 723 [MH⁺].

e.1-{5-tert-Butyl-2-[1-(2-hydroxy-ethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Intermediate 119e)

To a solution of intermediate 119d (135 mg, 0.19 mmol) in MeOH (2 mL)was added pyridinium p-toluenesulfonate (94 mg, 0.37 mmol) and thereaction mixture was heated at 60° C. for 3 h. The resultant mixture waspoured into water and a saturated aqueous solution of NaHCO₃ was added.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of2-10% MeOH in DCM, to give the title compound (65 mg, 53%). LCMS (Method4): Rt 2.96 min, m/z 639 [MH⁺].

f. Methanesulfonic acid2-[4-(3-tert-butyl-5-{3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-imidazol-1-yl]ethylester (Intermediate 119f)

To an ice-bath cooled solution of Intermediate 119e (65 mg, 0.10 mmol)in DCM (1.5 mL) was added DIPEA (71 μL, 0.41 mmol) followed bymethanesulfonyl chloride (16 μL, 0.20 mmol). The reaction mixture wasstirred for 1 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the following step withoutfurther purification. LCMS (Method 4): Rt 3.23 min, m/z 717 [MH⁺].

g.1-{5-tert-Butyl-2-[1-(2-dimethylamino-ethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea(Example 119).

To a solution of Intermediate 119f (0.10 mmol) in THF (2 mL) was addeddimethylamine (2M in MeOH, 0.4 mL, 0.8 mmol) and the reaction stirred at50° C. for 24 h. The crude reaction mixture was cooled and partitionedbetween EtOAc and water. The aqueous phase was extracted with EtOAc (×3)and the combined organic layers were washed with brine, dried (MgSO₄)and concentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-10% [2M NH₃ in MeOH] in DCM followed byHPLC (XBridge C18 column, 30-98% MeCN in H₂O, 0.1% NH₄OH), to give thetitle compound (12 mg, 18%). LCMS (Method 5): Rt 3.43 min, m/z 666[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.21 (9H, s), 1.54-1.60 (2H, m),1.65-1.71 (4H, m), 1.86-1.94 (2H, m), 1.95-2.05 (1H, m) 2.13 (6H, s),2.13-2.16 (1H, m), 2.55 (2H, t, J=6.3 Hz), 3.10 (4H, t, J=5.2 Hz), 4.05(2H, t, J=7.1 Hz), 4.86 (1H, td, J=8.4, 5.5 Hz), 5.51 (1H, t, J=4.5 Hz),6.32 (1H, s), 7.12 (1H, dd, J=10.0, 1.9 Hz), 7.20-7.25 (2H, m),7.28-7.36 (3H, m), 7.56-7.59 (2H, m), 7.63 (1H, d, J=1.4 Hz), 7.90 (1H,d, J=8.6 Hz), 9.63 (1H, br s).

Example 1201-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-1-Methyl-piperidine-2-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 120a)

To a solution of (S)-1-methyl-piperidine-2-carboxylic acid (250 mg, 1.74mmol) and (5-fluoro-pyridin-2-yl)-hydrazine (244 mg, 1.92 mmol) in DCM(20 mL) was added HATU (790 mg, 2.09 mmol) and DIPEA (606 μL, 3.48 mmol)and the reaction stirred for 18 h. The reaction was then heated to 45°C. for 1 h then cooled and partitioned between EtOAc and water. Theaqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of0-10% [2M NH₃ in MeOH] in DCM to give the title compound (272 mg, 62%).LCMS (Method 4): Rt 0.87 min, m/z 253 [MH⁺].

b.6-Fluoro-3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 120b)

Hexachloroethane (505 mg, 2.14 mmol) was added portionwise over 5 min atRT to a stirred mixture of Intermediate 120a (270 mg, 1.07 mmol),triethylamine (595 μL, 4.28 mmol) and triphenylphosphine (560 mg, 2.14mmol) in THF (10 mL). The reaction mixture was stirred for 1.5 h andthen diluted with methanol and loaded onto an SCX cartridge. Thecartridge was washed with MeOH and the product eluted with 2M NH₃ inMeOH and concentrated in vacuo. The resultant residue was purified byFCC on silica, using a gradient of 0-8% [2M NH₃ in MeOH] in EtOAc togive the title compound (105 mg, 42%). ¹H NMR (400 MHz, CDCl₃):1.34-1.51 (1H, m), 1.62-1.92 (5H, m), 2.00 (3H, s), 2.20 (1H, td,J=11.4, 3.7 Hz), 3.06 (1H, m), 3.87 (1H, dd, J=10.9, 3.3 Hz), 7.18 (1H,ddd, J=9.8, 7.6, 2.3 Hz), 7.71 (1H, ddd, J=9.9, 5.0, 0.7 Hz), 8.75-7.79(1H, m).

c.(1S,4R)-4-[3-((S)-1-Methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 120c)

To a suspension of sodium hydride (60% in mineral oil, 54 mg, 1.34 mmol)in DMF (1 mL) was added Intermediate A (88 mg, 0.54 mmol) and thereaction mixture was stirred for 20 min. A solution of Intermediate 120b(105 mg, 0.45 mmol) in DMF (1 mL) was added and the reaction mixture washeated at 60° C. for 90 min. After cooling, the reaction mixture wasquenched by careful addition of MeOH and then loaded onto an SCXcartridge. The cartridge was washed with MeOH and the product elutedwith 2M NH₃ in MeOH. The product containing fractions were concentratedin vacuo and the resultant residue was purified by FCC on silica, usinga gradient of 0-10% [2M NH₃ in MeOH] in DCM, to give the title compound(77 mg, 45%). ¹H NMR (400 MHz, CDCl₃): 1.38-1.51 (1H, m), 1.52-1.90 (6H,m), 1.90-2.05 (1H, m), 2.03 (3H, s), 2.04-2.15 (1H, m), 2.15-2.22 (1H,m), 2.33-2.44 (1H, m), 2.99-3.06 (1H, m), 3.82 (1H, dd, J=11.3, 3.2 Hz),3.99 (1H, dd, J=7.9, 5.1 Hz), 5.23 (1H, t, J=4.5 Hz), 7.11 (1H, dd,J=9.9, 2.2 Hz), 7.23-7.30 (1H, m), 7.34-7.41 (2H, m), 7.60 (1H, d, J=7.7Hz), 7.65 (1H, dd, J=9.9, 0.7 Hz), 8.42 (1H, d, J=2.2 Hz).

d.1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 120).

A mixture of Intermediate 120c (35 mg, 0.10 mmol), Intermediate 110b (54mg, 0.15 mmol) and DIPEA (53 μL, 4, 0.30 mmol) in dioxane (1 mL) wasstirred at 50° C. overnight. After cooling, the reaction mixture wasloaded onto an SCX cartridge. The cartridge was washed with MeOH and theproduct eluted with 2M NH₃ in MeOH. The resultant residue was purifiedby FCC on silica, using a gradient of 1-8% MeOH in DCM followed by MDAP(Method 7) purification, to afford the title compound (4 mg, 7%) as aglassy white solid. LCMS (Method 5): Rt 3.02 min, m/z 586 [MH⁺]. ¹H NMR(400 MHz, d₄-MeOD): 1.20-1.30 (2H, m), 1.25 (9H, s), 1.40-1.52 (1H, m),1.63-1.83 (3H, m), 1.85-1.92 (2H, m), 2.01 (3H, s), 2.06-2.20 (3H, m),2.24 (1H, td, J=11.7, 3.1 Hz), 2.31-2.38 (1H, m), 3.04-3.09 (1H, m),3.76-3.81 (1H, m), 3.81 (2H, t, J=5.4 Hz), 4.08 (2H, t, J=5.4 Hz), 4.98(1H, dd, J=8.1, 6.5 Hz), 5.36 (1H, t, J=3.8 Hz), 6.12 (1H, s), 7.24 (1H,t, J=7.4 Hz), 7.28-7.37 (3H, m), 7.44 (1H, d, J=7.8 Hz), 7.66 (1H, dd,J=9.9, 0.6 Hz), 8.46 (1H, d, J=1.9 Hz).

Example 1211-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. Methanesulfonic acid2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-ethylester (Intermediate 121a)

To an ice-bath cooled solution of Example 118 (43 mg, 0.07 mmol) in DCM(1.5 mL) was added DIPEA (49 μL, 0.18 mmol) followed by methanesulfonylchloride (11 μL, 0.11 mmol). The reaction mixture was stirred for 1 hand then quenched with water. The aqueous phase was extracted with DCM(×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo to afford the title compound(Quantitative). Product used in the following step without furtherpurification. LCMS (Method 4): Rt 3.38 min, m/z 679 [MH⁺].

b.1-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 121).

To a solution of Intermediate 121a (0.07 mmol) in THF (2 mL) was addedDIPEA (50 μL, 0.29 mmol) and morpholine (25 μL, 0.29 mmol) and thereaction stirred at 50° C. for 24 h. The crude reaction mixture wascooled and partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-10% [2M NH₃in MeOH] in DCM followed by MDAP (Method 7) purification, to give thetitle compound (19 mg, 39%). LCMS (Method 5): Rt 3.65 min, m/z 670[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.56 (3H, d, J=6.2 Hz), 0.59 (3H, d,J=6.2 Hz), 1.16 (9H, s), 1.37-1.55 (3H, m), 1.63-1.69 (2H, m), 1.73-1.79(1H, m), 1.85-2.00 (2H, m), 2.04-2.10 (2H, m), 2.34 (4H, t, J=4.5 Hz),2.57 (2H, t, J=7.2 Hz), 3.09-3.19 (2H, m), 3.50 (4H, t, J=4.5 Hz), 3.95(2H, t, J=7.2 Hz), 4.82 (1H, td, J=8.6, 5.7 Hz), 5.50 (1H, t, J=4.2 Hz),5.99 (1H, s), 6.92 (1H, d, J=8.6 Hz), 7.18 (1H, dd, J=9.8, 2.3 Hz),7.20-7.26 (1H, m), 7.30-7.36 (3H, m), 7.62 (1H, dd, J=9.7, 0.6 Hz), 7.86(1H, d, J=2.1 Hz), 8.19 (1H, s).

Example 1221-{(1S,4R)-4-[3-(8-Aza-bicyclo[3.2.1]oct-8-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-ureaformate salt

a. 8-Aza-bicyclo[3.2.1]octane-8-carbonyl chloride (Intermediate 122a)

To a cooled (10° C.) solution 8-aza-bicyclo[3.2.1]octane (295 mg, 2.00mmol) and pyridine (486 μL, 6.02 mmol) in DCM (10 mL) was addedtriphosgene (595 mg, 2.00 mmol) portionwise. The reaction was allowed toreach room temperature and stirred overnight. The mixture was quenchedwith HCl (1M aqueous, 10 mL) and stirred for 30 min. The aqueous phasewas extracted with DCM (×3) and the combined organic layers were washedwith HCl (1M aqueous), brine, dried (MgSO₄) and concentrated in vacuo,to give the title compound (244 mg, 70%). ¹H NMR (400 MHz, CDCl₃):1.46-1.70 (4H, m), 1.72-1.92 (5H, m), 2.04-2.11 (2H, m), 4.39-4.44 (2H,m).

b. 8-Aza-bicyclo[3.2.1]octane-8-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 122b)

To a solution of Intermediate 122a (240 mg, 1.38 mmol) and(5-fluoro-pyridin-2-yl)-hydrazine (176 mg, 1.38 mmol) in DCM (10 mL) wasadded DIPEA (721 μL, 4.15 mmol) and the reaction stirred for 5 days. Thereaction was then partitioned between DCM and water. The aqueous phasewas extracted with DCM (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-10% MeOH inDCM to give the title compound (170 mg, 47%). LCMS (Method 3): Rt 2.31min, m/z 265 [MH⁺].

c.3-(8-Aza-bicyclo[3.2.1]oct-8-yl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 122c)

Hexachloroethane (296 mg, 1.25 mmol) was added portionwise over 5 min atRT to a stirred mixture of Intermediate 122b (165 mg, 0.62 mmol),triethylamine (350 μL, 2.50 mmol) and triphenylphosphine (327 mg, 1.25mmol) in THF (10 mL). The reaction mixture was stirred for 3.5 h andthen heated to 60° C. overnight. The temperature was increased to 70° C.for 5 days, then cooled and concentrated in vacuo. The residue was takenup in dioxane, and re-treated with hexachloroethane (150 mg, 0.63 mmol)and triethylamine (200 μL, 1.43 mmol) at 115° C. overnight. The mixturewas cooled and concentrated in vacuo. The residue was taken up inmethanol and loaded onto an SCX cartridge. The cartridge was washed withMeOH and the product eluted with 2M NH₃ in MeOH and concentrated invacuo to give the title compound (117 mg, 76%). LCMS (Method 3): Rt 2.88min, ink 247 [MH⁺].

d.(1S,4R)-4-[3-(8-Aza-bicyclo[3.2.1]oct-8-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 122d)

To a suspension of sodium hydride (60% in mineral oil, 51 mg, 1.3 mmol)in DMF (1.5 mL) was added Intermediate A (73 mg, 0.45 mmol) followed byintermediate 122c (110 mg, 0.45 mmol) and the reaction mixture washeated at 60° C. for 1 h. After cooling, the reaction mixture wasquenched by careful addition of NH₄Cl (saturated aqueous) and theaqueous phase was extracted with EtOAc (×3). The combined organic layerswere washed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-10% [2M NH₃ in MeOH] in DCM to give the title compound (98 mg, 56%).LCMS (Method 3): Rt 2.26 min, m/z 390 [MH⁺].

e.1-{(1S,4R)-4-[3-(8-Aza-bicyclo[3.2.1]oct-8-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-ureaformate salt (Example 122).

The titled compound was prepared using Intermediate 95c and Intermediate122d following the procedures described in Example 95. LCMS (Method 5):Rt 3.55 min, m/z 318.5 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.27 (9H, s),1.46-1.58 (3H, m), 1.63-1.79 (3H, m), 1.87-2.16 (8H, m), 2.19 (6H, s),2.61 (2H, t, J=5.9 Hz), 3.99 (2H, m), 4.08 (2H, t, J=5.9 Hz), 4.81 (1H,m), 5.52 (1H, m), 6.32 (1H, s), 6.96 (1H, m), 7.05-7.17 (4H, m),7.25-7.42 (5H, m), 7.56-7.61 (2H, m), 8.14 (1H, s), 8.19 (1H, s).

Example 1231-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((R)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

a.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((R)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 123a)

The title compound was prepared from (R)-2-methyl piperidine usinganalogous procedures to those described for the preparation ofIntermediate 95e. LCMS (Method 3): Rt 3.63 min, m/z 679 [MH⁺].

b.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((R)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt (Example 123).

To a solution of Intermediate 123a (108 mg, 0.159 mmol) and DIPEA (0.083mL, 0.48 mmol) in DCM (4 mL) was added methanesulfonyl chloride (36.5mg, 0.318 mmol) and the resulting yellow solution stirred at RT for 20min. Water (2 mL) and sat. aq. NaHCO₃ solution (2 mL) were added, thenthe aqueous extracted with DCM (4 mL). The combined organics were passedthrough a hydrophobic frit and concentrated in vacuo to leave a yellowsolid. The solid was dissolved in THF (2 mL), then dimethylamine (2 M inTHF, 1.6 mL, 3.2 mmol) added, and the mixture stirred at 60° C. in asealed vial for 18 h. The cooled solution was concentrated in vacuo,redissolved in MeOH (1 mL), applied to an SCX-2 cartridge (5 g), washedwith MeOH (20 mL) and eluted with 2 M NH₃ in MeOH (20 mL); concentrationin vacuo gave a glassy yellow solid (98 mg). MDAP (Method 7) gave a paleyellow solid (63 mg). Additional purification by HPLC (Gemini C18,15-65% MeCN in water, 0.1% HCO₂H, 20 min, ×2) gave the title compound asa white solid (18.6 mg, 17%). LCMS (Method 5): Rt 3.62 min, m/z 706.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.88 (3H, d, J=6.3 Hz), 1.28 (9H, s),1.48-1.56 (2H, m), 1.65-1.71 (2H, m), 1.76-1.96 (4H, m), 2.00-2.14 (2H,m), 2.17 (6H, s), 2.59 (2H, t, J=5.8 Hz), 2.95 (1H, ddd, J=12.2, 8.1,4.8 Hz), 3.18 (1H, dt, J=12.1, 4.3 Hz), 3.26-3.29 (1H, m), 4.07 (2H, t,J=5.8 Hz), 4.81 (1H, td, J=8.6, 5.6 Hz), 5.53 (1H, t, J=4.3 Hz), 6.31(1H, s), 6.95 (1H, dd, J=8.4, 2.2 Hz), 7.09 (2H, m), 7.18 (1H, dd,J=9.8, 2.2 Hz), 7.25-7.41 (6H, m), 7.64 (1H, d, J=9.9 Hz), 7.70 (1H, d,J=2.1 Hz), 8.34 (1H, s), 8.50 (0.3H, s).

Example 1241-[3-tert-Butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.1-{3-tert-Butyl-1′-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1′H-[1,4′]bipyrazolyl-5-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 124a)

A mixture of Intermediate 96c (200 mg, 0.51 mmol), Intermediate 108b(261 mg, 0.51 mmol) and DIPEA (178 μL, 1.02 mmol) in dioxane (5 mL) wasstirred at 80° C. overnight. After cooling, the reaction mixture waspartitioned between water and DCM. The aqueous phase was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resultant residue was purified byFCC on silica, using a gradient of 1-10% MeOH in DCM to afford the titlecompound (364 mg, 95%) as a glassy white solid %). LCMS (Method 4): Rt3.69 min, m/z 751 [MH⁺].

b.1-[3-tell-Butyl-1′-(2-hydroxy-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 124b)

To a solution of Intermediate 124a (239 mg, 0.32 mmol) in MeOH (3.5 mL)was added pyridinium p-toluenesulfonate (160 mg, 0.64 mmol) and thereaction mixture was heated at 60° C. for 3 h. The resultant mixture waspoured into water and a saturated aqueous solution of NaHCO₃ was added.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of3-10% MeOH in DCM, to give the title compound (174 mg, 82%). LCMS(Method 4): Rt 3.22 min, m/z 667 [MH⁺].

c. Methanesulfonic acid2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-[1,4′]bipyrazolyl-1′-yl]-ethylester (Intermediate 124c)

To an ice-bath cooled solution of Intermediate 124b (174 mg, 0.26 mmol)in DCM (3 mL) was added DIPEA (182 μL, 1.0 mmol) followed bymethanesulfonyl chloride (41 μL, 0.52 mmol). The reaction mixture wasstirred for 1 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the following step withoutfurther purification. LCMS (Method 4): Rt 3.47 min, m/z 746 [MH⁺].

d.1-[3-tert-Butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 124).

To a solution of Intermediate 124c (0.13 mmol) in THF (2.5 mL) was addedDIPEA (90 μL, 0.52 mmol) and morpholine (45 μL, 0.52 mmol) and thereaction stirred at 50° C. for 24 h. The crude reaction mixture wascooled and partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-10% [2M NH₃in MeOH] in DCM, followed by MDAP (Method 7) purification, to give thetitle compound (26 mg, 26%). LCMS (Method 5): Rt 3.70 min, m/z 736[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.55 (3H, d, J=6.2 Hz), 0.58 (3H, d,J=6.2 Hz), 1.20 (9H, s), 1.34-1.54 3H, m), 1.63-1.68 (2H, m), 1.72-1.86(2H, m), 1.89-1.97 (1H, m), 2.01-2.07 (2H, m), 2.37 (4H, t, J=4.4 Hz),2.69 (2H, t, J=6.7 Hz), 3.08-3.18 (2H, m), 3.49 (4H, t, J=4.6 Hz), 4.19(2H, t, J=6.7 Hz), 4.80 (1H, dt, J=8.6, 5.6 Hz), 5.49 (1H, t, J=4.3 Hz),6.22 (1H, s), 7.11 (1H, d, J=8.6 Hz), 7.16 (1H, dd, J=9.8, 2.2 Hz),7.19-7.25 (1H, m), 7.28-7.33 (3H, m), 7.59 (1H, s), 7.62 (1H, d, J=9.6Hz), 7.84 (1H, d, J=1.9 Hz), 7.96 (1H, s), 8.02 (1H, s), 8.14 (0.6H, brs).

Example 1251-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

To a solution of Intermediate 124c (0.13 mmol) in THF (2.5 mL) was addeddimethylamine (2M in MeOH, 1.3 mL, 2.6 mmol) and the reaction stirred at50° C. for 24 h. The crude reaction mixture was cooled and partitionedbetween EtOAc and water. The aqueous phase was extracted with EtOAc (×3)and the combined organic layers were washed with brine, dried (MgSO₄)and concentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 2-10% [2M NH₃ in MeOH] in DCM, followed byMDAP (Method 7) purification, to give the title compound (26 mg, 29%).LCMS (Method 5): Rt 3.68 min, m/z 694 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.55 (3H, d, J=6.2 Hz), 0.58 (3H, d, J=6.2 Hz), 1.20 (9H, s), 1.34-1.543H, m), 1.63-1.68 (2H, m), 1.72-1.86 (2H, m), 1.89-1.97 (1H, m),2.01-2.07 (2H, m), 2.23 (6H, br s), 2.77 (2H, br s), 3.08-3.18 (2H, m),4.22 (2H, br s), 4.80 (1H, dt, J=8.6, 5.6 Hz), 5.49 (1H, t, J=4.3 Hz),6.22 (1H, s), 7.11 (1H, d, J=8.6 Hz), 7.16 (1H, dd, J=9.8, 2.2 Hz),7.19-7.25 (1H, m), 7.28-7.33 (3H, m), 7.60 (1H, s), 7.62 (1H, d, J=9.6Hz), 7.84 (1H, d, J=1.9 Hz), 7.98 (1H, s), 8.02 (1H, s).

Example 1261-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea

a. (5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid2,2,2-trichloro-ethyl ester (Intermediate 126a)

A solution of 5-tert-butyl-2-methyl-2H-pyrazol-3-ylamine (0.5 g, 3.26mmol) in EtOAc (10 mL) was treated with aqueous NaOH (1M, 5.87 mmol),followed by 2,2,2-trichloroethyl chloroformate (0.54 mL, 3.92 mmol) andthe reaction mixture was stirred at RT for 1 h. The mixture waspartitioned between EtOAc (10 mL) and water (2×10 mL). The organic layerwas dried (MgSO₄), filtered and concentrated in vacuo. The residue waspurified by FCC, using 0-100% EtOAc in cyclohexane to afford the titlecompound as a pale orange gum (0.915 g, 86%). LCMS (Method 3): Rt 3.88min, m/z 328/330 [MH⁺].

b.1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea(Example 126).

A solution of intermediate 126a (70 mg, 0.21 mmol), intermediate 81d (80mg, 0.21 mmol) and DIPEA (55 μL, 0.32 mmol) in dioxane (1 mL) was heatedat 70° C. for 18 h. The mixture was triturated with diethyl ether (1 mL)and the solid obtained was purified by MDAP (Method 7) to afford thetitle compound as a glassy solid (25 mg, 21%). LCMS (Method 5): Rt 4.19min, m/z 557.3 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.1 Hz),1.20 (9H, s), 1.44-1.57 (2H, m), 1.61-1.73 (2H, m), 1.74-1.87 (2H, m),1.87-2.03 (2H, m), 2.03-2.22 (2H, m), 2.87-2.95 (1H, m), 3.13-3.20 (1H,m), 3.39 (1H, m, obscured by water), 3.57 (3H, s), 4.83-4.91 (1H, m),5.54 (1H, t, J=4.0 Hz), 6.02 (1H, s), 6.93 (1H, d, J=8.9 Hz), 7.22 (1H,dd, J=9.8 Hz), 7.26-7.32 (1H, m), 7.35-7.42 (3H, m), 7.65 (1H, dd,J=9.7, 1.0 Hz), 7.70-7.73 (1H, m), 8.28 (1H, s).

Example 1271-[5-tert-Butyl-2-(2-dimethylamino-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a. Methanesulfonic acid2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-ethylester (Intermediate 127a)

To a solution of Example 110 (176 mg, 0.300 mmol) and DIPEA (0.157 mL,0.900 mmol) in DCM (5 mL) at 0° C. was added methanesulfonyl chloride(0.047 mL, 0.600 mmol) and the resulting orange solution stirred at 0°C. for 30 min. Water (2 mL) and sat. aq. NaHCO₃ solution (2 mL) wereadded and the mixture shaken. The aqueous was extracted with DCM (5 mL)then the combined organics passed through a hydrophobic frit andconcentrated in vacuo to leave the title compound as a yellow gum (199mg, 100%). LCMS (Method 3): Rt 3.59 min, m/z 665 [MH⁺].

b.1-[5-tert-Butyl-2-(2-dimethylamino-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 127).

A yellow solution of Intermediate 127a (0.100 mmol) and dimethylamine(2M in THF, 1.0 mL, 2.0 mmol) in THF (1 mL) was stirred in a sealed vialat 60° C. for 16 h. The cooled solution was concentrated in vacuo,redissolved in MeOH (2 mL), applied to an SCX-2 cartridge (5 g) andwashed with MeOH (15 mL). The product was eluted with 2M NH₃ in MeOH (15mL); concentration in vacuo left a yellow film. MDAP (Method 7) gave thetitle compound as an off-white solid (42 mg, 62%). LCMS (Method 5): Rt3.43 min, m/z 614.4 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3Hz), 1.21 (9H, s), 1.46-1.56 (2H, m), 1.63-1.72 (2H, m), 1.76-1.85 (2H,m), 1.92-2.01 (2H, m), 2.03-2.11 (1H, m), 2.15-2.19 (1H, m), 2.21 (6H,s), 2.61 (2H, t, J=6.9 Hz), 2.91 (1H, ddd, J=12.2, 9.2, 4.0 Hz), 3.17(1H, dt, J=12.2, 4.3 Hz), 3.28-3.36 (1H, m), 3.99 (2H, t, J=6.9 Hz),4.87 (1H, td, J=8.5, 6.2 Hz), 5.53 (1H, t, J=4.1 Hz), 6.03 (1H, s), 6.97(1H, d, J=8.7 Hz), 7.21 (1H, dd, J=9.8, 2.2 Hz), 7.29 (1H, td, J=7.3,2.0 Hz), 7.34-7.41 (3H, m), 7.65 (1H, dd, J=9.8, 0.8 Hz), 7.71 (1H, d,J=2.1 Hz), 8.17 (1.4H, s), 8.48 (1H, s).

Example 1281-[5-tert-Butyl-2-(2-piperidin-1-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A yellow solution of Intermediate 127a (0.100 mmol) and piperidine(0.049 mL, 0.50 mmol) in dry DMF (2 mL) was stirred at 75° C. for 2.5 h.The cooled solution was concentrated in vacuo, redissolved in MeOH (2mL), applied to an SCX-2 cartridge (2 g) and washed with MeOH (20 mL).The product was eluted with 2M NH₃ in MeOH (15 mL); concentration invacuo left a yellow solid. MDAP (Method 7) gave the title compound as anoff-white solid (37 mg, 52%). LCMS (Method 5): Rt 3.68 min, m/z 654.5[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.20 (9H, s),1.33-1.38 (2H, m), 1.45-1.55 (6H, m), 1.63-1.72 (2H, m), 1.75-1.86 (2H,m), 1.89-2.02 (2H, m), 2.04-2.12 (1H, m), 2.14-2.21 (1H, m), 2.40 (4H,t, J=4.7 Hz), 2.61 (2H, t, J=7.1 Hz), 2.91 (1H, ddd, J=12.2, 9.2, 4.2Hz), 3.16 (1H, dt, J=12.0, 4.3 Hz), 3.32 (1H, m), 3.99 (2H, t, J=7.1Hz), 4.87 (1H, td, J=8.5, 5.7 Hz), 5.54 (1H, t, J=4.3 Hz), 6.04 (1H, s),6.95 (1H, d, J=8.6 Hz), 7.22 (1H, dd, J=9.8, 2.2 Hz), 7.29 (1H, td,J=7.2, 1.8 Hz), 7.34-7.41 (3H, m), 7.65 (1H, dd, J=9.8, 0.8 Hz), 7.71(1H, d, J=2.1 Hz), 8.16 (1.4H, s), 8.29 (1H, s).

Example 1291-{5-tert-Butyl-2-[2-(4-methyl-piperazin-1-yl)-ethyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A yellow solution of Intermediate 127a (0.100 mmol) and N-methylpiperazine (0.056 mL, 0.50 mmol) in dry DMF (2 mL) was stirred at 75° C.for 2.5 h. The cooled solution was concentrated in vacuo, redissolved inMeOH (2 mL), applied to an SCX-2 cartridge (5 g) and washed with MeOH(20 mL). The product was eluted with 2M NH₃ in MeOH (15 mL);concentration in vacuo left an orange solid. MDAP (Method 7) gave thetitle compound as an off-white solid (12 mg, 17%). LCMS (Method 5): Rt3.36 min, m/z 669.5 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3Hz), 1.20 (9H, s), 1.49-1.56 (2H, m), 1.63-1.72 (2H, m), 1.75-1.85 (2H,m), 1.91-2.02 (2H, m), 2.04-2.10 (1H, m), 2.12 (3H, s), 2.14-2.21 (1H,m), 2.29 (4H, br s), 2.40 (4H, br s), 2.60 (2H, t, J=7.1 Hz), 2.91 (1H,ddd, J=12.2, 9.0, 4.0 Hz), 3.17 (1H, dt, J=12.0, 4.3 Hz), 3.28-3.36 (1H,m), 3.97 (2H, t, J=7.1 Hz), 4.87 (1H, td, J=8.5, 5.7 Hz), 5.54 (1H, t,J=4.3 Hz), 6.04 (1H, s), 6.95 (1H, d, J=8.6 Hz), 7.22 (1H, dd, J=9.8,2.1 Hz), 7.29 (1H, td, J=7.2, 1.7 Hz), 7.34-7.41 (3H, m), 7.65 (1H, dd,J=9.8, 0.8 Hz), 7.71 (1H, d, J=2.1 Hz), 8.20 (1H, s), 8.27 (1H, s).

Example 1301-[5-tert-Butyl-2-(3-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea formate salt

a.1-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 130a)

A mixture of Intermediate 96c (150 mg, 0.38 mmol), Intermediate 29c (161mg, 0.38 mmol) and DIPEA (133 μL, 0.77 mmol) in dioxane (4 mL) wasstirred at 80° C. for 7 hours. After cooling, the reaction mixture waspartitioned between water and DCM. The aqueous phase was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resultant residue was purified byFCC on silica, using a gradient of 1-10% MeOH in DCM to afford the titlecompound (364 mg, 95%) as a glassy white solid %). LCMS (Method 4): Rt3.50 min, m/z 663 [MH⁺].

b. Methanesulfonic acid3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzylester (Intermediate 130b)

To an ice-bath cooled solution of Intermediate 130a (175 mg, 0.26 mmol)in DCM (2.5 mL) was added DIPEA (184 μL, 1.0 mmol) followed bymethanesulfonyl chloride (41 μL, 0.52 mmol). The reaction mixture wasstirred for 1 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the following step withoutfurther purification. LCMS (Method 4): Rt 3.72 min, m/z 741 [MH⁺].

c.1-[5-tert-Butyl-2-(3-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 130).

To a solution of Intermediate 130b (0.17 mmol) in THF (2 mL) was addedDIPEA (122 μL, 0.70 mmol) and morpholine (62 μL, 0.70 mmol) and thereaction stirred at 50° C. for 24 h. The crude reaction mixture wascooled and partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-10% (2M NH₃in MeOH) in DCM, followed by MDAP (Method 7) purification, to give thetitle compound (25 mg, 19%). LCMS (Method 5): Rt 3.75 min, m/z 732[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.55 (3H, d, J=6.2 Hz), 0.58 (3H, d,J=6.2 Hz), 1.23 (9H, s), 1.35-1.53 3H, m), 1.63-1.68 (2H, m), 1.72-1.86(2H, m), 1.86-1.92 (1H, m), 2.01-2.07 (2H, m), 2.32 (4H, t, J=4.1 Hz),308-3.20 (2H, m), 3.46 (2H, s), 3.50 (4H, t, J=4.5 Hz), 4.78 (1H, td,J=8.6, 5.9 Hz), 5.47 (1H, t, J=4.2 Hz), 6.28 (1H, s), 6.98 (1H, d, J=8.6Hz), 7.15 (1H, dd, J=9.8, 2.1 Hz), 7.17-7.23 (2H, m), 7.25-7.31 (3H, m),7.32-7.44 (3H, m), 7.61 (1H, d, J=9.7 Hz), 7.83 (1H, d, J=1.8 Hz), 8.05(1H, s), 8.12 (1.6H, s).

Example 1311-{5-tert-Butyl-2-[3-(2-morpholin-4-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a. 2-[3-(5-Amino-3-tert-butyl-pyrazol-1-yl-phenol]-ethanol (Intermediate131a)

A mixture of 5-tert-butyl-2H-pyrazol-3-ylamine (629 mg, 4.52 mmol),2-(3-bromophenyl)-ethanol (1 g, 4.52 mmol), copper (I) iodide (43 mg,0.23 mmol), (1S,2S)—N,N′-dimethyl cyclohexane-1,2-diamine (129 mg, 0.90mmol) and potassium carbonate (1.31 g, 9.50 mmol) in toluene (8 mL) wasde-gassed and flushed with argon (3×). The reaction mixture was thentreated with microwave irradiation, at 150° C. for 3 h and then at 160°C. for 16 h. The mixture was diluted with EtOAc (10 mL) and washed withwater (10 mL). The aqueous layer was extracted with a further 10 mL ofEtOAc and the combined organic layers were washed with brine (10 mL),dried (MgSO₄), filtered and concentrated in vacuo. The residue obtainedwas purified by FCC, using 0-100% EtOAc in cyclohexane to afford thetitle compound as a brown gum (364 mg, 31%). LCMS (Method 3): Rt0.43/2.00/2.24 min, m/z 260 [MH⁺].

b.{5-tert-Butyl-2-[3-[2-(hydroxyethyl)-phenyl]-2H-pyrazol-3-yl}-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 131b)

A solution of Intermediate 131a (364 mg, 1.40 mmol) in EtOAc (5 mL) wastreated with aqueous NaOH (1M, 2.53 mmol), followed by2,2,2-trichloroethyl chloroformate (231 μL, 1.68 mmol) and the reactionmixture was stirred at RT for 1 h. The mixture was partitioned betweenEtOAc (5 mL) and water (5 mL). The layers were separated and the aqueouslayer was extracted with a further 5 mL EtOAc. The combined organiclayers were dried (MgSO4), filtered and concentrated in vacuo. Theresidue was purified by FCC, using 0-50% EtOAc in cyclohexane to affordthe title compound as a red gum (516 mg, 85%). LCMS (Method 3): Rt 4.03min, m/z 434/436 [MH⁺].

c.1-{5-tert-Butyl-2-[3-(2-(hydroxyethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 131c)

A mixture of Intermediate 131b (328 mg, 0.75 mmol), Intermediate 81d(285 mg, 0.75 mmol) and DIPEA (197 μL, 1.13 mmol) in dioxane (4.5 mL)was heated at 70° C. for 20 h. The reaction mixture was cooled to RT,diluted with DCM (10 mL) and washed with water (2×10 mL). The organiclayer was passed through a hydrophobic frit and concentrated in vacuo.The residue was purified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM toafford the title compound as a beige solid (358 mg, 72%). LCMS (Method3): Rt 3.67 min, m/z 663 [MH⁺].

d. Methanesulfonic acid2-{3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-phenyl}-ethylester (Intermediate 131d)

To a yellow solution of Intermediate 131c (358 mg, 0.540 mmol) and DIPEA(0.28 mL, 1.6 mmol) in DCM at 0° C. was added mesyl chloride (0.084 mL,1.1 mmol) dropwise over 30 seconds, then the solution stirred at 0° C.for 30 min. Water (10 mL) and sat. aq. NaHCO₃ (10 mL) were added and themixture shaken. The aqueous was extracted with DCM (10 mL), then thecombined organics passed through a hydrophobic frit and concentrated invacuo to leave a brown gum. LCMS (Method 3): Rt 3.91 min, m/z 741 [MH⁺].

e.1-{5-tert-Butyl-2-[3-(2-morpholin-4-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 131).

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) and morpholine(25.9 μL, 0.30 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in asealed tube. The mixture was concentrated in vacuo and the residuepurified by MDAP (Method 7). The title product was isolated as anoff-white solid (12 mg, 27%). LCMS (Method 5): Rt 3.64 min, m/z 732.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.2 Hz), 1.28 (9H, s),1.50 (2H, m), 1.66 (2H, m), 1.76-2.18 (6H, overlapped m), 2.40 (4H, m),2.53 (m, obscured by solvent), 2.80 (2H, m), 2.90 (1H, m), 3.15 (1H, m,obscured by solvent), 3.31 (m, obscured by solvent), 3.54 (4H, m), 4.82(1H, m), 5.51 (1H, t, J=4.0 Hz), 6.32 (1H, s), 7.09 (1H, d, J=8.7 Hz),7.19 (1H, dd, J=9.8, 2.4 Hz), 7.24-7.44 (8H, m), 7.63 (1H, m), 7.69 (1H,m), 8.10 (1H, s), 8.20 (1H, s).

Example 1321-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) and pyrrolidine(24.8 μL, 0.30 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in asealed tube. The mixture was concentrated in vacuo and the residuepurified by MDAP (Method 7). The title product was isolated as anoff-white solid (15 mg, 35%). LCMS (Method 5): Rt 3.70 min, ink 716.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.6 Hz), 1.28 (9H, s),1.50 (2H, m), 1.61-1.72 (6H, m), 1.76-2.18 (6H, overlapped m), 2.53 (m,obscured by solvent), 2.72 (2H, m), 2.82 (2H, m), 2.90 (1H, m), 3.16(1H, m, obscured by solvent), 3.31 (m, obscured by solvent), 4.82 (1H,m), 5.52 (1H, t, J=4.2 Hz), 6.33 (1H, s), 7.10 (1H, d, J=8.4 Hz), 7.19(1H, dd, J=10.0, 2.0 Hz), 7.24-7.44 (8H, m), 7.64 (1H, m), 7.69 (1H, m),8.14 (1H, s), 8.19 (1H, s).

Example 1331-(5-tert-Butyl-2-{3-[2-(ethyl-methyl-amino)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) andN-ethylmethylamine (25.8 μL, 0.30 mmol) in THF (1 mL) was stirred at 60°C. for 20 h in a sealed tube. The mixture was concentrated in vacuo andthe residue purified by MDAP (Method 7). The title product was isolatedas an off-white solid (10 mg, 24%). LCMS (Method 5): Rt 3.68 min, m/z704.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.2 Hz), 0.96(3H, t, J=7.5 Hz), 1.28 (9H, s), 1.50 (2H, m), 1.66 (2H, m), 1.76-2.17(6H, overlapped m), 2.20 (3H, s), 2.42 (2H, q, J=7.5 Hz), 2.60 (2H, m),2.78 (2H, m), 2.90 (1H, m), 3.16 (1H, m, obscured by solvent), 3.31 (m,obscured by solvent), 4.82 (1H, m), 5.52 (1H, t, J=4.4 Hz), 6.33 (1H,s), 7.10 (1H, d, J=8.5 Hz), 7.19 (1H, dd, J=9.7, 2.2 Hz), 7.24-7.43 (8H,m), 7.64 (1H, d, J=9.6 Hz), 7.69 (1H, m), 8.12 (1H, s), 8.20 (1H, s).

Example 1341-{5-tert-Butyl-2-[3-(2-dimethylamino-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) and dimethylaminesolution (2M in THF, 0.6 mL, 1.2 mmol) in THF (1 mL) was stirred at 60°C. for 20 h in a sealed tube. The mixture was concentrated in vacuo andthe residue purified by MDAP (Method 7). The title product was isolatedas an off-white solid (18 mg, 41%). LCMS (Method 5): Rt 3.63 min, m/z690.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.28(9H, s), 1.47-1.55 (2H, m), 1.63-1.71 (2H, m), 1.75-1.97 (4H, m),2.00-2.16 (2H, m), 2.19 (6H, s), 2.53 (2H, t, J=8.1 Hz), 2.78 (2H, t,J=7.6 Hz), 2.90 (1H, ddd, J=12.2, 9.0, 4.0 Hz), 3.16 (1H, dt, J=12.1,4.2 Hz), 3.31 (1H, m), 4.82 (1H, td, J=8.6, 5.5 Hz), 5.52 (1H, t, J=4.3Hz), 6.33 (1H, s), 7.09 (1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.8, 2.2 Hz),7.24-7.42 (8H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, d, J=2.1 Hz),8.12 (1H, s), 8.19 (1H, s).

Example 1351-{5-tert-Butyl-2-[3-(2-piperidin-1-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) and piperidine (30μL, 0.30 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in a sealedtube. The mixture was concentrated in vacuo and the residue purified byMDAP (Method 7). The title product was isolated as an off-white solid(26 mg, 55%). LCMS (Method 5): Rt 3.75 min, m/z 730.7 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.28 (9H, s), 1.31-1.37 (2H, m),1.43-1.55 (6H, m), 1.62-1.71 (2H, m), 1.75-1.97 (4H, m), 2.00-2.17 (2H,m), 2.41 (4H, t, J=4.4 Hz), 2.52-2.56 (2H, m), 2.79 (2H, t, J=7.9 Hz),2.90 (1H, ddd, J=12.1, 9.1, 4.0 Hz), 3.16 (1H, dt, J=11.8, 4.1 Hz),3.28-3.35 (1H, m), 4.82 (1H, td, J=8.6, 5.5 Hz), 5.52 (1H, t, J=4.3 Hz),6.32 (1H, s), 7.09 (1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.9, 2.1 Hz),7.24-7.42 (8H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, d, J=2.1 Hz),8.11 (1H, s), 8.19 (1.4H, s).

Example 1361-(5-tert-Butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) andN-methylpiperazine (33 μL, 0.30 mmol) in THF (1 mL) was stirred at 60°C. for 20 h in a sealed tube. The mixture was concentrated in vacuo andthe residue purified by MDAP (Method 7). The title product was isolatedas an off-white solid (16 mg, 33%). LCMS (Method 5): Rt 3.54 min, m/z745.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.28(9H, s), 1.47-1.55 (2H, m), 1.63-1.71 (2H, m), 1.75-1.97 (4H, m),2.00-2.08 (1H, m), 2.11 (3H, s), 2.12-2.17 (1H, m), 2.29 (4H, br s),2.42 (4H, br s), 2.51-2.55 (2H, m), 2.76-2.80 (2H, m), 2.90 (1H, ddd,J=12.1, 9.1, 4.1 Hz), 3.16 (1H, dt, J=11.9, 4.2 Hz), 3.28-3.34 (1H, m),4.82 (1H, td, J=8.6, 5.6 Hz), 5.52 (1H, t, J=4.3 Hz), 6.32 (1H, s), 7.08(1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.8, 2.2 Hz), 7.24-7.42 (8H, m), 7.64(1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, d, J=2.1 Hz), 8.10 (1H, s), 8.19(1.4H, s).

Example 1371-{5-tert-Butyl-2-[3-(2-[1,4]oxazepan-4-yl-ethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) and homomorpholine(30.4 mg, 0.30 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in asealed tube. The mixture was concentrated in vacuo and the residuepurified by MDAP (Method 7). The title product was isolated as anoff-white solid (15 mg, 31%). LCMS (Method 5): Rt 3.66 min, m/z 746.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.28 (9H, s),1.47-1.55 (2H, m), 1.63-1.71 (2H, m), 1.73-1.97 (6H, m), 2.00-2.17 (2H,m), 2.66-2.81 (8H, m), 2.90 (1H, ddd, J=12.2, 9.0, 4.0 Hz), 3.16 (1H,dt, J=12.2, 4.4 Hz), 3.28-3.34 (1H, m), 3.56-3.59 (2H, m), 3.63 (2H, t,J=6.0 Hz), 4.82 (1H, td, J=8.6, 5.5 Hz), 5.52 (1H, t, J=4.3 Hz), 6.33(1H, s), 7.08 (1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.8, 2.2 Hz), 7.24-7.42(8H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, dd, J=2.1, 0.9 Hz),8.09 (1H, s), 8.18 (1.3H, s).

Example 1381-(5-tert-Butyl-2-{3-[2-(4-methyl-[1,4]diazepan-1-yl)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 131d (44.5 mg, 0.06 mmol) andN-methylhomopiperazine (34.3 mg, 0.300 mmol) in THF (1 mL) was stirredat 60° C. for 20 h in a sealed tube. The mixture was concentrated invacuo and the residue purified by MDAP (Method 7) to give an off-whitesolid (22 mg). Prep HPLC (Gemini C18, 20-60% MeCN in water, 0.1% HCO₂H,20 min) and concentration of the desired fractions removed the MeCN. Theaqueous was washed with DCM (30 mL), then basified with aq. NaOHsolution (1M, 0.5 mL) and extracted with DCM (2×10 mL). The combinedorganics were passed through a hydrophobic frit, then HCO₂H (0.01 mL)added and the mixture concentrated in vacuo to leave the title compoundas a clear film that became a solid on standing (10.6 mg, 23%). LCMS(Method 5): Rt 3.19 min, m/z 759.7 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.91 (3H, d, J=6.3 Hz), 1.28 (9H, s), 1.48-1.55 (2H, m), 1.64-1.74 (4H,m), 1.77-1.96 (4H, m), 2.00-2.16 (2H, m), 2.29 (3H, s), 2.58-2.62 (4H,m), 2.69-2.80 (8H, m), 2.91 (1H, ddd, J=12.4, 9.3, 4.3 Hz), 3.16 (1H,dt, J=11.9, 4.3 Hz), 3.28-3.34 (1H, m), 4.82 (1H, td, J=9.0, 5.7 Hz),5.52 (1H, t, J=4.3 Hz), 6.33 (1H, s), 7.09 (1H, d, J=8.6 Hz), 7.19 (1H,dd, J=9.8, 2.2 Hz), 7.24-7.42 (8H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz),7.69 (1H, dd, J=2.2, 0.9 Hz), 8.10 (1H, s), 8.19 (1.4H, s).

Example 1391-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. (S)-3-Methyl-morpholine-4-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 139a)

Pyridine (1.60 mL, 19.8 mmol) was added dropwise to an ice coldsuspension of triphosgene (2.94 g, 9.90 mmol) in DCM (20.0 mL).(S)-3-Methylmorpholine (1.00 mL, 9.90 mmol) was added and the reactionstirred for 3 hours, then quenched by dropwise addition of HCl (1Maqueous, 20 mL). The mixture was extracted into DCM (3×). The combinedorganic layers were washed with brine, dried (MgSO₄), filtered andevaporated in vacuo to give (S)-3-methylmorpholine-carbamoylchloride(1.25 g, 77%). The product was used in the next reaction withoutpurification. (S)-3-Methylmorpholine-carbamoylchloride (766 mg, 4.33mmol) was dissolved in DCM (35.0 mL) and DIPEA (1.03 mL, 5390 mmol) wasadded followed by (5-fluoro-pyridin-2-yl)-hydrazine (WO2010022076, 500mg, 3.94 mmol) and the reaction heated to 45° C. overnight. The reactionwas cooled and quenched into water. The mixture was extracted into DCM(3×). The combined organic layers were washed with brine, dried (MgSO₄),filtered and evaporated in vacuo. The residue was purified by FCC using0-10% [2M NH₃ in MeOH] in DCM to give the title compound (574 mg, 57%).¹H NMR (300 MHz, CDCl₃): 1.36 (3H, d, J=6.9 Hz), 3.30 (1H, td, J=12.5,3.9 Hz), 3.47-3.74 (4H, m), 3.89-4.03 (2H, m), 6.41 (1H, br s), 6.45(1H, br s), 6.73 (1H, dd, J=9.0, 3.5 Hz), 7.29 (1H, ddd, J=9.0, 7.9, 2.9Hz), 8.04 (1H, d, J=2.9 Hz).

b.6-Fluoro-3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 139b)

To an ice cold solution of Intermediate 139a (574 mg, 2.26 mmol) in THF(23.0 mL) was added sequentially triphenylphosphine (1.18 g, 4.52 mmol),triethylamine (1.26 mL, 9.04 mmol) and hexachloroethane (1.07 g, 4.52mmol). The cooling bath was removed and the reaction was heated to 55°C. overnight. The reaction was cooled and partitioned between EtOAc andwater. The aqueous layer was then extracted with EtOAc (3×). Thecombined organic layers were washed with brine, dried (MgSO₄), filteredand evaporated in vacuo. The residue was taken up in MeOH and loadedonto an SCX-2 cartridge, which was washed with MeOH and eluted with 2MNH₃ in MeOH. The residue was concentrated in vacuo and then re-submittedto the above reaction conditions overnight. The reaction was cooled andpartitioned between EtOAc and water. The aqueous layer was thenextracted with EtOAc (3×). The combined organic layers were washed withbrine, dried (MgSO₄), filtered and evaporated in vacuo. The residue waspurified by FCC using 0-10% [2M NH₃ in MeOH] in DCM to give the titlecompound (154 mg, 29%). ¹H NMR (300 MHz, CDCl₃); 0.94 (3H, d, J=6.3 Hz),3.13 (1H, dt, J=12.2, 3.1 Hz), 3.32 (1H, ddd, J=12.4, 9.5, 3.2 Hz), 3.49(1H, dd, J=11.1, 8.6 Hz), 3.56-3.68 (1H, m), 3.84 (1H, ddd, J=12.1, 9.4,2.7 Hz), 3.92-4.01 (2H, m), 7.16 (1H, ddd, J=9.9, 7.5, 2.3 Hz), 7.68(1H, ddd, J=10.0, 4.8, 0.8 Hz), 7.85 (1H, m).

c.(1S,4R)-4-[3-((S)-3-Methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 139c)

To a suspension of sodium hydride (60% in mineral oil, 187 mg, 4.68mmol) in DMF (6.0 mL) was added Intermediate A (191 mg, 1.17 mmol) andthe reaction stirred for 20 min. Intermediate 139b (276 mg, 1.17 mmol)was added in DMF (2.00 mL) and the reaction heated to 60° C. for 1 h.The reaction was cooled and quenched by dropwise addition of methanol,before being diluted with methanol and loaded onto an SCX-2 cartridge,which was washed with MeOH. The product was eluted with 2M NH₃ in MeOH.The residue was purified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, togive the title compound (250 mg, 56%). LCMS (Method 4): Rt 1.83, m/z 380[MH⁺].

d.1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 139).

A mixture of Intermediate 139c (125 mg, 0.33 mmol), Intermediate 110b(115 mg, 0.33 mmol) and DIPEA (115 μL, 0.66 mmol) in dioxane (3 mL) wasstirred at 80° C. overnight. After cooling, the reaction mixture waspartitioned between water and DCM. The aqueous phase was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resultant residue was purified byFCC, using a gradient of 0-10% MeOH in DCM, to afford the title compound(94 mg, 48%). A sample of this (40.0 mg) was further purified by MDAP(Method 7) purification to afford the title compound (20 mg) as a whitesolid. LCMS (Method 5): Rt 3.64 min, m/z 589 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 0.83 (3H, d, J=5.6 Hz), 1.16 (9H, s), 1.83-1.96 (2H, m),1.97-2.07 (1H, m), 2.08-2.17 (1H, m), 2.95 (1H, ddd, J=12.0, 7.2, 4.9Hz), 3.17 (1H, dt, J=12.2, 3.3 Hz), 3.36-3.44 (2H, m), 3.62 (2H, q,J=5.5 Hz), 3.72-3.80 (2H, m), 3.81-3.88 (1H, m), 3.88-3.92 (2H, t, J=6.0Hz), 4.81 (1H, td, J=8.5, 6.1 Hz), 4.96 (1H, t, J=5.0 Hz), 5.52 (1H, t,J=4.2 Hz), 6.02 (1H, s), 7.05 (1H, d, J=8.6 Hz), 7.18 (1H, dd, J=9.9,2.1 Hz), 7.22-7.27 (1H, m), 7.30-7.37 (3H, m), 7.62 (1H, d, J=9.9 Hz),7.79 (1H, d, J=1.9 Hz), 8.16 (1H, s).

Example 1401-(5-tert-Butyl-2-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a. 5-tert-Butyl-2-(2-chloro-pyrimidin-4-yl)-2H-pyrazol-3-ylamine(Intermediate 140a)

A mixture of 2,4-dichloropyrimidine (1.0 g, 6.7 mmol),3-(tert-butyl)-1H-pyrazol-5-amine (1.03 g, 7.4 mmol) and sodiumcarbonate (1.42 g, 13.4 mmol) in 1,4-dioxane was treated with4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantphos) (58 mg, 0.10mmol) followed by tris(dibenzylideneacetone)dipalladium (31 mg, 0.03mmol). The mixture was degassed then heated to 70° C. under N₂ for 5 h.After cooling to room temperature the mixture was filtered and thefiltrate was concentrated in vacuo. The residue was partitioned betweenEtOAc and water and the phases were separated. The aqueous layer wasextracted with EtOAc (×2) and the combined organic phase was washed withbrine, dried (Na₂SO₄) and concentrated in vacuo. The residue waspurified by FCC, using 0-15% EtOAc in cyclohexane, to give the titlecompound (0.59 g, 35%). LCMS (Method 3): Rt 3.97 min, m/z 252.2 [MH⁺].

b.N-[4-(5-Amino-3-tert-butyl-pyrazol-1-yl)-pyrimidin-2-yl]-N,N′,N′-trimethyl-ethane-1,2-diamine(Intermediate 140b)

A solution of Intermediate 140a (250 mg, 0.99 mmol) andN,N,N′-trimethylethylenediamine (0.32 mL, 2.48 mmol) in IPA (2.5 mL) washeated to 120° C. for 10 mins under microwave irradiation. The cooledreaction mixture was concentrated in vacuo and the residue waspartitioned between EtOAc and water. The phases were separated and theaqueous layer was extracted with EtOAc (×2). The combined organic phasewas washed with brine, dried (Na₂SO₄) and concentrated in vacuo to givethe title compound (0.31 g, quant.) as a golden oil that was used in thenext step without purification. LCMS (Method 3): Rt 2.51 min, m/z 318.3[MH⁺].

c.(5-tert-Butyl-2-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yl}-2H-pyrazol-3-yl)-carbamicacid phenyl ester (Intermediate 140c)

A solution of Intermediate 140b (129 mg, 0.41 mmol) in DCM (4.1 mL) wastreated with pyridine (0.046 mL, 0.57 mmol) and the mixture was cooled0° C. Phenyl chloroformate (0.066 mL, 0.53 mmol) was added and theresulting mixture was stirred at RT for 16 h. The mixture was cooled to0° C. and treated with pyridine (0.013 mL, 0.16 mmol) then phenylchloroformate (0.015 mL, 0.12 mmol) and stirred at RT for a further 1.75h. Once again the mixture was cooled to 0° C. and treated with pyridine(0.013 mL, 0.16 mmol) then phenyl chloroformate (0.015 mL, 0.12 mmol)and stirred at RT for 1.75 h. The mixture was diluted with water and thephases were separated. The aqueous layer was extracted with DCM (×2) andthe combined organic phase was washed with brine, dried (Na₂SO₄), andconcentrated in vacuo to give a yellow gum (236 mg). Trituration withether and filtration of the resulting solid gave the title compound as awhite solid (75 mg, 39%). LCMS (Method 3): Rt 3.21 min, m/z 438.4 [MH⁺].

d.1-(5-tert-Butyl-2-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 140).

A solution of Intermediate 81d (25 mg, 0.066 mmol) in 1,4-dioxane (0.7mL) was treated with Intermediate 140c (32 mg, 0.073 mmol) and DIPEA(0.014 mL, 0.083 mmol) and the mixture was stirred at 70° C. for 18 h.The cooled solution was concentrated in vacuo, and the residue waspartitioned between DCM and water. The phases were separated and theaqueous layer was extracted with DCM (×2). The combined organic phasewas washed with brine, dried (Na₂SO₄) and concentrated in vacuo to abrown gum. FCC, using 0-8% MeOH in DCM, gave a colourless glass (27 mg).The glass was purified further by HPLC (Phenomenex Gemini C18 column,5-95% MeCN in H₂O, 0.1% HCO₂H) over 30 mins. Concentration of thefractions in vacuo gave a colourless glass that was dissolved in ether.A solid was precipitated out of solution by addition of cyclohexane. Thesolid was filtered off to give the title compound as a white solid (8mg, 17%). LCMS (Method 5): Rt 4.07 min, m/z 721.6 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO, 353K): 0.92 (3H, d, J=6.4 Hz), 1.29 (9H, s), 1.49-1.58(2H, m), 1.65-1.72 (2H, m), 1.77-1.86 (2H, m), 1.99 (6H, s), 2.00-2.14(4H, m), 2.20-2.29 (1H, m), 3.12-3.19 (5H, m), 3.30-3.39 (1H, m),3.58-3.72 (2H, m), 4.94-5.02 (1H, m), 5.42 (1H, t, J=3.9 Hz), 6.55 (1H,s), 7.03 (1H, d, J=5.5 Hz), 7.15 (1H, dd, J=9.8, 2.3 Hz), 7.22-7.27 (1H,m), 7.31-7.37 (2H, m), 7.41-7.45 (1H, m), 7.56-7.61 (2H, m), 7.70 (1H,br s), 8.35 (1H, d, J=5.5 Hz), 10.18 (1H, br s).

Example 1411-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.1-(5-tert-Butyl-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 141a)

A mixture of Intermediate 139c (125 mg, 0.33 mmol), Intermediate 39b(177 mg, 0.33 mmol) and DIPEA (115 μL, 0.66 mmol) in dioxane (3 mL) wasstirred at 80° C. overnight. After cooling, the reaction mixture waspartitioned between water and DCM. The aqueous phase was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resultant residue was purified byFCC on silica, using a gradient of 0-10% MeOH in DCM, to afford thetitle compound (214 mg, 85%). LCMS (Method 4): Rt 3.65 min, m/z 765[MH⁺].

b.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 141b)

To a solution of Intermediate 141a (214 mg, 0.28 mmol) in MeOH (3.0 mL)was added pyridinium p-toluenesulfonate (141 mg, 0.56 mmol) and thereaction mixture was heated at 60° C. for 3 h. The resultant mixture waspoured into water and a saturated aqueous solution of NaHCO₃ was added.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of0-10% MeOH in DCM, to give the title compound (132 mg, 69%). LCMS(Method 4): Rt 3.04 min, m/z 681 [MH⁺].

c. Methanesulfonic acid2-{3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-phenoxy}-ethylester (Intermediate 141c)

To an ice-bath cooled solution of Intermediate 141b (132 mg, 0.19 mmol)in DCM (2.0 mL) was added DIPEA (135 μL, 0.78 mmol) followed bymethanesulfonyl chloride (30 μL, 4, 0.39 mmol). The reaction mixture wasstirred for 2 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the subsequent step withoutfurther purification. LCMS (Method 4): Rt 3.30 min, m/z 759 [MH⁺].

d.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 141).

To a solution of Intermediate 141c (0.19 mmol) in THF (2.0 mL) was addeddimethylamine (2M in MeOH, 1.9 mL, 3.8 mmol) and the reaction was heatedto 50° C. in a sealed tube overnight. The crude reaction mixture waspartitioned between EtOAc and water. The aqueous phase was extractedwith EtOAc (×3) and the combined organic layers were washed with brine,dried (MgSO₄) and concentrated in vacuo. The resulting residue waspurified by FCC on silica, using a gradient of 0-10% [2M NH₃ in MeOH] inDCM, followed by MDAP (Method 7) purification, to give the titlecompound (50 mg, 34%). LCMS (Method 5): Rt 3.33 min, m/z 708 [MH⁺]. ¹HNMR (400 MHz, d₆-DMSO): 0.83 (3H, d, J=5.7 Hz), 1.23 (9H, s), 1.78-1.92(2H, m), 1.94-2.04 (1H, m), 2.04-2.12 (1H, m), 2.16 (6H, s), 2.59 (2H,t, J=5.7 Hz), 2.94 (1H, ddd, J=12.2, 7.3, 4.7 Hz), 3.16 (1H, dt, J=12.2,3.3), 3.35-3.43 (2H, m), 3.72-3.80 (2H, m), 3.81-3.87 (1H, m), 4.04 (2H,t, J=5.7 Hz), 4.77 (1H, td, J=8.5, 5.9 Hz), 5.50 (1H, t, J=4.1 Hz), 6.28(1H, s), 6.90-6.94 (1H, m), 7.01-7.09 (3H, m), 7.14-7.18 (1H, dd, J=9.8,2.1 Hz), 7.20-7.26 (2H, m), 7.26-7.30 (1H, m), 7.30-7.38 (2H, m), 7.62(1H, d, J=9.8 Hz), 7.78 (1H, d, J=1.8 Hz), 8.09 (1H, s), 8.12 (1.4H, s).

Example 1421-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a. Methanesulfonic acid2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]ethylester (Intermediate 142a)

To an ice-bath cooled solution of Example 139 (54 mg, 0.092 mmol) in DCM(2.0 mL) was added DIPEA (65 μL, 0.37 mmol) followed by methanesulfonylchloride (14 μL, 0.18 mmol). The reaction mixture was stirred for 1 hand then quenched with water. The aqueous phase was extracted with DCM(×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo to afford the title compound(Quantitative). Product used in the following step without furtherpurification. LCMS (Method 4): Rt 3.04 min, m/z 667 [MH⁺].

b.1-[5-tert-Butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 142).

To a solution of Intermediate 142a (0.092 mmol) in THF (2 mL) was addedDIPEA (64 μL, 0.37 mmol) and morpholine (21 μL, 0.37 mmol) and thereaction stirred at 50° C. for 24 h. The crude reaction mixture wascooled and partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-10% [2M NH₃in MeOH] in DCM, followed by MDAP (Method 7) purification, to give thetitle compound (21 mg, 34%). LCMS (Method 5): Rt 3.16 min, m/z 658[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.83 (3H, d, J=5.6 Hz), 1.16 (9H, s),1.83-1.96 (2H, m), 1.97-2.07 (1H, m), 2.08-2.17 (1H, m), 3.34 (4H, t,J=4.5 Hz), 2.57 (2H, t, J=7.1 Hz), 2.95 (1H, ddd, J=12.0, 7.2, 4.9 Hz),3.17 (1H, dt, J=12.2, 3.3 Hz), 3.36-3.43 (2H, m), 3.50 (4H, t, J=4.5Hz), 3.72-3.80 (2H, m), 3.81-3.88 (1H, m), 3.92-3.98 (2H, t, J=7.1 Hz),4.82 (1H, td, J=8.5, 6.1 Hz), 5.52 (1H, t, J=4.2 Hz), 5.99 (1H, s), 6.89(1H, d, J=8.6 Hz), 7.18 (1H, dd, J=9.9, 2.1 Hz), 7.22-7.27 (1H, m),7.30-7.38 (3H, m), 7.62 (1H, d, J=9.9 Hz), 7.79 (1H, d, J=1.9 Hz), 8.16(1H, s), 8.16 (0.2H, s).

Example 1431-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 130b (0.25 mmol) in THF (2.5 mL) was addedN-methylpiperazine (277 μL, 2.50 mmol) and the reaction stirred at 50°C. for 24 h. After cooling, the mixture was partitioned between EtOAcand water. The aqueous phase was extracted with EtOAc (×3) and thecombined organic layers were washed with brine, dried (MgSO₄) andconcentrated in vacuo. The resulting residue was purified by FCC onsilica, using a gradient of 0-10% [2M NH₃ in MeOH] in DCM, followed byMDAP (Method 7) purification, to give the title compound (37 mg, 19%).LCMS (Method 5): Rt 3.77 min, m/z 745 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.55 (3H, d, J=6.2 Hz), 0.58 (3H, d, J=6.2 Hz), 1.23 (9H, s), 1.35-1.54(3H, m), 1.63-1.68 (2H, m), 1.72-1.86 (2H, m), 1.86-1.92 (1H, m),2.01-2.06 (2H, m), 2.07 (3H, s), 2.26 (4H, br s), 2.34 (4H, br s),3.08-3.20 (2H, m), 3.46 (2H, s), 4.78 (1H, td, J=8.6, 5.9 Hz), 5.47 (1H,t, J=4.2 Hz), 6.28 (1H, s), 7.00 (1H, d, J=8.6 Hz), 7.15 (1H, dd, J=9.8,2.1 Hz), 7.18-7.25 (2H, m), 7.25-7.31 (3H, m), 7.32-7.37 (2H, m), 7.41(1H, t, J=7.6 Hz), 7.61 (1H, d, J=9.7 Hz), 7.83 (1H, d, J=1.8 Hz), 8.05(1H, s), 8.12 (1.1H, s).

Example 1441-[5-tert-Butyl-2-(3-pyrrolidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 130b (0.32 mmol) in THF (3.0 mL) was addedpyrrolidine (530 μL, 6.4 mmol) and the reaction stirred at 50° C. for 24h. After cooling, the mixture was partitioned between EtOAc and water.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resulting residue was purified by FCC on silica, using a gradient of0-10% [2M NH₃ in MeOH] in DCM, followed by MDAP (Method 7) purification,to give the title compound (60 mg, 24%). LCMS (Method 5): Rt 3.79 min,m/z 716 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.55 (3H, d, J=6.2 Hz), 0.58(3H, d, J=6.2 Hz), 1.23 (9H, s), 1.35-1.54 (3H, m), 1.60-1.68 (6H, m),1.72-1.85 (2H, m), 1.86-1.92 (1H, m), 2.01-2.06 (2H, m), 2.38-2.44 (4H,m), 3.08-3.20 (2H, m), 3.58 (2H, s), 4.77 (1H, td, J=8.6, 5.9 Hz), 5.48(1H, t, J=4.2 Hz), 6.28 (1H, s), 7.00 (1H, d, J=8.6 Hz), 7.15 (1H, dd,J=9.8, 2.1 Hz), 7.18-7.25 (2H, m), 7.26-7.35 (4H, m), 7.37 (1H, s), 7.41(1H, t, J=7.6 Hz), 7.61 (1H, d, J=9.7 Hz), 7.83 (1H, d, J=1.8 Hz), 8.05(1H, s), 8.13 (1.2H, s).

Example 1451-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

Pyrrolidine (36 μL, 0.43 mmol) was added to a solution of Intermediate96f (111 mg, 0.14 mmol) in THF (2 mL). The reaction was heated to 60° C.in a sealed vial overnight. The mixture was cooled, evaporated in vacuoand the residue was purified by FCC, using 0-15% MeOH in DCM, thentriturated with Et₂O to give the title compound (27 mg, 25%) as anoff-white solid. LCMS (Method 5): Rt 3.87 min, m/z 746.6 [MH⁺]. ¹H NMR(400 MHz, d₆-DMSO): 0.55 (3H, d, J=6.0 Hz), 0.58 (3H, d, J=6.0 Hz), 1.23(9H, s), 1.32-1.54 (3H, m), 1.53-1.78 (7H, m), 1.79-1.95 (2H, m),1.96-2.10 (2H, m), 2.49-2.60 (2H, m), 2.68-2.94 (2H, m), 3.06-3.20 (3H,m), 3.27 (1H, m, obscured by water), 4.03-4.14 (2H, m), 4.74-4.83 (1H,m), 5.49 (1H, t, J=4.0 Hz), 6.29 (1H, s), 6.90-6.96 (1H, m), 7.01-7.09(3H, m), 7.16 (1H, dd, J=9.7, 2.0 Hz), 7.19-7.25 (2H, m), 7.26-7.32 (2H,m), 7.33-7.39 (1H, m), 7.62 (1H, d, J=9.7 Hz), 7.84 (1H, m), 8.06 (1H,s).

Example 1461-(5-tert-Butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

1-Methylpiperazine (48 μL, 0.43 mmol) was added to a solution ofIntermediate 96f (111 mg, 0.14 mmol) in THF (2 mL). The reaction washeated to 60° C. in a sealed vial overnight. 1-Methylpiperazine (48 μL,0.43 mmol) was added and the reaction continued for a further 24 h. Themixture was cooled, evaporated in vacuo and the residue was purified byFCC, using 0-15% MeOH in DCM, then triturated with Et₂O to give thetitle compound (42 mg, 38%) as an off-white solid. LCMS (Method 5): Rt3.76 min, m/z 775.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.60 (3H, d, J=6.0Hz), 0.63 (3H, d, J=6.0 Hz), 1.28 (9H, s), 1.36-1.62 (3H, m), 1.65-1.75(2H, m), 1.76-1.99 (3H, m), 2.03-2.12 (2H, m), 2.14-2.26 (3H, m),2.34-2.61 (5H, m, obscured by solvent), 2.63-2.74 (3H, m), 3.11-3.24(2H, m), 3.28-3.38 (2H, m), 4.1 (2H, t, J=5.8 Hz), 4.78-4.87 (1H, m),5.50-5.56 (1H, m), 6.33 (1H, s), 6.93-7.00 (1H, m), 7.05-7.13 (3H, m),7.20 (1H, dd, J=9.9, 2.4 Hz), 7.23-7.31 (2H, m), 7.34 (2H, t, J=8.0 Hz),7.40 (1H, t, J=8.0 Hz), 7.67 (1H, d, J=9.9 Hz), 7.87-7.91 (1H, m), 8.11(1H, s).

Example 1471-(5-tert-Butyl-2-{3-[2-(ethyl-methyl-amino)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

N-Ethylmethylamine (37 μL, 0.43 mmol) was added to a solution ofIntermediate 96f (111 mg, 0.14 mmol) in THF (2 mL). The reaction washeated to 60° C. in a sealed vial overnight. N-Ethylmethylamine (37 μL,0.43 mmol) was added and the reaction continued for a further 24 h. Themixture was cooled, evaporated in vacuo and the residue was purified byFCC, using 0-15% MeOH in DCM, then triturated with Et₂O. Furtherpurification by HPLC (Gemini C18 column, 10-98% MeCN in H₂O, 0.1% formicacid) followed by evaporation of the fractions and trituration with Et₂Ogave the title compound (12 mg, 11%) as an off-white solid. LCMS (Method5): Rt 3.85 min, ink 734.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.55 (3H,d, J=6 Hz), 0.58 (3H, d, J=6 Hz), 0.89 (3H, t, J=7.0 Hz), 1.23 (9H, m),1.33-1.57 (3H, m), 1.62-1.70 (2H, m), 1.71-1.95 (3H, m), 1.96-2.09 (2H,m), 2.13 (3H, s), 2.35 (2H, q, J=7.2 Hz), 2.63 (2H, t, J=5.7 Hz),3.06-3.20 (3H, m), 3.21-3.36 (2H, m, obscured by solvent), 4.03 (2H, t,J=5.7 Hz), 4.74-4.83 (1H, m), 5.48 (1H, t, J=5.5 Hz), 6.28 (1H, s),6.88-6.94 (1H, m), 7.00-7.10 (3H, m), 7.16 (1H, dd, J=9.8, 2.0 Hz),7.18-7.26 (2H, m), 7.26-7.32 (2H, m), 7.35 (1H, t, J=8.0 Hz), 7.62 (1H,d, J=9.8 Hz), 7.81-7.86 (1H, m), 8.09 (1H, s), 8.37 (0.2H, s).

Example 1481-{(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-ureaformate salt

a. 4-Aza-spiro[2.5]octane-4-carbonyl chloride (Intermediate 148a)

To a vigorously stirred pale yellow solution of 4-azaspiro[2,5]octanehydrochloride (ABCR, 443 mg, 3.00 mmol), pyridine (0.36 mL, 4.5 mmol)and DIPEA (0.52 mL, 3.0 mmol) in DCM (10 mL) at 0° C. was added asolution of triphosgene (594 mg, 2.00 mmol) in DCM (5 mL) dropwise over5 min. The resulting orange solution was stirred at 0° C. for 30 min,and at RT for 66 h. Aq. HCl solution (1M, 15 mL) was added and themixture stirred for 30 min. The aqueous was extracted with DCM (4×15mL), then the combined organics passed through a hydrophobic frit andconcentrated in vacuo to leave the title compound as a red-brown oil(100% yield). ¹H NMR (300 MHz, CDCl₃): ˜2:1 ratio of rotamers, 0.71-0.76(1.33H, m), 0.82 (0.67H, br s), 1.00-1.04 (1.33H, m), 1.09 (0.67H, brs), 1.53-1.59 (2H, m), 1.64-1.72 (2H, m), 1.75-1.83 (2H, m), 3.61-3.74(2H, m).

b. 4-Aza-spiro[2,5]octane-4-carboxylic acidN′-(5-fluoro-pyridin-2-yl)-hydrazide (Intermediate 148b)

A red solution of (5-fluoro-pyridin-2-yl)-hydrazine (477 mg, 3.75 mmol),Intermediate 148a (3.00 mmol) and DIPEA (0.78 mL, 4.5 mmol) in DCM (20mL) was stirred at reflux for 40 h. To the cooled solution was addedwater (20 mL) and the mixture shaken. The aqueous was extracted with DCM(2×10 mL), then the combined organics passed through a hydrophobic fritand concentrated in vacuo. Flash chromatography (silica 40 g, 1-5% [2MNH₃ in MeOH] in DCM) gave the title compound as a yellow solid (587 mg,74%). LCMS (Method 3): Rt 2.66 min, m/z 265 [MH⁺].

c. 3-(4-Aza-spiro[2.5]oct-4-yl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine(Intermediate 148c)

To a solution of Intermediate 148b (587 mg, 2.22 mmol), triphenylphosphine (1.17 g, 4.44 mmol) and triethylamine (1.24 mL, 8.88 mmol) indioxane (25 mL) at RT was added hexachloroethane (1.05 g, 4.44 mmol).The resulting opaque solution was stirred at RT for 30 min, and atreflux for 16 h. The cooled solution was filtered, and the filter-cakewashed with THF (5 mL). The combined organics were applied to an SCX-2cartridge, which was washed with MeOH (100 mL). The product was elutedwith 2M NH₃ in MeOH (75 mL); concentration in vacuo left a brown oil.Flash chromatography (silica 40 g, 1.5-4.5% MeOH in DCM) gave the titlecompound as a brown gum (82%). LCMS (Method 3): Rt 2.92 min, m/z 247[MH⁺].

d.(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine (Intermediate 148d)

To an opaque brown solution of Intermediate A (371 mg, 2.28 mmol) in dryDMF (5 mL) under N₂ was added sodium hydride (60% dispersion in mineraloil, 273 mg, 6.83 mmol) and the resulting mixture stirred at RT for 30min. (CARE: gas evolution) A solution of Intermediate 148c (448 mg, 1.82mmol) in dry DMF (5 mL) was added and the resulting dark brown solutionstirred at 60° C. for 1 h. The solution was cooled to RT, then water(0.2 mL) added (CARE: gas evolution) and the mixture concentrated invacuo. The residue was redissolved in MeOH (10 mL), applied to an SCX-2cartridge (25 g) and washed with MeOH (100 mL). The product was elutedwith 2M NH₃ in MeOH (75 mL); concentration in vacuo left a dark browngum. Flash chromatography (silica 40 g, 4-7% [2M NH₃ in MeOH] in DCM)gave the title compound as a pale brown foam (446 mg, 63%). LCMS (Method3): Rt 2.31 min, m/z 390 [MH⁺].

e.{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 148e)

A colourless solution of Intermediate 39b (120 mg, 0.224 mmol) andpyridinium p-toluenesulfonate (169 mg, 0.673 mmol) in MeOH (5 mL) wasstirred at 40° C. for 90 min. The solution was concentrated in vacuo,suspended in water (3 mL) and sat. aq. NaHCO₃ solution (3 mL), thenextracted with DCM (2×5 mL). The combined organics were passed through ahydrophobic frit, concentrated in vacuo and azeotroped with toluene (2×5mL) to leave the title compound as a white solid (100 mg, 99%). LCMS(Method 3): Rt 4.01 min, m/z 450, 452 [MH⁺].

f.1-{(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-urea(Intermediate 148f)

An orange-brown solution of Intermediate 148d (87.2 mg, 0.224 mmol),Intermediate 148e (100 mg, 0.224 mmol) and DIPEA (0.049 mL, 0.28 mmol)in dry dioxane (3 mL) was stirred at 75° C. for 16 h. The cooledsolution was concentrated in vacuo, suspended in water (5 mL) andextracted with DCM (2×5 mL). The combined organics were passed through ahydrophobic frit and concentrated in vacuo to leave a brown gum. Flashchromatography (silica 12 g, 4-8% MeOH in DCM) gave the title compoundas a pale yellow solid (138 mg, 89%). LCMS (Method 3): Rt 3.57 min, m/z691 [MH⁺].

g. Methanesulfonic acid2-{3-[5-(3-{(1S,4R)-4-[3-(4-aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-3-tert-butyl-pyrazol-1-yl]-phenoxy}-ethylester (Intermediate 148g)

A yellow-orange solution of Intermediate 148f (137 mg, 0.198 mmol),DIPEA (0.10 mL, 0.60 mmol) and methanesulfonyl chloride (45 mg, 0.40mmol) in DCM (5 mL) was stirred at 0° C. for 30 min, and at RT for 30min. DIPEA (0.052 mL, 0.30 mmol) and MsCl (23 mg, 0.20 mmol) were addedand the solution stirred at RT for 30 min. Water (2 mL) and sat. aq.NaHCO₃ solution (2 mL) were added and the mixture shaken. The aqueouswas extracted with DCM (5 mL), then the combined organics passed througha hydrophobic frit and concentrated in vacuo to leave the title compoundas a yellow solid (100%). LCMS (Method 3): Rt 3.80 min, m/z 769 [MH⁺].

h.1-{(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-ureaformate salt (Example 148).

A brown solution of Intermediate 148g (0.099 mmol) and dimethylamine (2Min THF, 0.99 mL, 1.98 mmol) in THF (1 mL) was stirred in a sealed vialat 60° C. for 16 h. The solution was decanted and concentrated. MDAP(Method 7) gave the title compound as a pale yellow solid (50 mg, 65%).LCMS (Method 5): Rt 3.62 min, m/z 718.6 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 0.42-0.53 (4H, m), 1.27 (9H, s), 1.53-1.61 (2H, m), 1.74-1.96(6H, m), 1.99-2.15 (2H, m), 2.20 (6H, s), 2.63 (2H, t, J=5.8 Hz),3.22-3.29 (2H, m), 4.09 (2H, t, J=5.8 Hz), 4.81 (1H, td, J=8.6, 5.5 Hz),5.48 (1H, t, J=4.3 Hz), 6.33 (1H, s), 6.95-6.98 (1H, m), 7.06-7.12 (3H,m), 7.14 (1H, dd, J=9.9, 2.2 Hz), 7.25-7.42 (5H, m), 7.56 (1H, d, J=2.1Hz), 7.61 (1H, dd, J=9.8, 0.8 Hz), 8.12 (1H, s), 8.17 (1.4H, s).

Example 1491-[5-tert-Butyl-2-(3-morpholin-4-yl-methyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt

a.1-[5-tert-butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-{1,2,4}triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 149a)

A solution of Intermediate 5c (1.60 g, 4.40 mmol) and Intermediate 29c(1.85 g, 4.40 mmol) in dioxane (20 mL) was treated with DIPEA (1.15 mL,6.60 mmol) and the reaction mixture was heated at 70° C. for 36 h. Themixture was concentrated in vacuo and the residue was dissolved in DCM(150 mL) and washed with water (2×75 mL) and brine (75 mL). The organiclayer was dried (MgSO₄), filtered and concentrated in vacuo and the foamobtained purified by FCC, using 0-5% MeOH in DCM then 0-5% [2M NH₃ inMeOH] in DCM to afford the title compound as a yellow foamy solid (0.94g, 85%). LCMS (Method 3): Rt 2.76 min, m/z 635 [MH⁺].

b. Methanesulfonic acid3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-{1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzylester (Intermediate 149b)

A solution of Intermediate 149a (200 mg, 0.32 mmol) and DIPEA (164 μL,0.95 mmol) in DCM (4 mL) was treated with methanesulfonyl chloride (32μL, 0.41 mmol) and the reaction mixture was stirred at RT for 0.5 h. Themixture was diluted with DCM (5 mL) and washed with water (10 mL) andbrine (10 mL). The layers were separated and the organic layer waspassed through a phase separator and concentrated in vacuo to afford thetitle compound as a pale yellow solid (208 mg, 92%). LCMS (Method 3): Rt3.02 min, m/z 713 [MH⁺].

c.1-[5-tert-Butyl-2-(3-morpholin-4-yl-methyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt (Example 149).

A mixture of Intermediate 149b (104 mg, 0.15 mmol) and morpholine (64μL, 0.73 mmol) in THF (2 mL) was stirred at 60° C. for 18 h. Thereaction mixture was cooled to RT, diluted with DCM (5 mL) and washedwith water (5 mL) and brine (5 mL). The organic layer was passed througha phase separator and concentrated in vacuo and the resultant residuewas purified by prep. HPLC, using 5-50% CH₃CN in water, buffered withformic acid, on a Gemini C₁₈ column, over 20 mins to afford the titlecompound as an off white solid (22 mg, 21%). LCMS (Method 5): Rt 2.66min, m/z 704.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s), 1.84-2.11(6H, m), 2.13 (3H, s), 2.15-2.26 (2H, m), 2.31-2.40 (5H, m), 3.10-3.17(1H, m, obscured by water), 3.51 (2H, s, obscured by water), 3.55 (4H,t, J=4.6 Hz), 3.99 (1H, t, J=8.0 Hz), 4.78-4.86 (1H, m), 5.39 (1H, t,J=4.2 Hz), 6.33 (1H, s), 7.06 (1H, d, J=8.6 Hz), 7.24-7.49 (9H, m), 7.75(1H, d, J=9.7 Hz), 8.10 (1H, s), 8.19 (0.6H, br s), 8.24 (1H, d, J=1.8Hz).

Example 1501-(5-tert-Butyl-2-{3-[(2-dimethylamino-ethyl)-methyl-amino]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformic acid salt

a. N-(3-Bromo-phenyl)-N,N′,N′-trimethyl-ethane-1,2-diamine (Intermediate150a)

A solution of N′-(3-bromo-phenyl)-N,N-dimethyl-ethane-1,2-diamine (400mg, 1.6 mmol) was formed in 1,2-dichloroethane (10 mL). Formaldehyde(250 μL, 37% in water, 3.3 mmol) was added and the mixture stirred for10 minutes at RT. Sodium triacetoxyborohydride (700 mg, 3.3 mmol) wasadded and the mixture stirred for 2 h at RT. Further formaldehyde (250μL, 37% in water, 3.3 mmol) and sodium triacetoxyborohydride (700 mg,3.3 mmol) were added and the mixture stirred at RT for 16 h. Mixturequenched with sat. NaHCO₃ (aq) and extracted with DCM. The combinedorganic phases were dried (Na₂SO₄) and concentrated in vacuo. Theresidue was purified by FCC, using 0-20% MeOH in DCM, to give the titlecompound (200 mg, 47%). LCMS (Method 3): Rt 2.35 min, ink 257, 259[MH⁺].

b.N-[3-(5-Amino-3-tert-butyl-pyrazol-1-yl)-phenyl]-N,N′,N′-trimethyl-ethane-1,2-diamine(Intermediate 150b)

A solution of Intermediate 150a (200 mg, 0.78 mmol),3-(tert-butyl)-1H-pyrazol-5-amine (130 mg, 0.93 mmol) andtrans-N,N′-dimethylcyclohexane diamine (22 mg, 0.16 mmol) was formed intoluene (2 mL). Potassium carbonate (226 mg, 1.6 mmol) was added and themixture degassed by bubbling nitrogen through it. Copper (I) iodide (15mg, 0.08 mmol) was added and the mixture was heated to 150° C. for 24 hunder microwave irradiation. The cooled reaction mixture wasconcentrated in vacuo and the residue was partitioned between EtOAc andwater. The phases were separated and the aqueous layer was extractedwith EtOAc. The combined organic phase was washed with brine, dried(Na₂SO₄) and concentrated in vacuo. The residue was purified by FCC,using 0-20% MeOH in DCM, to give the title compound (50 mg, 20%). LCMS(Method 3): Rt 1.84 min, m/z 316 [MH⁺].

c.(5-tert-Butyl-2-{3-[(2-dimethylamino-ethyl)-methyl-amino]-phenyl}-2H-pyrazol-3-yl)-carbamicacid phenyl ester (Intermediate 150c)

A solution of Intermediate 150b (50 mg, 0.16 mmol) in DCM (2 mL) wastreated with pyridine (26 μL, 0.32 mmol) and phenyl chloroformate (32μL, 0.25 mmol). The resulting mixture was stirred at RT for 2 h. Furtherpyridine (26 μL, 0.32 mmol) and phenyl chloroformate (32 μL, 0.25 mmol)were added and the mixture stirred at RT for 16 h. The mixture wasdiluted with water and the phases separated. The aqueous layer wasextracted with DCM and the combined organic phase was washed with brine,dried (Na₂SO₄), and concentrated in vacuo. The residue was purified byFCC, using 0-20% MeOH in DCM, to give the title compound (30 mg, 43%).LCMS (Method 3): Rt 2.97 min, m/z 436 [MH⁺].

d.1-(5-tert-Butyl-2-{3-[(2-dimethylamino-ethyl)-methyl-amino]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformic acid salt (Example 150).

A solution of Intermediate 81d (26 mg, 0.07 mmol) in 1,4-dioxane (2 mL)was treated with Intermediate 150c (30 mg, 0.07 mmol) and DIPEA (24 μL,0.13 mmol) and the mixture was stirred at 70° C. for 18 h. After coolingto RT the mixture was concentrated in vacuo. The residue was purified byFCC, using 0-20% MeOH in DCM, then by prep HPLC (C18 column, 10-98% MeCNin H₂O, 0.1% HCO₂H) over 20 mins. Concentration of the fractions invacuo gave pale yellow glass. Trituration with Et₂O gave the titlecompound as an off white solid (20 mg, 40%). LCMS (Method 5): Rt 3.70min, m/z 719.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.4 Hz),1.27 (9H, s), 1.47-1.53 (2H, m), 1.64-1.71 (2H, m), 1.77-1.97 (4H, m),2.00-2.15 (2H, m), 2.16 (3H, s), 2.39 (2H, t, J=7.2 Hz), 2.87-2.92 (1H,m), 2.93 (3H, s), 3.13-3.21 (4H, m), 3.35-3.46 (4H, m), 4.80-4.87 (1H,m), 5.52 (1H, t, J=4.3 Hz), 6.32 (1H, s), 6.68-6.72 (3H, m), 7.13 (1H,d, J=8.6 Hz), 7.19 (1H, dd, J=9.7, 2.2 Hz), 7.24-7.38 (5H, m), 7.64 (1H,d, J=9.7 Hz), 7.69 (1H, m), 8.11 (1H, s).

Example 1511-{5-tert-Butyl-2-[3-((R)-2-dimethylamino-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.2-[3-((R)-2-Benzyloxy-1-methyl-ethoxy)-phenyl]-5-tert-butyl-2H-pyrazol-3-ylamine(Intermediate 151a)

A mixture of Intermediate 95a (0.50 g, 2.2 mmol) in dry THF (17 mL) wastreated with triphenylphosphine (1.13 g, 4.32 mmol) and(S)-(+)-1-Benzyloxy-2-propanol (0.52 mL, 3.24 mmol). The mixture wascooled to 0° C. then diisopropylazodicarboxylate (0.85 mL, 4.32 mmol)was added dropwise. After stirring at ambient temperature for 1.75 h themixture was treated with water (0.2 mL) then applied to apre-conditioned (with MeOH) SCX-2 cartridge. The cartridge was elutedwith MeOH then 2N NH₃ in MeOH. The product containing fractions werecombined and concentrated in vacuo to a viscous brown oil. The oil waspurified by FCC, using 0-30% EtOAc in cyclohexane, to give the titlecompound as a golden oil (0.37 g, 45%). LCMS (Method 3): Rt 3.71 min,m/z 380.3 [MH⁺].

b. (R)-2-[3-(5-Amino-3-tert-butyl-pyrazol-1-yl)-phenoxy]-propan-1-ol(Intermediate 151b)

A solution of Intermediate 151a (0.37 g, 0.97 mmol) in ethanol (IMSgrade, 8 mL) was treated with water (1 mL) and ammonium formate (0.61 g,9.7 mmol). The mixture was purged with N₂ then 10% Pd/C (0.31 g, 0.29mmol Pd) was added. The mixture was heated to reflux for 16 h thenfiltered through celite and the filtrate was concentrated in vacuo. Theresidue was partitioned between EtOAc and water. The phases wereseparated and the aqueous layer was extracted with EtOAc (×2). Thecombined organic phase was washed with saturated aqueous sodiumbicarbonate solution and brine, dried (Na₂SO₄) and concentrated invacuo. The residue was purified by FCC, using 0-75% EtOAc in cyclohexaneto give the title compound (0.22 g, 79%) as a pink gum. LCMS (Method 3):Rt 2.44 min, m/z 290.3 [MH⁺].

c.{5-tert-Butyl-2-[3-((R)-2-hydroxy-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 151c)

A solution of Intermediate 151b (112 mg, 0.39 mmol) in EtOAc (2.1 mL)was treated with aqueous 1N NaOH (0.7 mL, 0.70 mmol) then2,2,2-trichloroethyl chloroformate (0.056 mL, 0.41 mmol) and the mixturewas stirred at RT for 2.5 h. The mixture was treated with anotherportion of 2,2,2-trichloroethyl chloroformate (0.015 mL, 0.11 mmol) andstirred at RT for a further 1 h. The mixture was diluted with EtOAc andwater and the phases were separated. The aqueous layer was extractedwith EtOAc (×2) and the combined organic phase was washed with brine,dried (Na₂SO₄), and concentrated in vacuo to give a pale red gum (195mg). The gum was purified by FCC, using 0-40% EtOAc in cyclohexane, togive the title compound as a pale golden gum (134 mg, 74%). LCMS (Method3): Rt 4.15 min, m/z 464.2, 466.2 [MH⁺].

d.1-{5-tert-Butyl-2-[3-((R)-2-hydroxy-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 151d)

A solution of Intermediate 151c (102 mg, 0.22 mmol) in 1,4-dioxane (2.0mL) was treated with Intermediate 81d (75 mg, 0.20 mmol) and DIPEA(0.043 mL, 0.25 mmol) and the mixture was stirred at 70° C. for 7.5 hthen at 50° C. for 64 h. The cooled solution was concentrated in vacuo,and the residue was partitioned between DCM and water. The phases wereseparated and the aqueous layer was extracted with DCM (×2). Thecombined organic phase was washed with brine, dried (Na₂SO₄) andconcentrated in vacuo to a brown gum. The gum was purified by FCC, using0-10% MeOH in DCM to give the title compound as a yellow glass (84 mg,61%). LCMS (Method 3): Rt 3.75 min, m/z 693.5 [MH⁺].

e. Methanesulfonic acid(R)-2-{3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-phenoxy}-propylurea (Intermediate 151e)

A solution of Intermediate 151d (81 mg, 0.12 mmol) in DCM (2.7 mL) wastreated with DIPEA (0.061 mL, 0.35 mmol) then methanesulfonyl chloride(0.012 mL, 0.15 mmol). After 30 mins the mixture was treated withmethanesulfonyl chloride (0.012 mL, 0.15 mmol) and then, after another30 mins, with DIPEA (0.030 mL, 0.18 mmol). The mixture was stirred at RTfor 16 h. Another portion of methanesulfonyl chloride (0.012 mL, 0.15mmol) was added and then after 30 mins another portion ofmethanesulfonyl chloride (0.012 mL, 0.15 mmol) and DIPEA (0.030 mL, 0.18mmol) were added. After 30 mins the mixture was diluted with DCM andsaturated aqueous sodium bicarbonate solution. The phases were separatedand the aqueous layer was extracted with DCM (×2). The combined organicphase was washed with water, saturated aqueous sodium bicarbonatesolution and brine, dried (Na₂SO₄) and concentrated in vacuo to give thetitle compound as a brown glass (92 mg, quant.). LCMS (Method 3): Rt3.97 min, m/z 771.5 [MH⁺].

f.1-{5-tert-Butyl-2-[3-((R)-2-dimethylamino-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 151).

A solution of Intermediate 151e (89 mg, 0.12 mmol) in THF (0.8 mL) wastreated with a 2M solution of dimethylamine in THF (1.2 mL, 2.3 mmol)and the mixture was stirred at 60° C. for 42 h. The cooled solution wasconcentrated in vacuo, and the residue was partitioned between DCM andwater. The phases were separated and the aqueous layer was extractedwith DCM (×2). The combined organic phase was washed with brine, dried(Na₂SO₄) and concentrated in vacuo to a brown glass. The glass waspurified by HPLC (Phenomenex Gemini C18 column, 5-95% MeCN in H₂O, 0.1%HCO₂H) over 25 mins. Concentration of the fractions in vacuo gave a paleyellow glass. The glass was triturated with ether to give a solid thatwas filtered off to give the title compound as a fawn coloured solid (16mg, 19%). LCMS (Method 5): Rt 3.68 min, m/z 720.5 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 0.91 (3H, d, J=6.5 Hz), 1.24 (3H, d, J=6.1 Hz), 1.27 (9H,s), 1.46-1.56 (2H, m), 1.61-1.72 (2H, m), 1.74-1.98 (4H, m), 1.99-2.16(2H, m), 2.17 (6H, s), 2.32-2.39 (1H, m), 2.86-2.95 (1H, m), 3.13-3.19(1H, m), 3.29-3.34 (1H, m), 4.56-4.65 (1H, m), 4.79-4.86 (1H, m), 5.52(1H, t, J=4.4 Hz), 6.32 (1H, s), 6.94-6.99 (1H, m), 7.03-7.12 (3H, m),7.19 (1H, dd, J=9.9, 2.0 Hz), 7.24-7.41 (5H, m), 7.64 (1H, d, J=10.2Hz), 7.68-7.70 (1H, m), 8.15 (1H, s), 8.20 (1H, s).

Example 1521-{5-tert-Butyl-2-[3-((S)-2-dimethylamino-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.2-[3-((S)-2-Benzyloxy-1-methyl-ethoxy)-phenyl]-5-tert-butyl-2H-pyrazol-3-ylamine(Intermediate 152a)

A mixture of Intermediate 95a (0.50 g, 2.2 mmol) in dry THF (17 mL) wastreated with triphenylphosphine (1.13 g, 4.32 mmol) and(R)-(−)-1-benzyloxy-2-propanol (0.52 mL, 3.24 mmol) thendiisopropylazodicarboxylate (0.85 mL, 4.32 mmol) was added dropwise (thereaction mixture became very warm). After stirring at ambienttemperature for 1.75 h the mixture was treated with water (0.2 mL) thenconcentrated in vacuo to a viscous orange oil. The oil was purified byFCC, using 0-7% EtOAc in DCM. The resulting oil was purified further byFCC, using 0-30% EtOAc in cyclohexane. The product was applied to apre-conditioned (with MeOH)SCX-2 cartridge and eluted with MeOH then 2NNH₃ in MeOH. The product containing fractions were combined andconcentrated in vacuo to give the title compound as a viscous golden oil(0.39 g, 48%). LCMS (Method 3): Rt 3.77 min, m/z 380.4 [MH⁺].

b. (S)-2-[3-(5-Amino-3-tert-butyl-pyrazol-1-yl)-phenoxy]-propan-1-ol(Intermediate 152b)

A solution of Intermediate 152a (0.39 g, 1.0 mmol) in ethanol (IMSgrade, 10 mL) was purged with N₂ then 10% Pd/C (0.11 g, 0.1 mmol Pd) wasadded. The mixture was purged with H₂ then stirred under an atmosphereof H₂ (balloon) at ambient temperature for 2 h, then at 50° C. for 1.5 hand 45° C. for 30 mins. Another portion of Pd/C (0.11 g, 0.1 mmol Pd)was added and the mixture was stirred at 45° C. for 16 h. The cooledreaction mixture was purged with N₂ and treated with water (2 mL) thenammonium formate (0.65 g, 10.3 mmol) and heated to reflux for 5. Anotherportion of ammonium formate (0.65 g, 10.3 mmol) and Pd/C (0.11 g, 0.1mmol) were added and the mixture was stirred at reflux for 16 h. Themixture was filtered through celite and the filtrate was concentrated invacuo. The residue was partitioned between EtOAc and water. The phaseswere separated and the aqueous layer was extracted with EtOAc (×2). Thecombined organic phase was washed with saturated aqueous sodiumbicarbonate solution and brine, dried (Na₂SO₄) and concentrated invacuo. The residue was purified by FCC, using 0-75% EtOAc in cyclohexaneto give the title compound (0.25 g, 83%) as a pink gum. LCMS (Method 3):Rt 2.44 min, m/z 290.3 [MH⁺].

c.{5-tert-Butyl-2-[3-((S)-2-hydroxy-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 152c)

A solution of Intermediate 152b (69 mg, 0.24 mmol) in EtOAc (1.2 mL) wastreated with aqueous 1N NaOH (0.4 mL, 0.43 mmol) then2,2,2-trichloroethyl chloroformate (0.034 mL, 0.25 mmol) and the mixturewas stirred at RT for 2.5 h. The mixture was treated with anotherportion of 2,2,2-trichloroethyl chloroformate (0.010 mL, 0.07 mmol) andstirred at RT for a further 0.75 h. The mixture was diluted with EtOAcand water and the phases were separated. The aqueous layer was extractedwith EtOAc (×2) and the combined organic phase was washed with brine,dried (Na₂SO₄), and concentrated in vacuo to give a pale red gum (121mg). The gum was purified by FCC, using 0-40% EtOAc in cyclohexane, togive the title compound as a pale golden gum (62 mg, 56%). LCMS (Method3): Rt 4.15 min, m/z 464.2, 466.2 [MH⁺].

d.1-{5-tert-Butyl-2-[3-((S)-2-hydroxy-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 152d)

A solution of Intermediate 152c (59 mg, 0.13 mmol) in 1,4-dioxane (1.3mL) was treated with Intermediate 81d (44 mg, 0.12 mmol) and DIPEA(0.025 mL, 0.14 mmol) and the mixture was stirred at 70° C. for 6.75 hthen at 50° C. for 64 h. The cooled solution was concentrated in vacuo,and the residue was partitioned between DCM and water. The phases wereseparated and the aqueous layer was extracted with DCM (×2). Thecombined organic phase was washed with brine, dried (Na₂SO₄) andconcentrated in vacuo to a brown gum. The gum was purified by FCC, using0-10% MeOH in DCM to give the title compound as a pale yellow glass (49mg, 61%). LCMS (Method 3): Rt 3.74 min, m/z 693.5 [MH⁺].

e. Methanesulfonic acid(S)-2-{3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-phenoxy}-propylurea (Intermediate 152e)

A solution of Intermediate 152d (46 mg, 0.066 mmol) in DCM (1.5 mL) wastreated with DIPEA (0.035 mL, 0.20 mmol) then methanesulfonyl chloride(0.0067 mL, 0.086 mmol). After 30 mins the mixture was treated withmethanesulfonyl chloride (0.0067 mL, 0.086 mmol) and then, after another30 mins, with DIPEA (0.018 mL, 0.10 mmol). The mixture was stirred at RTfor 16 h. Another portion of methanesulfonyl chloride (0.0067 mL, 0.086mmol) was added and then after 30 mins another portion ofmethanesulfonyl chloride (0.0067 mL, 0.086 mmol) and DIPEA (0.018 mL,0.10 mmol) were added. After 30 mins the mixture was diluted with DCMand saturated aqueous sodium bicarbonate solution. The phases wereseparated and the aqueous layer was extracted with DCM (×2). Thecombined organic phase was washed with water, saturated aqueous sodiumbicarbonate solution and brine, dried (Na₂SO₄) and concentrated in vacuoto give the title compound as a brown glass (54 mg, quant.). LCMS(Method 3): Rt 3.99 min, m/z 771.5 [MH⁺].

f.1-{5-tert-Butyl-2-[3-((S)-2-dimethylamino-1-methyl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 152).

A solution of Intermediate 152e (51 mg, 0.066 mmol) in THF (0.4 mL) wastreated with a 2M solution of dimethylamine in THF (0.66 mL, 1.32 mmol)and the mixture was stirred at 60° C. for 42 h. The cooled solution wasconcentrated in vacuo, and the residue was partitioned between DCM andwater. The phases were separated and the aqueous layer was extractedwith DCM (×2). The combined organic phase was washed with brine, dried(Na₂SO₄) and concentrated in vacuo to a brown glass. The glass waspurified by HPLC (Phenomenex Gemini C18 column, 5-95% MeCN in H₂O, 0.1%HCO₂H) over 25 mins. Concentration of the fractions in vacuo gave a paleyellow glass. The glass was triturated with diethyl ether to give titlecompound as a fawn coloured solid (2.5 mg, 5%). LCMS (Method 5): Rt 3.68min, m/z 720.5 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.5 Hz),1.24 (3H, d, J=6.5 Hz), 1.27 (9H, s), 1.46-1.56 (2H, m), 1.61-1.72 (2H,m), 1.74-1.98 (4H, m), 1.99-2.16 (2H, m), 2.18 (6H, s), 2.32-2.38 (1H,m), 2.86-2.95 (1H, m), 3.12-3.19 (1H, m), 4.56-4.65 (1H, m), 4.78-4.86(1H, m), 5.52 (1H, t, J=4.1 Hz), 6.32 (1H, s), 6.94-6.99 (1H, m),7.03-7.11 (3H, m), 7.19 (1H, dd, J=9.6, 2.4 Hz), 7.24-7.41 (5H, m), 7.64(1H, d, J=10.0 Hz), 7.68-7.70 (1H, m), 8.15 (1H, s), 8.21 (1H, s).

Example 1531-[2-[3-(2-Dimethylamino-ethoxy)-phenyl]-5-(2-hydroxy-1,1-dimethyl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthal en-1-yl}-urea formate salt

a. 3-(tert-Butyl-diphenyl-silanyloxy)-2,2-dimethyl-propionic acid methylester (Intermediate 153a)

A solution of methyl 2,2-dimethyl-3-hydroxypropionate (5.0 g, 37.8 mmol)in DMF (75 mL) was cooled to 0° C. and treated with imidazole (3.86 g,56.7 mmol) then tert-butyl diphenylchlorosilane (11.8 mL, 45.4 mmol).The mixture was stirred at RT for 22 h then concentrated in vacuo. Theresidue was partitioned between EtOAc and water. The phases wereseparated and the aqueous layer was extracted with EtOAc (×2). Thecombined organic phase was washed with 10% aqueous citric acid solution,saturated aqueous sodium bicarbonate solution and brine, dried (Na₂SO₄)and concentrated in vacuo to give the title compound as a golden oil(15.93 g, quant.). LCMS (Method 3): Rt 5.32 min, m/z 393.3 [M+Na⁺].

b. 5-(tert-Butyl-diphenyl-silanyloxy)-4,4-dimethyl-3-oxo-pentanenitrile(Intermediate 153b)

A suspension of sodium hydride (60% dispersion in oil) (2.12 g, 52.9mmol) in toluene (65 mL) at reflux under N₂ was added over 55 mins asolution of Intermediate 153a (15.93 g, assumed 37.8 mmol) andacetonitrile (2.87 mL, 54.9 mmol) in toluene (31 mL). The mixture washeated at reflux for 67 h. The cooled reaction mixture was slowlyacidified to pH 5 with aqueous 1N HCl and extracted with EtOAc. Theaqueous layer was extracted with EtOAc (×2) and the combined organicphase was washed with brine, dried (Na₂SO₄) and concentrated in vacuo.The residue was purified by FCC, using 0-50% ether in pentane, to givethe title compound (3.52 g, 25%) as a yellow oil. LCMS (Method 3): Rt4.94 min, m/z 402.3 [M+Na⁺].

c.2-(3-Benzyloxy-phenyl)-5-[2-(tert-butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-2H-pyrazol-3-ylamine(Intermediate 153c)

A solution of Intermediate 153b (1.00 g, 2.63 mmol) in ethanol (IMSgrade, 20 mL) was treated with 3-benzyloxyphenylhydrazine hydrochloride(0.66 mL, 2.63 mmol) then DIPEA (0.46 mL, 2.63 mmol) and the mixture washeated to reflux for 114 h. The cooled reaction mixture was diluted withEtOAc and a saturated aqueous sodium bicarbonate solution and themixture was filtered and the phases separated. The aqueous layer wasextracted with EtOAc (×2) and the combined organic phase was washed withbrine, dried (Na₂SO₄), and concentrated in vacuo to give an orange oil(1.62 g). The gum was purified by FCC, using 0-20% EtOAc in cyclohexane,to give the title compound as a yellow oil (1.21 g, 80%). LCMS (Method3): Rt 5.40 min, m/z 576.5 [MH⁺].

d.3-{5-Amino-3-[2-(tert-butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-pyrazol-1-yl}-phenol(Intermediate 153d)

A solution of Intermediate 153c (1.21 g, 2.1 mmol) in ethanol (IMSgrade, 20 mL) was treated with water (1 mL) and ammonium formate (1.33g, 21 mmol). The mixture was purged with N₂ then 10% Pd/C (0.67 g, 0.63mmol Pd) was added. The mixture was heated to reflux for 1 h thenfiltered through celite and the filtrate was concentrated in vacuo. Theresidue was partitioned between EtOAc and water. The phases wereseparated and the aqueous layer was extracted with EtOAc (×2). Thecombined organic phase was washed with brine, dried (Na₂SO₄) andconcentrated in vacuo. The residue was purified by FCC, using 0-40%EtOAc in cyclohexane, to give the title compound (0.53 g, 41% over 2steps) as a golden gum. LCMS (Method 3): Rt 4.55 min, m/z 486.5 [MH⁺].

e.5-[2-(tert-Butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-ylamine(Intermediate 153e)

A mixture of Intermediate 153d (0.53 g, 1.09 mmol) in dry THF (8 mL) wastreated with triphenylphosphine (0.57 g, 2.18 mmol) and2-(tetrahydro-2H-pyran-2-yloxy)ethanol (0.22 mL, 1.64 mmol). The mixturewas cooled to 0° C. then diisopropylazodicarboxylate (0.43 mL, 2.18mmol) was added dropwise. After stirring at ambient temperature for 20 hthe mixture was treated with water (0.1 mL) and concentrated in vacuo toa yellow oil. The oil was purified by FCC, using 0-30% EtOAc incyclohexane, to give the title compound as an orange oil (0.41 g, 61%).LCMS (Method 3): Rt 5.25 min, m/z 614.6 [MH⁺].

f.(5-[2-(tert-Butyl-diphenyl-silanyloxy)-1,1-dimethyl-ethyl]-2-{3-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 153f)

A solution of Intermediate 153e (0.41 g, 0.67 mmol) in EtOAc (3.6 mL)was treated with aqueous 1N NaOH (1.2 mL, 1.2 mmol) then2,2,2-trichloroethyl chloroformate (0.10 mL, 0.74 mmol) and the mixturewas stirred at RT for 4 h. The mixture was diluted with EtOAc and waterand the phases were separated. The aqueous layer was extracted withEtOAc (×2) and the combined organic phase was washed with brine, dried(Na₂SO₄), and concentrated in vacuo to give a pale red oil (0.67 g). Theoil was purified by FCC, using 0-25% EtOAc in cyclohexane to give thetitle compound as a pale golden gum (0.38 g, 72%). LCMS (Method 3): Rt5.86 min, m/z 788.3, 790.3 [MH⁺].

g.1-[3-(1-{[tert-Butyl(diphenyl)silyl]oxy}-2-methylpropan-2-yl)-1-{3-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]phenyl}-1H-pyrazol-5-yl]-3-[(1S,4R)-4-({3-[(2S)-2-methylpiperidin-1-yl][1,2,4]triazolo[4,3-a]pyridin-6-yl}oxy)-1,2,3,4-tetrahydronaphthalen-1-yl]urea(Intermediate 153g)

A solution of Intermediate 153f (377 mg, 0.48 mmol) in 1,4-dioxane (4.8mL) was treated with Intermediate 81d (164 mg, 0.43 mmol) and DIPEA(0.095 mL, 0.54 mmol) and the mixture was stirred at 70° C. for 30 minsthen at 50° C. for 64 h then at 70° C. for 22 h. The cooled solution wasconcentrated in vacuo, and the residue was partitioned between DCM andwater. The phases were separated and the aqueous layer was extractedwith DCM (×2). The combined organic phase was washed with brine, dried(Na₂SO₄) and concentrated in vacuo to a brown gum. The gum was purifiedby FCC, using 0-7% MeOH in DCM to give the title compound as a brownglass (320 mg, 72%). LCMS (Method 3): Rt 5.66 min, m/z 1017.7 [MH⁺].

h.1-{3-(1-{[tert-Butyl(diphenyl)silyl]oxy}-2-methylpropan-2-yl)-1-[3-(2-hydroxyethoxy)phenyl]-1H-pyrazol-5-yl}-3-[(1S,4R)-4-({3-[(2S)-2-methylpiperidin-1-yl][1,2,4]triazolo[4,3-a]pyridin-6-yl}oxy)-1,2,3,4-tetrahydronaphthalen-1-yl]urea(Intermediate 153h)

A solution of Intermediate 153 g (317 mg, 0.31 mmol) in MeOH (3.1 mL)was treated with pyridinium para-toluenesulfonate (235 mg, 0.93 mmol)and the mixture was stirred at 45° C. for 19 h. The cooled solution wasconcentrated in vacuo, and the residue was partitioned between DCM and asaturated aqueous sodium bicarbonate solution. The phases were separatedand the aqueous layer was extracted with DCM (×2). The combined organicphase was washed with water, a saturated aqueous sodium bicarbonatesolution, and brine, dried (Na₂SO₄) and concentrated in vacuo to a creamcoloured foam. The foam was purified by FCC, using 0-10% MeOH in DCM, togive the title compound as a colourless glass (217 mg, 75%). LCMS(Method 3): Rt 5.06 min, m/z 933.7 [MH⁺].

i.2-{3-[3-(1-{[tert-Butyl(diphenyl)silyl]oxy}-2-methylpropan-2-yl)-5-({[(1S,4R)-4-({3-[(2S)-2-methylpiperidin-1-yl][1,2,4]triazolo[4,3-a]pyridin-6-yl}oxy)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}amino)-1H-pyrazol-1-yl]phenoxy}ethylmethanesulfonate (Intermediate 153i)

A solution of Intermediate 153h (214 mg, 0.23 mmol) in DCM (2.3 mL) wastreated with DIPEA (0.12 mL, 0.69 mmol) then methanesulfonyl chloride(0.037 mL, 0.48 mmol). After 30 mins the mixture was diluted with DCMand saturated aqueous sodium bicarbonate solution. The phases wereseparated and the aqueous layer was extracted with DCM (×2). Thecombined organic phase was washed with water, saturated aqueous sodiumbicarbonate solution and brine, dried (Na₂SO₄) and concentrated in vacuoto an orange gum. The gum was purified by FCC, using 0-8% MeOH in DCM,to give the title compound as a pale brown glass (134 mg, 58%). LCMS(Method 3): Rt 5.18 min, m/z 1011.7 [MH⁺].

j.1-[3-(1-{[tert-Butyl(diphenyl)silyl]oxy}-2-methylpropan-2-yl)-1-{3-[2-(dimethylamino)ethoxy]phenyl}-1H-pyrazol-5-yl]-3-[(1S,4R)-4-({3-[(2S)-2-methylpiperidin-1-yl][1,2,4]triazolo[4,3-a]pyridin-6-yl}oxy)-1,2,3,4-tetrahydronaphthalen-1-yl]urea(Example 153j).

A solution of Intermediate 153i (131 mg, 0.13 mmol) in THF (0.8 mL) wastreated with a 2M solution of dimethylamine in THF (1.3 mL, 2.6 mmol)and the mixture was stirred at 60° C. for 18 h. The cooled solution wasconcentrated in vacuo, and the residue was partitioned between DCM andwater. The phases were separated and the aqueous layer was extractedwith DCM (×2). The combined organic phase was washed with brine, dried(Na₂SO₄) and concentrated in vacuo to a brown gum. The gum was purifiedby FCC, using 0-8% (2N NH₃/MeOH) in DCM, to give the title compound as awhite foam (93 mg, 75%). LCMS (Method 3): Rt 3.91 min, m/z 960.6 [MH⁺].

1-[2-[3-(2-Dimethylamino-ethoxy)-phenyl]-5-(2-hydroxy-1,1-dimethyl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 153).

A solution of Intermediate 153j (90 mg, 0.09 mmol) in THF (0.5 mL) wastreated with a 1M solution of tetrabutylammonium fluoride in THF (0.5mL, 0.5 mmol) and the reaction mixture was stirred at RT for 1 h then at50° C. for 16 h. The cooled solution was concentrated in vacuo, and theresidue was partitioned between DCM and a saturated aqueous sodiumbicarbonate solution. The phases were separated and the aqueous layerwas extracted with DCM (×2). The combined organic phase was washed withbrine, dried (Na₂SO₄) and concentrated in vacuo to a brown gum. The gumwas purified by FCC, using 0-8% [2M NH₃ in MeOH] in DCM, and thenpurified further by HPLC (Phenomenex Gemini C18 column, 5-95% MeCN inH₂O, 0.1% HCO₂H) over 25 mins to give a colourless glass. The glass wastriturated with diethyl ether to give the title compound as a whitesolid (11 mg, 16%). LCMS (Method 5): Rt 3.17 min, m/z 722.6 [MH⁺]. ¹HNMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.21 (6H, s), 1.44-1.57(2H, m), 1.62-1.73 (2H, m), 1.74-1.98 (4H, m), 1.99-2.17 (2H, m), 2.18(6H, s), 2.61 (2H, t, J=6.0 Hz), 2.86-2.95 (1H, m), 3.12-3.20 (1H, m),3.27-3.36 (1H, m), 3.44 (2H, s), 4.08 (2H, t, J=6.0 Hz), 4.78-4.86 (1H,m), 5.52 (1H, t, J=4.0 Hz), 6.32 (1H, s), 6.94-6.99 (1H, m), 7.06-7.14(3H, m), 7.19 (1H, dd, J=10.1, 2.0 Hz), 7.24-7.43 (5H, m), 7.64 (1H, d,J=9.7 Hz), 7.68-7.71 (1H, m), 8.15 (1H, s), 8.20 (1H, s).

Example 1541-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a. Methanesulfonic acid2-{3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]phenoxy}-ethylester (Intermediate 154a)

Methanesulfonyl chloride (81 μL, 1.05 mmol) was added to a stirredsolution of Intermediate 95e (545 mg, 803 mmol) and DIPEA (420 μL, 2.41mmol) in DCM (20 mL), under argon and the reaction mixture was stirredat RT for 1.5 h. A further 25 μL, 0.32 mmol of methanesulfonyl chloridewas added and the reaction mixture continued to stir at RT for 2 h.Water (20 mL) was added and the two layers were shaken thoroughly beforebeing separated. The aqueous layer was extracted with DCM (2×20 mL) andthe combined organics were passed through a phase separator andconcentrated in vacuo to afford the title compound as an orange glass(690 mg, >100%). LCMS (Method 3): Rt 3.89 min, m/z 757 [MH⁺].

b.1-{5-tert-Butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 154).

A solution of Intermediate 154a (50.5 mg, 0.067 mmol) and pyrrolidine(27 μL, 0.33 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in asealed tube. The mixture was concentrated in vacuo and the residuepurified by MDAP (Method 7). The title product was isolated as anoff-white solid (29 mg, 59%). LCMS (Method 5): Rt 3.72 min, m/z 732.6[MH⁺]. ¹H NMR (400 MHz, d₅-DMSO): 0.91 (3H, d, J=8.0 Hz), 1.28 (9H, s),1.46-1.56 (2H, m), 1.61-1.72 (6H, m), 1.75-1.98 (4H, m), 1.99-2.18 (2H,m), 2.52 (4H, m, obscured by solvent), 2.80 (2H, t, J=8.0 Hz), 2.86-2.95(1H, m), 3.12-3.19 (1H, m, obscured by water), 3.27-3.35 (1H, m,obscured by water), 4.11 (2H, t, J=8.0 Hz), 4.78-4.86 (1H, m), 5.52 (1H,t, J=4.0 Hz), 6.33 (1H, s), 6.97 (1H, dd, J=8.0 Hz, 4.0 Hz), 7.05-7.14(3H, m), 7.19 (1H, dd, J=8.0 Hz, 4.0 Hz), 7.24-7.42 (5H, m), 7.64 (1H,d, J=8.0 Hz), 7.69 (1H, d, J=4.0 Hz), 8.14 (1H, s), 8.18 (1.3H, s).

Example 1551-{5-tert-Butyl-2-[3-(2-diethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 0.067 mmol) and diethylamine(34 μL, 0.33 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in asealed tube. Additional diethylamine (102 μL, 0.99 mmol) was added andthe mixture subsequently stirred at 60° C. in a sealed tube for 24 h.The mixture was concentrated in vacuo and the residue purified by MDAP(Method 7). The title product was isolated as an off-white solid (22 mg,45%). LCMS (Method 5): Rt 3.74 min, m/z 734.6 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 0.89-0.96 (9H, m), 1.28 (9H, s), 1.46-1.56 (2H, m), 1.62-1.73(2H, m), 1.74-1.98 (4H, m), 1.99-2.18 (2H, m), 2.52 (4H, m, obscured bysolvent), 2.76 (2H, t, J=8.0 Hz), 2.87-2.94 (1H, m), 3.12-3.19 (1H, m,obscured by water), 3.30 (1H, m, obscured by water), 4.05 (2H, t, J=8.0Hz), 4.77-4.86 (1H, m), 5.52 (1H, t, J=4.0 Hz), 6.33 (1H, s), 6.95 (1H,dd, J=8.0 Hz, 4.0 Hz), 7.05-7.13 (3H, m), 7.19 (1H, dd, J=8.0 Hz, 4.0Hz), 7.24-7.42 (5H, m), 7.64 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=4.0 Hz),8.13 (1H, s), 8.19 (1H, s).

Example 1561-{5-tert-Butyl-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

A solution of Intermediate 154a (50.5 mg, 0.067 mmol) and morpholine (29μL, 0.33 mmol) in THF (1 mL) was stirred at 60° C. for 20 h in a sealedtube. Additional morpholine (29 μL, 0.33 mmol) was added and the mixturesubsequently stirred at 60° C. in a sealed tube for 24 h. The mixturewas concentrated in vacuo and the residue purified by MDAP (Method 7).The title product was isolated as an off-white solid (25 mg, 50%). LCMS(Method 5): Rt 3.66 min, m/z 748.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.91 (3H, d, J=6.0 Hz), 1.27 (9H, s), 1.46-1.56 (2H, m), 1.61-1.73 (2H,m), 1.75-1.98 (4H, m), 1.99-2.19 (2H, m), 2.42 (4H, t, J=4.0 Hz), 2.67(2H, t, J=8.0 Hz), 2.86-2.95 (1H, m), 3.12-3.20 (1H, m, obscured bywater), 3.30 (1H, m, obscured by water), 3.53 (4H, t, J=8.0 Hz), 4.12(2H, t, J=8.0 Hz), 4.77-4.86 (1H, m), 5.52 (1H, t, J=4.0 Hz), 6.33 (1H,s), 6.95-6.99 (1H, m), 7.07-7.13 (3H, m), 7.19 (1H, dd, J=8.0 Hz, 4.0Hz), 7.25-7.43 (5H, m), 7.64 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=4.0 Hz),8.13 (1H, s), 8.21 (0.5H, s).

Example 1571-{5-tert-Butyl-2-[3-(2-piperidin-1-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (66 mg, 88 μmol) and piperidine (44 μL,0.45 mmol) in THF (2 mL) was heated at 60° C. overnight in a sealedvessel. The reaction mixture was concentrated in vacuo and the residuepurified by MDAP (Method 7) to give the title compound as a white solid(31 mg, 46%). LCMS (Method 5): Rt 3.77 min, m/z 746 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 0.91 (3H, d, J=6.2 Hz), 1.24-1.34 (11H, m), 1.39-1.55(6H, m), 1.61-2.18 (8H, m), 2.34-2.43 (4H, m), 2.63 (2H, t, J=6.1 Hz),2.86-2.94 (1H, m), 3.11-3.19 (1H, m), 3.27-3.36 (1H, m), 4.09 (2H, t,J=5.9 Hz), 4.77 (1H, m), 5.52 (1H, t, J=4.0 Hz), 6.32 (1H, s), 6.93-6.98(1H, m), 7.04-7.13 (3H, m), 7.19 (1H, dd, J=9.5 Hz, 2.6 Hz), 7.24-7.42(5H, m), 7.64 (1H, d, J=9.9 Hz), 7.69 (1H, d, J=1.8 Hz), 8.12 (1H, s),8.17 (1.5H, s).

Example 1581-(5-tert-Butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 0.067 mmol) and1-methylpiperazine (37 μL, 0.33 mmol) in THF (1 mL) was stirred at 60°C. for 20 h in a sealed tube. The mixture was concentrated in vacuo andthe residue purified by MDAP (Method 7). The title product was isolatedas an off-white solid (28 mg, 55%). LCMS (Method 5): Rt 3.62 min, ink761.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=8.0 Hz), 1.28(9H, s), 1.47-1.56 (2H, m), 1.61-1.73 (2H, m), 1.74-1.97 (4H, m),2.00-2.19 (5H, m), 2.21-2.35 (4H, m), 2.36-2.49 (4H, m), 2.66 (2H, t,J=8.0 Hz), 2.86-2.95 (1H, m), 3.12-3.19 (1H, m, obscured by water),3.27-3.35 (1H, m, obscured by water), 4.10 (2H, t, J=8.0 Hz), 4.78-4.86(1H, m), 5.52 (1H, t, J=4.0 Hz), 6.33 (1H, s), 6.94-6.98 (1H, m),7.05-7.13 (3H, m), 7.19 (1H, dd, J=8.0 Hz, 4.0 Hz), 7.24-7.42 (5H, m),7.64 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=4.0 Hz), 8.13 (1H, s), 8.17(1.4H, s).

Example 1591-{5-tert-Butyl-2-{3-[2-(4-fluoropiperidin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 0.067 mmol) and4-fluoropiperidine (34 mg, 0.33 mmol) in THF (1 mL) was stirred at 60°C. for 20 h in a sealed tube. Additional 4-fluoropiperidine (34 mg, 0.33mmol) was added and the mixture subsequently stirred at 60° C. in asealed tube for 24 h. The mixture was concentrated in vacuo and theresidue purified by MDAP (Method 7). The title product was isolated asan off-white solid (24 mg, 47%). LCMS (Method 5): Rt 3.75 min, m/z 764.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=8.0 Hz), 1.27 (9H, s),1.44-1.64 (2H, m), 1.59-1.72 (4H, m), 1.72-1.98 (6H, m), 1.99-2.19 (2H,m), 2.31-2.40 (2H, m), 2.55-2.64 (2H, m), 2.68 (2H, t, J=8.0 Hz),2.87-2.95 (1H, m), 3.12-3.19 (1H, m, obscured by water), 3.30 (1H, m,completely obscured by water), 4.10 (2H, t, J=8.0 Hz), 4.51-4.59 (0.5H,m), 4.64-4.71 (0.5H, m), 4.78-4.86 (1H, m), 5.52 (1H, t, J=4.0 Hz), 6.33(1H, s), 6.95-6.99 (1H, m), 7.06-7.13 (3H, m), 7.19 (1H, dd, J=8.0 Hz,4.0 Hz), 7.25-7.42 (5H, m), 7.64 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=4.0Hz), 8.12 (1H, s), 8.18 (1H, s).

Example 1601-(5-tert-Butyl-2-{3-[2-(4-methyl-[1,4]-diazepan-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 0.066 mmol) and N-methylhomopiperazine (39 mg, 0.34 mmol) in THF (1 mL) was heated at 60° C.overnight in a sealed vessel. The reaction mixture was concentrated invacuo and the residue purified by MDAP (Method 7) to give a white solidof the title compound (28 mg, 54%). LCMS (Method 5): Rt 3.28 min, m/z775 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.0 Hz), 1.27 (9H,s), 1.47-1.56 (2H, m), 1.62-1.73 (4H, m), 1.75-2.18 (6H, m), 2.28 (3H,s), 2.56-2.63 (4H, m), 2.70-2.77 (4H, m), 2.85 (2H, t, J=6.0 Hz),2.87-2.95 (1H, m), 3.12-3.20 (1H, m), 3.27-3.35 (1H, m), 4.07 (2H, t,J=5.6 Hz), 4.77-4.86 (1H, m), 5.52 (1H, t, J=3.8 Hz), 6.32 (1H, s),6.93-6.98 (1H, m), 7.04-7.10 (2H, m), 7.14 (1H, d, J=8.9 Hz), 7.19 (1H,dd, J=9.8 Hz, 2.2 Hz), 7.24-7.42 (5H, m), 7.64 (1H, d, J=4.9 Hz), 7.69(1H, d, J=1.8 Hz), 8.18 (1H, s), 8.20 (2H, s).

Example 1611-{5-tert-Butyl-2-[3-(2-[1,4]oxazepan-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 66 μmol) and [1,4]oxazepine(70 mg, 0.68 mmol) in THF (1 mL) was heated at 60° C. for 48 h in asealed vessel. The reaction mixture was concentrated in vacuo and theresidue purified by MDAP (Method 7) to give the title compound as awhite solid (27 mg, 53%). LCMS (Method 5): Rt 3.68 min, m/z 762 [MH⁺].¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.2 Hz), 1.27 (9H, s),1.46-1.54 (2H, m), 1.62-2.17 (12H, m), 2.67-2.72 (3H, m), 2.86 (2H, t,J=6.0 Hz), 2.88-2.94 (1H, m), 3.12-3.19 (1H, m), 3.28-3.34 (1H, m,obscured by water peak), 3.53-3.58 (2H, m), 3.61 (2H, t, J=6.0 Hz), 4.09(2H, t, J=6.1 Hz), 4.77-4.86 (1H, m), 5.52 (1H, t, J=4.3 Hz), 6.33 (1H,s), 6.94-6.99 (1H, m), 7.05-7.12 (2H, m), 7.19 (1H, dd, J=8.6 Hz, 2.0Hz), 7.24-7.42 (5H, m), 7.64 (1H, d, J=9.8 Hz), 7.69 (1H, d, J=2.0 Hz),8.17 (1H, s), 8.18 (1H, s).

Example 1621-(2-{3-[2-(8-Aza-bicyclo[3.2.1]oct-8-yl)-ethoxy]-phenyl}-5-tert-butyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 66 μmol) and8-aza-bicyclo[3.2.1]octane (38 mg, 0.34 mmol) in THF (1 mL) was heatedat 60° C. overnight in a sealed vessel. The reaction mixture wasconcentrated in vacuo and the residue purified by MDAP (Method 7) togive the title compound as a white solid (32 mg, 62%). LCMS (Method 5):Rt 3.84 min, ink 772 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d,J=6.4 Hz), 1.21-1.36 (11H, m), 1.37-1.54 (4H, m), 1.58-1.72 (4H, m),1.74-2.18 (8H, m), 2.72 (2H, d, J=6.4 Hz), 2.86-2.95 (1H, m), 3.11-3.20(1H, m), 3.22-3.36 (5H, m), 4.09 (2H, t, J=6.1 Hz), 4.77-4.86 (1H, m),5.52 (1H, t, J=4.1 Hz), 6.33 (1H, s), 6.94-6.99 (1H, m), 7.04-7.11 (2H,m), 7.14 (1H, d, J=8.6 Hz), 7.18 (1H, dd, J=10.2 Hz, 2.1 Hz), 7.24-7.42(5H, m), 7.64 (1H, d, J=10.2 Hz), 7.69 (1H, d, J=2.0 Hz), 8.17 (1H, s),8.19 (1.6H, s).

Example 1631-(5-tert-Butyl-2-{3-[2-(ethyl-methyl-amino)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 66 μmol) andN-ethylmethylamine (40 mg, 0.68 mmol) in THF (1 mL) was heated at 60° C.for 48 h in a sealed vessel. The reaction mixture was concentrated invacuo and the residue purified by MDAP (Method 7) to give the titlecompound as a white solid (24 mg, 50%). LCMS (Method 5): Rt 3.69 min,m/z 720 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 0.94(3H, t, J=7.2 Hz), 1.27 (9H, s), 1.46-1.55 (2H, m), 1.64-1.72 (2H, m),1.76-2.09 (6H, m), 2.19 (3H, s), 2.41 (2H, quart, J=7.0 Hz), 2.68 (2H,t, J=4.7 Hz), 2.86-2.94 (1H, m), 3.12-3.19 (1H, m), 3.29-3.34 (1H, m,obscured by water peak), 4.08 (2H, t, J=6.1 Hz), 4.77-4.86 (1H, m), 5.52(1H, t, J=4.4 Hz), 6.33 (1H, s), 6.94-6.98 (1H, m), 7.05-7.13 (3H, m),7.19 (1H, dd, J=9.6 Hz, 2.2 Hz), 7.23-7.42 (5H, m), 7.64 (1H, d, J=10.2Hz), 7.69 (1H, d, J=2.2 Hz), 8.13 (1H, s), 8.18 (1H, s).

Example 1641-{5-tert-Butyl-2-(3-{2-[(2-methoxy-ethyl)-methyl-amino]-ethoxy}-phenyl}-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 0.067 mmol) andN-(2-methoxyethyl)methylamine (35 μL, 0.33 mmol) in THF (1 mL) wasstirred at 60° C. for 20 h in a sealed tube. AdditionalN-(2-methoxyethyl)methylamine (35 μL, 0.33 mmol) was added and themixture subsequently stirred at 60° C. in a sealed tube for 24 h. Themixture was concentrated in vacuo and the residue purified by MDAP(Method 7). The title product was isolated as an off-white solid (24 mg,48%). LCMS (Method 5): Rt 3.72 min, m/z 750.6 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 0.91 (3H, d, J=8.0 Hz), 1.27 (9H, s), 1.44-1.56 (2H, m),1.61-1.73 (2H, m), 1.73-1.98 (4H, m), 1.98-2.22 (2H, m), 2.24 (3H, s),2.55 (2H, t, J=8.0 Hz), 2.74 (2H, t, J=8.0 Hz), 2.86-2.95 (1H, m),3.12-3.18 (1H, m, obscured by water), 3.19 (3H, s, obscured by water),3.30 (1H, m, obscured by water), 3.38 (2H, t, J=8.0 Hz, obscured bywater), 4.07 (2H, t, J=8.0 Hz), 4.78-4.86 (1H, m), 5.52 (1H, t, J=4.0Hz), 6.33 (1H, s), 6.94-6.99 (1H, m), 7.05-7.14 (3H, m), 7.19 (1H, dd,J=8.0 Hz, 4.0 Hz), 7.24-7.42 (5H, m), 7.64 (1H, d, J=8.0 Hz), 7.69 (1H,d, J=4.0 Hz), 8.13 (1H, s), 8.19 (1H, s).

Example 1651-(5-tert-Butyl-2-{3-[2-(4-methoxy-piperidin-1-yl-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 0.066 mmol) and4-methoxypiperidine (39 □L, 0.34 mmol) in THF (1 mL) was heated at 60°C. overnight in a sealed vessel. The reaction mixture was concentratedin vacuo and the residue purified by MDAP (Method 7) to give a whitesolid of the title compound (31 mg, 60%). LCMS (Method 5): Rt 3.75 min,m/z 776 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.2 Hz), 1.27(9H, s), 1.30-1.42 (2H, m), 1.45-1.57 (2H, m), 1.61-2.18 (13H, m), 2.66(2H, t, J=5.7 Hz), 2.68-2.76 (1H, m), 2.86-2.95 (1H, m), 3.04-3.19 (2H,m), 3.16 (3H, s), 3.28-3.34 (1H, m), 4.09 (2H, t, J=5.9 Hz), 4.77-4.85(1H, m), 5.52 (1H, t, J=4.3 Hz), 6.33 (1H, s), 6.93-6.98 (1H, m),7.04-7.13 (3H, m), 7.18 (1H, dd, J=10.3 Hz, 2.3 Hz), 7.24-7.42 (5H, m),7.64 (1H, d, J=9.5 Hz), 7.69 (1H, d, J=2.3 Hz), 8.12 (1H, s), 8.16(1.7H, s).

Example 1661-(5-tert-Butyl-2-{3-[2-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A solution of Intermediate 154a (50.5 mg, 66 μmol) and3-oxa-8-aza-bicyclo[3.2.1]octane (76 mg, 0.68 mmol) in THF (1 mL) washeated at 60° C. for 48 h in a sealed vessel. The reaction mixture wasconcentrated in vacuo and the residue purified by MDAP (Method 7) togive the title compound as a white solid (24 mg, 46%). LCMS (Method 5):Rt 3.72 min, m/z 774 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d,J=6.3 Hz), 1.28 (9H, s), 1.46-1.54 (2H, m), 1.64-1.71 (4H, m), 1.75-2.17(8H, m), 2.59 (2H, t, J=5.9 Hz), 2.86-2.95 (1H, m), 3.07-3.11 (2H, m),3.12-3.19 (1H, m), 3.28-3.34 (3H, m, obscured by water peak), 3.49 (2H,d, J=9.6 Hz), 4.09 (2H, t, J=6.3 Hz), 4.78-4.85 (1H, m), 5.52 (1H, t,J=4.3 Hz), 6.33 (1H, s), 6.94-6.99 (1H, m), 7.05-7.14 (3H, m), 7.19 (1H,dd, J=9.6 Hz, 2.4 Hz), 7.24-7.42 (5H, m), 7.64 (1H, d, J=10.0 Hz), 7.69(1H, d, J=2.2 Hz), 8.15 (1H, s), 8.20 (1H, s).

Example 1671-{5-tert-Butyl-2-[3-(4-methoxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.1-[5-tert-Butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 167a)

A mixture of Intermediate 81d (319 mg, 0.85 mmol), Intermediate 29c (335mg, 0.85 mmol) and DIPEA (294 μL, 1.69 mmol) in dioxane (10 mL) wasstirred at 80° C. for 18 hours. After cooling, the reaction mixture waspartitioned between water and DCM. The aqueous phase was extracted withEtOAc (×3) and the combined organic layers were washed with brine, dried(MgSO₄) and concentrated in vacuo. The resulting residue was purified byFCC on silica, using a gradient of 0-10% MeOH in DCM, to afford thetitle compound (362 mg, 66%). LCMS (Method 4): Rt 3.29 min, m/z 649[MH⁺].

b. Methanesulfonic acid3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]benzylester (Intermediate 167b)

To an ice-bath cooled solution of Intermediate 167a (316 mg, 0.49 mmol)in DCM (5.0 mL) was added DIPEA (339 μL, 1.95 mmol) followed bymethanesulfonyl chloride (76 μL, 0.97 mmol). The reaction mixture wasstirred for 3 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative, assumed 0.49 mmol). The isolated product wasused in the following step without further purification. LCMS (Method4): Rt 3.61 min, m/z 727 [MH⁺].

c.1-{5-tert-Butyl-2-[3-(4-methoxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 167).

To a solution of Intermediate 167b (0.19 mmol) in THF (2 mL) was addedDIPEA (130 μL, 0.75 mmol) and 4-methoxypiperidine (86 mg, 0.75 mmol) andthe reaction stirred at 50° C. for 24 h. The crude reaction mixture wascooled and partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultingresidue was purified by FCC on silica, using a gradient of 0-10% (2M NH₃in MeOH) in DCM, followed by MDAP (Method 7) purification, to give thetitle compound (20 mg, 14%). LCMS (Method 5): Rt 3.66 min, m/z 746[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.86 (3H, d, J=6.2 Hz), 1.23 (9H, s),1.30-1.40 (2H, m), 1.42-1.50 (2H, m), 1.58-1.67 (2H, m), 1.70-1.83 (5H,m), 1.83-1.93 (1H, m), 1.96-2.12 (4H, m), 2.56-2.64 (2H, m), 2.86 (1H,ddd, J=12.7, 9.0, 3.9 Hz), 3.05-3.12 (3H, m), 3.13 (3H, s), 3.45 (2H,s), 4.77 (1H, td, J=8.4, 5.7 Hz), 5.47 (1H, t, J=4.2 Hz), 6.28 (1H, s),7.00 (1H, d, J=8.6 Hz), 7.14 (1H, dd, J=9.8, 2.1 Hz), 7.20-7.30 (4H, m),7.30-7.37 (3H, m), 7.40 (1H, t, J=7.7 Hz), 7.59 (1H, d, J=10.0 Hz), 7.64(1H, d, J=1.8 Hz), 8.07 (1H, s), 8.23 (0.3H, s).

Example 1681-[5-tert-Butyl-2-(3-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.19 mmol) in THF (2 mL) was addedDIPEA (130 μL, 0.75 mmol) and N-(methoxyethyl)methylamine (81 μL, 0.75mmol) and the reaction stirred at 50° C. for 24 h. The crude reactionmixture was cooled and partitioned between EtOAc and water. The aqueousphase was extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by FCC on silica, using a gradient of0-10% (2M NH₃ in MeOH) in DCM, followed by MDAP (Method 7) purification,to give the title compound (20 mg, 14%). LCMS (Method 5): Rt 3.65 min,m/z 720 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.86 (3H, d, J=6.2 Hz), 1.23(9H, s), 1.42-1.48 (2H, m), 1.58-1.67 (2H, m), 1.72-1.92 (4H, m),1.96-2.12 (2H, m), 2.12 (3H, s), 2.49 (2H, t, J=6.0 Hz), 2.86 (1H, ddd,J=12.7, 9.0, 3.9 Hz), 3.12 (1H, dt, J=12.1, 4.3 Hz), 3.16 (3H, s), 3.39(2H, t, J=6.0 Hz), 3.50 (2H, s), 4.77 (1H, td, J=8.4, 5.7 Hz), 5.47 (1H,t, J=4.2 Hz), 6.28 (1H, s), 7.02 (1H, d, J=8.6 Hz), 7.14 (1H, dd, J=9.8,2.1 Hz), 7.20-7.25 (2H, m), 7.25-7.30 (2H, m), 7.30-7.35 (2H, m), 7.38(1H, s), 7.40 (1H, t, J=7.7 Hz), 7.59 (1H, d, J=10.0 Hz), 7.64 (1H, d,J=1.8 Hz), 8.07 (1H, s), 8.28 (0.2H, s).

Example 1691-{5-tert-Butyl-2-[3-(4-fluoro-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.19 mmol) in THF (2 mL) was addedDIPEA (260 μL, 1.5 mmol) and 4-fluoropiperidine hydrochloride (104 mg,0.75 mmol) and the reaction stirred at 50° C. for 24 h. The crudereaction mixture was cooled and partitioned between EtOAc and water. Theaqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resulting residue was purified by FCC on silica, using a gradient of0-10% (2M NH₃ in MeOH) in DCM, followed by MDAP (Method 7) purification,to give the title compound (25 mg, 16%). LCMS (Method 5): Rt 3.68 min,m/z 734 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.86 (3H, d, J=6.2 Hz), 1.23(9H, s), 1.42-1.50 (2H, m), 1.58-1.70 (4H, m), 1.70-1.92 (6H, m),1.95-2.12 (2H, m), 2.23-2.31 (2H, m), 2.86 (1H, ddd, J=12.7, 9.0, 3.9Hz), 3.11 (1H, dt, J=12.2, 4.3 Hz), 3.24-3.30 (2H, m), 3.48 (2H, s),4.60 (1H, dsp, J=48.9, 3.5 Hz), 4.77 (1H, td, J=8.4, 5.7 Hz), 5.47 (1H,t, J=4.2 Hz), 6.28 (1H, s), 6.98 (1H, d, J=8.6 Hz), 7.14 (1H, dd, J=9.8,2.1 Hz), 7.20-7.25 (2H, m), 7.25-7.34 (3H, m), 7.35-7.38 (2H, m), 7.40(1H, t, J=7.7 Hz), 7.59 (1H, d, J=10.0 Hz), 7.62 (1H, d, J=1.8 Hz), 8.05(1H, s), 8.10 (1.8H, s).

Example 1701-[5-tert-Butyl-2-(3-dimethylaminomethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.16 mmol) in THF (2.5 mL) was addeddimethylamine solution (2M THF, 1.6 mL, 3.27 mmol) and the reactionstirred at 50° C. for 24 h in a sealed vessel. The crude reactionmixture was cooled and partitioned between EtOAc and water. The aqueousphase was extracted with EtOAc (×3) and the combined organic layers werewashed with brine, dried (MgSO₄) and concentrated in vacuo. Theresulting residue was purified by FCC on silica, using a gradient of0-10% (2M NH₃ in MeOH) in DCM, followed by MDAP (Method 7) purification,to give the title compound (20 mg, 16%). LCMS (Method 5): Rt 3.58 min,m/z 676 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.86 (3H, d, J=6.2 Hz), 1.23(9H, s), 1.42-1.50 (2H, m), 1.58-1.67 (2H, m), 1.70-1.90 (4H, m),1.94-2.03 (1H, m), 2.04-2.12 (2H, m), 2.11 (6H, s), 2.86 (1H, ddd,J=12.7, 9.0, 3.9 Hz), 3.12 (1H, dt, J=11.9, 4.1 Hz), 3.39 (2H, s), 4.77(1H, td, J=8.4, 5.7 Hz), 5.46 (1H, t, J=4.2 Hz), 6.27 (1H, s), 7.02 (1H,d, J=8.6 Hz), 7.15 (1H, dd, J=9.8, 2.1 Hz), 7.20-7.29 (4H, m), 7.29-7.34(1H, m), 7.35-7.41 (3H, m), 7.59 (1H, d, J=10.0 Hz), 7.64 (1H, d, J=1.8Hz), 8.07 (1H, s), 8.25 (0.3H, s).

Example 1711-[5-tert-Butyl-2-(3-pyrrolidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.16 mmol) in THF (2 mL) was addedpyrrolidine (273 μL, 3.27 mmol) and the reaction stirred at 50° C. for24 h. The crude reaction mixture was cooled and partitioned betweenEtOAc and water. The aqueous phase was extracted with EtOAc (×3) and thecombined organic layers were washed with brine, dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-10% (2M NH₃ in MeOH) in DCM, followed byMDAP (Method 7) purification, to give the title compound (26 mg, 22%).LCMS (Method 5): Rt 3.64 min, m/z 702 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.86 (3H, d, J=6.2 Hz), 1.23 (9H, s), 1.42-1.50 (2H, m), 1.58-1.66 (6H,m), 1.70-1.84 (3H, m), 1.84-1.92 (1H, m), 1.95-2.12 (2H, m), 2.36-2.42(4H, m), 2.86 (1H, ddd, J=12.7, 9.0, 3.9 Hz), 3.12 (1H, dt, J=11.9, 4.1Hz), 3.58 (2H, s), 4.77 (1H, td, J=8.4, 5.7 Hz), 5.46 (1H, t, J=4.2 Hz),6.28 (1H, s), 7.01 (1H, d, J=8.6 Hz), 7.15 (1H, dd, J=9.8, 2.1 Hz),7.20-7.25 (2H, m), 7.26-7.34 (4H, m), 7.35 (1H, s), 7.39 (1H, t, J=7.8Hz), 7.59 (1H, d, J=10.0 Hz), 7.64 (1H, d, J=1.8 Hz), 8.07 (1H, s), 8.19(0.7H, s).

Example 1721-{(1S,4R)-4-[3-(4-Aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-ureaformate salt

A brown solution of Intermediate 148g (0.099 mmol) and morpholine (43mg, 0.50 mmol) in THF (1 mL) was stirred in a sealed vial at 60° C. for18 h. The solution was decanted and concentrated. MDAP (Method 7) gavethe title compound as an off-white solid (44 mg, 54%). LCMS (Method 5):Rt 3.64 min, m/z 760.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.41-0.54 (4H,m), 1.27 (9H, s), 1.52-1.62 (2H, m), 1.72-1.81 (3H, m), 1.83-1.96 (3H,m), 1.99-2.15 (2H, m), 2.42 (4H, t, J=4.4 Hz), 2.66 (2H, t, J=5.7 Hz),3.22-3.29 (2H, m), 3.52 (4H, t, J=4.58 Hz), 4.11 (2H, t, J=5.7 Hz), 4.81(1H, td, J=8.6, 5.5 Hz), 5.48 (1H, t, J=4.3 Hz), 6.33 (1H, s), 6.95-6.98(1H, m), 7.06-7.12 (3H, m), 7.14 (1H, dd, J=9.9, 2.2 Hz), 7.25-7.42 (5H,m), 7.57 (1H, dd, J=2.1, 0.9 Hz), 7.61 (1H, dd, J=9.8, 0.8 Hz), 8.11(1H, s), 8.16 (1.3H, s).

Example 1731-[5-tert-Butyl-2-(3-piperidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.22 mmol) in THF (2.5 mL) was addedpiperidine (424 μL, 4.3 mmol) and the reaction stirred at 50° C. for 24h. The crude reaction mixture was cooled and partitioned between EtOAcand water. The aqueous phase was extracted with EtOAc (×3) and thecombined organic layers were washed with brine, dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-10% (2M NH₃ in MeOH) in DCM, followed byMDAP (Method 7) purification, to give the title compound (44 mg, 25%).LCMS (Method 5): Rt 3.69 min, m/z 716 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.86 (3H, d, J=6.2 Hz), 1.23 (9H, s), 1.28-1.33 (2H, m), 1.38-1.48 (6H,m), 1.58-1.66 (2H, m), 1.70-1.92 (4H, m), 1.95-2.12 (2H, m), 2.26-2.34(4H, m), 2.86 (1H, ddd, J=12.7, 9.0, 3.9 Hz), 3.11 (1H, dt, J=11.9, 4.1Hz), 3.23-3.29 (1H, m), 3.44 (2H, s), 4.77 (1H, td, J=8.4, 5.7 Hz), 5.46(1H, t, J=4.2 Hz), 6.28 (1H, s), 6.99 (1H, d, J=8.6 Hz), 7.15 (1H, dd,J=9.8, 2.1 Hz), 7.20-7.25 (2H, m), 7.25-7.29 (2H, m), 7.29-7.36 (3H, m),7.39 (1H, t, J=7.8 Hz), 7.59 (1H, d, J=10.0 Hz), 7.64 (1H, d, J=1.8 Hz),8.06 (1H, s), 8.12 (1.8H, s).

Example 1741-{5-tert-Butyl-2-[3-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.22 mmol) in THF (2.5 mL) was added1-methylhomopiperazine (534 μL, 4.3 mmol) and the reaction stirred at50° C. for 24 h. The crude reaction mixture was cooled and partitionedbetween EtOAc and water. The aqueous phase was extracted with EtOAc (×3)and the combined organic layers were washed with brine, dried (MgSO₄)and concentrated in vacuo. The resultant residue was purified by FCC onsilica, using a gradient of 0-10% (2M NH₃ in MeOH) in DCM, followed byMDAP (Method 7) purification, to give the title compound (28 mg, 15%).LCMS (Method 5): Rt 3.27 min, m/z 745 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.86 (3H, d, J=6.2 Hz), 1.23 (9H, s), 1.42-1.50 (2H, m), 1.58-1.66 (2H,m), 1.68-1.84 (5H, m), 1.84-1.92 (1H, m), 1.95-2.05 (1H, m), 2.05-2.12(1H, m), 2.32 (3H, s), 2.58-2.66 (6H, m), 2.69 (2H, t, J=5.7 Hz), 2.86(1H, ddd, J=12.7, 9.0, 3.9 Hz), 3.11 (1H, dt, J=11.9, 4.1 Hz), 3.23-3.29(1H, m), 3.62 (2H, s), 4.77 (1H, td, J=8.4, 5.7 Hz), 5.47 (1H, t, J=4.2Hz), 6.28 (1H, s), 7.04 (1H, d, J=8.6 Hz), 7.14 (1H, dd, J=9.8, 2.1 Hz),7.20-7.25 (2H, m), 7.26-7.36 (4H, m), 7.38-7.43 (2H, m), 7.59 (1H, d,J=10.0 Hz), 7.64 (1H, d, J=1.8 Hz), 8.12 (1H, s), 8.16 (2.4H, s).

Example 1751-{5-tert-Butyl-2-[3-((1S,4S)-5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-aphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 167b (0.15 mmol) in THF (20 mL) was added(1S,4S)-2-methyl-2,5-diaza-bicyclo[2.2.1]heptane (366 mg, 3.3 mmol) andthe reaction stirred at 50° C. for 24 h. The crude reaction mixture wascooled and partitioned between EtOAc and water. The aqueous phase wasextracted with EtOAc (×3) and the combined organic layers were washedwith brine, dried (MgSO₄) and concentrated in vacuo. The resultantresidue was purified by FCC on silica, using a gradient of 0-10% (2M NH₃in MeOH) in DCM, then further purified by HPLC (C18 X-select column,10-75% MeCN in H₂O, 0.1% formic acid) to give the title compound (11 mg,9%). LCMS (Method 5): Rt 3.45 min, m/z 743 [MH⁺]. ¹H NMR (400 MHz,d₆-DMSO): 0.86 (3H, d, J=6.2 Hz), 1.23 (9H, s), 1.42-1.50 (2H, m),1.54-1.66 (4H, m), 1.72-1.84 (3H, m), 1.84-1.92 (1H, m), 1.95-2.15 (2H,m), 2.22 (3H, s), 2.46-2.48 (1H, m), 2.52 (1H, dd, J=9.6, 2.4 Hz), 2.59(1H, d, J=9.7 Hz), 2.71 (1H, d, J=9.6 Hz), 2.86 (1H, ddd, J=12.7, 9.0,3.9 Hz), 3.09-3.13 (2H, m), 3.22 (1H, s), 3.28-3.32 (1H, m), 3.63 (1H,d, J=13.9 Hz), 3.70 (1H, d, J=13.9 Hz), 4.77 (1H, td, J=8.4, 5.7 Hz),5.47 (1H, t, J=4.2 Hz), 6.28 (1H, s), 7.04 (1H, d, J=8.6 Hz), 7.14 (1H,dd, J=9.8, 2.1 Hz), 7.20-7.25 (2H, m), 7.26-7.36 (4H, m), 7.36-7.41 (2H,m), 7.59 (1H, d, J=10.0 Hz), 7.64 (1H, d, J=1.8 Hz), 8.11 (1H, s), 8.25(0.7H, s).

Example 1761-[5-tert-Butyl-2-(4-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

a.1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureadichloromethane solvate (Intermediate 176a)

A red-brown solution of Intermediate 33a (883 mg, 2.10 mmol),Intermediate 81d (755 mg, 2.00 mmol) and DIPEA (0.44 mL, 2.5 mmol) indry dioxane (20 mL) was stirred at 70° C. for 16 h, and at 80° C. for 5h. The cooled solution was concentrated in vacuo, suspended in water (15mL) and extracted with DCM (2×15 mL). The combined organics were passedthrough a hydrophobic frit and concentrated in vacuo to leave a brownoil. Flash chromatography (silica 80 g, 4-8% MeOH in DCM) gave the titlecompound as a pale yellow foam (1.27 g, 87%). LCMS (Method 3): Rt 3.61min, m/z 649 [MH⁺].

b.1-[5-tert-Butyl-2-(4-formyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 176b)

To a solution of Intermediate 176a (1.10 g, 1.70 mmol) in DCM (25 mL) at0° C. was added Dess-Martin periodinane (791 mg, 1.86 mmol) and theresulting red-brown solution stirred at 0° C. for 45 min. Sodiummetabisulfite (920 mg), water (10 mL) and sat. aq. NaHCO₃ solution (10mL) were added and the mixture stirred at RT until gas evolution ceased(15 min). The mixture was diluted with water (25 mL) and extracted withDCM (2×25 mL). The combined organics were passed through a hydrophobicfit and concentrated in vacuo to leave the title compound as a glassyorange solid (1.10 g, 100%). LCMS (Method 3): Rt 3.91 min, m/z 647[MH⁺].

c.1-[5-tert-Butyl-2-(4-morpholin-4-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Example 176).

To a solution of Intermediate 176b (0.10 mmol) and morpholine (17.4 mg,0.200 mmol) in DCM (3 mL) was added sodium triacetoxyborohydride (31.8mg, 0.15 mmol) and the resulting yellow solution stirred at RT for 1 h.Water (3 mL) was added and the mixture shaken. The aqueous was extractedwith DCM (3 mL), then the combined organics passed through a hydrophobicfrit and concentrated in vacuo to leave a vivid yellow gum. Flashchromatography (silica 12 g, 3.5-4.5% (2M NH3 in MeOH) in DCM) gave avivid yellow gum (70 mg). Prep HPLC (Gemini C18, 25-75% MeCN in water,0.1% HCO₂H, 20 min) and concentration of the desired fractions removedthe MeCN. The aqueous was extracted with DCM (3×15 mL), then thecombined organics passed through a hydrophobic frit and concentrated invacuo to leave a glassy orange solid (43.7 mg). Prep HPLC (Gemini C18,25-50% MeCN in water, 20 min) and concentration of the desired fractionsremoved the MeCN. The aqueous was extracted with DCM (3×5 mL), then thecombined organics passed through a hydrophobic fit and concentrated invacuo to leave the title compound as a white solid (25.4 mg, 35%). LCMS(Method 5): Rt 3.61 min, m/z 718.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO):0.91 (3H, d, J=6.3 Hz), 1.27 (9H, s), 1.47-1.55 (2H, m), 1.63-1.71 (2H,m), 1.76-1.95 (4H, m), 2.00-2.16 (2H, m), 2.37 (4H, t, J=4.3 Hz), 2.90(1H, ddd, J=12.1, 9.0, 3.9 Hz), 3.16 (1H, dt, J=12.2, 4.3 Hz), 3.29-3.34(1H, m, obscured by water signal), 3.50 (2H, s), 3.56 (4H, t, J=4.5 Hz),4.81 (1H, td, J=8.6, 5.6 Hz), 5.51 (1H, t, J=4.3 Hz), 6.34 (1H, s), 7.09(1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.9, 2.2 Hz), 7.25-7.37 (4H, m), 7.43(2H, d, J=8.7 Hz), 7.45 (2H, d, J=8.7 Hz), 7.64 (1H, dd, J=9.8, 0.8 Hz),7.69 (1H, dd, J=2.2, 0.9 Hz), 8.08 (1H, s).

Example 1771-[5-tert-Butyl-2-(4-dimethylaminomethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

To an orange solution of Intermediate 176b (0.188 mmol) anddimethylamine solution (2M in THF, 0.19 mL, 0.38 mmol) in DCM (3 mL) wasadded sodium triacetoxyborohydride (60 mg, 0.28 mmol) and the mixturestirred at RT for 1 h. Water (3 mL) was added and the mixture shaken.The aqueous was extracted with DCM (3 mL) then the combined organicspassed through a hydrophobic frit and concentrated in vacuo to leave abrown gum. Flash chromatography (silica 12 g, 4-6.5% [2M NH₃ in MeOH] inDCM) gave a yellow solid (88 mg). Prep HPLC (Gemini C18, 25-50% MeCN inwater, 0.1% HCO₂H, 20 min) and concentration in vacuo of the relevantfractions gave a pale yellow film. Trituration with diethyl ether gavethe title compound as on off-white solid (48.4 mg, 36%). LCMS (Method3): Rt 2.99 min, m/z 676 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d,J=6.3 Hz), 1.27 (9H, s), 1.45-1.56 (2H, m), 1.62-1.71 (2H, m), 1.75-1.96(4H, m), 2.00-2.15 (2H, m), 2.17 (6H, s), 2.90 (1H, dd, J=12.3, 9.1,3.9), 3.16 (1H, dt, J=12.3, 4.3 Hz), 3.28-3.34 (1H, m obscured by waterpeak), 3.44 (2H, s), 4.82 (1H, td, J=8.6, 5.7 Hz), 5.51 (1H, t, J=4.3Hz), 6.34 (1H, s), 7.10 (1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.8, 2.2 Hz),7.25-7.47 (8H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, dd, J=2.2,0.9 Hz), 8.10 (1H, s), 8.16 (0.7H, s).

Example 1781-{5-tert-Butyl-2-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

To an orange solution of Intermediate 176b (0.188 mmol) and N-methylpiperazine (38 mg, 0.38 mmol) in DCM (3 mL) was added sodiumtriacetoxyborohydride (60 mg, 0.28 mmol) and the mixture stirred at RTfor 1 h. Water (3 mL) was added and the mixture shaken. The aqueous wasextracted with DCM (3 mL) then the combined organics passed through ahydrophobic frit and concentrated in vacuo to leave a brown gum. Flashchromatography (silica 12 g, 5-8% (2M NH₃ in MeOH) in DCM) gave a yellowsolid (47 mg). Prep HPLC (Gemini C18, 25-50% MeCN in water, 0.1% HCO₂H,20 min) and concentration in vacuo of the relevant fractions gave a paleyellow film. Trituration with diethyl ether gave the title compound ason off-white solid (20.6 mg, 14%). LCMS (Method 3): Rt 2.98 min, m/z 731[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.27 (9H, s),1.45-1.56 (2H, m), 1.62-1.71 (2H, m), 1.75-1.95 (4H, m), 1.99-2.16 (2H,m), 2.14 (3H, s), 2.26-2.45 (8H, m), 2.90 (1H, ddd, J=12.2, 9.0, 4.0Hz), 3.16 (1H, dt, J=12.2, 4.2 Hz), 3.28-3.34 (1H, m, obscured by watersignal), 3.49 (2H, s), 4.81 (1H, td, J=8.6, 5.6 Hz), 5.51 (1H, t, J=4.3Hz), 6.33 (1H, s), 7.10 (1H, d, J=8.6 Hz), 7.20 (1H, dd, J=9.9, 2.1 Hz),7.25-7.47 (8H, m), 7.64 (1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, dd, J=2.2,0.9 Hz), 8.10 (1H, s), 8.17 (0.6H, s).

Example 1791-{5-tert-Butyl-2-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea

To an orange solution of Intermediate 176b (0.188 mmol) and N-methylhomopiperazine (43 mg, 0.38 mmol) in DCM (3 mL) was added sodiumtriacetoxyborohydride (60 mg, 0.28 mmol) and the mixture stirred at RTfor 1 h. Water (3 mL) was added and the mixture shaken. The aqueous wasextracted with DCM (3 mL) then the combined organics passed through ahydrophobic frit and concentrated in vacuo to leave a brown gum. Flashchromatography (silica 12 g, 7-11% [2M NH₃ in MeOH] in DCM) gave thetitle compound as a yellow solid (102 mg, 73%). LCMS (Method 3): Rt 2.84min, m/z 745 [MH⁺]. ¹H NMR (300 MHz, CDCl₃): 0.91 (3H, d, J=6.2 Hz),1.34 (9H, s), 1.40-1.55 (2H, m), 1.62-1.99 (7H, m), 2.15-2.02-2.14 (2H,m), 2.21-2.30 (1H, m), 2.33 (3H, s), 2.55-2.69 (8H, m), 2.90 (1H, ddd,J=12.1, 9.3, 4.1), 3.04 (1H, dt, J=12.1, 4.2 Hz), 3.23-3.32 (1H, m),3.58 (2H, s), 5.09 (1H, td, J=8.9, 5.2 Hz), 5.19 (1H, t, J=3.9 Hz), 6.04(1H, br d, J=8.6 Hz), 6.33 (1H, s), 6.94 (1H, dd, J=9.9, 2.1 Hz), 7.22(1H, br s), 7.25-7.39 (7H, m), 7.43 (1H, d, J=2.2 Hz), 7.47 (2H, m).

Example 1801-{5-tert-Butyl-2-[4-(4-methoxy-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

To an orange solution of Intermediate 176b (0.188 mmol) and4-methoxypiperidine (43 mg, 0.38 mmol) in DCM (3 mL) was added sodiumtriacetoxyborohydride (60 mg, 0.28 mmol) and the mixture stirred at RTfor 1 h. Water (3 mL) was added and the mixture shaken. The aqueous wasextracted with DCM (3 mL) then the combined organics passed through ahydrophobic fit and concentrated in vacuo to leave a brown gum. Flashchromatography (silica 12 g, 3.5-6% [2M NH₃ in MeOH] in DCM) gave ayellow solid (140 mg). Prep HPLC (Gemini C18, 25-50% MeCN in water, 0.1%HCO₂H, 20 min, ×2) and concentration in vacuo of the relevant fractionsgave a pale yellow film. Trituration with diethyl ether gave the titlecompound as on off-white solid (70.5 mg, 48%). LCMS (Method 5): Rt 3.69min, m/z 746.6 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz),1.27 (9H, s), 1.37-1.56 (4H, m), 1.62-1.71 (2H, m), 1.75-1.95 (6H, m),2.00-2.16 (4H, m), 2.62-2.69 (2H, m), 2.90 (1H, ddd, J=12.2, 9.1, 4.1Hz), 3.12-3.18 (2H, m), 3.20 (3H, s), 3.29-3.34 (1H, m), 3.49 (2H, s),4.82 (1H, td, J=8.6, 5.6 Hz), 5.51 (1H, t, J=4.3 Hz), 6.33 (1H, s), 7.10(1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.8, 2.2 Hz), 7.25-7.46 (8H, m), 7.64(1H, dd, J=9.8, 0.8 Hz), 7.69 (1H, dd, J=2.2, 0.9 Hz), 8.10 (1H, s),8.16 (0.75H, s).

Example 1811-[5-tert-Butyl-2-(4-pyrrolidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 176b (0.188 mmol) and pyrrolidine (31.1μL, 0.38 mmol) in DCM (3 mL), sodium triacetoxyborohydride (59.8 mg,0.28 mmol) was added. The mixture was stirred at RT for 1 h. Water wasadded and the mixture extracted with DCM. The combined organics werepassed through a phase separator and concentrated to dryness. Theresulting residue was purified by RP-HPLC (C18, 18 mL/min, 20-85% MeCNin H₂O+0.1% HCO₂H) and the relevant fractions combined and concentratedto dryness. The title product was isolated as a light orange solid (49.5mg). LCMS (Method 5): Rt 3.66 min, m/z 702.6 [MH+]. ¹H NMR (400 MHz,d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.27 (9H, s), 1.50 (2H, m), 1.69 (6H,m), 1.75-1.95 (4H, m), 1.98-2.17 (2H, m), 2.47 (4H, m, obscured bysolvent), 2.90 (1H, m), 3.15 (1H, m, obscured by solvent), 3.63 (2H, s,obscured by solvent), 4.81 (1H, m), 5.51 (1H, t, J=4.3 Hz), 6.33 (1H,s), 7.09 (1H, d, J=8.9 Hz), 7.19 (1H, dd, J=9.6, 2.2 Hz), 7.24-7.38 (4H,m), 7.43 (4H, m), 7.64 (1H, d, J=9.6 Hz), 7.69 (1H, d, J=1.3 Hz), 8.09(1H, s), 8.16 (1.4H, s).

Example 1821-[5-tert-Butyl-2-(4-piperidin-1-ylmethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 176b (0.188 mmol) and piperidine (37.2 μL,0.38 mmol) in DCM (3 mL), sodium triacetoxyborohydride (59.8 mg, 0.28mmol) was added. The mixture was stirred at RT for 1 h. Water was addedand the mixture extracted with DCM. The combined organics were passedthrough a phase separator and concentrated to dryness. The resultingresidue was purified by RP-HPLC (C18, 18 mL/min, 20-85% MeCN in H₂O+0.1%HCO₂H) and the relevant fractions combined and concentrated to dryness.The title product was isolated as an off white solid (14 mg). LCMS(Method 5): Rt 3.71 min, m/z 716.6 [MH+]. ¹H NMR (400 MHz, d₆-DMSO):0.91 (3H, d, J=6.4 Hz), 1.27 (9H, s), 1.36 (2H, m), 1.47 (6H, m), 1.67(2H, m), 1.76-1.96 (4H, m), 1.98-2.16 (2H, m), 2.33 (4H, m), 2.90 (1H,m), 3.15 (1H, m, obscured by solvent), 3.46 (2H, s, obscured bysolvent), 4.81 (1H, m), 5.51 (1H, t, J=4.1 Hz), 6.33 (1H, s), 7.09 (1H,d, J=8.6 Hz), 7.19 (1H, dd, J=10.0, 2.2 Hz), 7.24-7.46 (8H, m), 7.64(1H, d, J=10.0 Hz), 7.69 (1H, d, J=1.5 Hz), 8.09 (1H, s), 8.17 (1H, s).

Example 1831-{5-tert-Butyl-2-[4-(4-fluoro-piperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 176b (0.188 mmol) and 4-fluoropiperidine(38.8 mg, 0.38 mmol) in DCM (3 mL), sodium triacetoxyborohydride (59.8mg, 0.28 mmol) was added. The mixture was stirred at RT for 1 h. Waterwas added and the mixture extracted with DCM. The combined organics werepassed through a phase separator and concentrated to dryness. Theresulting residue was purified by RP-HPLC (C18, 18 mL/min, 20-85% MeCNin H₂O+0.1% HCO₂H) and the relevant fractions combined and concentratedto dryness. The title product was isolated as an off white solid (31mg). LCMS (Method 5): Rt 3.71 min, m/z 734.6 [MH+]. ¹H NMR (400 MHz,d₆-DMSO): 0.91 (3H, d, J=6.1 Hz), 1.27 (9H, s), 1.50 (2H, m), 1.67 (4H,m), 1.76-1.96 (6H, m), 1.98-2.17 (2H, m), 2.31 (2H, m), 2.54 (m,obscured by solvent), 2.90 (1H, m), 3.16 (1H, m, obscured by solvent),3.51 (2H, s, obscured by solvent), 4.66 (1H, dm, J=48 Hz), 4.82 (1H, m),5.51 (1H, t, J=4.2 Hz), 6.33 (1H, s), 7.09 (1H, d, J=8.7 Hz), 7.19 (1H,dd, J=9.8, 2.3 Hz), 7.24-7.50 (8H, m), 7.63 (1H, d, J=10.2 Hz), 7.69(1H, d, J=1.4 Hz), 8.10 (1H, s), 8.16 (1H, s).

Example 1841-(5-tert-Butyl-2-{4-[(ethyl-methyl-amino)-methyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 176b (0.188 mmol) and N-ethylmethylamine(32.3 μL, 0.38 mmol) in DCM (3 mL), sodium triacetoxyborohydride (59.8mg, 0.28 mmol) was added. The mixture was stirred at RT for 1 h. Waterwas added and the mixture extracted with DCM. The combined organics werepassed through a phase separator and concentrated to dryness. Theresulting residue was purified by RP-HPLC (C18, 18 mL/min, 20-85% MeCNin H₂O+0.1% HCO₂H) and the relevant fractions combined and concentratedto dryness. The title product was isolated as an off white solid (26.1mg). LCMS (Method 5): Rt 3.65 min, m/z 690.6 [MH+]. ¹H NMR (400 MHz,d₆-DMSO): 0.91 (3H, d, J=6.4 Hz), 1.02 (3H, t, J=7.1 Hz), 1.27 (9H, s),1.50 (2H, m), 1.66 (2H, m), 1.74-1.97 (4H, m), 1.98-2.11 (2H, m), 2.12(3H, s), 2.40 (2H, q, J=7.1 Hz), 2.90 (1H, m), 3.16 (1H, m, obscured bysolvent), 3.49 (2H, s, obscured by solvent), 4.81 (1H, m), 5.51 (1H, t,J=4.6 Hz), 6.33 (1H, s), 7.09 (1H, d, J=8.6 Hz), 7.19 (1H, dd, J=9.6,2.1 Hz), 7.24-7.47 (8H, m), 7.64 (1H, d, J=10.2 Hz), 7.69 (1H, d, J=1.6Hz), 8.09 (1H, s), 8.17 (1H, s).

Example 1851-[5-tert-Butyl-2-(4-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

To a solution of Intermediate 176b (0.188 mmol) andN-(2-methoxyethyl)methyl amine (32.7 mg, 0.38 mmol) in DCM (3 mL),sodium triacetoxyborohydride (59.8 mg, 0.28 mmol) was added. The mixturewas stirred at RT for 1 h. Water was added and the mixture extractedwith DCM. The combined organics were passed through a phase separatorand concentrated to dryness. The resulting residue was purified byRP-HPLC (C18, 18 mL/min, 20-85% MeCN in H₂O+0.1% HCO₂H) and the relevantfractions combined and concentrated to dryness. The title product wasisolated as an off white solid (23.9 mg). LCMS (Method 5): Rt 3.68 min,m/z 720.5 [MH+]. ¹H NMR (400 MHz, d₆-DMSO): 0.91 (3H, d, J=6.3 Hz), 1.27(9H, s), 1.50 (2H, m), 1.66 (2H, m), 1.74-1.96 (4H, m), 1.98-2.16 (2H,m), 2.17 (3H, s), 2.54 (2H, t, J=6.0 Hz, obscured by solvent), 2.90 (1H,m), 3.16 (1H, m, obscured by solvent), 3.23 (3H, s, obscured bysolvent), 3.45 (2H, t, J=6.0 Hz, obscured by solvent), 3.54 (2H, s,obscured by solvent), 4.82 (1H, m), 5.51 (1H, t, J=4.3 Hz), 6.33 (1H,s), 7.09 (1H, d, J=8.8 Hz), 7.19 (1H, dd, J=9.7, 2.2 Hz), 7.24-7.50 (8H,m), 7.64 (1H, d, J=10.0 Hz), 7.69 (1H, d, J=1.5 Hz), 8.09 (1H, s), 8.17(1H, s).

Example 1861-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4S)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea

a. 2-[3-(5-Amino-3-tert-butyl-pyrazol-1-yl)-phenoxy]-ethanol(Intermediate 186a)

A solution of Intermediate 95a (1.2 g, 5.2 mmol) and triphenyl phosphine(2.72 g, 10.4 mmol) in THF (30 mL), under an atmosphere of argon wastreated with 2-(tetrahydro-pyran-2-yloxy)-ethanol (1.05 mL, 7.78 mmol),followed by the dropwise addition of diisopropylazodicarboxylate (1.64mL, 10.4 mmol). The reaction mixture was then stirred at RT for 1 h. Thereaction mixture was eluted on a SCX-2 cartridge using MeOH and 2M NH₃in MeOH. The basic fractions were evaporated under reduced pressure andthe product was purified by FCC, using EtOAc/DCM 0-60% to afford thetitle compound as a brown gum (1.0 g, 80%). LCMS (Method 3): Rt 2.27min, m/z 276 [MH⁺].

b.{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-carbamicacid 2,2,2-trichloro-ethyl ester (Intermediate 148e)

A solution of Intermediate 186a (1.0 g, 3.63 mmol) in EtOAc (20 mL) wastreated with aqueous NaOH (1M, 6.53 mmol), followed by2,2,2-trichloroethyl chloroformate (0.529 mL, 3.85 mmol) and thereaction mixture was stirred at RT for 1 h. The mixture was partitionedbetween EtOAc (20 mL) and water (20 mL). The layers were separated andthe aqueous layer was extracted with a further 20 mL EtOAc. The combinedorganic layers were dried (Na₂SO4), filtered and concentrated in vacuo.The residue was purified by FCC, using 0-40% EtOAc in DCM. The combinedfractions were evaporated under reduced pressure and the product wastriturated with DCM. The solid was filtered and washed with Diethylether to afford the title compound as a white solid (0.930 g, 58%). LCMS(Method 3): Rt 4.01 min, m/z 450 [M].

c.(1S,4S)-4-[3-((S)-2-Methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine(Intermediate 186b)

To a solution of Intermediate B (232 mg, 1.6 mmol) in dry DMF (10 mL)under N₂ was added sodium (60% dispersion in oil, 320 mg, 8.0 mmol) andthe resulting opaque brown solution was stirred at RT for 45 min (CARE:gas evolution). A solution of Intermediate 81c (342 mg, 1.46 mmol) indry DMF (7 mL) was added and the dark brown solution stirred at 60° C.under N₂ for 90 min. The cooled solution was concentrated in vacuo,redissolved in MeOH (3 mL) and then applied to an SCX-2 cartridge (20g), washing with MeOH (50 mL). The product was eluted with 2M NH₃ inMeOH (50 mL); concentration in vacuo gave a dark brown solid. FCC, using0-10% [2M NH₃ in MeOH] in DCM, gave the title compound as a pale brownfoam (262 mg, 45%). LCMS (Method 3): Rt 2.30 min, m/z 378 [MH⁺].

d.1-{5-tert-Butyl-2-[3-(2-hydroxy-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4S)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 186c)

A mixture of Intermediate 148e (313 mg, 0.7 mmol), Intermediate 186b(262 mg, 0.7 mmol) and DIPEA (182 μL, 1.05 mmol) in dioxane (4 mL) washeated at 70° C. for 20 h. The reaction mixture was cooled to RT andeluted directly on SCX-2 using MeOH and 2M NH₃ in MeOH. The basicfractions were evaporated under reduced pressure. The residue waspurified by FCC, using 0-10% [2M NH₃ in MeOH] in DCM, to afford thetitle compound as a yellow glass (293 mg). LCMS (Method 3): Rt 3.63 min,m/z 679 [MH⁺].

e.1-{5-tert-Butyl-2-[3-(2-dimethylamino-ethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4S)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]urea(Example 186).

To a solution of Intermediate 186c (293 mg, 0.44 mmol) and DIPEA (304μL, 1.76 mmol) in DCM (10 mL) was added methanesulfonyl chloride (103μL, 1.33 mmol). The reaction mixture was stirred at RT for 1 hour. Themixture was concentrated in vacuo. The residue was taken up in THF (2mL) and dimethylamine solution in THF (2M, 3.3 mL) was added. Thereaction mixture was heated at 60° C. in a sealed tube for 72 h. Thereaction mixture was cooled to RT and concentrated in vacuo. The productwas purified by HPLC using a gemini C18 column and using a gradient of20-35%+0.1% Formic acid over 10 minutes. The combined fractions wereevaporated under reduced pressure and crystallised by MeCN/Et2O toafford the title compound as a white solid (90 mg, 30%). LCMS (Method3): Rt 3.01 min, m/z 706 [MH⁺]. ¹H NMR (300 MHz, d₆-DMSO): 0.91 (3H, d,J=6.7 Hz), 1.23 (9H, s), 1.46-1.54 (2H, m), 1.63-1.72 (2H, m), 1.75-1.76(2H, m), 2.00-2.18 (2H, m), 2.43 (6H, s), 2.66 (2H, t, J=5.8 Hz),2.85-2.95 (2H, m), 3.12-3.20 (4H, m), 4.10 (2H, t, J=5.4 Hz), 4.78-4.86(1H, m), 5.52 (1H, t, J=4.0 Hz), 6.33 (1H, s), 6.95-6.99 (2H, m),7.06-7.14 (2H, m), 7.19 (1H, dd, J=10.0 Hz), 7.25-7.32 (3H, m),7.33-7.42 (2H, m), 7.58 (1H, d, J=10.6 Hz), 7.63 (1H, d, J=1.8 Hz), 8.17(1H, s).

Example 1871-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

a.1-{3-tert-Butyl-1′-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1′H-[1,4′]bipyrazolyl-5-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 187a)

A mixture of Intermediate 81d (240 mg, 0.64 mmol), Intermediate 108b(325 mg, 0.64 mmol) and DIPEA (221 μL, 1.27 mmol) in dioxane (6 mL) wasstirred at 80° C. overnight. After cooling, the reaction mixture waspartitioned between water and EtOAc. The aqueous phase was extractedwith EtOAc (×3) and the combined organic layers were washed with brine,dried (MgSO₄) and concentrated in vacuo. The resultant residue waspurified by FCC on silica, using a gradient of 0-10% MeOH in DCM toafford the title compound (377 mg, 80%). LCMS (Method 4): Rt 3.48 min,m/z 737 [MH⁺].

b.1-[3-tert-Butyl-1′-(2-hydroxy-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea(Intermediate 187b)

To a solution of Intermediate 187a (377 mg, 0.51 mmol) in MeOH (5 mL)was added pyridinium p-toluenesulfonate (257 mg, 1.02 mmol) and thereaction mixture was heated at 55° C. for 3 h. The resultant mixture waspoured into water and a saturated aqueous solution of NaHCO₃ was added.The aqueous phase was extracted with EtOAc (×3) and the combined organiclayers were washed with brine, dried (MgSO₄) and concentrated in vacuo.The resultant residue was purified by FCC on silica, using a gradient of3-10% MeOH in DCM, to give the title compound (250 mg, 75%). LCMS(Method 1): Rt 3.09 min, m/z 653 [MH⁺].

c. Methanesulfonic acid2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-[1,4′]bipyrazolyl-1′-yl]-ethylester (Intermediate 187c)

To an ice-bath cooled solution of Intermediate 187b (250 mg, 0.38 mmol)in DCM (4 mL) was added DIPEA (267 μL, 1.53 mmol) followed bymethanesulfonyl chloride (60 μL, 0.77 mmol). The reaction mixture wasstirred for 2 h and then quenched with water. The aqueous phase wasextracted with DCM (×3) and the combined organic layers were washed withbrine, dried (MgSO₄) and concentrated in vacuo to afford the titlecompound (Quantitative). Product used in the following step withoutfurther purification. LCMS (Method 4): Rt 3.25 min, m/z 732 [MH⁺].

d.1-[3-tert-Butyl-1′-(2-dimethylamino-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt (Example 187).

To a solution of Intermediate 187c (0.19 mmol) in THF (3 mL) was addeddimethylamine (2M in MeOH, 1.9 mL, 3.8 mmol) and the reaction stirred at50° C. in a sealed vial overnight. The crude reaction mixture waspartitioned between EtOAc and water. The aqueous phase was extractedwith EtOAc (×3) and the combined organic layers were washed with brine,dried (MgSO₄) and concentrated in vacuo. The resultant residue waspurified by FCC on silica, using a gradient of 0-10% [2M NH₃ in MeOH] inDCM followed by MDAP (Method 7) purification, to give the title compound(46 mg, 33%). LCMS (Method 5): Rt 3.50 min, m/z 680 [MH⁺]. ¹H NMR (400MHz, d₆-DMSO): 0.87 (3H, d, J=6.4 Hz), 1.20 (9H, s), 1.43-1.51 (2H, m),1.58-1.69 (2H, m), 1.70-1.88 (3H, m), 1.88-1.96 (1H, m), 1.96-2.12 (2H,m), 2.13 (6H, s), 2.63 (2H, t, J=6.5 Hz), 2.87 (1H, ddd, J=12.6, 9.1,3.9 Hz), 3.12 (1H, dt, J=12.1, 4.2 Hz), 4.16 (2H, t, J=6.5 Hz), 4.80(1H, td, J=8.5, 5.8 Hz), 5.48 (1H, t, J=4.3 Hz), 6.22 (1H, s), 7.12 (1H,d, J=8.5 Hz), 7.15 (1H, dd, J=9.9, 2.2 Hz), 7.21-7.26 (1H, m), 7.28-7.36(3H, m), 7.58 (1H, s), 7.60 (1H, d, J=9.5 Hz), 7.66 (1H, d, J=2.1 Hz),7.96 (1H, s), 8.00 (1H, s), 8.13 (1H, s).

Example 1881-[3-tert-Butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt

To a solution of Intermediate 187c (0.19 mmol) in THF (3 mL) was addedmorpholine (166 μL, 1.9 mmol) and the reaction stirred at 50° C.overnight. The crude reaction mixture was partitioned between EtOAc andwater. The aqueous phase was extracted with EtOAc (×3) and the combinedorganic layers were washed with brine, dried (MgSO₄) and concentrated invacuo. The resultant residue was purified by FCC on silica, using agradient of 2.5-10% (2M NH₃ in MeOH) in DCM followed by MDAP (Method 7)purification, to give the title compound (49 mg, 35%). LCMS (Method 5):Rt 3.53 min, m/z 722 [MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 0.87 (3H, d,J=6.4 Hz), 1.20 (9H, s), 1.43-1.51 (2H, m), 1.58-1.69 (2H, m), 1.70-1.88(3H, m), 1.88-1.96 (1H, m), 1.96-2.12 (2H, m), 2.37 (4H, t, J=4.5 Hz),2.69 (2H, t, J=6.5 Hz), 2.87 (1H, ddd, J=12.6, 9.1, 3.9 Hz), 3.12 (1H,dt, J=12.1, 4.2 Hz), 1H UNDER SOLVENT, 3.50 (4H, t, J=4.6 Hz), 4.20 (2H,t, J=6.5 Hz), 4.80 (1H, td, J=8.5, 5.8 Hz), 5.48 (1H, t, J=4.3 Hz), 6.22(1H, s), 7.11 (1H, d, J=8.5 Hz), 7.15 (1H, dd, J=9.9, 2.2 Hz), 7.21-7.26(1H, m), 7.28-7.35 (3H, m), 7.60 (1H, d, J=9.8 Hz), 7.60 (1H, s), 7.66(1H, d, J=2.1 Hz), 7.96 (1H, s), 8.02 (1H, s), 8.12 (0.5H, s).

Example 1891-{5-tert-Butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt

A mixture of Intermediate 149b (87 mg, 0.12 mmol) and 1-methylpiperazine(68 μL, 0.61 mmol) in THF (2 mL) was stirred at 60° C. for 18 h. Thereaction mixture was cooled to RT, diluted with DCM (5 mL) and washedwith water (5 mL). The aqueous layer was extracted with DCM (5 mL). Thecombined organic extracts were washed with water (2×5 mL) and passedthrough a phase separator. The filtrate was concentrated in vacuo andthe resultant residue was purified by MDAP (Method 7) to afford thetitle compound (23 mg, 27%). LCMS (Method 5): Rt 2.69 min, m/z 717.6[MH⁺]. ¹H NMR (400 MHz, d₆-DMSO): 1.28 (9H, s), 1.84-2.11 (6H, m), 2.13(6H, br s), 2.15-2.26 (2H, m), 2.26-2.46 (8H, m), 3.13 (1H, m, obscuredby water), 3.50 (2H, s, obscured by water), 3.99 (1H, t, J=8.4 Hz), 4.82(1H, m), 5.39 (1H, t, J=4.3 Hz), 6.33 (1H, s), 7.06 (1H, d, J=8.8 Hz),7.24-7.48 (9H, m), 7.75 (1H, d, J=9.7 Hz), 8.10 (1H, s), 8.19 (1.9H, brs), 8.24 (1H, d, J=1.7 Hz).

Biological Assays.

P38alpha Enzyme Inhibition Assay.

The inhibitory activity of compounds was determined using anAlphascreen® (Perkin Elmer) based kinase activity assay. Kinasereactions consisted of 25 mM HEPES pH 7.5, 10 mM MgCl₂, 100 μM Na₃VO₄, 2mM DTT, 0.05 mg/ml Tween 20, 100 pM p38alpha (Invitrogen, PV3304), 1%DMSO and 0.3 μg/ml ATF-2 fusion protein (New England Biolabs, 9224).Compounds were incubated under these conditions for 2 hours, at 25° C.,prior to the initiation of the kinase activity by the addition of the250 μM ATP. Reaction volumes were 20 uL. After 1 hr at 25° C. reactionswere stopped by the adding 10 uL of 25 mM HEPES pH 7.5 containing 62.5mM EDTA, 0.05% Triton X-100, 10% BSA and 0.83 ng/uL anti-phospho-ATF2antibody (Abeam, ab28812). Detection was performed by measuringluminescence following the addition of Alphascreen Donor beads (PerkinElmer 6765300) and Protein A Alphascreen Acceptor beads (Perkin Elmer6760137), both at a final concentration of 20 ug/ml. IC₅₀ values weredetermined from concentration-response curves. Results are shown in thefollowing Table:

Example p38α inhibition 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18,19, 20, 22, ++++ 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107,108, 109, 110, 111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122,123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136,137, 138, 139, 140, 141, 142, 143, 144, 148, 154, 155, 156, 157, 158,159, 160, 162, 163, 165, 166, 167, 168, 169, 170, 171, 176, 178, 181,182, 183, 184, 185 21 +++ 32 ++In the table above, p38α binding potencies (IC₅₀ values) are indicatedas follows: 7000 to 500 nM ‘+’; 500 to 100 nM, ‘++’; 100 to 10 nM,‘+++’; <10 nM, ‘++++’.LPS-Stimulated PBMC TNFα Release Assay.

Peripheral Blood Mononuclear Cells (PBMCs) were isolated from healthyhuman volunteer blood using a standard density gradient centrifugationtechnique. Citrated blood was placed onto Histopaque™ and centrifuged.The PBMCs were removed from the density gradient interface and washed inphosphate buffered saline (PBS). The PBMCs were suspended in RPMI 1640medium (without serum), dispensed into a 96-well plate and incubated at37° C. for 3 h in a humidified incubator. After incubation, the mediumwas replaced (with medium containing 1% foetal bovine serum) and theplate incubated at 37° C., for 1 h, in the presence of test compound orthe appropriate vehicle. LPS (10 ng/ml), or an appropriate vehiclecontrol, was then added to the cells and the plate returned to theincubator for 18 h. Cell-free supernatants were removed and assayed forTNFα levels using an ELISA kit from R&D Systems.

A dose response curve to each test compound was performed and the effectof compound in each experiment was expressed as a percentage inhibitionof the control TNFα release. Dose response curves were plotted andcompound potency (IC₅₀) was determined. Compounds were tested in atleast three separate experiments. Results are shown in the followingTable:

p38α Example numbers inhibition 3, 5, 8, 10, 12, 13, 15, 16, 18, 19, 20,23, 24, 25, 26, 27, 28, 29, ++++ 30, 31, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 46, 47, 48, 49, 50, 52, 53, 54, 55, 58, 59, 60, 61, 62,63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 95, 96, 97, 98, 99, 100,101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114,115, 116, 117, 118, 120, 121, 122, 123, 124, 125, 126, 127, 128, 130 1,2, 11, 14, 21, 57, 94, 119, 129 +++ 4, 7, 9, 22 ++In the table above, p38α potencies (IC₅₀ values) are indicated asfollows: >1000 nM, ‘+’; 1000 to 100 nM, ‘++’; 100 to 10 nM, ‘+++’; <10nM, ‘++++’. All compounds tested exhibited IC₅₀ values <1000 nM.Pre-Clinical Mouse Model of COPD—Tobacco Smoke Induced PulmonaryInflammation.

Previous studies have established that the number of inflammatory cellsrecovered by bronchoalveolar lavage (BAL) is significantly elevated 24 hfollowing the final of four consecutive daily tobacco smoke (TS)exposures. This timepoint was used in the studies reported here.

Protocols for the exposure of mice to TS, obtaining bronchoalveolarlavage fluid (BALF) and preparation of cytospin slides for differentialcell counts are as outlined below.

Daily Exposure of Mice to TS for 4 Consecutive Days.

In this exposure protocol, mice were exposed in groups of 5 inindividual clear polycarbonate chambers (27 cm×16 cm×12 cm). The TS fromthe cigarettes was allowed to enter the exposure chambers at a flow rateof 100 ml/min. In order to minimise any potential problems caused byrepeated exposure to a high level of TS, the exposure of the mice to TSwas increased gradually over the exposure period to a maximum of 6cigarettes. The exposure schedule used over the four days was asfollows:

Day 1: 5 cigarettes (approximately 25 min exposure) Day 2: 7 cigarettes(approximately 35 min exposure) Day 3: 9 cigarettes (approximately 45min exposure) Day 4: 9 cigarettes (approximately 45 min exposure)A further group of mice were exposed to air on a daily basis forequivalent lengths of time as controls (no TS-exposure).Bronchoalveolar Lavage (BAL) Analysis.

Bronchoalveolar lavage was performed as follows: the trachea wascannulated using a 10 mm long Luer-fitting stainless steel cannula.Phosphate buffered saline (PBS) was used as the lavage fluid. A volumeof 0.4 ml was gently instilled and withdrawn 3 times, using a 1 mlsyringe and then placed in an Eppendorf tube and kept on ice prior tosubsequent determinations.

Cell Counts:

Lavage fluid was separated from cells by centrifugation and thesupernatant decanted and frozen for subsequent analyses. The cell pelletwas re-suspended in a known volume of PBS and total cell numberscalculated by counting a stained (Turks stain) aliquot under amicroscope using a haemocytometer.

Differential Cell Counts were Performed as Follows:

The residual cell pellet was diluted to approximately 10⁵ cells per ml.A volume of 500 μl was placed in the funnel of a cytospin slide andcentrifuged for 6 min at 800 rpm, RCF=72.26×g (Shandon Cytospin 3). Theslide was air-dried and stained using Wrights/Giemsa stain as per theproprietary instructions. When dried and cover-slipped, differentialcell counts were performed using light microscopy. Approximately fourhundred cells were counted by an unbiased operator using lightmicroscopy. Cells were differentiated using standard morphometrictechniques.

Drug Treatment

Rodents such as mice and rats are obligate nose breathers, thus oraldelivery of test materials (such as therapeutic agents) for inhalationwill not produce good lung exposure. As a consequence, delivery oftherapeutic agents to the lungs in rodents is generally achieved byintranasal, intratracheal or inhalation by either nose-only or wholebody aerosol exposure.

Nose-only or whole body aerosol exposure methods utilise large amountsof test material and are generally reserved for inhalation toxicologystudies rather than more routine pharmacological efficacy studies.Intratracheal administration is a very efficient delivery method asalmost all of the test material is delivered to the lungs but is aninvasive technique. For studies in the mouse particularly, it is alsotechnically demanding as the diameter of the trachea is small. Theintranasal route is less invasive than the intratracheal route and so isparticularly suitable for repeat dosing studies such as the four daymouse model described. Following intranasal administration, ˜50% of thedose administered is delivered to the lungs (Eyles J E, Williamson E Dand Alpar H O. 1999, Int Pharm, 189(1):75-9, which is incorporatedherein by reference in its entirety).

As a surrogate route for oral inhalation, mice were dosed intra-nasallywith vehicle (0.2% tween 80 in saline) containing test compound. Thecontrol groups of mice received vehicle 1 hr prior to being exposed toair or TS.

Data Management and Statistical Analysis:

All results are presented as individual data points for each animal andthe mean value was calculated for each group. Since tests for normalitywere positive, the data were subjected to a one-way analysis of variancetest (ANOVA), followed by a Bonferroni correction for multiplecomparisons in order to test for statistically significant differencesbetween treatment groups. A “p” value of <0.05 was considered to bestatistically significant. Percentage inhibitions were automaticallycalculated within Excel spreadsheets for the cell data using the formulabelow:

${\%\mspace{14mu}{Inhibition}} = {( {1 - ( \frac{{{Treatment}\mspace{14mu}{group}\mspace{14mu}{result}} - {{air}\mspace{14mu}{group}\mspace{14mu}{result}}}{{{TS}\mspace{14mu}{vehicle}\mspace{14mu}{group}\mspace{14mu}{result}} - {{air}\mspace{14mu}{group}\mspace{14mu}{result}}} )} ) \times 100}$

Inhibition data for other parameters were calculated manually using theabove formula.

Example 5 of the invention was tested in the above reported model andresults are herebelow reported.

As illustrated in FIG. 1, Example 5 significantly inhibited the BAL cellinflux induced by TS at 3, 30 or 100 μg/kg when administered by theintranasal route. Similar findings were observed with BAL neutrophils(FIG. 2). The results demonstrate a clear anti-inflammatory effect inthe lungs of mice exposed to TS.

Where a numerical limit or range is stated herein, the endpoints areincluded. Also, all values and subranges within a numerical limit orrange are specifically included as if explicitly written out.

As used herein the words “a” and “an” and the like carry the meaning of“one or more.”

Obviously, numerous modifications and variations of the presentinvention are possible in light of the above teachings. It is thereforeto be understood that, within the scope of the appended claims, theinvention may be practiced otherwise than as specifically describedherein.

All patents and other references mentioned above are incorporated infull herein by this reference, the same as if set forth at length.

The invention claimed is:
 1. A method of treating a disease or conditionin a human subject which benefits from inhibition of p38 MAP kinaseactivity, comprising administering, to a subject in need thereof, aneffective amount of a compound represented by formula (I) or apharmaceutically acceptable salt thereof:

wherein; W is N, wherein N is substituted with hydrogen, C₁-C₆ alkyl; Yis —O(CR³R⁴)_(n)—; R³ and R⁴ are each independently hydrogen, fluorine,or C₁-C₆ alkyl; n is 0 or 1; R¹ is a group represented by formula (IIc):

X² is a group —(CH)—, X⁴ is a carbon atom, and X³ and X⁵ are a nitrogenatom; such that each combination thereof forms an aromatic ring system;R¹¹ is linked to X⁴ and is —NR^(A)R^(B); R^(A) and R^(B) are at eachoccurrence independently hydrogen, C₁-C₆ alkyl, or C₃-C₇ cycloalkyl,such C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by aC₁-C₃ alkyl group, C₃-C₇cycloalkyl group, —OR^(D), —CN or halo;alternatively, R^(A) and R^(B), form, together with the nitrogen atom towhich they are attached, a 5-11-membered saturated heterocyclicmonocyclic or bicyclic ring system which is optionally substituted byone or more of —OR^(D), —CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, suchC₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by a C₁-C₃alkyl group, C₃-C₇cycloalkyl group, —OR^(D), —CN or halo; and which5-11-membered saturated heterocyclic monocyclic or bicyclic ringoptionally contains a further heteroatom which is oxygen or nitrogen,said nitrogen atom optionally substituted by C₁-C₆ alkyl or C₃-C₆cycloalkyl, wherein any of said C₁-C₆ alkyl or C₃-C₆ cycloalkyl may beoptionally substituted by a C₁-C₆ alkyl group, C₃-C₇ cycloalkyl group,—OR^(D), —CN, or halo; or R^(A) and R^(B) may be linked to one carbonatom of the —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)- or—(C₃-C₇cycloalkylene)- portion of the group linked to the nitrogen towhich they are connected to form a saturated cycle of up to 6 ringatoms; R^(D) is at each occurrence independently hydrogen, —CH₃, or—C₂H₅; R¹³ is hydrogen, C₁-C₆ alkyl, or halogen; A is a divalentcycloalkylene radical having 5, 6, or 7 ring atoms; said cycloalkylenering being attached to W and Y, and fused to a phenyl ring or to amonocyclic heteroaryl ring having 5 or 6 ring atoms, said phenyl orheteroaryl ring being optionally substituted by one or two groups R²⁴;R²⁴ is at each occurrence independently C₁-C₆ alkyl, halogen, or cyano;R² is a group of formula (IIIb):

wherein R¹⁷ is a group of formula (IV)

wherein R²⁰ is —CH₃, or —CH₂OMe; R²¹ is —CH₃; R¹⁸ is lone electron pair,hydrogen, aryl, heteroaryl, —(C₁-C₆alkyl), —(C₃-C₇cycloalkyl),—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) or(C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such aryl,heteroaryl, —(C₁-C₆alkyl), —(C₃-C₇cycloalkyl), —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆cycloalkyl) may be optionally substituted by one moiety selected fromthe group consisting of —CN, —OH, halo, —COOR^(M), C₁-C₆alkyl,C₃-C₆cycloalkyl, —O—(C₁-C₆alkyl), —O—(C₃-C₆cycloalkyl), —NR^(H)R^(J),—N(R^(L))(C₂-C₆alkylene)-NR^(H)R^(J),—N(R^(L))(C₃-C₇cycloalkylene)-NR^(H)R^(J), —(C₁-C₆alkylene)-NR^(H)R^(J),—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-NR^(H)R^(J),—O—(C₃-C₇cycloalkylene)-NR^(H)R^(J), —O—(C₂-C₆alkylene)-OR^(M),—O—(C₃-C₇cycloalkylene)-OR^(M), OR^(L), —(C₃-C₇heterocycloalkyl),(C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such C₁-C₆alkyl,C₃-C₆cycloalkyl, —(C₂-C₆alkylene)-, —(C₃-C₇cycloalkylene)-,—(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆ alkyl) and(C₅-C₇ heterocycloalkyl)-(C₃-C₆ cycloalkyl) portion in the above listedgroups may be optionally substituted by one moiety selected from thegroup consisting of a C₁-C₆ alkyl group, C₃-C₇ cycloalkyl group, —OR^(L)and halo; R^(H) and R^(J), are at each occurrence independentlyhydrogen, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl, said C₁-C₆ alkyl or C₃-C₆cycloalkyl being optionally substituted by a C₁-C₃ alkyl group, —OR^(M),CN, or halo; alternatively, R^(H) and R^(J) form, together with thenitrogen atom to which they are attached, a 5-11-membered saturatedmonocyclic or bicyclic heterocyclic ring system which is optionallysubstituted by one or more of —OR^(M), —CN, halo, C₁-C₆ alkyl, or C₃-C₇cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionallysubstituted by a C₁-C₃ alkyl group, C₃-C₇cycloalkyl group, —OR^(M), CNor halo; and which 5-11-membered saturated monocyclic or bicyclicheterocyclic ring optionally contains a further heteroatom which isoxygen or nitrogen, said nitrogen atom optionally substituted by C₁-C₆alkyl or C₃-C₆ cycloalkyl, wherein any of said C₁-C₆ alkyl or C₃-C₆cycloalkyl may be optionally substituted by a C₁-C₆ alkyl group, C₃-C₇cycloalkyl group, —OR^(M), CN, or halo; and/or R^(H) and R^(J) may belinked to one carbon atom of the —(C₁-C₆alkylene)-, —(C₂-C₆alkylene)- or—(C₃-C₇cycloalkylene)- portion of the group linked to the nitrogen towhich they are connected to form a saturated cycle of up to 6 ringatoms; R^(L) is at each occurrence independently hydrogen, C₁-C₆ alkyl,or C₃-C₆ cycloalkyl, said C₁-C₆ alkyl or C₃-C₆ cycloalkyl beingoptionally substituted by a C₁-C₃ alkyl group, —OR^(M), —CN, or halo;R^(M) is at each occurrence independently hydrogen, C₁-C₆ alkyl, orC₃-C₆ cycloalkyl, said C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionallysubstituted by hydroxyl, —CN, or halo; z¹, z², z³, and z⁴ areindependently C, N, O, a group —CH—, or a group —NH—, in such acombination that the resulting ring formed is pyrazolyl ring, animidazolyl ring, or an isoxazolyl ring, wherein said disease orcondition is chronic eosinophilic pneumonia, asthma, COPD, adultrespiratory distress syndrome, exacerbation of airways hyper-reactivityconsequent to other drug therapy or airways disease that is associatedwith pulmonary hypertension.
 2. A method according to claim 1, whichcomprises administering a compound of formula (Ia) wherein the carbonstereogenic center on the cycloalkylene portion of ring A which islinked to group W and identified with number (1) herebelow, possess theabsolute configuration herebelow represented:


3. A method according to claim 1, which comprises administering acompound of formula (Ib) wherein the carbon stereogenic centers on thecycloalkylene portion of ring A which are linked to group W and Y andidentified, respectively, with numbers (1) and (2) herebelow, possessthe absolute configuration herebelow represented:


4. A method according to claim 1, wherein A is group represented by oneof the following formulae:


5. A method according to claim 1, wherein W is NH.
 6. A method accordingto claim 1, wherein n is
 0. 7. A method according to claim 1, wherein Wis NH, n is 0, and A is group represented by one of the followingformulae:

R¹³ is hydrogen; R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl, and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴; z¹=—CH—,z²=C, z³ and z⁴ are N and R¹⁷ is a group of formula (IV):

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃.
 8. A method according toclaim 1, wherein W is NH, n is 0, A is represented by one of thefollowing formulae:

R¹³ is hydrogen; R¹¹ is a group:

wherein R²⁵ is optionally present and represents one, two, or threesubstituents independently selected from the group consisting of C₁-C₆alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl,hydroxyl, and halo; and wherein the asterisk represents the point ofattachment for group R¹¹ to the rest of the molecule via X⁴; z¹=—CH—,z²=C, z³ and z⁴ are N and R¹⁷ is a group of formula (IV)

wherein R²⁰ is —CH₃ or —CH₂OH, and R²¹ is —CH₃.
 9. A method according toclaim 1, which comprises administering an effective amount of a compoundor pharmaceutically acceptable salt thereof, which is a compoundselected from the group consisting of1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[2-(4-methylpiperazin-1-yl)-ethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-ureaformate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((S)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperazin-1-yl-methyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-isopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-((R)-3-pyrrolidin-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-piperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-morpholin-4-yl-methyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-ureaformate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-ylmethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-({(1S,4R)-4-[3-(1-methyl-piperidin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[1-(2,2-difluoroethyl)-piperidin-4-ylmethyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-[3-(4-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-{3-[(2-hydroxyethyl)methyl-amino]-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-({(1S,4R)-4-[3-((S)-3-hydroxypyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[5-tert-butyl-2-(3-hydroxymethylphenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;3-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]-triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureido)-pyrazol-1-yl]-benzoicacid ethyl ester;1-[5-tert-butyl-2-(3-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea,partial formate salt;1-[5-tert-butyl-2-(4-hydroxymethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}urea;1-[5-tert-butyl-2-(4-hydroxymethylphenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-{5-tert-butyl-2-[3-(2-hydroxyethylsulfanyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;1-[5-(2-hydroxy-1,1-dimethylethyl)-2-p-tolyl-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-[5-tert-butyl-2-(4-hydroxymethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,3S)-3-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-indan-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{5-tert-butyl-2-[3-(2-hydroxyethoxy)phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-ureapartial formate salt;1-{5-tert-butyl-2-[3-(4-methylpiperazin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;1-{5-tert-butyl-2-[3-(2-hydroxyethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(2-dimethylaminoethyl)-methylamino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-urea;1-[5-tert-butyl-2-(3-piperidin-1-ylmethylphenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[methyl(2-morpholin-4-yl-ethyl)amino]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-morpholin-4-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,2-dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{5-tert-butyl-2-[3-(2-hydroxyethoxymethyl)phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-[1,4]oxazepan-4-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-{3-[4-(2-hydroxy-ethyl)piperazin-1-ylmethyl]-phenyl}-2-H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(2-tert-butyl-5-p-tolyl-3H-imidazol-4-yl)-3-[(1S,4R)-4-(3-piperidin-1-y-l-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-y-l]-urea;1-{5-tert-butyl-2-[3-(4-hydroxypiperidin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;1-{5-tert-butyl-2-[3-(2-hydroxyethylsulfanyl)phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4S)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(3-hydroxymethyl-4-methylpiperazin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;1-[5-tert-butyl-2-(4-hydroxymethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(4-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea,partial formate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-dimethylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-ethylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methylpiperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxypiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[5-tert-butyl-2-(4-hydroxymethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methylpiperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea,partial formate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxyethy-1-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[(1S,4R)-4-(3-azepan-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-methyl-[1,4]diazepan-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}urea;1-[5-tert-butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-[5-tert-butyl-2-(4-cyanophenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4S)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[5-tert-butyl-2-(4-hydroxyphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(1-hydroxy-1-methyl-ethyl)piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-pyrrolidin-1-y-l-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-y-l]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-1-methylethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureapartial formate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(4-hydroxy-4-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-methyl-1-pyrrolidin-1-yl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-4-methylmorpholin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea,partial formate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[(S)-1-(3-hydroxy-propyl)pyrrolidin-2-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-hydroxymethyl-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1,4-dimethylpiperazin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,4,4-trimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methylpiperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methylpiperidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-1-methylpyrrolidin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-({(1S,4R)-4-[3-((R)-3-hydroxymethyl-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-((1S,4R)-4-{3-[4-(2-hydroxyethyl)-piperazin-1-yl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-1,2,3,4-tetrahydronaphthalen-1-yl)-urea;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)-phenyl]-2H-pyrazol-3-yl-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-(cis-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-morpholin-4-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl-oxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-cyclopentyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[(1S,4R)-4-(3-amino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea;1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-diisopropylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[8-methyl-3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{5-tert-butyl-2-[4-(4-methylpiperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;1-(3-tert-butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-[3-tert-butyl-1′-(2-dimethylaminoethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-[5-tert-butyl-2-(2-hydroxyethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-isoxazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[3-tert-butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yl-oxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-ureaformate salt;1-[3-tert-butyl-1′-(3-dimethylaminopropyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-ureaformate salt;1-[3-tert-butyl-1′-(3-morpholin-4-yl-propyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]-ureaformate salt;1-[5-tert-butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[5-tert-butyl-2-(2-hydroxyethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{5-tert-butyl-2-[1-(2-dimethylaminoethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea;1-[5-tert-butyl-2-(2-hydroxyethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-[5-tert-butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{(1S,4R)-4-[3-(8-aza-bicyclo[3.2.1]oct-8-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)-phenyl]-2H-pyrazol-3-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((R)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt;1-[3-tert-butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-({(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[3-tert-butyl-1′-(2-dimethylaminoethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-[5-tert-butyl-2-(2-dimethylaminoethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(2-piperidin-1-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[2-(4-methylpiperazin-1-yl)-ethyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-morpholin-4-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-morpholin-4-yl-ethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-pyrrolidin-1-yl-ethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-({3-[2-(ethylmethylamino)-ethyl]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-dimethylamino-ethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-piperidin-1-yl-ethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-[1,4]oxazepan-4-yl-ethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(4-methyl-[1,4]diazepan-1-yl)-ethyl]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo-[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methyl-morpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-{2-[(2-dimethylaminoethyl)-methyl-amino]pyrimidin-4-yl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)phenyl]2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-3-methylmorpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(2-morpholin-4-yl-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-3-methylmorpholin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(4-methylpiperazin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo-[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-pyrrolidin-1-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-{3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-(5-tert-butyl-2-({3-[2-(ethylmethylamino)ethoxy]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo-[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt; 1-{(1S,4R)-4-[3-(4-aza-spiro[2.5]oct-4-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)phenyl]-2H-pyrazol-3-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-morpholin-4-yl-methylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[(2-dimethylaminoethyl)methylamino]phenyl}-2H-pyrazol-3-yl)-3-({(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo-[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformic acid salt;1-{5-tert-butyl-2-[3-((R)-2-dimethylamino-1-methylethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-((S)-2-dimethylamino-1-methyl-ethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[2-[3-(2-dimethylaminoethoxy)phenyl]-5-(2-hydroxy-1,1-dimethylethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-pyrrolidin-1-yl-ethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-diethylaminoethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureapartial formate salt;1-{5-tert-butyl-2-[3-(2-piperidin-1-yl-ethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-2H-pyrazol-3-yl)-3-{((1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-{3-[2-(4-fluoropiperidin-1-yl)-ethoxy]phenyl}-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(4-methyl-[1,4]-diazepan-1-yl)ethoxy]-phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]-triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-[1,4]oxazepan-4-yl-ethoxy)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(2-{3-[2-(8-aza-bicyclo[3.2.1]oct-8-yl)-ethoxy]phenyl}-5-tert-butyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(ethylmethylamino)ethoxy]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-(3-{2-[(2-methoxyethyl)methylamino]ethoxy}phenyl}-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(4-methoxypiperidin-1-yl-ethoxy]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{3-[2-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)ethoxy]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(4-methoxypiperidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]-pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-{[(2-methoxyethyl)methylamino]methyl}phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(4-fluoropiperidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-dimethylaminomethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-pyrrolidin-1-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{(1S,4R)-4-[3-(4-aza-spiro[2.5]oct-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-{5-tert-butyl-2-[3-(2-morpholin-4-yl-ethoxy)phenyl]-2H-pyrazol-3-yl}-ureaformate salt;1-[5-tert-butyl-2-(3-piperidin-1-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl-oxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(4-methyl-[1,4]diazepan-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-((1S,4S)-5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(4-morpholin-4-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl-oxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea;1-[5-tert-butyl-2-(4-dimethylaminomethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt;1-{5-tert-butyl-2-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureapartial formate salt;1-{5-tert-butyl-2-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea;1-{5-tert-butyl-2-[4-(4-methoxypiperidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]-pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureapartial formate salt;1-[5-tert-butyl-2-(4-pyrrolidin-1-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(4-piperidin-1-ylmethylphenyl)-2H-pyrazol-3-yl]-3-{(S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[4-(4-fluoropiperidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-(5-tert-butyl-2-{4-[(ethylmethylamino)methyl]phenyl}-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-[5-tert-butyl-2-(4-{[(2-methoxyethyl)methylamino]methyl}phenyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt;1-{5-tert-butyl-2-[3-(2-dimethylaminoethoxy)phenyl]-2H-pyrazol-3-yl-3-{(1S,4S)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-urea;1-[3-tert-butyl-1′-(2-dimethylaminoethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureaformate salt;1-[3-tert-butyl-1′-(2-morpholin-4-yl-ethyl)-1′H-[1,4′]bipyrazolyl-5-yl]-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureapartial formate salt; and1-{5-tert-butyl-2-[3-(4-methylpiperazin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-1-methylpyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-ureaformate salt, or a pharmaceutically acceptable salt of said compound.